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1.1 The Scientific interest towards Pharmaceutical compounds as emerging 
contaminants 
Pharmaceutical compounds (PhCs) have been characterized as “new” or 
“emerging” contaminants in the environment. However, PhCs have been around for 
several decades now. To that effect, a more accurate characterization is the fact that our 
attention to their presence in the environment is new or just emerging ( Jjemba 2008).  
 Interest in their presence in the environment is directly or indirectly stimulated by the 
fact that they are produced in increasingly large quantities and the improvements in 
detection methods, in fact enhanced sensitivity of analytical chemistry methods has 
enabled the detection of low-levels of pharmaceuticals in the environment, resulting in 
questions about the safety of the ecosystem and surface waters used for drinking supplies. 
Furthermore, their use and diversity is also steadily increasing every year. In addition, the 
continually ageing population and improving quality of life worldwide mean that their 
consumption is set to increase in future years (Van der Aa et al., 2011), recent 
investigations document that PhCs production and administration may vary both between 
countries and over time (Goossens et al., 2007, Kümmerer, 2009a), fluctuating not only on 
an annual basis, but also from one year to the next (Alexy et al., 2006). In recent years, 
PhCs have provoked increasing concern, particularly as no legal requirements have been 
set for discharge into surface water bodies of these ubiquitous, persistent and biologically 
active substances (Furhacker, 2008; Salgot et al., 2006; Ternes et al., 2007). Hence, over 
the last ten to fifteen years, PhC concentrations in raw and treated urban wastewater (WW) 
have been extensively monitored. Nevertheless, this is still a largely unregulated area, and 
there is ongoing debate within the scientific community regarding which PhCs to include 
among the priority substances (Bottoni et al. 2010). According to the new European draft 
annex (EC 2012), the anti-inflammatory diclofenac and the hormones 17β-estradiol and 
17α-ethinylestradiol are prime candidates to be added to the European Priority List, while 
according to the U.S. EPA, erythromycin, nitroglycerin, and 9 hormones (17α-
ethinylestradiol, 17α-estradiol, 17β-estradiol, equilenin, equilin, estriol, estrone, mestranol 
and norethindrone), need to be considered a priority (Richardson and Ternes 2011). 
Once administered, these compounds are only partially metabolized by the human 
body, and therefore enter the water cycle either as parent (unchanged) compounds, which 
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are excreted largely through urine (generally 55-80 % of the total, with few exceptions) 
and partially in the feces, or as a mixture of metabolites and/or conjugated compounds 
(Jjemba et al., 2006, Lienert et al., 2007).  
Municipal wastewater treatment plants (WWTPs) were not designed to remove 
trace organic contaminants, and as a results PhCs found their way into the environment 
through the discharge of treated WWs (Bendz et al., 2005; Castiglioni et al., 2006; 
Glassmeyer et al., 2005; Gomez et al., 2007; Joss et al., 2005; Verlicchi et al., 2012b), and 
as a result, their occurrence in surface water has been documented by a number of authors 
(Ashton et al., 2004; Calamari et al., 2003; Fatta-Kassinos et al., 2011; Gros et al., 2006, 
Kolpin et al., 2002, 2004; Spongberg et al., 2011) from around the world.  
While the presence of pharmaceuticals in the environment is established, sources of 
these compounds in the environment, the pathways by which they reach sensitive receptors 
and their effects on these receptors are less characterized, moreover the latter must be 
determined before the effectiveness of risk mitigation measures can be assessed. Hospital 
wastewater (HWWs) represent an important source of PhCs ( Le Corre et al. 2012, Jean et 
al. 2012), but has only recently been investigated, and in a far fewer number of studies. Not 
only high analysis costs, but also the difficulties in organizing water-sampling campaigns 
inside health facilities have delayed these investigations. Nonetheless, according to the 
recent literature (Verlicchi et al. 2010a,b; Ort et al. 2010a) HWWs may be considered a hot 
spot in terms of PhC load generated, prompting the scientific community to question the 
acceptability of the general practice of discharging HWWs into public sewers ( Verlicchi et 
al. 2010 b), where they are conveyed to municipal WWTPs and co-treated with UWWs 
(Verlicchi et al. 2010 a,b; Pauwels and Verstraete 2006; Kummerer and Helmers 2000).  
Through the evaluation of a compound’s risk quotient (RQ), that is the ratio between 
its measured or predicted concentration and its predicted no-effect concentration (PNEC), 
Escher et. al. (2011) found that the presence of PhCs in raw HWWs, UWWs pose a risk for 
the environment, and this risk remains high in the WWTP effluent. However, once the 
effluent is discharged into the receiving water body, its dilution with surface water can 
mitigate the effect of residual PhCs and the associated risk quotient may decrease ( Gros et 
al. 2010).  
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1.2 Aim and Objectives 
The general aims of this thesis were to characterized the sources and pathways of 
PhCs in the environment, to monitor the occurrence, to assess the removal and fate of 
selected PhCs in WWTPs and in the water environment, and to carry out environmental 
risk analysis based on their occurrence as a basis to prioritize the hazardous compounds 
and to manage the risk posed by their exposure. In particular, this work focused on HWWs 
in order to assess their potential as a point source of 73 PhCs and their role in spreading 
these compounds into the environment, and consequently the impact of WWTPs on the 
receiving water bodies. The last aim was to develop a tool to estimate the level of 
environmental risk posed by PhCs originated from HWWs at site specific catchment area 
to aid the authorities and decision makers in the management of HWWs and the reducing 
of PhCs discharged into the environment. To achieve these aims the following objectives 
were set: 
 
Objective 1: To review of the current knowledge on the sources, pathways, fate, and 
behaviour of PhCs in WWTPs from the literature (Chapter 2).  
In this Chapter, an in-depth literature review has been carried out, collating data 
pertaining to 264 WWTPs from various global locations, mostly in Europe. The data 
pertaining to a wide spectrum of PhCs, 118 compounds belonging to 17 different classes 
distinguished by their function or biological activity, were considered: 23 analgesics/anti-
inflammatories, 36 antibiotics, 1 antidiabetic, 1 antifungal, 3 antihypertensives, 1 
barbiturate, 12 beta-blockers, 2 diuretics, 9 lipid regulators, 10 psychiatric drugs, 6 
receptor antagonists, 4 hormones, 4 beta-agonists, 3 antineoplastics, 1 topical product, 1 
antiseptic and 1 contrast agent.  
 
Objective 2: To assess the occurrence of selected PhCs in HWWs and to evaluate their 
potential as point sourc of PhCs to the total load in the Influent of WWTP (Chapter 3).  
In this chapter, an experimental investigation has been conducted in the area of Ferrara, 
Italy. Sixteen water samples were withdrawal from the effluents of two different sized 
hospitals and the influent and effluent of the receiving municipal treatment plant of one of 
the examined hospitals. The aim was to investigate 73 selected pharmaceuticals, belonging 
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to twelve different classes, comparing their occurrence in the effluent directly exiting the 
hospital with that, mixed with the local urban effluent, at the points of its entry and exit 
from the treatment plant. PhCs were selected due to their high prescription rates or 
volumes, the availability of a reliable analysis methods, as well as due to their occurrence 
and ubiquity in the aquatic environment 
 
Objective 3: To assess the removal and release of 27 selected PhCs in full-scale WWTPs 
and their impacts on the receiving water bodies (Chapter 4).  
An investigation on the occurrence of 27 PhCs, belonging to different classes has been 
carried out. Twenty one water samples were withdrawal from the influent, effluent of two 
full-scale WWTPs and their receiving water bodies in the sensitive area of the Po Valley 
(northern Italy). The receiving water bodies were monitored upstream and downstream of 
the effluent discharge points in order to evaluate the effluent impact on the quality of 
surface waters, commonly used for irrigation. 
 
Objective 4: To determine the relative accuracy of the prediction models, and the 
limitations of on-site monitoring campaigns, that regard the occurrence of PhCs in the 
influent, effluent of a large municipal WWTP and downstream of its discharge point in the 
receiving water body, and their effect on the estimation of the environmental risk. (Chapter 
5).  
 
Objective 5: To estimate the potential impact of HWWs on the environment, and to assess 
the relative importance of PhCs pathways (HWWS, UWWs) for the priority candidate 
diclofenac as a case study for individual WWTP. (Chapter 6). 
 
Scientific researches that study the occurrence of pharmaceuticals in the 
environment are hindered by many challenges, chemical analysis and sampling protocol 
represent the most important and they are a key part in the process of gathering 
environmental data (Ort et al. 2010b). These two factors are time and monetary consuming, 
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indeed they required an adequate quality assurance and control protocols. For these reasons 
and in order to maximize the value of measured data for the experimental investigations, 
chemical analysis of investigated PhCs in the different withdrawal water samples (HWWs, 
raw UWWs, treated WWs and surface water) in this work are done thanks to the 
collaboration with the Department of Environmental Chemistry, Institute of Environmental 
Assessment and Water Research (IDAEA), Spanish Council for Scientific Research 
(CSIC), Barcelona, Spain. Moreover, This work is conducted in parallel with the European 
project “PILLS” (www.pills-project.eu), that part of its aims were the aims investigated in 
this Ph.D thesis, and during the years of this work, our results and knowledge have been 
discussed. 
 
The results obtained from this research have been presented at international 
conferences, workshops, as well as in book chapters (see Appendix D). Moreover , three 
scientific papers are published in international journals as following: 
1. Verlicchi P, Al Aukidy M, Zambello E. Occurrence of Pharmaceutical 
Compounds in Urban Wastewater: Removal, Mass Load and Environmental Risk 
after a Secondary Treatment – A Review. Science of the Total Environment 429 
(2012) 123– 155. 
2. Verlicchi P., Al Aukidy M., Galletti A., Petrovic M., Barceló D.. Hospital 
Effluent: Investigation of the Concentrations and Distribution of Pharmaceuticals 
and Environmental Risk Assessment. Science of the Total Environment 430 (2012) 
109– 118. 
3. Al Aukidy M., Verlicchi P., Jelic A., Petrovic M., Barcelo D. Monitoring release 
of pharmaceutical compounds: Occurrence and environmental risk assessment of 
two WWTP effluents and their receiving bodies in the Po Valley, Italy. Science of 
the Total Environment 438 (2012) 15 – 25. 
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2.1 Introduction 
The problem of PhCs in the Environment, is not a new issue (there has much work in 
this area since the 1990s, and a lot of information is available in the scientific literature) 
but recently it has become a priority concern, particularly for politicians and the general 
public. PhCs have been found in various environmental compartments (waters, soils, 
sediments) and have been suspected of having an affect on the integrity of the aquatic 
ecosystems ( Kummerer, 2008 ). 
 
Pharmaceuticals are classified according to their purpose (e.g., antibiotics, 
analgesics, anti-neoplastics, anti-inflammatory substances, antihistamines, X-ray contrast 
media, etc.). PhCs are complex molecules with different physicochemical and biological 
properties and functionalities. They are developed and used because of their more or less 
specific biological activity and are most notably characterized by their ionic nature. The 
molecular weights of the chemical molecules range typically from 200 to 1000 Dalton. 
This chapter gives an introduction to the PhCs properties, consumption, toxicity, sources 
and pathways through a full litereature review that deals also with their occurrence, 
removal, fate and factors effecting their removal in WWTPs, and finaly the total 
discharged load of PhCs from WWTP and an evaluation of their risk posed to the 
envieonment is presented. 
 
2.2 Physico-chemical properties of pharmaceutical compounds (PhCs) 
Once a PhCs is discharged into wastewater, it will be distributed between the 
different environmental compartments (e.g. surface water, soil, sediment) according to its 
physico-chemical properties, including the solubility, volatility, acidity, lipophilicity and 
sorption potential. Moreover, its persistence will depend on its resistance to be degraded 
biologically or abiotically. Appendix A.1. shows the physico-chemical characteristics and 
biodegradability of selected PhCs. 
 
2.2.1 Volatility 
Volatility is the tendency of a compound to volatilize, that is to leave the liquid 
phase and enter into the gas phase. It is strictly correlated to Henry coefficient. Ternes and 
Joss (2006) observed that a significant amount of a compound will be stripped in a 
bioreactor with fine bubble aeration if Henry constant > 0.003. Therefore, since most of 
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PhCs has low henry constant (Appendix A.1.), it can be concluded that stripping process is 
in general not relevant for the removal of pharmaceuticals during WWTPs. 
 
2.2.2 Acidity  
Acidity (i.e. dissociation constant pKa) describes the degree of ionization of the 
compound at a known pH. The pH of relevance in the environment ranges between 4 and 
8, with activated sludge typically presenting a pH in the range of 7 – 8 (Christofi et al., 
2003). The pKa values that are less than 7 indicate that the compound is negatively charged 
under acidic conditions and vice versa. Most PhCs are acids or bases with pKa values of 2 
– 12. Weakly acidic pharmaceuticals such as the nonsteroidal anti-inflammatory drugs 
(NSAIDs) (i.e., naproxen, ibuprofen, and acetysalicylic acid) with pKa values of 4.2, 5.2, 
and 3.5 as well as clofibric acid ( pKa = 2.95) have a low tendency to adsorb onto sludge. 
 
2.2.3 Lipophilicity  
Lipophilicity (Hydrophobicity) is related to the physical property of a compound to 
be repelled from a mass of water. Different coefficients were used to evaluate the tendency 
of a substance to stay in the water phase. The most common parameters are the octanol-
water partition coefficient (Kow) and the octanol-water distribution coefficient (Dow). In the 
past, Kow was generally used for evaluating and predicting pharmaceutical behavior in 
aquatic compartment by considering that high Kow values are characteristics of 
hydrophobic substances, poor hydrosolubility and in some case of a high potential to sorb 
on organic material of sludge (Rogers, 1996).  
As known, PhCs are complex molecules, multifunctional organic compounds in 
some cases ionized in the aquatic environment: the un-ionized species will be the 
predominant species to partition into octanol from water, the ionized species 
predominantly remaining in the aqueous compartment. The pH at which measurements are 
made for evaluating Kow is a crucial parameter. For these reason, recently Cunnigham 
(2008) reported that Kow does not properly describe environmental partitioning and 
dynamic in the environment of polar and ionizable compounds such as PhCs and for them 
the coefficient Dow is more adequate as it is pKa dependent at the pH of the environment. 
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2.2.4 Sorption Potential 
The sorption potential of a given compound is indicated by the solid-water 
distribution coefficient (Kd), which combines two driving forces for sorption: acidity and 
lipophilicity. Ternes and Joss (2006) indicated that only compounds having Kd values 
higher than 500 L kg−1 will be sorbed significantly onto sludge during primary and 
secondary treatment. In the case of sludge treatment, Carballa et al. (2007) showed that the 
limit of relevance below which sorption can be neglected is around Kd < l L kg−1, since the 
sorbed amount is not only dependent on the distribution coefficient but also on the 
concentration of solids.  
 
2.3 Pharmaceutical consumption 
Large amounts of pharmaceuticals, representing a wide spectrum of therapeutic 
classes, are used and prescribed in human medicine world wide (Dìaz-Cruz and Barcelo 
2004). In most cases, only a rough estimation of pharmaceutical consumption is available, 
because they are often sold as over-the-counter drugs (Dìaz-Cruz and Barcelo 2004; 
Stackelberg et al. 2004). A rough estimation of the global consumption of human PhCs 
showed that about 100 000 tons of PhCs are used each year, which corresponds to a 
worldwide average consumption of 15 g/pro capite year (Kummerer 2004). More detailed 
analyses about PhC consumption for area, country are available in terms of sales (WHO, 
2004) of the specific therapeutic classes, but these data are not useful to evaluate the mass 
flow of PhCs consumed in a specific area and time. Usage data for active compounds sold 
in four different European countries are summarised in Table 2.1. These data indicate that, 
in general, the analgesic acetaminophen and the analgesic and anti-inflammatory drugs 
acetylsalicylic acid and ibuprofen are the pharmaceuticals sold in highest quantities, 
followed by the antibiotics, and the antiepileptic carbamazepine.  
 
Table 2.1. Volume of pharmaceutically active compounds sold in different countries 
(kg/yr) 
Therapeutic class Compound 
France 
(2004)a 
UK 
(2004)b 
Spain 
(2003)c 
Italy 
(2010)d 
Analgesics/anti-inflammatories 
Acetaminophen 3303077 3534737 - - 
Acetylsalicylic acid 396212 177623 - - 
Diclofenac 9896 35361 32300 9602 
Ibuprofen 240024 330292 276100 - 
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Therapeutic class Compound 
France 
(2004)a 
UK 
(2004)b 
Spain 
(2003)c 
Italy 
(2010)d 
Naproxen 37332 33580 42600 - 
Antibiotics 
Azithromycin 4073 756 - 13870 
Clarithromycin 15105 8807 - 64470 
Erythromycin - 48654 8100 - 
Penicillin V - 32472 - - 
Amoxicillin 333223 149764 - - 
Sulfamethoxazole 16730 3113 12700 - 
Sulfadiazine - 362 - - 
Ciprofloxacin 12186 16445 - 21672 
Tetracycline - 2101 - - 
Trimethoprim 3346 11184 3700 13896 
Beta-blockers 
Acebutolo - 943 - - 
Atenolol 18337 49547 - 18084 
Metoprolol 8786 3907 2300 - 
Propranolol 12487 9986 - - 
Hormones 
Progesterone - 751 - - 
Testosterone - - - - 
Lipid regulators 
Gemfibrozil - 1418 - - 
Fenofibrate 85670 2815 - - 
Atorvastatin 7924 - - 7682 
Simvastatin 6943 14596 - - 
Lovastatin - - - - 
Psychiatric drugs 
Fluoxetine 3740 4826 4200 - 
Paroxetine 5515 2663 - - 
Citalopram 3487 4799 1600 - 
Carbamazepine 33514 52245 20000 31190 
Contrast media Iopromide - - 20000 - 
Data from:  a Besse et al. (2007), b Environment Agency (2008), C Carballa et al. (2008), d Al Aukidy et al. (2012) 
 
2.4 Toxicity of PhCs 
The most important issue of concern about the presence of pharmaceuticals in the 
aquatic environment and the main reason why they are of interest for inclusion in 
monitoring programs as environmental contaminants is the ecotoxicological effects that 
they may cause. Even today, little is known about this subject. Some studies, however, 
have reported that some compounds, such as diclofenac (anti-inflammatory), propranolol 
(β-blocker), and fluoxetine (antidepressant), show chronic lowest-observed-effect 
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concentrations for fish toxicity, zooplankton, and benthic organisms in the range of WWTP 
effluent concentrations (Fent et al.2006). This indicates that for some compounds, the 
margin of safety is narrow and that chronic effects at highly contaminated sites cannot be 
completely ruled out, particularly when combined effects of pharmaceutical mixtures are 
taken into account (Fent et al.2006). Nevertheless, dilution in receiving waters results in 
lower levels, enabling the reduction of environmental risks. 
It is impossible to rule out acute effects entirely without further testing since certain 
species may be particularly susceptible to certain class of drugs. Pharmaceuticals are 
created with the intent of causing a biological effect, they often have similar types of 
physiochemical behavior that are characteristic of harmful xenobiotics (e.g. they are able to 
pass membranes, and they are relatively persistent in order to avoid being inactivated 
before having their therapeutic effect). In non-target aquatic life many pharmaceuticals act 
as baseline toxicants. However, some exhibit the therapeutic effect also in aquatic life as 
the unwanted estrogenic effects on fish ( Kidd et al., 2007). Others act via a different 
specific mode of toxic action, as evidenced for fluoxetine effects on algae ( Neuwoehner et 
al., 2009). It is generally accepted that mixtures with components exhibiting the same 
mode of action act according to the model of concentration addition. In wastewater 
pharmaceuticals are present as mixture with varying modes of toxic action, and their 
toxicity was found at concentrations at which the single compound showed no or only little 
effects. Thus it could be assumed that the toxicity of a very complex mixture is governed 
by the underlying baseline toxicity, not the specific mode of toxic action of single 
components ( Escher et a.2011).  
Pomati et al. (2006, 2008) investigated the effects and interactionsof a mixture of 
commonly used pharmaceuticals, including carbamazepine, ibuprofen and 
sulfamethoxazole at low concentrations, designed to mimic those found in the environment 
using in vitro tests on human and zebrafish cells. They concluded that a mixture of drugs at 
ng/L levels can inhibit cell proliferation by affecting their physiology and morphology and 
that waterborne pharmaceuticals may have an effect on aquatic life. Synergy remains an 
important topic with the complex mixtures of trace organic compounds being released to 
the environment ( Stuart et al. 2012). 
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2.5 Legislation on PhCs in the aquatic environment 
From a legislation point of view, it is quite important to note that the Directives 
concerning the protection of aquatic environments and related organisms are the Water 
Framework Directive 2000/60/EC (WFD), the daughter Directice 2006/118/EC (GWD) for 
the protection of groundwater and the daughter Directive 2008/105/EC (PSD) stating the 
List of Priority Substances (also known as Annex X to WFD) for surface waters and 
related Environmental Quality Standards (EQSs). Pharmaceuticals are not included among 
those compounds to be monitored, outwithstanding their occurrence have been 
documented since more than 20 years in many European countries. The revision of the list 
of compounds and the subsequent definition of pertinent new EQSs are based on 
significant risks to or via aquatic environment in compliance with Art. 16 of the WFD.  
Bottoni et al. (2010) report that a simplified and pragmatic methodology was 
developed under the WFD Common Implementation Strategy (CIS), taking into 
consideration both monitoring data and modelling data. According to these Authors, 
possible priority pharmaceuticals could be antineoplastics (including tamoxifen and 
cyclophosphamide), synthetic estrogens and hormones. The inclusion of target PhCs in the 
EU List of Priority Substances implies the definition of their corresponding EQSs and the 
necessity to subject to monitoring ambient water, sediment and biota in the different EU 
countries. In addition further attempts to define prioritisation lists have been made by other 
Commissions. For instance that by Oslo and Paris Commission (OSPAR) including mainly 
antibiotics, psychiatric drugs, receptor antagonists, that by Global Water Research 
Coalition (GWRC 2008) that defined a high priority level for a group of substances 
belonging to different classes: carbamazepine, sulfamethoxazole, diclofenac, ibuprofen, 
naproxen, bezafibrate, atenolol, ciprofloxacin, erythromycin and gemfibrozil. National 
prioritisation procedures have also taken place and prioritised PhCs based on the potential 
risk that they are perceived to pose to aquatic environment. In the United Kingdom, 12 
compounds were prioritised for targeted monitoring based upon their predicted 
environmental concentrations, predicted no effect concentration (PNECs), and persistence, 
bioaccumulation and toxic (PBT) properties: mainly analgesics, antidepressants, 
antibiotics,antineoplastics (Ashton et al., 2004). In the United States the contaminants 
candidate to be included into the priority lists are the antibiotic erythromycin and the 
estrogens ethinylestradiol, estradiol, equilenin, estriol, estrone, mestranol and 
norethindrone (Richardson and Ternes, 2011). All these attemps provide a good start in 
focusing efforts, but they should be considered with caution as they are based on acute, 
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principally lethal, ecotoxicological test data and may therefore not include those substances 
taht may be exerting effects following chronic exposure. Occurrence data have to be used 
not only to confirm the presence of a compound in the aquatic environment, but it is used 
in combination with relevant ecotoxicol test data to allow the refinement of risk 
assessments. 
 
2.6 Environmental risk assessment of PhCs. 
The European Union Directive 92/18/EEC introduced for the first time, the 
requirement for an environmental risk assessment, as a prerequisite to obtain marketing 
authorization for veterinary pharmaceuticals. For this purpose, the European Agency for 
the Evaluation of Medicinal Products (EMEA) published a “Note for Guidance” (EMEA 
1998) where guidelines to assess the environmental risk of veterinary medicinal products 
are established. The European Commission extended its concerns to pharmaceuticals for 
human use by publishing Directive 2001/83/EC which was subsequently amended by 
Directive 2004/27/EC (EudraLex 2009). These directives established that marketing 
authorization for new medical products for human use should be accompanied by an 
environmental risk assessment, whose guidelines were set out by (EMEA,2006). 
Nevertheless, the environmental impact does not provide sufficient grounds for a refusal. 
Environmental risk assessment of both veterinary and human pharmaceuticals is assessed 
in a stepwise approach, divided into two phases. In Phase I, environmental exposure to the 
pharmaceutical or its metabolites is estimated. Phase II comprises its fate and effects in the 
environment. For this reason, Phase II is sub-divided into two parts: Tier A, in which 
possible fate and effects of the pharmaceutical and/or its major metabolites are evaluated; 
and Tier B, which focuses on the effects on fauna and flora within environmental 
compartments that are likely to be affected (EMEA 1998,2006). However, medicinal 
products for human use only require Phase II studies if the predicted environmental 
concentration in surface water is equal to or above 0.01 µgL−1 (EMEA 2006). In the US, 
issues concerning pharmaceuticals in the environment are regulated by the U.S. Food and 
Drug Administration (FDA). This institution requires environmental assessments to obtain 
marketing authorisations which are specified in the “Guidance for Industry-Environmental 
Assessment of Human Drug and Biologic Applications” (FDA 1998). However, an 
environmental assessment is required only if the estimated environmental concentration of 
the pharmaceutical at the point of the entry is above 1 µgL−1 (FDA 1998). As EMEA, the 
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FDA also requires environmental assessments for veterinary medicinal products, using a 
tiered approach. With a view to harmonising the guidelines that govern these 
environmental impact assessments, the EU, US and Japan elaborated two guidelines: 
“Environmental Impact Assessment (EIAs) for Veterinary Medicinal Products (VMPs)-
Phase I” (EMEA 2000) and “Environmental Impact Assessment for Veterinary Medicinal 
Products-Phase II Guidance” (EMEA 2005) so that environmental fate and toxicity data 
obtained could be used to obtain marketing authorisation in all these regions. 
 
In synthesis, the basic principle of Environmental Risk Assessment (ERA) is the 
comparison of a predicted or measured environmental concentration (PEC or MEC) of a 
substance with a predicted, no effect concentration (PNEC), the concentration at which no 
effects on environmental organisms are expected to occur. If the PEC or MEC of a 
substance is higher than or equal to the PNEC, i.e. the risk characterisation ratio is ≥ 1, and 
thus an unacceptable risk for the environment is indicated, either a refined ERA with 
improved data is conducted or a risk management with appropriate measures has to be 
realised. PECs are derived from model calculations, whereas MECs can be determined 
from monitoring studies. Preference should be given to adequately representative exposure 
data, the discrypancis between these two approches are discussed in Chapter 5.  
 
2.7 Source and pathways of PhCs 
The origins of aquatic pollution by PhCs are derived from diverse sources that can 
be divided into point sources which include municipal wastewater effluent from STWs, 
industrial effluent and leachates from waste disposal sites, and non point sources which 
may consist of agricultural run-off (Figure 2.1.). The principal sources of human 
pharmaceuticals that discharge into wastewater treatment facilities include hospitals, 
extended-care facilities, and private households, all of these sources also contribute via the 
disposal of unused medicines as trash. This occurs through the hospital sewage system for 
admitted patients and urban wastewaters. Pharmaceuticals applied in veterinary medicin, as 
growth promoters and for other purposes, are excreted by the animals, usually, it is 
assumed that emission from pharmaceutical manufacturing and production are low in 
Europe and north America (Kummerer 2010). Contaminants applied to the soil surface will 
migrate through the soil zone, the unsaturated zone and the saturated zone in the well 
established way. This may be the route for components of sewage sludge used as fertilizer. 
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The potential for organic contaminants present in sewage sludge to leach following 
application to agricultural land was highlighted by (Wilson et al. 1996, Montiero et 
al.2010). 
 
Figure 2.1. Sources and pathways of pharmaceutical compounds. 
 
Another important pathway is groundwater–surface water interaction. In many 
instances treated effluent from industrial premises and sewage works is discharged to 
surface water. This may then infiltrate to groundwater from losing reaches of rivers (Stuart 
et al., 2012). 
 
2.8 Occurrence and fate of PhCs in wastewaters 
Once administered, PhCs are metabolised to varying degrees, and their excreted 
metabolites and unaltered parent compounds can also undergo further modification due to 
biological, chemical and physical processes in both sewage treatment facilities and 
receiving water bodies (Deblonde et al., 2011; Fatta-Kassinos et al., 2011; Miège et al., 
2009; Monteiro et al., 2010; Onesios et al., 2009). Municipal wastewater treatment plants 
(WWTPs) are generally not equipped to deal with complex pharmaceuticals, as they were 
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built and upgraded with the principal aim of removing easily or moderately biodegradable 
carbon, nitrogen and phosphorus compounds and microbiological organisms, which 
regularly arrive at the WWTP in concentrations to the order of mg L-1 and at least 106 
MPN/100 mL, respectively. PhCs in raw wastewaters are generally in the range of 10-3 – 
10-6 mg L-1, in addition, their chemical and physical properties, namely solubility, 
volatility, adsorbability, absorbability, biodegradability, polarity and stability, vary greatly 
(Le Minh et al., 2010; Ziylan and Ince, 2011), with obvious repercussions on their 
behaviour during the treatments and consequently their removal efficiencies.  
Indeed, several PhCs have been found in river biota, some at high levels (Rimkus, 
1999), thereby evidencing the risk that environmental concentrations of PhCs can be 
higher than their (PNECs) (Santos et al., 2007; Stuer-Lauridsen et al., 2000), especially in 
effluent-dominant rivers whose dilution capacity and self-purifying processes are 
insufficient to temper the risk to aquatic life (Kasprzyk-Horder et al., 2009).  
Although much research has been conducted on this topic, studies have generally 
been limited to single treatment plants. Hence, in order to provide an overview of the 
findings, a full litereature review is set out, collating data pertaining to 264 WWTPs from 
various global locations, mostly in Europe. Reflecting the abundance of conventional 
activated sludge systems (CAS) among existing municipal WWTPs, 244 of them were 
considered in this study, the remaining 20 plants examined were membrane biological 
reactors (MBR), included for comparative purposes. Data pertaining to a wide spectrum of 
PhCs, 118 compounds belonging to 17 different classes distinguished by their function or 
biological activity, were considered: 23 analgesics/anti-inflammatories, 36 antibiotics, 1 
antidiabetic, 1 antifungal, 3 antihypertensives, 1 barbiturate, 12 beta-blockers, 2 diuretics, 
9 lipid regulators, 10 psychiatric drugs, 6 receptor antagonists, 4 hormones, 4 beta-
agonists, 3 antineoplastics, 1 topical product, 1 antiseptic and 1 contrast agent.  
Raw influent and secondary effluent concentrations for the 118 PhCs, and their 
removal efficiencies observed in CAS and MBRs were reported, the objective being to 
provide a snapshot of their occurrence and of the efficacy of suspended growth mass 
biological processes in their removal. Based on the collected data, the average daily mass 
load (mg/1000 inhabitants/ day) in the secondary effluent for the majority of the 
compounds under study has been evaluated, ranking them accordingly. The PhCs were 
then also ranked according to their environmental risk, using a quotient derived from the 
ratio between their measured concentrations in secondary effluents and their corresponding 
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PNEC. This strategy provides an overview of the situation, clearly identifying a group of 
compounds in need of more intensive monitoring further to safeguarding the environment. 
 
Compounds are grouped according to their therapeutic class and presented in terms 
of their chemical formula and molecular weight; literature references are also provided for 
each (Table 2.2.). In addition, in the Appendix A.1., their main physical and chemical 
properties (protonation constant as pKa, octanol-water partition coefficient as Log Kow, 
solubility Sw, sludge-water distribution coefficient as Log Kd, reaction rate constant kbiol, 
molecular charge at pH 7) as well as their molecular structure are provided. The main 
features of the WWTPs investigated in each study and details of the corresponding 
experimental campaigns are compiled in Table 2.3. Through the last column of Table 2.2., 
it is possible to know the previous works investigating the substance under study and then, 
once known the cited work, through Table 2.3. to know the details of the experimental 
campaign and the characteristics of the WWTPs under consideration. 
Based on the collected literature data, the variability ranges for the concentration of 
each examined compound in both raw urban influent has been defined (Figures 2.3.-2.8. 
and Appendix A.2.) and secondary effluent (Figures 2.9.-2.14. and Appendix A.3.), as well 
as for their corresponding removal efficiencies (Figures 2.16.-2.20. and Appendix A.4.). 
To complete the analysis of literature data, the percentage partitions, for some of the 
compounds under study, among biodegradation, sorption onto sludge and occurrence in the 
secondary effluent are provided (Table 2.4.) as well as removal efficiencies for the 
different selected PhCs with respect to the sludge retention time of the corresponding 
biological reactor (referring to CAS in Table 2.5. and MBR in Table 2.6.).  
Subsequently, the average daily mass discharged from the secondary biological 
system was evaluated, where possible, for the examined compounds, and their 
corresponding risk quotients (average concentration/PNEC) in the secondary effluent 
(Figures 2.21. and 2.22.). As a whole, the results of these two analyses revealed the most 
critical compounds in terms of mass load and/or environmental risk. 
 
2.8.1 Mostly Investigated PhCs  
Table 2.2. reports the list of the investigated contaminants, grouped according to 
their therapeutic class, in addition to their molecular weight (MW) and chemical formula, 
together with the number and details of the references reviewed. The majority of the 
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compounds mentioned in the various studies are administrated orally, intramuscularly, 
endovenously or by inhalation, and in few cases on the skin.  
An analysis of the data compiled in Appendix A.1., referring to selected PhCs 
evidences their very different molecular structures, also in terms of basic or acidic 
functional groups (charge at pH = 7). These, if found on the same molecule (e.g. 
ciprofloxacin), can cause it to be neutral, cationic, anionic or zwitterionic under different 
environmental conditions, (Kümmerer, 2009a; Ternes and Joss, 2006) resulting in (very) 
different behaviours during treatment processes as it will be discussed later. 
 
2.8.2 Main features of the mostly investigated wastewater treatment plants 
(WWTPs)  
Table 2.3. lists the main features of the WWTPs investigated in each study (second 
column), as well as the details of the experimental campaigns (sampling mode, number of 
samples, observation period, number of investigated PhCs). 244 CAS systems (242 full-
scale and 2 pilot plants) and 20 MBRs (all pilot plants) situated in various world locations 
were included in this study: 68 % of the WWTPs are situated in European countries (Spain, 
Germany, Italy, Switzerland, Sweden, Austria, UK, Finland, France, Greece and 
Denmark), 14 % in the Americas (USA, Canada and Brazil), 14 % in Asia (China, Japan, 
South Korea and North Korea) and 4 % in Australia.  
The raw wastewaters influent to these plants are generally subjected to preliminary 
treatments (bar screening and grit removal), then primary sedimentation followed by the 
secondary biomass growth treatment (CAS or MBR, the majority of the latter equipped 
with ultrafiltration or, in a few cases microfiltration, membranes). This final step usually 
included denitrification-nitrification and carbon removal processes, and in some cases 
simultaneous precipitation of phosphate by the addition of Fe salts. CAS operates at a HRT 
ranging from 2-24 h and at a SRT generally equal to 2-20 d with some exceptions, while 
MBR at a HRT of 7-15 h (with few exceptions) and at a SRT equal to 15-80 d (with a few 
exceptions). Figure 2.2. shows the historical development of the activated sludge process: 
from CAS for BOD removal to MBR and MBBR for enhancing the quality of the final 
effluent and upgrading the existing CAS maintaining the same footprint or reducing it. 
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Figure 2.2. Historical development of the activated sludge process: from CAS for BOD removal to MBR and 
MBBR for enhancing the quality of the final effluent and upgrading the existing CAS maintaining the same 
footprint or reducing it. 
 
In general, chemical analysis of PhCs was performed on 24-h composite water 
samples, quite often flow-proportional, thereby avoiding the risk of under- or over-
estimating the average daily concentrations in the wastewater. Experimental investigations 
were mainly based on a number of samples ranging between 3 and 12. Few studies 
collected multiple data sets for each sampling point. Water samples were generally taken in 
dry days in order to avoid dilution of the influent in case of combine sewage and due to 
parasite streams and dilution of the effluent caused by washout of the biological tanks. 
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Table 2.2. Pharmaceutical compounds examined, grouped according to their therapeutical class. For each substance, chemical formula and 
molecular weight (MW) are provided as well as number of papers and references dealing with it. 
Therapeutic class Pharmaceutical 
compound MW 
Chemical 
formula 
Number of 
papers References 
Analgesics/ 
Anti-
inflammatories 
A 
 
5-aminosalicylic acid 153 C7H7NO3 1 Kasprzyk-Hordern et al., 2009 
Acetaminophen 151 C8H9NO2 15 Choi et al., 2008; Coetsier et al., 2009; Foster, 2007; Gómez et al., 2007; Jones et al., 
2007; Kasprzyk-Hordern et al., 2009; Khan and Ongerth, 2005; Kim et al., 2007; 
Radjenovic et al., 2007, 2009; Roberts and Thomas, 2006; Rosal et al., 2010; Snyder 
et al., 2006; Ternes, 1998; Yu et al., 2006 
Acetylsalicylic acid 180 C9H8O4 2 Kasprzyk-Hordern et al., 2009; Ternes, 1998 
Aminopyrine  231 C13H17N3O 2 Andreozzi et al., 2003; Ternes, 1998 
Codeine 299 C18H21NO3 5 Foster, 2007; Gómez et al., 2007; Kasprzyk-Hordern et al.,2009; Rosal et al., 2010; 
Wick et al., 2009 
Dextropropoxyphene 339 C22H29NO2 1 Roberts and Thomas, 2006 
Diclofenac 296 C14H11Cl2NO2 36 Andreozzi et al., 2003; Bendz et al., 2005; Bernhard et al., 2006; Clara et al., 2004, 
2005a, 2005b; Coetsier et al., 2009; Gómez et al., 2007; Kasprzyk-Hordern et al., 
2009; Kim et al., 2007; Kimura et al., 2005, 2007; Kreuzinger et al., 2004; Lindqvist 
et al., 2005; Lishman et al., 2006; Muñoz et al., 2009; Paxéus, 2004; Quintana et al., 
2005; Radjenovic et al., 2007, 2009; Reif et al., 2008; Roberts and Thomas, 2006; 
Rosal et al., 2010; Santos et al., 2007, 2009; Snyder et al., 2006; Stumpf et al., 1999; 
Suárez et al., 2005; Tauxe-Wuersch et al., 2005; Ternes et al., 2003; Ternes, 1998; 
Thomas and Foster, 2005; Vieno et al., 2005; Weigel et al., 2004; Yu et al., 2006; 
Zorita et al., 2009  
Dipyrone 333 C13H16N3NaO4S 1 Gómez et al., 2007 
Fenoprofen 242 C15H14O3 6 Andreozzi et al., 2003; Bendz et al., 2005; Coetsier et al., 2009; Lishman et al., 2006; 
Nakada et al., 2006; Ternes, 1998 
Flurbiprofen 244 C15H13FO2 2 Andreozzi et al., 2003; Bendz et al., 2005 
Hydrocodone 299 C18H21NO3 1 Snyder et al., 2006 
Ibuprofen 206 C13H18O2 43 Andreozzi et al., 2003; Bendz et al., 2005; Bernhard et al., 2006; Carballa et al., 
2004, 2005; Castiglioni et al., 2006; Clara et al., 2004, 2005a, 2005b; Coetsier et al., 
2009; Gómez et al., 2007; Jones et al., 2007; Kasprzyk-Hordern et al., 2009; Khan 
and Ongerth, 2005; Kim et al., 2007; Kimura et al., 2005, 2007; Kreuzinger et al., 
2004; Lindqvist et al., 2005; Lishman et al., 2006; Muñoz et al., 2009; Nakada et al., 
2006; Paxéus, 2004; Quintana et al., 2005; Radjenovic et al., 2007, 2009; Reif et al., 
2008; Roberts and Thomas, 2006; Rodriguez et al., 2003; Rosal et al., 2010; Santos 
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Therapeutic class Pharmaceutical 
compound MW 
Chemical 
formula 
Number of 
papers References 
et al., 2007, 2009; Snyder et al., 2006; Stumpf et al., 1999; Suárez et al., 2005; 
Tauxe-Wuersch et al., 2005; Ternes et al., 2003; Ternes, 1998; Thomas and Foster, 
2005; Vieno et al., 2005; Weigel et al., 2004; Yu et al., 2006; Zorita et al., 2009 
Indomethacin 358 C19H16ClNO4 8 Bendz et al., 2005; Lishman et al., 2006, Radjenovic et al., 2007, 2009; Rosal et al., 
2010; Stumpf et al., 1999; Ternes et al., 2003; Ternes, 1998  
Ketoprofen 254 C16H14O3 21 Andreozzi et al., 2003; Bendz et al., 2005; Kasprzyk-Hordern et al., 2009; Khan and 
Ongerth, 2005; Kimura et al., 2005, 2007; Lindqvist et al., 2005; Lishman et al., 
2006; Nakada et al., 2006; Quintana et al., 2005; Radjenovic et al., 2007, 2009; Rosal 
et al., 2010; Santos et al., 2007, 2009; Stumpf et al., 1999; Tauxe-Wuersch et al., 
2005; Ternes, 1998; Thomas and Foster, 2005; Vieno et al., 2005; Yu et al., 2006  
Ketorolac 255 C15H13NO3 1 Rosal et al., 2010 
Meclofenamic acid 296 C14H11Cl2NO2 1 Ternes, 1998 
Mefenamic acid 241 C15H15NO2 9 Jones et al., 2007; Kasprzyk-Hordern et al., 2009; Kimura et al., 2005, 2007; 
Radjenovic et al., 2007, 2009; Roberts and Thomas, 2006; Rosal et al., 2010; Tauxe-
Wuersch et al., 2005 
Naproxen 230 C14H14O3 30 Andreozzi et al., 2003; Bendz et al., 2005; Carballa et al., 2004, 2005; Kasprzyk-
Hordern et al., 2009; Khan and Ongerth, 2005; Kim et al., 2007; Kimura et al., 2005, 
2007; Lindqvist et al., 2005; Lishman et al., 2006; Nakada et al., 2006; Paxéus, 2004; 
Quintana et al., 2005; Radjenovic et al., 2007, 2009; Reif et al., 2008; Rodriguez et 
al., 2003; Rosal et al., 2010; Santos et al., 2007, 2009; Snyder et al., 2006; Stumpf et 
al., 1999; Suárez et al., 2005; Ternes, 1998; Ternes et al., 2003; Thomas and Foster, 
2005; Vieno et al., 2005; Yu et al., 2006; Zorita et al., 2009 
Phenazone  188 C11H12N2O 3 Andreozzi et al., 2003; Rosal et al., 2010; Ternes, 1998 
Propyphenazone 230 C14H18N2O 3 Nakada et al., 2006; Radjenovic et al., 2007,  2009 
Salicylic acid 138 C7H6O3 4 Kasprzyk-Hordern et al., 2009; Khan and Ongerth, 2005; Lishman et al., 2006; 
Ternes, 1998 
Tolfenamic acid 262 C14H12ClO2 1 Ternes, 1998 
Tramadol 263 C16H25NO2 2 Kasprzyk-Hordern et al, 2009; Wick et al., 2009 
Antibiotics 
B 
 
Amoxicillin 365 C16H19N3O5S 1 Watkinson et al., 2007 
Azithromycin 749 C38H72N2O12 4 Ghosh et al., 2009; Göbel et al., 2005, 2007; Yasojima et al., 2006 
Cefaclor 368 C15H14ClN3O4S 1 Watkinson et al., 2007 
Cefalexin  347 C16H17N3O4S 4 Costanzo et al., 2005; Gulkowska et al., 2008; Li and Zhang, 2011; Watkinson et al., 
2007 
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Therapeutic class Pharmaceutical 
compound MW 
Chemical 
formula 
Number of 
papers References 
Cefotaxime 456 C16H17N5O7S2 2 Gulkowska et al., 2008; Li and Zhang, 2011 
Chloramphenicol 323 C11H12Cl2N2O5 3 Kasprzyk-Hordern et al., 2009; Li and Zhang, 2011; Peng et al., 2006 
Chlortetracycline 479 C22H23ClN2O8 2 Li and Zhang, 2011; Watkinson et al., 2007 
Ciprofloxacin 331 C17H18FN3O3 15 Andreozzi et al., 2003; Baumgarten et al., 2007; Castiglioni et al., 2006; Costanzo et 
al., 2005; Ghosh et al., 2009; Golet et al., 2003; Karthikeyan and Meyer, 2006; Li 
and Zhang, 2011; Lindberg et al., 2005, 2006; Muñoz et al., 2009; Rosal et al., 2010; 
Vieno et al., 2007; Watkinson et al., 2007; Zorita et al., 2009 
Clarithromycin 748 C38H69NO13 7 Castiglioni et al., 2006; Ghosh et al., 2009; Göbel et al., 2005, 2007; Sahar et al., 
2011; Ternes et al., 2003; Yasojima et al., 2006 
Clindamycin 425 C18H33ClN2O5S 1 Watkinson et al., 2007 
Cloxacillin 436 C19H18ClN3O5S 1 Watkinson et al., 2007 
Doxycycline 463 C22H24N2O8 2 Lindberg et al., 2005; Watkinson et al., 2007  
Enoxacin 320 C15H17FN4O3 1 Andreozzi et al., 2003 
Enrofloxacin 359 C19H22FN3O3 3 Baumgarten et al., 2007; Ghosh et al., 2009; Watkinson et al., 2007 
Erythromycin  734 C37H67NO13 19 Castiglioni et al., 2006; Göbel et al., 2005, 2007; Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; Kasprzyk-Hordern et al., 2009; Kim et al., 2007; Li 
and Zhang, 2011; Muñoz et al., 2009; Radjenovic et al., 2007, 2009; Reif et al., 2008; 
Roberts and Thomas, 2006; Rosal et al., 2010; Sahar et al., 2011; Snyder et al., 2006; 
Ternes et al., 2003; Watkinson et al., 2007; Xu et al., 2007 
Lincomycin 407 C18H34N2O6S 3 Castiglioni et al., 2006; Ghosh et al., 2009; Watkinson et al., 2007 
Lomefloxacin 351 C17H19F2N3O3 1 Andreozzi et al., 2003  
Metronidazole 171 C6H9N3O3 2 Kasprzyk-Hordern et al., 2009; Rosal et al., 2010 
Norfloxacin 319 C16H18FN3O3 12 Andreozzi et al., 2003; Coetsier et al., 2009; Costanzo et al., 2005; Ghosh et al., 
2009; Golet et al., 2003; Gulkowska et al., 2008; Li and Zhang, 2011; Lindberg et al., 
2005, 2006; Watkinson et al., 2007; Xu et al., 2007; Zorita et al., 2009 
Ofloxacin 361 C18H20FN3O4 12 Andreozzi et al., 2003; Brown et al., 2006; Castiglioni et al., 2006; Li and Zhang, 
2011; Lindberg et al., 2005; Peng et al., 2006; Radjenovic et al., 2007, 2009; Rosal et 
al., 2010; Vieno et al., 2007; Xu et al., 2007; Zorita et al., 2009 
Oxytetracycline 460 C22H24N2O9 2 Li and Zhang, 2011; Watkinson et al., 2007 
Penicillin G 334 C16H18N2O4S 2 Gulkowska et al., 2008; Watkinson et al., 2007 
Penicillin V 350 C16H18N2O5S 1 Watkinson et al., 2007 
Roxithromycin 837 C41H76N2O15 12 Clara et al., 2005b; Ghosh et al., 2009; Göbel et al., 2005, 2007; Kreuzinger et al., 
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Therapeutic class Pharmaceutical 
compound MW 
Chemical 
formula 
Number of 
papers References 
2004; Li and Zhang, 2011; Reif et al., 2008; Ruel et al., 2010; Sahar et al., 2011; 
Ternes et al., 2003, Watkinson et al., 2007; Xu et al., 2007 
Spiramycin 843 C43H74N2O14 1 Castiglioni et al., 2006 
Sulfachloropyridazine 285 C10H9ClN4O2S 1 Choi et al., 2008 
Sulfadiazine 250 C10H10N4O2S 3 Li and Zhang, 2011; García-Galán et al., 2011; Peng et al., 2006 
Sulfadimethoxine 310 C12H14N4O4S 3 Choi et al., 2008; García-Galán et al., 2011; Ghosh et al., 2009 
Sulfamethazine 278 C12H14N4O2S 4 García-Galán et al., 2011, Karthikeyan and Meyer, 2006; Li and Zhang, 2011; Sahar 
et al., 2011 
Sulfamethoxazole 253 C10H11N3O3S 31 Andreozzi et al., 2003; Bendz et al., 2005; Brown et al., 2006; Carballa et al., 2004, 
2005; Castiglioni et al., 2006; Choi et al., 2008; Clara et al., 2005b; Foster, 2007; 
García-Galán et al., 2011; Ghosh et al., 2009; Göbel et al., 2005, 2007; Karthikeyan 
and Meyer, 2006; Kasprzyk-Hordern et al., 2009; Kim et al., 2007; Kreuzinger et al., 
2004; Li and Zhang, 2011; Lindberg et al., 2005; Muñoz et al., 2009; Peng et al., 
2006; Radjenovic et al., 2007, 2009; Reif et al., 2008; Rosal et al., 2010; Ruel et al., 
2010; Sahar et al., 2011; Snyder et al., 2006; Ternes et al., 2003; Watkinson et al., 
2007; Xu et al., 2007 
Sulfapyridine 249 C11H11N3O2S 4 García-Galán et al., 2011; Göbel et al., 2005, 2007; Kasprzyk-Hordern et al., 2009 
Sulfasalazine 398 C18H14N4O5S 2 Kasprzyk-Hordern et al., 2009;  Watkinson et al., 2007 
Sulfathiazole 255 C9H9N3O2S2 3 Choi et al., 2008; García-Galán et al., 2011; Watkinson et al., 2007 
Tetracycline 444 C22H24N2O8 5 Ghosh et al., 2009; Gulkowska et al., 2008; Li and Zhang, 2011; Karthikeyan and 
Meyer, 2006; Watkinson et al., 2007 
Trimethoprim 290 C14H18N4O3 25 Andreozzi et al., 2003; Batt 2006; Bendz et al., 2005; Brown et al., 2006; Foster, 
2007; Ghosh et al., 2009; Göbel et al., 2005, 2007; Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; Kasprzyk-Hordern et al., 2009; Choi et al., 2008; Kim 
et al., 2007; Li and Zhang, 2011; Lindberg et al., 2005, 2006; Paxéus, 2004; 
Radjenovic et al., 2009; Reif et al., 2008; Roberts and Thomas, 2006; Rosal et al., 
2006; Sahar et al., 2011; Snyder et al., 2006; Ternes et al., 2003; Watkinson et al., 
2007 
Tylosin  916 C46H77NO17 1 Watkinson et al., 2007 
Antidiabetics  
C 
Glibenclamide 494 C23H28ClN3O5S 1 Radjenovic et al., 2007, 2009 
Antifungals  
D 
Clotrimazole 345 C22H17ClN2 1 Roberts and Thomas, 2006 
Antihypertensives Diltiazem 415 C22H26N2O4S 3 Choi et al., 2008 Foster, 2007; Kasprzyk-Hordern et al., 2009; 
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Therapeutic class Pharmaceutical 
compound MW 
Chemical 
formula 
Number of 
papers References 
E 
 
Enalapril 377 C20H28N2O5 1 Castiglioni et al., 2006 
Hydrochlorothiazide 298 C7H8ClN3O4S2 5 Castiglioni et al., 2006; Muñoz et al., 2009; Radjenovic et al., 2007, 2009; Rosal et 
al., 2010; 
Barbiturates 
 F 
Phenobarbital 232 C12H12N2O3 1 Yu et al., 2006 
Beta-blockers 
G 
 
Acebutolol 336 C18H28N2O4 2 Andreozzi et al., 2003; Vieno et al., 2007 
Atenolol 266 C14H22N2O3 14 Alder et al., 2010; Bendz et al., 2005; Carucci et al., 2006; Castiglioni et al., 2006; 
Kasprzyk-Hordern et al., 2009; Maurer et al., 2007; Muñoz et al., 2009; Paxéus, 
2004; Radjenovic et al., 2007, 2009; Rosal et al., 2010; Ternes et al., 2003; Vieno et 
al., 2007; Wick et al., 2009 
Betaxolol 307 C18H29NO3 3 Andreozzi et al., 2003; Ternes, 1998; 
Wick et al., 2009 
Bisoprolol 325 C18H31NO4 2 Ternes, 1998; Wick et al., 2009 
Carazolol 298 C18H22N2O2 1 Ternes, 1998 
Celiprolol 379 C20H33N3O4 2 Ternes et al., 2003; Wick et al., 2009 
Metoprolol 267 C15H25NO3 12 Alder et al., 2010; Andreozzi et al., 2003; Kasprzyk-Hordern et al., 2009; Maurer et 
al., 2007; Paxéus, 2004; Radjenovic et al., 2007, 2009; Rosal et al., 2010; Ternes, 
1998; Ternes et al., 2003; Vieno et al., 2007; Wick et al., 2009 
Nadolol 309 C17H27NO4 1 Ternes, 1998 
Oxprenolol 265 C15H23NO3 1 Andreozzi et al., 2003 
Propranolol 259 C16H21NO2 12 Alder et al., 2010; Andreozzi et al., 2003; Bendz et al., 2005; Coetsier et al., 2009; 
Kasprzyk-Hordern et al., 2009; Maurer et al., 2007; Radjenovic et al., 2009; Roberts 
and Thomas, 2006; Rosal et al., 2010; Ternes, 1998; Ternes et al., 2003; Wick et al., 
2009 
Sotalol 272 C12H20N2O3S 6 Alder et al., 2010; Maurer et al., 2007; Radjenovic et al., 2009; Ternes et al., 2003; 
Vieno et al., 2007; Wick et al., 2009 
Timolol 316 C13H24N4O3S 1 Ternes, 1998 
Diuretics 
H 
Bendroflumethiazide 421 C15H14F3N3O4S2 1 Kasprzyk-Hordern et al., 2009 
Furosemide 331 C12H11ClN2O5S 3 Castiglioni et al., 2006; Kasprzyk-Hordern et al., 2009; Rosal et al., 2010 
Lipid regulators 
I 
Bezafibrate 362 C19H20ClNO4 15 Andreozzi et al., 2003; Castiglioni et al., 2006; Clara et al., 2004, 2005a, 2005b; 
Kasprzyk-Hordern et al., 2009; Kreuzinger et al., 2004; Lindqvist et al., 2005; 
Quintana et al., 2005; Radjenovic et al., 2007, 2009; Rosal et al., 2010; Stumpf et al., 
1999; Ternes, 1998; Vieno et al., 2005 
Clofibrate 243 C12H15ClO3 2 Andreozzi et al., 2003; Ternes, 1998 
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Therapeutic class Pharmaceutical 
compound MW 
Chemical 
formula 
Number of 
papers References 
Clofibric acid 215 C10H11O3Cl 16 Andreozzi et al., 2003;Bendz et al., 2005; Bernhard et al., 2006; Kasprzyk-Hordern et 
al., 2009;Kimura et al., 2005, 2007; Lishman et al., 2006; Radjenovic et al., 
2007;Roberts and Thomas, 2006; Rosal et al., 2010;Stumpf et al., 1999; Tauxe-
Wuersch et al., 2005;Ternes, 1998; Ternes et al., 2003; Weigel et al., 2004; Zorita et 
al., 2009 
Etofibrate 364 C18H18ClNO5 1 Ternes, 1998 
Fenofibrate 361 C20H21ClO4 3 Andreozzi et al., 2003; Lishman et al., 2006;Ternes, 1998 
Fenofibric acid 319 C17H15ClO4 5 Muñoz et al., 2009; Rosal et al., 2010;Stumpf et al., 1999; Ternes, 1998; Ternes et 
al., 2003 
Gemfibrozil 250 C15H22O3 14 Andreozzi et al., 2003; Bendz et al., 2005; Khan and Ongerth, 2005;Kim et al., 2007; 
Lishman et al., 2006; Muñoz et al., 2009;Paxéus, 2004;Radjenovic et al., 2007, 
2009;Rosal et al., 2010; Snyder et al., 2006; Stumpf et al., 1999; Ternes, 1998;Yu et 
al., 2006 
Pravastatin 425 C23H36O7 4 Coetsier et al., 2009; Kasprzyk-Hordern et al., 2009; Radjenovic et al., 2007, 2009 
Simvastatin 419 C25H38O5 1 Kasprzyk-Hordern et al., 2009 
Psychiatric drugs 
J 
Amitriptyline 277 C20H23N 1 Kasprzyk-Hordern et al., 2009 
Carbamazepine 236 C15H12N2O 31 Andreozzi et al., 2003;Bendz et al., 2005; Bernhard et al., 2006; Castiglioni et al., 
2006; Clara et al., 2004, 2005a, 2005b; Conti et al., 2011; Coetsier et al 2009;Foster, 
2007; Gómez et al., 2007;Kasprzyk-Hordern et al., 2009; Khan and Ongerth, 2005; 
Choi et al., 2008; Kim et al., 2007;Kreuzinger et al., 2004; Muñoz et al., 2009; 
Nakada et al., 2006; Paxéus, 2004;Radjenovic et al., 2007, 2009; Reif et al., 2008; 
Rosal et al., 2010;Santos et al., 2007, 2009;Snyder et al., 2006; Suárez et al., 2005; 
Ternes, 1998;Ternes et al., 2003; Vieno et al., 2007; Wick et al, 2009 
Diazepam 285 C16H13ClN2O 6 Clara et al., 2005b;Kreuzinger et al., 2004; Reif et al., 2008;Suárez et al., 
2005;Ternes, 1998; Wick et al., 2009 
Fluoxetine 309 C17H18F3NO 8 Foster, 2007; Kim et al., 2007; Metcalfe et al., 2010; Muñoz et al., 2009; Radjenovic 
et al., 2009; Rosal et al., 2010; Snyder et al., 2006; Zorita et al., 2009 
Gabapentin 171 C9H17N1O2 2 Kasprzyk-Hordern et al., 2009; Yu et al., 2006 
Lorazepam 321 C15H10Cl2O2N2 1 Coetsier et al., 2009 
Norfluoxetine 295 C16H16F3NO 2 Metcalfe et al., 2010; Zorita et al., 2009 
Oxcarbazepine 252 C15H12N2O2 1 Conti et al., 2011  
Paroxetine 329 C19H20FNO3 2 Metcalfe et al., 2010; Radjenovic et al., 2007  
Valproic acid 144 C8H16O2 1 Yu et al., 2006 
Receptor 
antagonists 
Cimetidine 252 C10H16N6S 2 Choi et al., 2008; Kasprzyk-Hordern et al., 2009; 
Famotidine 337 C8H15N7O2S3 1 Radjenovic et al., 2009 
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Chemical 
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K 
 
Loratadine 383 C22H23ClN2O2 1 Radjenovic et al., 2009 
Omeprazole  C17H19N3O3S 1 Rosal et al., 2010 
Ranitidine 314 C13H22N4O3S 6 Carucci et al., 2006; Castiglioni et al., 2006; Kasprzyk-Hordern et al., 2009; 
Radjenovic et al., 2007, 2009; Rosal et al., 2010 
Valsartan 436 C24H29N5O3 1 Kasprzyk-Hordern et al., 2009 
Hormones  
L 
 
Estradiol 272 C18H24O2 11 Andersen et al., 2003; Baronti et al., 2000; Carballa et al., 2004, 2005; Clara et al., 
2005a; Foster, 2007; Joss et al., 2004; Kim et al., 2007; Lishman et al., 2006; Ternes 
et al., 1999a; Zorita et al., 2009 
Estriol 288 C18H24O3 4 Baronti et al., 2000; Clara et al., 2005a;Kim et al, 2007; Nakada et al., 2006 
Estrone 270 C18H22O2 12 Andersen et al., 2003; Baronti et al., 2000; Carballa et al., 2004, 2005; Clara et al., 
2005a; Joss et al., 2004; Kim et al., 2007; Lishman et al., 2006; Nakada et al., 2006; 
Ternes et al., 1999a, 2003; Zorita et al., 2009  
Ethinylestradiol 296 C20H24O2 10 Andersen et al., 2003; Baronti et al., 2000; Clara et al., 2004, 2005a; Foster, 2007; 
Joss et al., 2004; Kim et al., 2007; Kreuzinger et al., 2004; Ternes et al., 1999; Zorita 
et al., 2009 
Beta-agonists  
M 
 
Clenbuterol 277 C12H18Cl2N2O 1 Ternes, 1998  
Fenoterol 303 C17H21NO4 1 Ternes, 1998 
Salbutamol 239 C13H21NO3 4 Castiglioni et al., 2006; Jones et al., 2007; Kasprzyk-Hordern et al., 2009; Ternes, 
1998 
Terbutaline 226 C12H19NO3 1 Ternes, 1998 
Antineoplastics  
N 
 
Cyclophosphamide 261 C7H15Cl2N2O2P 1 Ternes, 1998 
Ifosfamide 261 C7H15Cl2N2O2P 3 Coetsier et al., 2009; Kümmerer et al., 1997; Ternes, 1998 
Tamoxifen 372 C26H29NO 2 Coetsier et al., 2009; Roberts and Thomas, 2006 
Topical products  
O 
Crotamitron 203 C13H17NO 1 Nakada et al., 2006 
Antiseptics 
P 
Triclosan 290 C12H7Cl3O2 13 Foster, 2007; Gómez et al., 2007; Kim et al., 2007; McAvoy et al., 2002; Muñoz et 
al., 2009; Nakada et al., 2006; Paxéus, 2004; Rosal et al., 2010; Ruel et al., 2010; 
Snyder et al., 2006; Thomas and Foster, 2005; Weigel et al., 2004; Yu et al., 2006 
Contrast media 
Q 
Iopromide 791 C18H24I3N3O8 5 Batt et al., 2006; Carballa et al., 2004; Clara et al., 2005b; Kim et al., 2007; 
Kreuzinger et al., 2004 
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Collected data report the pharmaceutical concentrations in raw urban wastewaters 
and in the corresponding treated biological effluent, as well as the global removal 
efficiencies achieved after the secondary treatment. The urban wastewater considered 
includes both the effluent produced by domestic users and that from (small) industrial 
activities, which, according to the local regulation, may be discharged into the public sewer 
network and conveyed to the municipal WWTP.  
Experimental investigations were carried out at different times of the year, and the 
overall data therefore covers periods characterized by higher and lower PhC consumption, 
enabling this study to provide a balanced overview, bolstered by taking into account the 
different consumption habits in the different countries worldwide. 
 
2.8.3 Quality assurance of literature data  
As reported by the EC Technical Guidance Document on risk assessment (EC, 2003) 
and as remarked by many Authors (among them Liebig et al., 2006; Ternes and Joss, 
2006), it is vital that the quality of literature data is assured. For this reason, to be included 
in the present study, references had to feature a description of the analytical methodology 
used for the assessment of measured concentrations and the quality assurance program 
adopted for sampling, analysis and elaboration. In particular, they provide the following 
information: list of analytes, solvents and chemicals used; details of sampling, transport 
and storage in addition to sample volume; analytical methods adopted, including pH 
adjustment, filtration and filter material, extraction and solvent evaporation techniques; 
derivatization and detection method; surrogate and/or instrumental standards used; 
methods and limits of quantification, recovery measurements, procedural and instrumental 
blanks used; sampling conditions, location, frequency and period and compartment 
characteristics.
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Table 2.3 Main characteristics of the treatment plants and monitoring campaigns included 
in the litereature review. 
 References  Details of treatment plants and experimental investigations  
1 Alder et al., 
2010 
24-h flow-proportional composite samples were taken at the influent and effluent of a conventional 
WWTP of Niederglatt, Switzerland (33 000 inhabitants, 16800 m3/d) and processed for four beta-
blockers: atenolol, metoprolol, propanolol and sotalol. The plant includes nitrification-
denitrification stages. Collected data refer to influent and effluent concentrations, average removal 
rates as well as average mass loads for each of the selected compounds. 
2 Andersen et 
al., 2003 
 
 
24-h flow-proportional composite samples were taken at the influent and effluent of a conventional 
WWTP in Wiesbaden, Germany (300 000 population equivalent, pe) and processed for three 
oestrogens (n = 2). The plant includes pretreatments (screening, aerated grit removal), primary 
clarification and activated sludge systems for biological and chemical phosphate removal, 
denitrification and nitrification. SRT is roughly 11-13 d. 
3 Andreozzi et 
al., 2003 
 
 
Grab samples and 24-h composite samples were taken between February and March 2001 at the 
inlet and outlet of the secondary treatment step of five CAS systems, treating domestic and 
industrial wastewaters, in different countries (Greece, Italy and Sweden). They serve populations 
ranging from 6000 to 900 000 inhabitants. All plants featured a primary settling phase and one a 
chemical phosphorus removal step. 26 PhCs were investigated. 
4 Baronti et 
al., 2000 
 
24-h composite samples of the influent and secondary effluent of six CAS systems in the area of 
Rome, Italy, were collected once a month over five months (n = 5) and processed for four 
oestrogens. The plants have flow rates ranging between 10 000 and 734 000 m3/d and HRT in the 
range 12-14 h. They serve populations ranging between 40 000 and 1 200 000 inhabitants. 
5 Batt et al., 
2006 
 
 
24-h flow-proportional composite samples were taken at the inlet and the outlet of the WWTP 
located in Amherst, NY. Samples were collected once a week for three consecutive weeks (n=3), in 
2006, and processed for iopromide and trimethoprim. The plant includes a primary clarifier and a 
two-stage secondary biological process (slurry system). Stage 1 is a CAS for substrate removal with 
HRT 1 h and SRT 6 d . Stage 2 is a CAS designed for nitrogen removal with HRT 2 h and SRT 49 
d. 
6 Baumgarten 
et al., 2007 
An investigation was carried out on an MBR pilot plant in order to evaluate the removal efficiencies 
of target pharmaceuticals during MBR treatment as well as to compare them with those obtained 
with simultaneously addition in the bioreactor of powdered activated carbon (PAC). Average 
elimination efficiencies are provided for some common antibiotics (in particular ciprofloxacin and 
enrofloxacin). 
7 Bendz et al., 
2005 
24-h flow-proportional and composite samples were taken at the inlet and secondary effluent of the 
Kallby WWTP (Sweden) in October 2002 (n = 1) and processed for 14 PhCs. 
8 Bernhard et 
al., 2006 
 
 
The investigation carried out at the WWTP of Wiesbaden, Germany, receiving domestic (90 %) and 
industrial (10 %) wastewater, with a capacity equal to 282 000 pe. The plant consists of a grit 
removal tank, a clarification tank, a CAS for carbon and nitrogen removal (HRT = 22 h), a final 
clarification tank and microscreen. Moreover, a pilot submerged-MBR equipped with 
microfiltration membranes (pore size 0.4 µm) was installed and fed with preclarified water (HRT = 
7-10 h). 
24-h composite water samples (n = 10-11) were taken at the influent, the MBR permeate and the 
WWTP effluent between July 2004 and March 2005. Average removal rates for the two 
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 References  Details of treatment plants and experimental investigations  
investigated systems were provided for 4 PhCs (diclofenac, ibuprofen, clofibric acid and 
carbamazepine). In addition, the concentrations of diclofenac are also provided at the three 
sampling points . 
9 Brown et al., 
2006 
48-h composite samples from the urban influent and the secondary effluent of the Albuquerque 
WWTP in New Mexico were taken and processed for 3 PhCs. 
10 Carballa et 
al., 2004 
 
 
24-h composite samples were taken at the inlet and outlet of Galicia municipal WWTP (Spain) in 
October 2001, and in January and April 2002, and analysed for 6 PhCs. The plant has a capacity of 
100 000 p.e. and consists of  preliminary treatments (coarse and fine screening and aerated 
chambers for grit and fat removal), primary sedimentation and CAS (HRT 24 h). 
11 Carballa et 
al., 2005 
 
 
24-h composite samples were taken at the influent and secondary effluent of the WWTP in Galicia 
(Spain, 100 000 inhabitants) in October 2001, January 2002, April 2002 and June 2002 and 
processed for five PhCs. The plant consists of preliminary treatment (fine screening, aerated 
chambre for grit and fat removal), primary sedimentation and CAS (mixed reactors followed by 
sedimentation tank). Average removal rates are provided for the selected compounds.  
12 Carucci et 
al., 2006 
 
The investigation refers to a 2-L lab-scale SBR, working through six 4-h cycles each day,  SRT 8-
14 d, using the activated sludge system coming from  municipal WWTP as inoculum and municipal 
wastewater as feed. Average removal rates are provided for ranitidine and atenolol. 
13 Castiglioni 
et al., 2006 
 
 
Six Italian large WWTPs were monitored for 16 PhCs during Winter (January-March 2004) and 
Summer (June-September 2004). All investigated plants are equipped with pre-treatments, primary 
sedimentation and CAS. 24-h composite samples were collected at the inlet and the outlet of each 
plant, and their average removal rates are provided. 
14 Choi et al., 
2008 
Grab samples (n = 3) were taken between April and August 2005 at the influent and secondary 
effluent of four large municipal WWTPs within Seoul city boundary (Korea) and analysed for 9 
PhCs.  
15 Clara et al., 
2004 
 
24-h composite samples were taken at the influent and the effluent of a CAS system in the South 
East of Austria (7000 pe, SRT 52-237 d) and in a pilot MBR (10-56 d, ultrafiltration membranes) 
during three monthly experimental campaigns in 2002. They were processed for 5 PhCs. 
16 Clara et al., 
2005a 
 
 
24-h composite samples of influent and the secondary effluent of four full-scale CAS plants (SRTs: 
2 d, 19 d, 48 d and 42 d) and a pilot MBR plant (SRT: 22-82) in Austria. Corresponding design 
capacities are 2.5 106 pe, 167 103 pe, 135 103 pe, 6 103 pe, and 50 pe. Mean average concentrations 
were provided for 8 PhCs.  
17 Clara et al., 
2005b 
 
 
Three urban CAS WWTPs and one pilot MBR plant, equipped with ultrafiltration membranes, were 
monitored in the South East of Austria. 24-h composite samples were taken at the inlet and outlet of 
each plant and analysed for 8 PhCs. The corresponding SRTs are: 52-114 d (CAS 1), 2 d (CAS 2) 
and 46 (CAS 3) and 10-55 d (MBR).  
18 Coetsier et 
al., 2009 
 
24-h averaged flow-proportional samples were collected (n=8) between June 2007 and February 
2008 at the effluent of the WWTP of Alès in France (90 000 pe). The plant consists of a CAS 
system with extended aeration and simultaneous phosphorus precipitation.  
19 Conti et al., 
2011 
24-h flow-proportional samples were taken at the inlet of the large conventional WWTP in Pavia, 
Italy (160 000 inhabitants, HRT = 4 h) and processed for carbamazepine and oxcarbamazepine.  
20 Costanzo et Samples were taken (n = 2) at the influent and effluent of a CAS in Brisbane (Australia) and 
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 References  Details of treatment plants and experimental investigations  
al., 2005 processed for three antibiotics (ciprofloxacin, norfloxacin and cephalexin). 
21 Foster 2007 
 
 
Grab samples were taken at the raw influent and secondary effluent of the municipal WWTP of San 
Marco, Texas (USA) during periods of normal operation from October 2006 to March 2007. The 
plant includes preliminary treatments (screening, degritting), primary clarification and CAS. 
Average concentrations and variability ranges were provided for 10 PhCs.  
22 García-
Galán et al., 
2011 
Collected data refer to the removal efficiencies observed for selected sulphonamide antibiotics in 
three municipal wastewater treatment plants in Spain, along the Ebro river basin. The three WWTPs 
consist of primary treatments followed by a conventional activated sludge system. HRT and SRT 
were respectively 10 h and 4 d for the first plant, 10 h and 6 d for the second one, 24-46 h and 19 d 
for the third one. 
23 Ghosh et al., 
2009 
 
 
Samples were collected at the influent and secondary effluent of four medium–large capacity CAS 
systems in Japan (flow rate: 576 000 m3/d, 9500 m3/d, 50 000 m3/d, 57 000 m3/d; SRT: 16-19 d, 13 
d, 17 d, 14-18 d and HRT: 9.5-12 h, 14 h, 11 h, 2.8-5.5 h). Average influent concentrations and 
average removal rates are reported for 11 antibiotics.  
24 Göbel et al., 
2005 
 
 
24-h composite samples were taken at the influent and effluent of two conventional municipal 
WWTPs in Switzerland (55 0000 pe and 80 000 pe) and processed for 7 antibiotics between March 
2002 and November 2003. The plants consist of preliminary treatments (screening and aerated 
gritting), primary clarification and nitrification-denitrification steps.  
25 Göbel et al., 
2007 
 
 
Two full-scale CAS systems (55 000 pe, HRT =15 h, SRT =10-12 d; and 80 000 pe, HRT = 31 h 
and SRT = 21-25 d, respectively) and one pilot MBR (100 pe, SRT = 16-80 d) were investigated in 
Switzerland in order to compare their capacity to remove 7 selected antibiotics. CASs include 
denitrification and nitrification tanks, and the MBR consists of a cascade of stirred anaerobic, 
anoxic, aerobic compartments. 
24-h flow-proportional composite samples were taken three times at each sampling point in each of 
the three experimental campaigns (March 2002, February 2003 and November 2003, n= 9). Only 
percentage removal rates are provided. 
26 Golet et al., 
2003 
 
 
24-h flow-proportional composite water samples were taken at the influent and secondary effluent 
of the largest urban WWTP in Zurich (600 000 pe), Switzerland and analysed for 2 antibiotics, 
ciprofloxacin and norfloxacin (n = 7), in October 2000. The plant consists of pretreatments 
(screening, gritting and primary clarification) and CAS steps (predenitrification-nitrification-
secondary clarifier; HRT = 20 h and SRT = 11 d). 
27 Gómez et 
al., 2007 
 
The inlet and the outlet of the municipal CAS system in Almeria (Spain, 62 000 inhabitants) were 
monitored during July 2003 and April 2004. Ten 24-h composite water samples and 12 discrete 
samples (monthly) were analysed for 7 PhCs.  
28 Gulkowska 
et al., 2008 
 
Grab samples at the inlet and secondary effluent of two large CAS systems in Hong Kong operating 
at different HRTs (16 h and 21 h) but the same SRT (20 d) were processed for 7 antibiotics in 
December 2006. 
29 Jones et al., 
2007 
 
 
Grab samples were taken every 6 hours at the inlet and outlet of a municipal CAS plant (150 000 
pe) in southern England during the four dry investigation days in June 2004. The plant consists of 
preliminary treatments (screening, gritting), primary clarification and biological treatment 
(nitrification-denitrification), operating at a SRT of 13 d and HRT of 13.5 h. Average removal rates 
are provided for 4 selected PhCs (ibuprofen, acetaminophen, salbutamol and mefenamic acid).  
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30 Joss et al., 
2004 
 
 
An experimental investigation was carried out in November 2002 at the conventional WWTP of 
Kloten (Switzerland) where a pilot-scale MBR was installed in parallel with the conventional 
WWTP of Altenrhein (Switzerland). The Kloten plant serves 55 000 pe and includes primary 
treatments (screening, aerated grit and primary clarifier), secondary treatments (denitrification, 
nitrification and simultaneous phosphorus removal with Fe+3); its SRT is about 10-12 d. The MBR 
is a 100-pe pilot plant fed with primary effluent from the Kloten plant and equipped with stirred 
anaerobic and anoxic tanks followed by an aerobic filtration compartment, operating at SRT 30 d. 
Microfiltration and ultrafiltration membranes were tested. 24-h composite flow-proportional 
samples were taken at the influent and effluent of each plant and processed for 3 compounds (n =6). 
31 Karthikeyan 
et al., 2006 
24-h composite samples were collected from the inlet and the outlet of two WWTPs in the USA 
(serving 73 000 and 150 000 inhabitants) and processed for 6 PhCs (n = 2) in October 2001 and 
December 2002.  
32 Kasprzyk-
Hordern et 
al., 2009 
24 h composite samples (n = 10) of urban influent and secondary effluent of the Coslech WWTP 
(UK) (flow rate range between 150–300 L/s) during the period April-August 2007. 35 compounds 
were investigated and their removal rates evaluated in the CAS plant deployed as an extended 
aeration/oxidation ditch for carbon and nitrogen removal.  
33 Khan and 
Ongerth 
2005 
24-h composite samples were taken at the influent and the effluent of the municipal WWTP located 
in the outer western suburbs of Sidney, Australia (23 000 inhabitants). The plant consists of 
preliminary and primary treatments followed by a CAS system with additional phosphorus removal. 
Seven compounds were monitored over five week-days. 
34 Kim et al., 
2007 
The influent and the secondary effluent of six South Korean urban CAS systems were sampled for 
15 PhCs between 2004-2005 .  
35 Kimura et 
al., 2005 
 
 
Samples were taken at the inlet and the outlet of a full-scale CAS system and two pilot MBRs to 
compare the removal rates of 6 PhCs. The two pilot plants were equipped with hollow-fibre 
microfiltration membranes and fed by raw (the same feeding the full-scale plant) and pretreated 
(pre-coagulated/clarified) municipal wastewater, respectively. In both MBRs HRT was 9 h, in CAS, 
HRT was 13 h
.
 
36 Kimura et 
al., 2007 
 
 
Grab samples (n = 11) were taken at the influent and outlet of 1 full-scale CAS (Soseigawa, Japan, 
125 000 m3/d, HRT = 12 h and SRT =7 d) and two MBRs (equipped with hollow fiber 
microfiltration membranes, fed by the same influent as the conventional treatment plant and 
operating at the same flow rate = 0.624 m3/d and HRT = 6.7 h but at different SRT: 15 d and 65 d) 
between August-November 2005. 6 compounds were monitored. 
37 Kreuzinger 
et al., 2004 
 
 
Samples were taken at the inlet and secondary effluent of two full-scale Austrian CAS systems and 
at a pilot MBR plant (equipped with ultrafiltration membranes) operating at different SRTs: 9.6 d 
and 96 d for the full-scale plants, 20 and 41 for the MBR over a period of 7-14 days. Average 
removal rates are given for 9 selected PhCs. 
38 Kümmerer 
1997 
8-h composite samples were taken from the influent to a WWTP in Forchheim (Germany) between 
January and April 1995 (n = 7) and processed for ifosfamide. 
39 Li and 
Zhang, 2011 
Removal efficiencies for selected antibiotics were investigated in two conventional Chinese 
WWTPs: Shatin, 600 000 inhabitants served and Stanley 27 000 inhabitants served. The two 
systems include an anoxic-aerobic activated sludge process, the first is characterized by HRT of 10 
h and SRT of 12 d, while the second by a RT of 17 h and SRT of 7 d. 
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40 Lindberg et 
al., 2005 
 
 
 
Fourteen 24-hour flow-proportional composite samples were taken at the inlet and outlet of four 
Swedish conventional WWTPs in August 2002 and February 2003 and analysed for 6 antibiotics. 
The plants receive municipal and industrial wastewaters and have a capacity ranging from 50 000 
and 644 000 inhabitants. HRTs are: 8 h, 11 h, 16 h and 24 h and corresponding SRTs are: 20 d, 22 
d, 11 d and 15 d. Each plant consists of preliminary treatments (screening, sand and fat removal, 
chemical phosphorus removal, primary clarification) followed by a CAS system. For three out of 
the four plants, nitrogen removal is also performed. 
41 Lindberg et 
al., 2006 
 
 
24-h composite samples of the influent and secondary effluent of the municipal WWTP of Umea, 
Sweden were investigated in the period November–December 2004. The influent is mechanically 
(3-mm split screen) and chemically (flocculation-precipitation) pretreated. Its HRT is 8 h and SRT 
20 d; 3 antibiotics were monitored. 
42 Lindqvist et 
al., 2005 
 
 
24-h composite samples of the influent and secondary effluent of seven full-scale CAS systems in 
Finland were taken in September 2003 and processed for 5 PhCs. Four of the CAS systems used a 
denitrification-nitrification process for nitrogen removal and all of them feature a simultaneous 
biological treatment for removal of P.  
43 Lishman et 
al., 2006 
24-h composite samples were taken at the influent and secondary effluent of 7 CAS systems in 
Canada. The investigation lasted between October and December 2002 and monitored 12 PhCs. 
44 Maurer t al., 
2007 
 
24-h composite samples were taken during a 3-day study period at the inlet and the outlet of two 
CAS systems (including nitrification-denitrification) near Zurich, Switzerland, and processed for 4 
beta-blockers. The first plant has a capacity of 50 000 inhabitants, an HRT of 6.6 h and an SRT of 
8-10 d. The second serves a population of about 36 000 inhabitants, operates at an HRT of 18 h and 
at an SRT of 14 d. 
45 McAvoy et 
al., 2002 
 
24-h flow-proportional composite samples (n = 2) were taken at the inlet and the outlet of one CAS 
plant in Loveland (27 000 p.e., 12 000 m3/d, HRT = 6 h) in the USA. They were processed for 
triclosan in November 1997.  
46 Metcalfe et 
al., 2010 
24-h composite water samples were collected at the influent and secondary outlet of a WWTP, in 
Southern Ontario, serving a population of approximately 69 000 using conventional activated 
sludge system and tertiary treatment followed by UV disinfection. The WWTP consists of two 
parallel trains (HRT = 11.9 h in both lines and SRT of 8.1 d and 10.4 d). 
47 Muñoz et 
al., 2009 
 
 
Samples were taken at the outlet of two large WWTPs in Spain: El Ejido (64 0000 inhabitants) and 
Alcalá (375 000 inhabitants) and processed for 12 PhCs. The plants include coarse-solid and grease 
removal, primary settling and anoxic-aerobic biological treatment with activated sludge for C and N 
removal. 
48 Nakada et 
al., 2006 
 
24-h composite samples (n =16) of the influent and secondary effluent of five conventional 
activated sludge plants serving populations ranging from 464 000 to 2 020 000 inhabitants (HRT 
from 7.1 to 9.4 h and SRT from 3.8 to 8.4 d) in Tokyo, Japan, from December 2001 and February 
2003. 10 PhCs from different classes were investigated. 
49 Paxéus, 
2004 
24-h composite flow-proportional and grab samples were taken at the inlet and secondary effluent 
of 10 different full-scale CAS systems processing domestic and industrial wastewater in different 
European countries. All feature primary settling followed by CAS. Investigations were carried out 
between February 2001 and March 2003 on 9 PhCs (n = 2-10). Effluent average concentrations are 
provided for each compound for all plant and average removal rates where possible. 
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50 Peng et al., 
2006 
Grab samples were taken at the influent and effluent of Guangzhou conventional WWTP (China, 
195 000 pe) and processed for 4 antimicrobials (sulfadiazine, sulfamethoxazole, ofloxacin and 
chloramphenicol). Average influent and effluent concentrations were provided. 
51 Quintana et 
al., 2005 
 
24-h composite samples (n = 7) were taken at the inlet and outlet of a pilot MBR plant (HRT = 8.8-
10 d; SRT = 37 d) equipped with Kubota plate membranes (0.4 µm) and fed by municipal 
wastewater in Germany. Average influent and effluent concentrations and average removal rates 
were provided for 5 PhCs (diclofenac, ketoprofen, bezafibrate, naproxen, ibuprofen) monitored 
between January and April 2004. 
52 Radjenovic 
et al., 2007 
 
24-h composite water samples were taken at the inlet and the outlet of the municipal CAS system in 
Rubi (Spain, 125 000 pe) and in a pilot MBR fed in parallel. Pretreatments consist of screening, 
gritting and primary sedimentation. Biological system includes denitrification-nitrification 
sedimentation and has SRT 3 d and HRT 12 h. MBR was equipped with Kubota flat sheet 
microfiltration membranes (0.4 µm) operating at HRT 14 h and “infinite” SRT (as no sludge was 
discharged from the reactor during the investigation period, May–June 2005). 22 selected PhCs 
were monitored, and their range of variability in the influent and the removal achieved by CAS and 
MBR were reported. 
53 Radjenovic 
et al., 2009 
 
 
24-h flow-proportional composite samples (n = 9) were taken at the influent and secondary effluent 
of the municipal conventional WWTP in Terrassa (Barcelona, Spain) and at the effluent of two pilot 
MBR plans fed in parallel after preliminary treatments and primary clarification. The full-scale 
plant serves 277 000 pe and has an average flow rate 42 000 m3/d, SRT 10 d and HRT 11.5 h. It 
consists of preliminary treatment (grit and sand removal), primary clarification and aeration, 
followed by secondary clarification. The first pilot plant is equipped with hollow-fibre ultra-
filtration membranes (nominal porosity 0.05 µm) and operates at HRT 7.2 h. The second features 
micro-filtration flat-sheet membranes (nominal porosity 0.4 µm) and operates at HRT 15 h. 
Variability ranges and average influent concentrations of 26 PhCs and their corresponding removal 
rate are given; data was collected between March and April 2007.  
54 Reif et al., 
2008 
 
The investigation carried out on a pilot MBR plant equipped with submerged hollow-fibre 
membrane module (0.04 µm) fed by synthetic water simulating domestic sewage. Its HRT is 12-24 
h and its SRT 44-72 d. Influent and permeate concentrations were sampled and processed for 9 
PhCs.  
55 Roberts and 
Thomas, 
2006 
 
24-h composite samples were taken at the influent and the effluent of Howdon WWTP (230 000 
m3/d) (UK) consisting of screening, primary clarification and CAS (SRT = 2.4 d, HRT = 12.5 h). 11 
PhCs were investigated, and average concentrations at the two sampling points and average removal 
rates are provided. 
56 Rodriguez et 
al., 2003 
 
24-h composite samples were taken at the influent and effluent of a municipal WWTP in Spain 
(serving 100 000 inhabitants) and processed for ibuprofen and naproxen between October 2001 and 
February 2002. Their influent and effluent concentrations as well as their average removal rates are 
reported. 
57 Rosal et al., 
2010 
 
The influent and secondary effluent of the 10 000 pe WWTP of Alcalà (Spain) was monitored every 
month over a year. The plant featured a traditional A2O multistage configuration with nitrification-
denitrification and enhanced simultaneously phosphorus removal. 30 PhCs were monitored. 
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58 Ruel et al., 
2010 
24-h composite water samples were taken at the influent and effluent of 6 different CAS plants 
(SRT range 13–26) in France and processed for 3 PhCs: the antibiotics roxythromycin and 
sulfamethoxazole and the antiseptic triclosan.  
59 Sahar et al., 
2011 
Water samples were taken at the raw influent of one municipal WWTP in Tel Aviv (Israel) and at 
the inlet and outlet of a municipal WWTP in Berlin (Germany) and processed for 6 antibiotics. The 
Berlin plant consists of a conventional CAS (HRT = 24 h, SRT = 9-15 d) and an MBR (HRT = 15 
h; SRT > 70 d, equipped with submerged non-woven flat sheet pillow membranes (10 µm). 
Variability ranges and average concentrations of the influents are provided, together with the 
average removal rates measured in the Berlin CAS and pilot MBR.  
60 Santos et al., 
2007 
 
24-h flow-proportional composite samples (n = 21) were taken at the inlet and secondary effluent of 
four urban full-scale CAS systems in Spain. 5 PhCs were analysed for 21 days between July and 
September 2004. The plants have nominal capacity ranges between 20 000 and 950 000 pe, HRT 
between 12 and 17 h, and SRT between 1.5-5 d. 
61 Santos et al., 
2009 
 
24-h flow-proportional composite samples (n = 63) were taken at the inlet and secondary effluent of 
two CAS systems in Spain between June 2004 and June 2005 and processed for 5 PhCs. Their 
design capacities are 350 000 pe and 950 000 pe, the corresponding operating conditions: HRT 12 h 
and 17 h and SRT 1.5 d and 2.7 d.  
62 Snyder et 
al., 2006 
 
The investigation refers to a pilot MBR equipped with ultrafiltration membranes (nominal pore size 
0.08 µm) fed by primary effluent. 12 selected PhCs were monitored at the influent of the WWTP 
and at the MBR permeate.  
63 Stumpf et 
al., 1999 
24-h composite samples were taken at the inlet and the outlet of one CAS system in Rio de Janeiro 
(Brazil) during June 1997 (n = 6) and processed for 9 PhCs (anti-inflammatories and lipid 
regulators). 
64 Suárez et al., 
2005 
Water samples were taken at the inlet and the outlet of a pilot CAS system and processed for 5 
common PhCs of different therapeutic classes. The plant operated at SRT = 60 d and HRT = 1 d. It 
includes a denitrification-nitrification sequence. 
65 Tauxe-
Wuerch et 
al., 2005 
24-h flow-proportional composite water samples were taken (n ranging between 4 and 7) at the inlet 
and outlet of three CAS systems in Berne (Switzerland, 23000 inhabitants, 9300 m3/d), Morges 
(Switzerland, 29000 inhabitants, 8500 m3/d) and Lausanne (Switzerland, 220 000 inhabitants, 
100200 m3/d). Each plant consists of a screen and sand trap, fat separator, primary clarifier and 
biological activated sludge reactor with simultaneous phosphorus chemical precipitation, and 
secondary clarifier. Variability ranges and average influent and effluent concentrations and average 
removal rates are provided for 5 PhCs. 
66 Ternes et al., 
1999 
 
24-h flow-proportional composite samples (n=6) were taken at the influent and effluent of two CAS 
systems in Frankfurt Main (German) and Penha Rio de Janeiro (Brazil) in 1997 and processed for 3 
oestrogens (estrone, 17β-estradiol, 17α-ethinylestradiol). In addition in the same periods, effluents 
of 16 municipal German WWTPs and 10 Canadian WWTPs were also investigated for the same 
PhCs. 
67 Ternes et al., 
2003 
The effluent of a conventional municipal WWTP (380 000 pe) was monitored (n = 6) and analysed 
for 18 PhCs. The plant consists of mechanical pretreatment, followed by nitrification-denitrification, 
biological phosphate removal and secondary clarification. 
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68 Ternes, 
1998 
 
 
24-h composite samples were taken at the inlet and outlet of a full scale conventional WWTP near 
Frankfurt (312 000 pe, preliminary clarification, followed by aerator tank and addition of 
Fe(II)chloride for phosphate removal and final clarification) over a period of six days covering 5 
weeks in different periods between May 1996 and November 1997. Average removal rates are 
provided for 14 PhCs.  
49 full-scale municipal treatment plants (all containing preliminary treatment, aeration tank and 
final clarification steps; 43 plants are equipped with phosphate removal, 25 plants with nitrification, 
and 13 denitrification steps) were also investigated between November 1995 and November 1997, 
and average effluent concentrations were provided for 35 PhCs. .  
69 Thomas and 
Foster, 2005 
24-h flow-and time integrated composite samples were collected at the influent and the secondary 
outlet of the urban WWTP in Arlington, VA, USA (194 000 served population) and processed for 
four analgesics/anti-inflammatories and one antiseptic. The same compounds were monitored in 
grab samples withdrawn at the influent and outlet of other two urban WWTPs (City of Alexandria 
Sanitation Authority and Noman M Cole Water Pollution Control Plant , serving a population of 
375 000 and 500 000 respectively). Each WWTP consists of preliminary treatments (bar screens 
and grit removal), primary settling, conventional activated sludge/biological nutrient removal. In 
addition phosphorus precipitation, gravity filtration and disinfection are included. 
70 Vieno et al., 
2005 
 
 
24-h composite samples were taken at the influent and effluent of Aura municipal WWTP (Finland) 
in four days between September 2003 and March 2004. The WWTP is a ditch oxidation tank, 
consisting of an activated sludge compartment (SRT 20 d and HRT 36 h) with simultaneous 
phosphorus precipitation by adding ferric salt. Average concentrations of 5 selected PhCs 
(bezafibrate, diclofenac, ketoprofen, naproxen and ibuprofen) were provided for the two sampling 
points. 
71 Vieno et al., 
2007 
 
24-h composite samples were taken at the inlet and outlet of 9 full-scale conventional municipal 
plants (SRT range 2-15 d and HRT  range 7-20 h) in Finland between 2004 and 2005 and processed 
for 7 common PhCs.  
72 Watkinson 
et al., 2007 
 
The urban influent and secondary effluent of a large CAS system (140 000 m3/d) in Brisbane, 
Australia, were monitored for the 22 most commonly administered PhCs (n = 5). Bioreactor HRT 
was 11 h and SRT 12.5 d. Pretreatments consisted of screening, gritting and primary settling. 
73 Weigel et 
al., 2006 
Samples were taken at the influent and effluent of Hamburg WWTP (Germany) in November 2002, 
and processed for 4 PhCs (ibuprofen, diclofenac, clofibric acid, triclosan).  
74 Wick et al, 
2009 
 
48-h and 72 h-composite samples were collected from the inlet and outlet of a German municipal 
WWTP in (1 350 000 pe) on 7 days in March 2007, May 2007 and July 2007 (n=9). The WWTP 
consists of a cascade of two CAS units operating under aerobic (HRT = 1 h and SRT = 0.5 d) and 
anoxic-aerobic conditions (HRT =5 h and SRT  =18 d), respectively. Pretreatments include screen, 
aerated grit-removal tank and primary clarifier. The second biological step includes simultaneous 
phosphate precipitation. 11 PhCs (beta-blockers and psychiatric drugs) were monitored. 
75 Xu et al., 
2007 
 
24-h composite water samples were taken at the inlet and effluent of the CAS system in New 
Territory (Hong Kong) and processed for 5 PhCs (n = 6). The plant serves 300 000 inhabitants and 
operates at HRT = 15-22 h and SRT = 5.6-8.2 d. It consists of preliminary treatments (screening, 
aerated gritting), primary clarifier and biological treatment, including denitrification-nitrification 
sequence. Sampling and analysis were performed in October 2005. 
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76 Yasojima et 
al., 2006 
 
24-hour flow-proportional composite samples were taken at the inlet and the outlet of six full-scale 
CAS systems in Japan and processed for two antimicrobials (clarythromycin and azythromycin). 
Their HRT range between 4 and12 h and their SRT 5-9 d.  
77 Yu et al., 
2006 
 
 
24-h composite samples were taken at the inlet and the effluent of the Baltimore WWTP that 
receives about 8.5x105 m3/d of residential and urban wastewaters. The plant is a CAS system (SRT 
= 8-10 d) designed for biological nutrient removal. 10 between pharmaceuticals and antiseptics 
were monitored. 
78 Zorita et al., 
2009 
 
24-h composite samples were collected from the inlet and outlet of the municipal WWTP in 
Kristianstad (Sweden, 150 000 inhabitants, HRT range 24 –40 h and SRT roughly 8 d) in June 2007 
and April 2008 (n = 3) and processed for 12 PhCs. Pretreatments include screening, aerated grit 
removal and primary sedimentation, the biological section includes denitrification-nitrification. 
 
2.9 Occurrence of PhCs in raw urban wastewaters (UWWs) 
Literature data referring to the concentrations of PhCs, grouped in alphabetic order in 
their therapeutic classes, in the raw influent to a municipal WWTP are reported in Figures 
2.3.-2.8. The average of the considered data is shown in brackets after the name of each 
compound on the X-axis. Influent data was not available for some compounds, for example 
the analgesic aminopyrine, but these are nevertheless included in the graphs as data 
referring to their secondary effluent concentrations and/or removal efficiencies were 
available.  
Referring to Fig. 2.3., the variability of analgesics/anti-inflammatories was found to 
range between 0.0016 and 373 µg/L. The most commonly investigated compounds were 
ibuprofen, diclofenac, naproxen and ketoprofen. Ibuprofen was the compound with the 
highest registered absolute influent concentration (373 µg/L), followed by acetaminophen 
(246 µg/L), tramadol (86 µg/L) and naproxen (53 µg/L). Acetaminophen and ibuprofen 
also had the highest average influent concentrations (respectively 38 µg/L and 37 µg/L), 
followed by tramadol (32 µg/L).  
As to Fig. 2.4., the range of variability of antibiotic concentrations was between 
0.001 and 32 µg/L. The most commonly investigated compounds were trimethoprim, 
sulfamethoxazole, erythromycin and ciprofloxacin. The highest absolute concentrations 
were found for ofloxacin (32 µg/L), roxithromycin (17 µg/L) and ciprofloxacin (14 µg/L). 
Other antibiotics exhibiting measured concentrations greater than 10 µg/L are: 
sulfapyridine (12.4 µg/L), trimethoprim (10.5 µg/L) and erythromycin (10.2 µg/L). The 
highest average antibiotic concentrations were found for ofloxacin and sulfadiazine (5.1 
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µg/L), followed by sulfapyridine (3.3 µg/L) and cefalexim (3.2 µg/L). No data were 
provided for enoxacin, lomefloxacin and spiramycin concentrations in the raw urban 
wastewater. 
 
 
Figure 2.3. Concentration of selected analgesics/anti-inflammatories measured in the raw influent to 
municipal WWTP (o refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
 
Figure 2.4. Concentrations of selected antibiotics measured in the raw influent to municipal WWTPs (o 
refers to CAS and x to MBR) and corresponding average values (in brackets). 
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Fig. 2.5. reports data for six, less investigated, classes, comprising 20 compounds; 
indeed, only one antifungal, barbiturate and antidiabetic were reported. The observed 
ranges of variability were: 0.12-16 µg/L for antidiabetics, 0.0025-10 µg/L for 
antihypertensives, 0.006-25 for beta-blockers, 0.004-6 for diuretics. The single values 
found for the antifungal and barbiturate were respectively: 0.029 µg/L (clotrimazole) and 
0.07 µg/L (phenobarbital). The highest concentrations were found for the beta-blocker 
atenolol (25 µg/L), followed by the antidiabetic glibenclamide (16 µg/L) and the 
antihypertensive hydrochlorothiazide (10 µg/L). The highest average concentrations were 
found for glibenclamide (8.7 µg/L), followed by atenolol (4.5 µg/L), hydrochlorotiazide 
(3.9 µg/L) and furosemide (2.4 µg/L). 
 
Raw urban wastewater concentration data were unavailable for five out of the 12 
beta-blockers and the antihypertensive enalapril. The data spread within the observed 
variability range was the greatest for diltiazem, another antihypertensive. 
 
Figure 2.5. Concentrations of selected PhCs belonging to six therapeutic classes measured in the raw influent 
to municipal WWTPs (o refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
Referring to Fig.2.6., the variability for the selected lipid regulators was found to 
range between 0.001 and 30 µg/L, and for psychiatric drugs between 0.0025 and 25 µg/L. 
In the former class, the most commonly detected compounds were bezafibrate, gemfibrozil 
and clofibric acid, in the second one carbamazepine and fluoxetine. The highest absolute 
concentrations were found for bezafibrate (30 µg/L), gabapentin (25 µg/L), diazepam (23 
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µg/L), carbamazepine (22 µg/L) and gemfibrozil (17 µg/L), whereas the highest average 
concentrations were found for diazepam (22 µg/L), gabapentin (13 µg/L), bezafibrate (3.5 
µg/L) and amitriptyline (3.1 µg/L). Only one datum are present for paroxetine (0.0016 
µg/L) as well as for valproic acid (0.0014 µg/L). Data are not available for the lipid 
regulators clofibrate, etofibrate and fenofibrate, or for the psychiatric drug lorazepam.  
 
Figure 2.6. Concentrations of selected lipid regulators and psychiatric drugs measured in the raw influent to 
municipal WWTPs (o refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
As to Fig. 2.7., the variability range of selected receptor antagonists was between 
0.014 and 11 µg/L, and that of hormones between 0.002-3 µg/L. The most frequently 
detected compounds were the four hormones (estrone, estradiol, ethinylestradiol and 
estriol) and cimetidine. The highest absolute concentrations were found for ranitidine (11 
µg/L) and cimetidine (10 µg/L), while the highest average values were found for 
cimetidine (4.1 µg/L), ranitidine (2.7 µg/L) and valsartan (2.5 µg/L). Among the four 
hormones included in this study, the estradiol presented the highest absolute concentration 
(3 µg/L) as well as the highest average observed value (0.25 µg/L). 
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Figure 2.7. Concentrations of selected receptor antagonists and hormones measured in the raw influent to 
municipal WWTPs (o refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
Fig. 2.8. reports data pertaining to 5 classes, three of which (topical products, 
antiseptics and contrast media) feature only one investigated compound. Out of the four 
beta-agonists under review, only one (salbutamol) exhibits values of influent 
concentrations and, out of the three antineoplastics, only two compounds were found 
(ifosfamide and tamoxifen). The observed ranges of variability are: 0.05-0.15 µg/L for 
beta-agonists, 0.019-0.36 µg/L for antineoplastics, 0.38-3 µg/L for the topical product 
crotamiton, 0.22-7 µg/L for the antiseptic triclosan and 0.01-6.6 µg/L for the contrast agent 
iopromide. The highest absolute concentrations were found for triclosan (7 µg/L) and 
iopromide (6.6 µg/L). The highest average concentrations were found for iopromide (2.2 
µg/L) and triclosan (1.9 µg/L).  
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Figure 2.8. Concentrations of other classes of micropollutants measured in the raw influent to municipal 
WWTPs (o refers to CAS and x to MBR) and their corresponding average values (in brackets). 
 
2.10 Occurrence of PhCs in secondary biological effluents 
Figures 2.9.-2.14. refer to the concentrations of PhCs detected in the effluent of the 
WWTPs included in this study. As reported in Table 2.3., these generally consist of 
preliminary treatments (bar screening and grit removal), primary sedimentation and 
secondary biological suspended mass reactor, i.e. CAS (with different configurations, quite 
often including an anoxic-aerobic reactor and sometimes with a simultaneous precipitation 
of phosphate), followed by a secondary settler or an advanced MBR with anoxic-aerobic 
compartments. As reported above, in the X-axis of the figures 2.9.-2.14., average 
concentrations are reported alongside each compound in brackets. 
Referring to Fig. 2.9., concentrations of analgesics/anti-inflammatories in the 
secondary effluent ranged between 0.001 and 57 µg/L. The most frequently detected 
compounds were ibuprofen, diclofenac, naproxen, ketoprofen and acetaminophen. The 
highest absolute concentrations were found for tramadol (57 µg/L), ibuprofen (48 µg/L) 
and diclofenac (11 µg/L), and the highest average values were found for tramadol (20 
µg/L), dipyrone (4.9) and ibuprofen (3.6 µg/L). 
Fig. 2.10. shows that, the range of variability for selected antibiotics in the 
secondary effluent was 0.001-6.7 µg/L. The most investigated compounds were 
trimethoprim, sulfamethoxazole, erythromycin, ciprofloxacin and norfloxacin. The highest 
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absolute concentrations were found for trimethoprim (6.7 µg/L), erythromycin (6.3 µg/L), 
ciprofloxacin (5.7 µg/L), sulfamethoxazole and roxithromycin (5 µg/L), while the highest 
average values were found for ciprofloxacin (0.86 µg/L), erythromycin (0.73 µg/L), 
roxithromycin (0.50 µg/L) and ofloxacin (0.45 µg/L). 
 
Figure 2.9. Concentration of selected analgesics/anti-inflammatories measured in the secondary effluent (o 
refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
Figure 2.10. Concentration of selected antibiotics measured in secondary effluent (o refers to CAS and x to 
MBR) and corresponding average values (in brackets). 
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Referring to Fig. 2.11., two classes (antidiabetics and barbiturates), represented by 
only one compound, were never detected in any investigation. The range of variability for 
antihypertensives was 0.0025 to 11 µg/L, beta-blockers were detected between 0.005 and 
73 µg/L, and diuretics between 0.004 and 1.8 µg/L. The most commonly detected 
compounds were the beta-blockers atenolol, metoprolol and propranolol and the 
antihypertensive diltiazem. The antifungal clotrimazole was found only once, while data 
are not available for the antihypertensive enalapril. The highest absolute concentrations in 
these classes were found for atenolol (73 µg/L), hydrochlorothiazide (11 µg/L) and 
furosemide (1.8 µg/L). The same compounds exhibited the highest average concentrations: 
atenolol 3.7 µg/L, hydrochlorothiazide 3.3 µg/L and furosemide 0.66 µg/L. It is worth 
remarking that the average concentration of all the other compounds remained less than 1 
µg/L. 
 
 
Figure2.11. Concentrations of selected PhCs from different classes measured in secondary biological effluent 
(o refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
As shown in Fig. 2.12., the range of variability observed in the secondary effluent 
was 0.0015-80 µg/L for lipid regulators and 0.001- 20 µg/L for psychiatric drugs. The 
most frequently investigated compounds were carbamazepine, gemfibrozil, bezafibrate and 
clofibric acid. Data were unavailable for oxcarbazepine and valproic acid. The highest 
absolute concentrations were found for fenofibric acid (80 µg/L), carbamazepine (20 
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µg/L), diazepam (19 µg/L) and gemfibrozil (5.2 µg/L), while the highest average 
concentrations were found for fenofibric acid (11 µg/L), diazepam (9.1 µg/L), gabapentin 
(2.6 µg/L) and carbamazepine (1.04 µg/L). All the other compounds had average values 
less than 1 µg/L. It is worth noting that the variability ranges are quite wide for most 
compounds: up to 5 orders of magnitude for carbamazepine. 
 
Figure2.12. Concentrations of selected lipid regulators and psychiatric drugs measured in secondary 
biological effluent (o refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
As to Fig. 2.13., the range of variability observed after the secondary treatment was 
0.006-7.8 µg/L for receptor antagonists and 0.0002-0.11 µg/L for hormones. The most 
commonly investigated compounds were estrone, estradiol, ethinylestradiol and 
cimetidine. The highest absolute and average concentrations were found for cimetidine 
(7.8 µg/L and 3.5 µg/L, respectively), which was the only receptor antagonist found with 
an average concentration greater  than 1 µg/L; famotidine and loratidine were never 
detected in the effluent. Hormones were found at consistently lower concentrations, always 
lower than 0.11 µg/L.  
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Figure 2.13. Concentrations of receptor antagonists and hormones measured in secondary biological effluent 
(o refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
Finally, the graph in Fig. 2.14. shows that the ranges of variability were 0.01-0.17 
µg/L for beta-agonists, 0.002-2.9 µg/L for antineoplastics, 0.25-0.97 µg/L for topical 
products, 0.005-2.5 µg/L for antiseptics and 0.01-9.3 µg/L for contrast media. The most 
investigated compound was triclosan, while the others were monitored at a far lower 
frequency. Iopromide showed both the highest measured (9.3 µg/L) and the highest 
average concentration (2.5 µg/L). 
 
Ci
m
et
id
in
e
(3.
5)
Fa
m
ot
id
in
e
(--
-
)
Lo
ra
ta
di
ne
(--
-
)
O
m
ep
ra
zo
le
(0.
63
)
Ra
ni
tid
in
e
(0.
51
)
Va
ls
ar
ta
n
(0.
33
)
Es
tra
di
ol
(0.
01
)
Es
tri
ol
(0.
01
6)
Es
tro
ne
 
(0.
03
)
Et
hi
ny
le
st
ra
di
ol
(0.
00
3)
Co
n
ce
n
tr
at
io
n
, 
µµ µµg
/L
10-1
1
10
10-2
10-3
10-4
K Receptor antagonists L Hormones
Chapter 2: Background 
 
50 
 
 
Figure 2.14. Concentrations of other classes of micropollutants measured in secondary biological effluent (o 
refers to CAS and x to MBR) and corresponding average values (in brackets). 
 
Figure 2.15. summarizes the range of variabilities of the different classes based on 
collected data for the influent and effluent of all CAS (244 plants) and MBRs (20 plants). 
At the bottom of the figure, a table reports the number of collected data for each class in 
the influent and effluent of all the CAS (circle) and MBRs (cross) under study. It is 
important to remark that data pertaining to MBRs are quite limited and these systems were 
always pilot plants. 
A rapid glance at these intervals shows that the different classes have different 
trends. In fact, the range of variability of measured concentrations in secondary effluents is 
narrower and lower than in the influent for analgesics/anti-inflammatories (A), antibiotics 
(B), antifungal (D), diuretics (H), psychiatric drugs (J), receptor antagonists (K), hormones 
(L), topical products (O) and antiseptics (P), being quite similar for antihypertensives (E) 
and beta-agonists (M), but higher for beta-blockers (G), lipid regulators (I), antineoplastics 
(N) and contrast media (Q). For antidiabetics (C), and barbiturates (F) the comparison is 
not possible as data are not available for the effluent. Moreover, ranges of variability 
referring to MBR permeates are narrower than those referring to CAS effluents for all of 
the investigated classes. 
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Figure 2.15. Comparison between the ranges of variability for the selected classes in the influent and effluent 
of all the CAS and MBRs under study. 
 
2.11 Observed removal efficiencies in WWTPs 
Figures 2.16.-2.20. report the observed removal efficiencies of PhCs from the 
aqueous phase achieved after secondary biological treatment in the WWTPs under study. 
These data are directly provided by listed references, in some cases, when it was possible, 
they were estimated by eq. 2.1, assuming a constant WWTP influent and effluent flow rate, 
equal to the average daily flow rate and as influent and effluent concentrations their 
corresponding average daily values (based on 24-h composite water samples). In the 
Appendix A-4 it is possible to distinguish between removal data provided by the Authors 
and those evaluated by means of eq. 2.1: 
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η is the percentage removal efficiency and c is the average PhC concentration measured in 
the raw influent (subscript inf) or secondary effluent (subscript eff). As stated in Table 2.3., 
almost all the plants investigated include preliminary and primary treatments. As a 
consequence, η refers to the overall WWTP removal efficiency and takes into 
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preliminary and primary treatments, and a combination of 
biodegradation/biotransformation due to suspended biomass and sorption onto particles, 
flocs and then sludge in biological processes.  
 
According to many Authors (Khan and Ongerth, 2005; Ternes and Joss, 2006; 
Yasojima et al., 2006; Watkinson et al., 2007; Zorita et al., 2009), the efficacy in removing 
PhCs by preliminary and primary treatments is in general quite poor, and in some cases 
compounds may even be released during the process, probably caused by the simultaneous 
presence of deconjugable substances, that is human metabolites, of these compounds in the 
raw influent (Carballa et al., 2004, Göbel et al., 2005). In particular, in the pre-treatment 
and sedimentation step no significant reduction was found for ibuprofen and naproxen 
(Carballa et al, 2004). This can be correlated to their acidic structures (negative charge of 
the molecule at pH 7, as shown in Appendix A.1., with very low solid-liquid partition 
coefficient Kd (according to Ternes et al., 2004, Kd < 500 L/kg or Log Kd < 2.7 implies 
very poor sorption onto sludge) which results in their presence mainly in the aqueous 
phase. For the hormone estrone, a higher concentration was observed at the end of the 
primary sedimentation with respect to the influent (Carballa et al., 2004), very likely due to 
the oxidation of the estradiol present, which explains the high negative removal 
efficiencies obtained for the estrone and the positive reduction of estradiol. (This is quite 
important to remember for the next sections as if the compound is found at a lower 
concentration in the secondary effluent than in the raw influent, the biological treatment is 
generally the greatest contributor).  
As remarked above, biodegradation/biotransformation and sorption are the two 
main mechanisms occurring in the biological reactor, volatilization being quite scarce. The 
constant Kd and kbiol reported in Appendix A.1. may provide some first simple information 
on the potential behaviour of a compound during treatment, but, as it will be discussed in 
the following, it is quite complex to describe its real removal mechanisms. 
Sorption on the sludge is a mechanism depending on many factors, including pH, 
redox potential, stereochemical structure and chemical nature of both the sorbent and the 
sorbed molecule (Kümmerer 2009b). It may occur by means of: (i) absorption due to 
hydrophobic interactions of the aliphatic and aromatic groups of a compound with the 
lipophilic cell membrane of the microorganisms or the lipid fractions of the suspended 
solids and (ii) adsorption due to electrostatic interactions of positively charged groups of 
chemicals with the negatively charhed surfaces of the microorganisms.  
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Biodegradation processes are strictly correlated to the characteristics of the 
biomass, the compounds (often quite persistent), the plant configuration and operation 
paramaters, in this case, in particular CAS and MBR. Apart from the final liquid/sludge 
separation stage, obtained by means of (ultrafiltration or microfiltration) membranes in 
MBR and sedimentation in CAS, these systems are mainly distinguished by their SRT, 
which is generally longer for MBR (15-80 d) with respect to CAS (7-20 d), as well as by 
their biomass concentration, generally higher in the MBR than in the CAS (8-10 kg/m3 in 
MBRs and 3-5 kg/m3 in CAS. Unfortunately these data were not always provided in the 
papers included in Table 2.3., hence the commonest operating values are reported). In 
order to better evidence the removal efficiencies achieved by both systems, at the bottom 
of each of Figures 2.16.-2.20. a table reports the average percentage removal achieved by 
CAS and MBR for each compound. It is important to remark again, that in any case, a 
comparison between these data has to consider that only 20 MBRs are included in the 
review (against 244 CAS), and they are always pilot plants, (against only 2 pilot CAS and 
242 full scale plants) and finally a limited number of PhC concentration is available (and 
collected) for MBRs with respect to CAS. 
Occasionally, negative removal efficiencies were found. These are not reported in 
the graphs of Figures 2.16.-2.20., but PhCs, with at least one negative percentage removal, 
are indicated with an asterisk and values are reported below the legend. While in some 
substances this phenomenon is clearly ascribable either to the presence of deconjugates 
interfering with biological transformation of the deconjugated compounds or to the release 
of PhC sorbed onto the particulate dissolving after the biological treatment, in others 
further investigation is required. Moreover, it is important to note that at the low level of 
concentrations found for some PhCs in the influent as well as in the secondary effluent, 
instrumental errors may lead to “apparent” releases of the investigated substance rather 
than a neglectable removal during the passage through the treatment plant. Sampling 
variation may also have contributed to this negative removal, as reported by Clara et al. 
(2005b), where the collection of effluent samples does not time-adjusted to account for 
long HRTs. Collecting composite samples over a period longer than plant HRT may 
improve the comparability between influent and effluent (Roberts and Thomas, 2006). 
Generally analysis were performed on influent and effluent water samples averaged over 
24 h, a period higher than the corresponding WWTP HRT (Table 2.3.). 
Fig. 2.16. reports the removal efficiencies for 18 out of 25 analgesics/anti-inflammatories 
in CAS and 9 out of 25 in MBR. The average percentage removals vary between 23 % 
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(tramadol) and 99 % (salicylic acid) in CAS, and between 43 % (indomethacin) and 99 % 
(acetaminophen) in MBR. For compounds investigated in both systems, MBR always 
exhibited a higher removal capacity than CAS. The graph shows that 12 compounds 
exhibited at least one value of their percentage removals in the range 90 – 100 % (5-
aminosalycilic acid, acetaminophen, acetylsalycic acid, codeine, diclofenac, fenoprofen, 
hydrocodone, ibuprofen, ketoprofen, mefenamic acid, naproxen and salicylic acid). 
Values lower than 10 % were found for five substances: diclofenac, ibuprofen, 
indomethacine, ketoprofen, mefenamic acid and tramadol. It is quite interesting to observe 
that some PhCs (diclofenac, ketoprofen, mefenamic acid) exhibited a wide range of 
variability in their removal by secondary treatments. According to Ziylan and Ince (2011), 
higher removal efficiencies of analgesics and anti-inflammatories are achieved at longer 
HRT and SRT, in reactors including nitrification and denitrification steps, at higher 
temperature. pH is another significant parameter especially for those compounds 
characterized by an increasing water-sludge partition coefficient and elevated acidity 
(acetaminophen, salicylic acid and ibuprofen).  
In addition, negative removal efficiencies were observed for diclofenac and 
ibuprofen. Possible release of diclofenac can be explained by deconjugation of 
glucoronidated or sulphated diclofenac (Kimura et al., 2005) or its desorption from 
particles (Zorita et al., 2009). Ibuprofen is largely (90 %) transformed to its hydroxyl and 
carboxy derivatives that may later be hydrolyzed and converted to the parent compounds 
(Ziylan and Ince, 2011; Roberts and Thomas, 2006). 
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Figure 2.16. Percentage removal rates for analgesics/anti-inflammatories in WWTPs, and corresponding 
average values for CAS (o) and MBR (x). 
 
Fig. 2.17. shows the removal efficiency variability for 29 antibiotics in CAS and 10 
in MBR out of 37 reviewed substances. The most investigated compounds are 
sulfamethoxazole, trimethoprim, ciprofloxacin, roxithromycin, norfloxacin and 
erythromycin. Their ranges of variability are generally wide. The corresponding average 
values vary between 0 % (spiramycin) and 98 % (cefachlor) in CAS and between 15 % 
(azithromycin) and 94 % (ofloxacin) in MBRs. Only one (azithromycin) out of 10 
compounds investigated in both systems featured higher average removal efficiencies in 
CAS than in MBR. 
Antibiotic release was observed for nine compounds. For some of them the 
phenomenon has been investigated whereas for other it is not completely clear. Referring 
to clindamycin, very low concentrations (0.002-0.005 ng/L) were detected in the influent 
and effluent and possible instrumental errors may influence the evaluation of the negative 
removal efficiency (Watkinson et al., 2007). As to the two sulphonamides 
sulfamethoxazole and sulfasalazine, their main metabolites entering the sewage are 
biologically inactive N4-acetylated products and may retransform back to the intial parent 
compound (Göbel et al., 2007).  
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The presence of de-conjugable metabolites seems unlikely for the macrolides 
erythromycin and roxithromycin. Since they are mainly excreted with bile and feces, they 
are probably partly enclosed in feces particles and released during biological treatment. 
The load entering biological treatment is therefore underestimated, taking only in 
consideration the dissolved fraction and sorption to the suspended solids (Göbel et al., 
2007). According to Lindberg et al. (2005), the increment in the effluent concentrations for 
trimethoprim can be explained by an underestimation of the actual amount entering the 
WWTP due to particulate matter with adsorbed antibiotics being filtered out during sample 
preparation. Higher concentration of ciprofloxacin, tetracycline and norfloxacin in the 
secondary effluent rather than the raw influent could be ascribed to a change in the 
adsorption behavior of the analytes to particles during treatment processes, influencing the 
ratio between influent and effluent (Gulkowska et al., 2008, Plósz et al., 2010). 
 
Figure 2.17. Percentage removal rates of antibiotics in WWTPs and corresponding average values for CAS 
(o) and MBR (x). 
 
Fig. 2.18. refers to twenty PhCs from six classes, but data are available only for 
fourteen, all of which were investigated in CAS and six in MBRs. Five compounds were 
only reported in one study (clotrimazole, enalapril, phenobarbital, acetobutol and 
bisoprolol), while more data, spread over quite wide ranges, were available for the 
remaining compounds. For compounds investigated in both systems, the average removal 
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efficiencies are consistently higher in MBR than in CAS, except in the case of 
hydrochlorothiazide (45 % in CAS and 25 % in MBR).  
Fig. 2.19. refers to the removal efficiencies obtained for selected lipid regulators 
and psychiatric drugs; the most investigated compounds were: bezafibrate, gemfibrozil, 
clofibric acid, pravastatin in the former group and carbamazepine and fluoxetine in the 
latter. Only one data set is available for fenofibrate, simvastatin, amitriptlyne, 
norfluoxetine and valproic acid in CAS and for paroxetine in CAS and MBR. No removal 
data were provided for clofibrate, etofibrate, lorazepam and oxcarbazepine, and few data 
sets were provided for the remaining compounds (fenofibric acid and gabapentin).For the 
most frequently investigated pharmaceuticals, the removal efficiencies variability ranges 
are generally quite wide, but, in general, higher removal efficiencies were achieved by 
MBRs except in the case of carbamazepine, which exhibited similar (low) average values 
in the two systems. This compound is not only one of the most persistent, but it can also be 
released in the WWTP, as shown in the data reported below the graph, presumably due to 
enzymatic cleavage of its glucuronic conjugate and release of the parent compound in the 
effluent (Radjenovic et al., 2007; Vieno et al., 2007). 
 
Figure 2.18. Percentage removal rates for some PhCs from different therapeutic classes in WWTPs, and 
corresponding average values for CAS (o) and MBR (x). 
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Figure 2.19. Percentage removal rates of selected lipid regulators and psychiatric drugs (o refers to CAS and 
x to MBR). 
 
Fig. 2.20. refers to receptor antagonists and hormones; more data is available for 
the latter. Removal efficiencies for receptor antagonists were lower than 80 %, with the 
exception of ranitidine and valsartan, and average values were between 50-60 %, with a 
few exceptions: valsartan (84 % in CAS), loratadine (15 % in CAS and 19 % in MBR) and 
omeoprazol (9 % in CAS). In contrast, observed removal efficiencies for hormones were 
consistently higher, on average between 67 % and 80 % in CAS and 60 % and 99 % in 
MBRs. Estradiol is the compound most removed (on average 80 % in CAS and 99 % in 
MBR). However, negative removals of estrone were observed in CAS in several 
investigations, the assumption being that this is produced in the sewage treatment system 
by the oxidation of estradiol and by partial deconjugation of other estrogens present in the 
wastewater (D’Ascenzo et al., 2003). 
Very few data are reported for the removal of the compounds belonging to the 
classes M-Q (Fig. 2.20.). A wide range was observed for the removal of salbutamol (0-98 
%) and a slightly smaller one (21-65 %) for clotamitron. Triclosan is removed to a greater 
extent, even exceeding 98 % in both CAS and MBR, and its average removal efficiency is 
quite high (76 % in CAS and 99 % in MBR). Iopromide, on the other hand, was scarcely 
removed by biological processes, and in some investigations it was found to be released, as 
shown by the data reported below the graph. Its persistence is due to the fact that, as a 
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diagnostic agent, it is designed to be highly stable. No reasonable justification for the 
increasing of iopromide concentrations within the WWTP could be identified, according to 
Clara et al., (2005b). As to crotamiton, its releases can be explained by breakdown of 
conjugates of the pharmaceutical (Nakada et al., 2006). 
  
Figure 2.20. Percentage removal rates for selected receptor antagonists, hormones another PhCs, and 
corresponding average removal rates in CAS (o) and MBR(x). 
 
All the data reported in the graphs above refer to PhC removal from aqueous phase, 
as defined by eq.2.1: in this way, attention is paid to the WWTP influent and effluent 
quality in order to evaluate how efficient is a specific treatment plant in retaining the 
selected compounds from the aqueous phase, without distinguishing between sorption onto 
sludge (hence transfer to another phase) and/or biological degradation/transformation 
processes. Sometimes it may be also called “apparent removal”.  
Another approach in evaluating PhC removal efficiencies considers the WWTP as a 
black box with one entrance (influent) and two outputs (liquid effluent and sludge). In this 
case, the removal efficiency, also called overall removal, ηoverall is evaluated through 
equation 2.2: 
( )
100xQc
PcQcQc
inf
sludgesludgeeffinf
overall
+−
=η
       (eq. 2.2)
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In eq. 2.2, csludge is the concentration of the selected PhC in the treated sludge (ng/g) and 
Psludge is the daily sludge production for the plant under examination (g/d). Influent and 
effluent flow rates are assumed constant and equal to Q. The numerator represents the 
mass load of the selected PhC, subjected to biological reactions.  
Few Authors investigated these two mechanisms in details, providing sorption and 
biodegradation contributions to the overall removal based on liquid and sludge 
concentration, influent and effluent flow rates and sludge production collected on full scale 
plants. Table 2.4. compiles these findings available only for some of the selected 
compounds with the corresponding references. 
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Table 2.4. Fractions with respect to the influent mass load of selected PhCs removed during secondary biological treatment, sorbed to sludge and 
discharged with secondary effluent. Data with a star as apex refer to MBR systems 
Therapeutic class Compound Sludge age 
[d] 
Biolog transform  
% 
Sorption onto sludge  
% 
Effluent 
% 
References 
Analgesic and anti-inflammatories 
A 
Diclofenac 
4-60 
6 
16 
<20 
>50 
5-45 
25 
10 
5 
10-30 
<5 
<5 
5 
0 
0 
55-95 
70-75 
85 
95 
70-90 
Joss et al.,2005 
Jelic et al., 2011 
Jelic et al., 2011 
Suarez et al., 2010 
Suarez et al., 2010 
Ibuprofen 
4-60 
2 
10-55* 
<20 
>50 
90-100 
<5 
95-100 
35-40 
95 
<5 
<5 
<5 
0 
0 
0-10 
95-100 
0-5 
60-65 
5 
Joss et al.,2005 
Clara et al., 2005b 
Clara et al., 2005b 
Suarez et al., 2010 
Suarez et al., 2010 
Indomethacin 6 16 
27 
40 
0 
<5 
73 
58-60 Jelic et al., 2011 
Ketoprofen 6 16 
70 
<95 
0 
 
30 
5-10 Jelic et al., 2011 
Mefenamic acid 6 16 
65 
55-58 
7 
<30 
28 
<20 Jelic et al., 2011 
Naproxen 
10-30 
6 
16 
<20 
>50 
55-85 
77 
95-98 
5 
85-90 
<5 
0 
0 
0 
15-45 
23 
<5 
95 
10-15 
Joss et al.,2005 
Jelic et al.2011 
Jelic et al., 2011 
Suarez et al., 2010 
Suarez et al., 2010 
Antibiotics 
B 
Azithromycin 10-30 < 40  < 10 60-90 Gobel et al., 2007 
Chloramphenicol 6 0 0 100 Jelic et al., 2011 
Ciprofloxacin 10-12 20 
< 10 
< 10 
70-80 
77 
≤30 
<4 
Golet et al., 2003 
Lindberg et al., 2006 
Clarithromycin 
< 20 
>50 
<20 
6 
16 
< 10 
90 
<10 
0 
0 
< 5 
<5 
≤10 
18 
<45 
75-90 
10 
>90 
82 
55-60 
Gobel et al., 2007 
Gobel et al., 2007 
Gobel et al., 2007 
Jelic et al., 2011 
Jelic et al., 2011 
Enrofloxacin 20-25 19 65 17 Jia et al., 2012 
Erythromycin <20 20  80 Suarez et al., 2010 
Lomefloxacin 20-25  60 40 Jia et al., 2010 
Metronidazole 6 16 
 
15-18  
100 
82-85 Jelic et al., 2011 
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Therapeutic class Compound Sludge age 
[d] 
Biolog transform  
% 
Sorption onto sludge  
% 
Effluent 
% 
References 
Norfloxacin 10-12 20 
< 10 
< 10 
80-90 
72 
≤ 20 
< 4 
Golet et al., 2003 
Lindberg et al., 2006 
Ofloxacin 20-25  60 40 Jia et al., 2012 
Roxithromycin 4-30 
<20 
< 60 
18 
< 5 
2 
>35 
80 
Gobel et al., 2007 
Suarez et al., 2010 
Sulfamethazine 6 16 
<85 
15-18 
0 
20 
<20 
60-65 Jelic et al., 2011 
Sulfamethoxazole 4-12 
<20 
50-90 
20 
< 5 
0 
10-50 
80 
Gobel et al., 2007 
Suarez et al., 2010 
Sulfapyridine 10-30 ≤ 70 < 10 ≥30 Gobel et al., 2007 
Trimethoprim 
<50 
<20 
6 
16 
<20 
~90 
<10 
40 
38-40 
18 
≤5 
≤5 
< 5 
5-10 
 
~10 
>90 
< 60 
50-55 
72 
Gobel et al., 2007 
Gobel et al., 2007 
Jelic et al., 2011 
Jelic et al., 2011 
Suarez et al., 2010 
Antidiabetics  
C Glibenclamide 
6 
16  
<10 
60 
90-95 
40 Jelic et al., 2011 
Antihypertensives 
E Enalapril 
6 
16 
95-98 
95-98  
2-5 
2-5 Jelic et al., 2011 
Hydrochlorothiazide 6 16  
100 
100  Jelic et al., 2011 
Beta-blockers  
G 
Atenolol 6 < 70 < 5 < 35 Jelic et al., 2011 
Metoprolol 6 16 
~35 
0 
0 
0 
~65 
100 Jelic et al., 2011 
Nadolol 6 16 
35-40 
70 
<5 
30 60 Jelic et al., 2011 
Sotalol 6 16 
10 
<50 
< 5 
<5 
< 90 
50 Jelic et al., 2011 
Timolol 6 16 
< 40 
40-45 
<5 
0 
< 65 
55-60 Jelic et al., 2011 
Diuretics  
H Furosemide 
6 
16 
35-40 
75-80 
<5 
2-5 
60-65 
20 Jelic et al., 2011 
Lipid regulators 
 I Bezafibrate 
6 
16 
2 
12 
<80 
45-50 
2 
<5 
<5 
86 
20-25 
50 
Jelic et al., 2011 
Jelic et al., 2011 
Clara et al., 2005b 
Fenofibrate 6 16 
0 
25-30 
100 
65-70 0 Jelic et al., 2011 
Gemfibrozil 6 16 
0 
90 
3 
<5 
97 
5-10 
Jelic et al., 2011 
Jelic et al., 2011 
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Therapeutic class Compound Sludge age 
[d] 
Biolog transform  
% 
Sorption onto sludge  
% 
Effluent 
% 
References 
Pravastatin 6 16 
45 
62 
0 
2 
55 
<40 Jelic et al., 2011 
Psychiatric drugs 
 J Carbamazepine 
4-60 
6 
16 
<40 
22 
0 
<5 
3 
5 
>60 
75 
95 
Joss et al., 2006 
Jelic et al., 2011 
Jelic et al., 2011 
Diazepam 6 16 
0 
 
42 
65 
58 
35 Jelic et al., 2011 
Fluoxetine <20 
>50 
80 
90 
0 
0 
20 
10 
Suarez et al., 2010 
Suarez et al., 2010 
Lorazepam 6 16 
30 
30 
<5 
5-8 
65-70 
65 Jelic et al., 2011 
Receptor antagonists  
K Cimetidine 
6 
16 
42 
60 
4 
5-8 
54 
32-35 Jelic et al., 2011 
Famotidine 6 16 
< 10 
80 
10 
20 
85 
0 Jelic et al., 2011 
Ranitidine 6 16 
< 20 
75 
< 5 
<5 
80 
20-25 Jelic et al., 2011 
Hormones 
 L 
Estradiol 10-30 85-99 <5 <15 Joss et al., 2004 
Estrone 10-30 35-97 ≤5 5-60 Joss et al., 2004 
Ethinylestradiol 
10-30 
<20 
>50 
45-95 
25 
80-90 
≤5 
5 
0 
5-50 
70 
10-20 
Joss et al., 2004 
Suarez et al., 2010 
Suarez et al., 2010 
Beta-agonist  
M Salbutamol 
6 
16 
<60 
40-42 
<5 
2 
<45 
55-60 Jelic et al., 2011 
Contrast agent  
Q Iopromide 10-30 20-95 <5 5-80 Joss et al.,2005 
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A rapid glance to the data compiled in Table 2.4. shows that sorption onto activated 
sludge is of minor importance for most of the selected PhCs: due to their hydrophilic 
characteristics (Log Kow < 2.5 high hydrophilic compound, see Appendix A.1.), their 
sorption removal keeps quite low (< 20 %). According to a simple rule (Ternes and Joss, 
2006), compounds with Kd > 500 L/kg (Log Kd > 2.7) potentially tend to adsorb onto 
sludge and particles. Appendix A.1. compiles Log Kd values for most of the selected 
substances and evidences that for most of them, they are less than 2.7 confirming their low 
tendency to adsorb. The value of the PhC molecular charge at pH 7 provides information 
about its potential to create electrostatic interactions with the (usually) negatively charged 
biomass surface. 
Data of Table 2.4. show that, only for the antibiotics ciprofloxacin, norfloxacin, 
ofloxacin and lomefloxacin, the antihypertensive hydrochlorotiazide and the lipid regulator 
fenofibrate, the removal percentage due to sorption is in the range 60-100 %. The 
antibiotics appear not be readily biodegradable (Ternes and Joss, 2006; Jia et al., 2012) and 
their removal during activated sludge processes is assumed to be due to the formation of 
flocs by microbial activity, via electrostatic and hydrophobic interactions (Lindberg et al., 
2006; Jia et al., 2012). The four antibiotics are characterized by high sorption constant Log 
Kd (> 4 as reported in Appendix A.1.), confirming a good tendency to sorption (Kümmerer, 
2009a) and to create electrostatic interactions, as suggested by Vieno et al. (2007) and 
Göbel et al. (2007). Data of high removal by sorption referring to hydrochlorothiazide 
(Jelic et al., 2011) were not expected by the Authors during their investigation as this 
compound was never detected in the influent and effluent of the WWTP, but only it was 
detected in the sludge. Perhaps its presence in the sludge is correlated to previous 
processes of accumulation in the solid phase, inside the biological reactor. Further research 
is necessary to better investigate the fate of hydrochlorothiazide as well as fenofibrate 
(Jelic et al., 2011).Sorption of compounds is in generally pH dependent, however, in 
WWTPs it is not significantly affected by the narrow range of pH variability normally 
observed (Lindberg et al., 2006).  
For compounds with a high sorption potential, the removal efficiency in an MBR 
may be slightly higher due to the absence of suspended solids in the effluent (Clara et al., 
2004): Fig. 2.18. shows that ciprofloxacin and norfloxacin have higher removals in MBRs 
rather than CAS systems. 
Attempts to correlate biodegradation removal of a compound to its molecular 
characteristics was made by Tunkel et al. (2000). On the basis of a large set of organic 
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chemicals, they found that compounds including esters, nitriles and aromatic alcohols have 
functional groups that may increase biodegradability, while aromatic amines, iodide, nitro 
and azo groups increase the persistence of the compound. Jones et al. (2005) reported that 
long and highly branched side chains (i.e. omeoprazole and ranitidine) render a compound 
more persistent as well as complicated aromatic ring structures (including norfluoxetine, 
diazepam) and halogen groups (i.e. iopromide, diazepam).  
 
2.11.1 Considerations on the observed removal efficiencies of the selected PhCs.  
As previously mentioned, compounds of the same class may have quite different 
chemical and physical properties (Ternes and Joss, 2006) resulting in different behaviours 
during treatment processes (tendency to remain in dissolved phase, to adhere to flocs or 
particles or to undergo biodegradation), which can explain why compounds belonging to 
the same therapeutic class do not exhibit similar removal efficiencies (Figures 2.16.-2.20.). 
However, as reported by Tadkaew et al. (2011), it is always difficult to correlate physical 
properties of pharmaceuticals to their corresponding removal efficiency achieved in an 
activated sludge system, as many other factors contribute to it, in particular operating 
parameters such as biomass concentration, SRT, HRT, pH, temperature, configuration and 
type of plant. A brief discussion is below reported. 
 
2.11.1.1 Effect of biomass concentration and sludge retention time (SRT)  
Many authors (among them Kreuzinger et al., 2004; Weiss and Reemtsma, 2008) 
have found that a long SRT promotes the adaptation of different kinds of microorganisms, 
as well as the presence of slower growing species that could have a greater capacity for 
removing xenobiotics while simultaneously greatly improving suspended solid separation: 
this is the case for ibuprofen and diclofenac as reported by Suarez et al. (2010) whose 
removal was only achieved after the growth of specific bacteria. Moreover, Kimura et al. 
(2007) found that a greater removal of diclofenac was achieved in an MBR operating at 
longer SRT (up to 65 d) with respect to a CAS (SRT on average 7 d) due to a different 
composition of the two sludges resulting in different sorption capacities with respect to the 
selected PhC. 
Schröder (2002) suggested that MBR systems provide a competitive advantage for 
organisms able to degrade persistent compounds by eliminating bacterial washout. The 
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high biomass concentrations in an MBR not only lead to a decreased sludge production, 
but also a higher stability and persistence to shock loads (Lee et al., 2003).  
The higher biomass concentration in MBRs results in a decrease of the food to 
microorganisms ratio (F/M). The relative shortage in biodegradable substance may induce 
microorganisms to metabolize also poorly degradable compounds. This can explain why 
removal efficiencies for some persistent PhCs (including ketoprofen and naproxen) are 
higher in MBRs than in CAS systems and why this can be obtained at lower HRT (Weiss 
and Reemtsma, 2008). High SRT combined with reduced F/M ratios may result in an 
increased biodiversity and may also favor elimination of compounds, like the antibiotics 
trimethoprim, erythromycin and other macrolides, by co-metabolism processes (Göbel et 
al., 2007). 
High SRTs have also beneficial effects on the removal of PhCs that tend to 
accumulate in the sludge flocs, either due to intrisec hydrofobicity or via electrostatic 
interactions with the biomass (i.e. tetracycline, ciprofloxacin, ofloxacin, norfloxacin) (Kim 
et al., 2007). Moreover the biomass in an MBR has a more viable fraction compared to 
CAS system (Cicek et al. 1999) that can be attributed to an improved mass transfer due to 
the presence of smaller flocs (10-100 µm in MBR against 100-500 µm in CAS) and a large 
fraction of planktonic microorganisms. These factors favor the contact between 
microorganisms and pollutants and stimulate their biodegradation, as well as some 
enzymatic activities (Cirja et al., 2008). Radjenovic et al. (2009) found higher 
concentrations in MBR sludge rather than CAS sludge for hydrochlorothiazide, 
azythromycin, carbamazepine and ketoprofen.  
Clara et al. (2005a) found that a SRT > 10 d is needed for some biodegradable 
PhCs (in particular hormones, bezafibrate and ibuprofen) to achieve low effluent 
concentrations, although other studies (Joss et al., 2005; Vieno et al., 2007) noticed no 
clear correlation between percentage elimination and SRT in particular for beta-blockers, 
carbamazepine and the antibiotics ciprofloxacin, ofloxacin and norfloxacin. 
Table 2.5. and Table 2.6. report removal efficiencies for the selected compounds 
with the corresponding SRT and references distinguishing between CAS and MBR. The 
positive effect of increasing SRT appear for several compounds, in particular for 
hormones, ibuprofen, ketoprofen, naproxen, bezafibrate, gemfibrozil, fluoxetine, 
antibiotics mainly removed by biodegradation, as also confimed by (Strenn et al., 2004). 
Increasing SRT beyond 30 days does not usually result in a consistent increment in 
the removal for most compounds, (Suarez et al., 2008). This could be explained with the 
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fact that biodegradation of micropollutants, including PhCs, is mostly due to cometabolic 
processes as the low concentrations do not likely sustain growth for specific 
microorganisms, because in this case the SRT necessary for an efficient biodegradation of 
the primary substrate is the relevant parameters (Sipma et al., 2010). 
Clara et al. (2004) reported that they did not find significant differences in the removal 
efficiency of pharmaceuticals like diclofenac, ibuprofen, carbamazepine, bezafibrate and 
ethinylestradiol between CAS and MBR systems when operated at similar sludge retention 
times, which suggests that the reactor type is of less importance than the SRT. Although 
SRT has been reported as determinative for pharmaceutical biodegradation due to 
enrichment of certain microbial communities who excrete enzymes able to break down 
PhCs (Cirja et al., 2008), the effect of an increasing SRT does not become clear for other 
compounds, including naproxen and sulfamethoxazole (Lishman et al., 2006;Vieno et al., 
2007): often very fluctuating removal efficiencies are encountered with increasing of its 
values, as reported in Tables 2.5. and 2.6. 
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Table 2.5. Average removal efficiencies obtained in CAS systems for the selected pharmaceuticals with respect to the operating SRT in the 
bioreactor and the corresponding references 
Class Pharmaceutical SRT [d] Removal efficiency CAS [%] 
References 
A 
 
Acetaminophen 2.4/3 
8/10/13 
100/86.4 
99.5/99.9/92 
Roberts and Thomas, 2006/Radjenovic et al., 2007 
Yu et al., 2006/Radjenovic et al., 2009/Jones et al., 2007 
Codeine 18.5 82 Wick et al., 2009 
Diclofenac 1.5/2/2.4/2.7/3 
5/7/8/9.6/10 
19/20 
42/46/48/52/52/60 
50/7.1/65.1/50/50 
50/42/18/9/22 
9.7/13 
47/14/14/63/60/3 
Santos et al.,2009/Clara et al., 2005a/Roberts and Thomas, 2006/Santos et 
al.2009/Radjenovic et al., 2007 
Santos et al., 2007/Kimura et al., 2007/Yu et al., 2006/Kreuzinger et al., 
2004/Radjenovic et al., 2009 
Clara et al., 2005a/Vieno et al., 2005 
Clara et al., 2005a /Clara et al., 2005b/Clara et al., 2005a /Clara et al., 2005b/Clara et al., 
2004/Suarez et al., 2005  
Ibuprofen 1.5/1.5/2/2.4/2.7/3 
5/7/8/8/9.6/10 
13/19/20 
42/46/48/52/60 
89.5/87/-4.4/-13/84/82.5 
88.4/98/87/99/92/99 
86/92/99.8 
99/98/98/97/82 
Santos et al., 2007/Santos et al., 2009/Clara et al., 2005a/ Roberts and Thomas, 2006/ 
Santos et al., 2009/ Radjenovic et al., 2007 
Santos et al., 2007/ Kimura et al., 2007/ Yu et al., 2006/Zorita et al., 2009/ Kreuzinger et 
al., 2004/ Radjenovic et al., 2009 
Jones et al. 2007/Clara et al. 2005a/Vieno et al.2005 
Clara et al., 2005a/ Clara et al., 2005b/ Clara et al., 2005a/Clara et al.,2004/Suarez et 
al.,2005 
Indomethacin 3/10 23/<10 Radjenovic et al., 2007;2009 
Ketoprofen 1.5/1.5/2.7/3 
5/7/8/10/20 
37/52/56/52 
30/55/77/55/92 
Santos et al., 2007/Santos et al.,2009/Santos et al.,2009/Radjenovic et al., 2007 
Santos et al., 2007/Kimura et al.,2007/Yu et al., 2006/Radjenovic et al., 2009/Vieno et 
al., 2005 
Mefenamic acid 3/7/10/13 29/72/5/92 Radjenovic et al., 2007/Kimura et al., 2007/Radjenovic et al., 2009/Jones et al., 2007 
Naproxen 1.5/1.5/2.7/3 
5/7/8/8/10 
20/60 
35/43/71/85 
89/64/88/93/72 
95/68 
Santos et al., 2007/Santos et al.,2009/Santos et al., 2007/Radjenovic et al., 2007 
Santos et al., 2007/Kimura et al.,2007/Yu et al., 2006/Zorita et al., 2009/Radjenovic et 
al., 2009 
Vieno et al.. 2005/Suarez et al., 2005 
Propyphenazone 3/10 42/38 Radjenovic et al., 2007;2009 
Tramadol 18.5 4 Wick et al., 2009 
B 
 
Amoxicillin 12.5 96 Watkinson et al., 2007 
Azithromycin 5/18 74/39;45 Yasojima et al., 2006/Ghosh et al., 2009; 
Cefaclor 12.5 98 Watkinson et al., 2007 
Cefalexin  7 
12/12.5/20 
91 
53/100/64;87 
Li and Zhang, 2011 
Li and Zhang, 2011/Watkinson et al., 2007/Gulkowska et al., 2008  
Cefotaxime 12/20 43/83 Li and Zhang, 2011/Gulkowska et al., 2008 
Chlortetracycline 7;12 82;85 Li and Zhang, 2011 
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Class Pharmaceutical SRT [d] Removal efficiency CAS [%] 
References 
Ciprofloxacin 7/8/11 
11/12/12.5/15/18/20 
22 
55/71/78 
93/18/83/96/50;73/79 
72 
Li and Zhang, 2011/Zorita et al., 2009/Golet et al., 2003/ 
Lindberg et al., 2005/ Li and Zhang, 2011/Watkinson et al., 2007/Lindberg et al., 2005/; 
Ghosh et al., 2009/Lindberg et al., 2006/ 
Lindberg et al., 2005 
Clarithromycin 5/9 
11/18 
46/62 
4.5/50;83 
Yasojima et al., 2006/Sahar et al., 2011 
Göbel et al., 2007/Ghosh et al., 2009 
Doxycycline 11/15;20 14/100;99 Lindberg et al., 2005/Lindberg et al., 2005 
Enrofloxacin 18 70;38 Ghosh et al., 2009  
Erythromycin  3 
5.6/7/9/10 
11/12/20 
24 
4.4/26/19/35 
3/15/19 
Radjenovic et al., 2007 
Xu et al., 2007/ Li and Zhang, 2011/Sahar et al., 2011/Radjenovic et al., 2009 
Göbel et al., 2007/ Li and Zhang, 2011/Gulkowska et al., 2008 
Lincomycin 12.5/18 17/57;33 Watkinson et al., 2007/Ghosh et al., 2009 
Norfloxacin 5.6/7/8 
11/11/12/12.5/15/18/20/20/20;22 
18/45/-6 
84/91/30/85/96/75;90/79/23;78/91;72 
Xu et al., 2007/ Li and Zhang, 2011/Zorita et al., 2009 
Golet et al., 2003/Lindberg et al., 2005/ Li and Zhang, 2011/Watkinson et al., 
2007/Lindberg et al., 2005/Ghosh et al., 2009/Lindberg et al., 2006/Gulkowska et al., 
2008/Lindberg et al., 2005 
Ofloxacin 3 
5.6/7/8/10 
11/12 
24 
38/59/13/76 
84/26 
Radjenovic et al.2007 
Xu et al., 2007/ Li and Zhang, 2011/Zorita et al., 2009/Radjenovic et al.2009 
Lindberg et al., 2005/ Li and Zhang, 2011 
Penicillin V 12.5 60 Watkinson et al., 2007 
Oxytetracycline 12 4 Li and Zhang, 2011 
Roxithromycin 2/5.6/7/9/9.6 
11/12/18 
46;52 
27/12.5/40/22/-4 
19/46/39;-32 
-80;44 
Clara et al., 2005b/Xu et al., 2007/ Li and Zhang, 2011/Sahar et al., 2011/Kreuzinger et 
al., 2004 
Göbel et al., 2007/ Li and Zhang, 2011/Ghosh et al., 2009 
Clara et al. 2005b 
Sulfadiazine 6/7/12 78-98/87/100 García-Galán et al., 2011/Li and Zhang, 2011 
Sulfadimethazine 6;19 100 García-Galán et al., 2011 
Sulfamethazine 4;6/7;12/19 100;16/100/100 García-Galán et al., 2011/Li and Zhang, 2011/ García-Galán et al., 2011 
Sulfamethoxazole 3/6/7/9/10 
11/12/12.5/15/18/18 
20/46 
56/54;71/62/10/74 
4.5/90/25/100/39/26 
42/32 
Radjenovic et al., 2007/García-Galán et al., 2011/Sahar et al., 2011/Radjenovic et al., 
2009/ Li and Zhang, 2011 
Göbel et al., 2007/ Li and Zhang, 2011/Watkinson et al., 2007/Lindberg et al., 
2005/Ghosh et al., 2009/Ghosh et al., 2009 
Lindberg et al., 2005/Clara et al., 2005b 
Sulfapyridine 4/6/19 20/77;89/6 García-Galán et al., 2011 
Sulfathiazole 4;6/12.5 100;65/75 García-Galán et al., 2011/Watkinson et al., 2007 
Tetracycline 7/12 
18/20 
36/24 
40;72/-88;72 
Li and Zhang, 2011 
Ghosh et al., 2009/Gulkowska et al., 2008 
Trimethoprim 2.4 
7/9/10 
-56 
42/0/40 
Roberts and Thomas, 2006 
Li and Zhang, 2011/Sahar et al., 2011/Radjenovic et al., 2009 
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Class Pharmaceutical SRT [d] Removal efficiency CAS [%] 
References 
11/11/12/12.5/15/18/20/20/22/55 -2/7/13/85/41/-88;35/14/-17;63/-
34/53 
Lindberg et al., 2005/Göbel et al., 2007/ Li and Zhang, 2011/Watkinson et al., 
2007/Lindberg et al., 2005/Ghosh et al., 2009/Lindberg et al., 2006/Gulkowska et al., 
2008/Lindberg et al., 2005/ Batt et al.,2006 
C Glibenclamide 3/10 44.5/46 Radjenovic et al., 2007;2009 
D Clotrimazole 2.4 31 Roberts and Thomas, 2006 
E Hydrochlorothiazide 3/10 76/<10 Radjenovic et al., 2007;2009 
F Phenobarbital 8 99.5 Yu et al., 2006 
G Atenolol 3/8/9/10 
14.6/18.5 
<10/71/76/61 
73/44 
Radjenovic et al., 2007/Carucci et al., 2006/Maurer et al., 2007/ Radjenovic et al., 2009 
Maurer et al., 2007/Wick et al., 2009 
Bisoprolol 18.5 0 Wick et al., 2009 
Metoprolol 3/9/10 
14.6/18.5 
<10/31/25 
29/21 
Radjenovic et al., 2007/Maurer et al., 2007/Radjenovic et al., 2009 
Maurer et al., 2007/Wick et al.,2009  
Propranolol 9/10 
14.6/18.5 
28/59 
35/0 
Maurer et al., 2007/Radjenovic et al., 2009 
Maurer et al., 2007/Wick et al.,2009  
Sotalol 9/10 
14.6/18.5 
26/21 
27/18 
Maurer et al., 2007/Radjenovic et al., 2009 
Maurer et al., 2007/Wick et al.,2009 
I 
 
Bezafibrate 2/3 
9.6/10 
19/20 
42/46/48/52/52 
36.8/48 
36/81 
37/94 
90/53.9/53.8/99.9/97 
Clara et al., 2005a/Radjenovic et al., 2007 
Kreuzinger et al., 2004/Radjenovic et al., 2009 
Clara et al., 2005a/Vieno et al., 2005 
Clara et al., 2005a /Clara et al., 2005b/Clara et al., 2005a /Clara et al., 2005b/Clara et al., 
2004  
Clofibric acid 2.4/3 
7/8 
84/28 
50/55 
Roberts and Thomas, 2006/Radjenovic et al., 2007 
Kimura et al., 2007/Zorita et al., 2009  
Gemfibrozil 3/8/10 39/68/5 Radjenovic et al., 2007/Yu et al., 2006/Radjenovic et al., 2009 
Pravastatin 3/10 62/59 Radjenovic et al., 2007;2009 
J 
 
Carbamazepine 1.5/1.5/2/2.7/3 
5/9.6/10 
18.5/19 
42/46/48/52/52/60 
-4/11/-3/7/<10 
-67/35/<10 
-12/-47 
-35/-43/-43/-11/0/<10 
Santos et al., 2007/Santos et al. 2009/Clara et al. 2005a/Santos et al., 2009/Radjenovic et 
al. 2007 
Santos et al., 2007/Kreuzinger et al., 2004/Radjenovic et al., 2009/ 
Wick et al, 2009/Clara et al., 2005a 
Clara et al., 2005a /Clara et al., 2005b/ Clara et al., 2005a/ Clara et al., 2005b/Clara et al., 
2004/ Suarez et al., 2005 
Diazepam 60 8 Suárez et al., 2005 
Fluoxetine 8/10 54.5/33 Zorita et al., 2009/Radjenovic et al., 2009 
Gabapentin 8 99.5 Yu et al., 2006 
Norfluoxetine 8 48 Zorita et al., 2009 
Paroxetine 3 91 Radjenovic et al., 2007  
Valproic acid 8 >99 Yu et al., 2006 
K Famotidine 10 60 Radjenovic et al., 2009 
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Class Pharmaceutical SRT [d] Removal efficiency CAS [%] 
References 
 
Loratadine 10 15 Radjenovic et al., 2009 
Ranitidine 3/8/10 42/28.5/25 Radjenovic et al., 2007/Carucci et al., 2006/Radjenovic et al., 2009 
L 
 
Estradiol 8/10 22/98 Zorita et al., 2009/Joss et al., 2004 
Estrone 10/11/19 
42/48 
96/99/-35 
94/99.9 
Joss et al., 2004/Andersen et al., 2003/ Clara et al., 2005a 
Clara et al., 2005a /Clara et al., 2005a 
Ethinylestradiol 9.6/10 
52 
70/94 
70 
Kreuzinger et al., 2004/Joss et al., 2004 
Clara et al., 2004 
M Salbutamol 13 95 Jones et al., 2007 
P Triclosan 8 69 Yu et al., 2006 
Q Iopromide 2/9.6 
55 
-32/50 
50 
Clara et al., 2005b/Kreuzinger et al., 2004 
Batt et al., 2006 
 
Table 2.6. Average removal efficiencies obtained in MBRs for the selected pharmaceuticals with respect to the operating SRT in the bioreactor 
and the corresponding references 
Class Pharmaceutical 
compound SRT [d] 
Removal efficiency 
MBR [%] 
References 
Analgesics/ 
Anti-
inflammatories 
A 
 
Diclofenac 10/15 
22/27/37/65 
60/51 
33/51/23/82 
Clara et al., 2004/Kimura et al., 2007 
Clara et al., 2005a/Clara et al., 2005b/Quintana et al., 2005/Kimura et al., 2007 
Ibuprofen 10/11/15/20 
22/27/37/65 
97/99/95/97 
97/99/97/98 
Clara et al., 2004/Kreuzinger et al., 2004/Kimura et al., 2007/Kreuzinger et al., 2004; 
Clara et al., 2005a/Clara et al., 2005b/Quintana et al., 2005/Kimura et al., 2007 
Ketoprofen 15 
37/65 
83 
62/99 
Kimura et al., 2007 
Quintana et al., 2005/Kimura et al., 2007 
Mefenamic acid 15/65 77/93 Kimura et al., 2007 
Naproxen 15 
37/65 
96 
71/98 
Kimura et al., 2007 
Quintana et al., 2005/Kimura et al., 2007 
Antibiotics 
B 
 
Azithromycin 33/70 5/24 Göbel et al., 2007 
Clarithromycin 16 
33/70/70 
57 
41/92/88 
Göbel et al., 2007 
Göbel et al., 2007/Sahar et al., 2011/Göbel et al., 2007/ 
Erythromycin  16 
33/70/70 
34 
26/79/87 
Göbel et al., 2007 
Göbel et al., 2007/Sahar et al., 2011/Göbel et al., 2007 
Roxithromycin 16/20 
27/33/70/70 
39/75 
34/62/59/59 
Göbel et al., 2007/Kreuzinger et al., 2004 
Clara et al., 2005b/Göbel et al., 2007/ Sahar et al., 2011/Göbel et al., 2007 
Sulfamethoxazole 11/16 
33/70/70 
57/37 
38/0/37 
Kreuzinger et al., 2004/Göbel et al., 2007 
Göbel et al., 2007/Sahar et al., 2011/Göbel et al., 2007 
Sulfapyridine 16 60 Göbel et al., 2007 
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Class Pharmaceutical 
compound SRT [d] 
Removal efficiency 
MBR [%] 
References 
33/70 50/58 Göbel et al., 2007/Göbel et al., 2007 
Trimethoprim 16 
33/70/70 
30 
34/88/87 
Göbel et al., 2007 
Göbel et al., 2007/Sahar et al., 2011/Göbel et al., 2007 
Lipid regulators 
I 
 
Bezafibrate 10/11/20 
22/27/37 
97/94/76 
77/96/91 
Clara et al., 2004/Kreuzinger et al., 2004/Kreuzinger et al., 2004 
Clara et al., 2005a/Clara et al., 2005b/Quintana et al., 2005 
Clofibric acid 15/65 50/82 Kimura et al., 2007 
Psychiatric drugs 
J 
 
Carbamazepine 10/11 
22/27 
0/11/ 
-13/4.4 
Clara et al., 2004/Kreuzinger et al., 2004 
Clara et al., 2005a/Clara et al., 2005b/ 
Hormones 
L 
 
Estradiol 30 99 Joss et al., 2004 
Estrone 22/30 97/96 Clara et al., 2005a/Joss et al., 2004 
Ethinylestradiol 10/11;20 
30 
70/66;25 
76 
Clara et al., 2004/Kreuzinger et al., 2004 
Joss et al., 2004 
Chapter 2: Background 
 
73 
 
As MBRs generally operate at longer SRTs (at least 15 d, as stated in Table 2.3.) 
than CAS (generally at maximum 15 d), this could explain higher removal efficiencies 
achieved by the former with respect to the latter as reported in Clara et al. (2005b), 
Radjenovic et al. (2009), Weiss and Reemtsma (2008). Moreover, in MBRs, membranes 
detain particulate matter, including any adsorbed or absorbed PhCs, leading to an effluent 
free of suspended solids and relatively free of contaminants (for instance glibenclamide).  
Weiss and Reemstma 2008 found that the major advantage of MBR lies in the 
range of compounds with moderate removal in CAS (including naproxen, diclofenac, 
phenazone, clofibric acid). For these MBR is capable of delivering lower and more stable 
effluent concentrations in comparison to CAS even with lower HRT. 
 
2.11.1.2 Effect of Hydraulic retention time (HRT)  
The influence of HRT on the removal efficiencies of selected PhCs was 
investigated by different Authors. Among them, Bernard et al. (2006) and Vieno et al. 
(2007) found no significant correlation between HRT and removal of respectively 
diclofenac and the beta-blockers atenolol, metoprolol, acebutolol and sotalol. Gros et al. 
(2010) and García-Galán et al. (2011) investigated in two full scale WWTPs in Spain 
operating at different HRT , respectively 7-10 h and 32 h, the removal of several 
compounds, covering different therapeutic classes: analgesics/anti-inflammatories, 
antibiotics, lipid regulators, diuretics, beta-blockers the former and sulphonamide 
antibiotics the latter. They correlated observed PhC removal efficiencies to the 
corresponding PhC half-lives t1/2 evaluated on the assumption that a decrease of the 
concentration through time is proportional to the concentration remaining in the matrix 
(that is assuming a pseudo-first order kinetic for the degradation). Half-lives were 
estimated through eq. 2.3 
 
k
ln
t /
2
21 =
             (eq. 2.3) 
 
where k is the loss rate constant calculated according to eq. 2.4, where c is the PhC 
concentration in the influent (subscript inf) and effluent (subscript eff). 
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( ) tkc/cln infeff −=
           (eq.2.4) 
 
They found that those compounds with a half-live time t1/2 less than WWTP HRT 
generally exhibited high removal efficiencies, concluding that t1/2 gives an idea about the 
required permanence time of the compounds in the biological reactor to ensure an efficient 
removal of them. 
In particular they found three different situations: (a) for compounds with high 
removal efficiency and high degradation rate (low t1/2), like ibuprofen, naproxen, salicylic 
acid, acetaminophen and enalapril; (b) for compounds with poor or no elimination and low 
degradation (high t1/2) like carbamazepine, HRT does not influence compound removal; (c) 
for compounds with medium removal and degradation rate, HRT seems to play a role, as 
their removal efficiencies were higher when increasing HRT (including famotidine, 
ranitidine and pravastatin). Gross et al. (2010) conclude that substances that are 
biodegradable (high kbiol or low t1/2) and have low Log Kd (low sludge-water distribution 
coefficient, corresponding to low tendency to adsorb on sewage sludge) are more 
influenced by HRT, while compounds with high Log Kd and low kbiol are more influenced 
by SRT. However, there are other PhCs like ibuprofen with high kbiol and low Log Kd that 
are well removed independently of HRT and SRT. Based on experimental findings on 
Canadian WWTPs (SRT from 2 to 10 d), Metcalfe et al. (2003) proposed the following 
correlation for naproxen and ibuprofen, between HRT and PhC percentage removal η:  
 
η = 1.735 e0.886 HRT           (eq. 2.5) 
 
They conclude that due to high half-lives observed for most of the investigated 
compounds in WWTP effluents, higher HRT should be required in order to enhance 
compound degradation. 
 
2.11.1.3 Effect of pH  
pH values can also greatly affect the behaviour of PhCs, in particular antibiotics 
(ciprofloxacin, tetracycline and penicillin G), which possess different functional groups 
within the same molecule. In fact, under different pH conditions, the molecule can be 
neutral, cationic, anionic or zwitterionic and so its physical, chemical and biological 
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properties (sorption, photo-reactivity, antibiotic activity and toxicity) will change 
accordingly (Kümmerer, 2009b, Cirja et al., 2008). Tadkaew et al. (2010) investigated the 
effects of mixed liquor pH (pH between 5 and 9) on the removal of trace organics 
(sulfamethoxazole, carbamazepine, diclofenac, ibuprofen and ketoprofen) by a submerged 
MBR system. They found that removal efficiencies of ionisable compounds 
(sulfamethoxazole, diclofenac, ibuprofen and ketoprofen) were strong pH-dependent. At 
pH 5, the high removal of the ionisable compounds can be due to their speciation 
behaviour. At this pH, these compounds exist mainly in their hydrophobic form. As a 
consequence, they could readily adsorb onto the activated sludge, resulting in higher 
removal efficiencies in comparison to under less acidic conditions in the reactor. Removal 
efficiencies of the non-ionisable carbamazepine were relatively independent of the mixed 
liquor pH. These findings are consistent with those by Urase et al. (2005). Watkinson et al. 
(2007) found a strong pH sensitivity for resulting in the formation of a degraded 
erythromycin product (erythromycin-H2O) through the loss of a water molecule and the 
inability to detect the parent erythromycin at pH < 7. 
 
2.11.1.4 Effect of temperature  
Biological reactions are greatly affected by temperature, and lower efficiencies 
have been observed during winter seasons in colder climates (Vieno et al., 2005). 
Moreover, based on removal data collected on six different large WWTPs in Italy, 
Castiglioni et al. (2006) found that there are PhCs that present really higher removal 
efficiencies in summer than in winter: amoxicillin (with a median of 75 % in winter and 
100 % in summer), atenolol (10 % and 55 %), bezafibrate (15% and 87 %), enalapril (18 % 
and 100 %), furosemide (8 % and 54 %), ibuprofen (38 % and 93 %), ranitidine (39 % and 
84 %) and sulfamethoxazole (17 % and 71 %). Another group of compounds has similar 
removal in the two seasons: ciprofloxacin (60 %), hydrochlorotiazide (30 %) and ofloxacin 
(50 %). Finally a third group has removal efficiencies close to zero in winter and in 
summer: carbamazepine, clarithromycin, erythromycin and salbutamol.  
Hai et al. (2011) investigated the effect of temperature on the removal of selected 
PhCs contained in a synthetic wastewater fed to a lab scale MBR. They reported that the 
removal of most hydrophobic compounds (including estrone, ethinyl-estradiol, estradiol 
and triclosan) was stable during operations under the temperature range of 10-35 °C. On 
the other hands, for the less hydrophobic compounds (salicylic acid, ketoprofen, naproxen, 
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metronidazole, ibuprofen, acetaminophen, diclofenac, gemfibrozil, carbamazepine and 
estriol) a comparatively more pronounced variation between removals in the lower 
temperature regimes (10-35 °C) was observed. With a few exception, operation at 45 °C 
clearly exerted detrimental effects on the removal efficiency of the investigated 
compounds. 
However, it is still unclear whether temperature dependence, commonly observed 
for biological degradation of common pollutants (C, N and P compounds), also applies to 
the transformation of antibiotics or PhCs in general (Göbel et al., 2007; Tauxe-Wuersch et 
al., 2005; Ternes, 1998).  
 
2.11.1.5 Effect of Treatment configuration  
Nitrifying bacteria have been found capable of co-metabolizing a wide range of 
persistent compounds like iopromide and trimethoprim (Batt et al., 2006; Perez et al., 
2005). Wastewater treatment processes performing a complete biological nutrient removal 
are characterized by separate zone with aerobic, anoxic and anaerobic conditions to 
optimize C and N removal that may affect PhCs removal as well (US EPA 2009Zwiener 
and Frimmel 2003). High removal efficiencies of PhCs have been suggested to occur in 
WWTPs with high levels of nitrogen removal (Batt et al., 2006; Clara et al., 2005a): Vieno 
et al. (2007) found that atenolol and sotalol were slightly more efficiently eliminated in the 
WWTPs where nitrogen removal was greater than 60 % compared with those that removed 
nitrogen only less than 30 %. Suarez et al. (2010) divided into three groups PhCs with 
respect to their potential to be removed in biological reactor: highly biodegradable 
compounds under aerobic and anoxic conditions, including ibuprofene, fluoxetine, natural 
estrogens; highly biodegradable compounds under aerobic conditions, but persistent in 
anoxic conditions, inbcluding diclofenac, naproxen, ethinylestradiol, roxythromycin and 
erythromycin and finally resistant compounds to biological transformations 
(sulfamethoxazole, trimethoprim, carbamazepine and diazepam). 
 
It is important to remark that low removal efficiencies could also be due to the fact 
that contaminants are present at very low concentrations in the influent, and unavoidable 
instrumental errors may affect their “observed” removal values. At the other extreme, high 
removal efficiencies, greater than 99 %, corresponding to a reduction of two orders of 
magnitude of the influent concentrations, may not be enough to consistently reduce the 
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PhC concentrations to a low level of risk to aquatic life. For instance if ibuprofen presents 
an influent concentration at 350 µg/L and 99 % is removed, its final concentration would 
still amount to 3.5 µg/L, i.e. a consistent mass load discharged by the WWTP, as described 
below. 
 
2.12 Average daily mass loads of PhCs in secondary effluents 
Where possible, to complete this analysis, the average daily mass load, Li, of each 
PhC, i, in the secondary biological effluent was estimated. Li was evaluated as the average 
of mass load Li,j at WWTP j, provided by the cited literature or evaluated via eq. 2.6, on the 
basis of the average effluent concentration ci,j from the WWTP j, the average treated flow 
rate Qj and the population served by the WWTP j. Each mass load is expressed in mg/1000 
inhabitants/day. 
WWTPgeneric;PhCgeneric1000x
populationserved
,
,
=== jiQcL jjiji   (eq. 2.6) 
 
It was possible to evaluate the average mass load of 75 out of 118 compounds, as 
those WWTPs lacking one or more of the following variables were excluded: effluent 
concentration, treated flow rate and population served.  
The graph in Figure 2.21 reports, in descending order, average mass loads Li 
greater than 10 mg/1000 inh/day, and below is a list of the references used in the 
evaluation. 
These findings may be affected by different sources of uncertainty as discussed in Ort and 
Gujer (2006), for this reason they have to be prudently considered. 
 
The highest average mass loads (greater than 200 mg/1000 inh/d) were found for 
the antihypertensive hydrochlorothiazide (368 mg/1000 inh/day), the psychiatric drug 
carbamazepine (364 mg/1000 inh/day), the receptor antagonist cimetidine (332 mg/1000 
inh/day) and the beta-blocker atenolol (316 mg/1000 inh/day), followed by the 
analgesics/anti-inflammatories: naproxen (295), ibuprofen (273), diclofenac (241), 
ketoprofen (217) and mefenamic acid (211). Antibiotics showed lower average daily mass 
loads: spyramycin (155), clarithromycin (140), trimethoprim (124), ofloxacin (123), 
erythromycin (100).  
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Figure 2.21. Average daily mass loads evaluated for most of the compounds under review. The 
number p of treatment plants considered in the analysis are shown in brackets after the name in the 
X-axis. Data from: Baronti et al., 2000; Bendz et al., 2005; Castiglioni et al., 2009; Conti et al., 2011; Gobel 
et al., 2005; Golet et al., 2003; Gulkulowska et al., 2008; Jones et al., 2007; Karthikejan and Meyer, 2006; 
Kimura et al., 2007; Lindberg et al., 2005; Lindqvist et al., 2005; Mc Avoy et al., 2002; Nakada et al., 2006; 
Paxéus et al., 2004; Radjenovic et al., 2007, 2009; Roberts and Tomas., 2006; Santos et al., 2009; Tauxe-
Wuerch et al., 2005; Ternes 1998; Ternes et al., 1999, 2003; Vieno et al., 2005, 2007; Xu et al., 2007; Yu et 
al., 2006; Zorita et al., 2009. 
 
Compounds with average mass loads of less than 10 mg/1000 inh/d (not reported in 
Fig. 2.21.) were: acetylsalicylic acid, doxycycline, cefotaxime, salbutamol, aminopyrine, 
glibenclamide, famotidine, loratadine, clotrimazole, phenazone, tylosil, cyclophosphamide, 
fenofibric acid, norfluoxetine, paroxetine, estradiol, estriol, ethinylestradiol, simvastatin, 
gabapentin, valproic acid, oxcarbazepine, fenoprofen, sulfamethazine and phenobarbital. 
 
2.13 Environmental risk assessment of secondary biological effluent 
The environmental risk posed by the presence of PhCs in water is still under 
discussion. Safety threshold values have been defined for a limited number of PhCs, but 
only in single compound-single organism toxicity studies, meaning that mixture effects 
have not yet been considered. 
Moreover, many compounds themselves have not been extensively studied, and, 
when available, PhC toxicity data tends to refer only to acute rather than chronic effects.  
Table 2.7. reports the PNEC values defined for 67 out of the 118 PhCs included in this 
study, the corresponding assayed species, the endopoint and the literature references. 
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Conforming to EC (EC, 2003), each of the reported PNECs is 1000 times lower than the 
toxicity concentration value found for the most sensitive species assayed, so as to take into 
account the effect on other, potentially more sensitive, aquatic species to those used in 
toxicity studies. 
An evaluation of the environmental risk posed by PhCs in secondary effluent was 
carried out by means of the risk quotient (RQ), that is the ratio between the average PhC 
concentrations measured in the secondary effluent and its corresponding PNEC (EMEA, 
2001). Average secondary effluent concentrations are reported in brackets after the name 
of the compounds in the x-axis of Figures 2.9.-2.14., and PNEC values are those reported 
in Table 2.7.  
A commonly used ranking criterion was applied, according to De Sousa et al. 
(2009) and Hernando et al. (2006): RQ < 0.1 low risk to aquatic organisms, 0.1≤ RQ ≤ 1, 
medium risk; RQ ≥ 1, high risk. The RQ values were found within the range 6.8 x 10-6-37 
for the 67 compounds considered; compounds with RQ greater than 0.01 are reported in 
Fig. 2.22., in descending order. The dotted lines in the graph represent the thresholds 
defining the three environmental risk levels: high, medium and low. 
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Table 2.7. PNECvalues for the PhCs under investigation and corresponding assayed species. 
Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Acetaminophen 
Daphnia EC50 (24h) 136 Stuer-Lauridsen et al., 2000 
1 
Daphnia  EC50 (48h) 9.2 Stuer-Lauridsen et al., 2000 
S. proboscideu LC50(24h) 29.6 Stuer-Lauridsen et al., 2000 
Fish EC50 ECOSAR 1 Sanderson et al., 2003 
Daphnia EC50 ECOSAR 42 Sanderson et al., 2003 
Algae EC50 ECOSAR 2549 Sanderson et al., 2003 
Invertebrates EC50 300 Boillot, 2008 
Algae EC50 105 Boillot, 2008 
Fish EC50 900 Boillot, 2008 
Daphnia EC50 (48h-immobility) 9.2 Kühn et al., 1989 
Acetylsalicylic acid 
Fish EC50 ECOSAR 796 Sanderson et al., 2003 
61 Daphnia EC50 ECOSAR 8858 Sanderson et al., 2003 Algae EC50 ECOSAR 61 Sanderson et al., 2003 
Daphnia EC50 ECOSAR 61 US EPA, 1999 
Aminopyrine 
Fish EC50 ECOSAR 3.7 Sanderson et al., 2003 
1.3 Daphnia EC50 ECOSAR 8.3 Sanderson et al., 2003 
Algae EC50 ECOSAR 1.3 Sanderson et al., 2003 
Codeine 
Fish EC50 ECOSAR 238 Sanderson et al., 2003 
16 Daphnia EC50 ECOSAR 16 Sanderson et al., 2003 
Algae EC50 ECOSAR 23 Sanderson et al., 2003 
Dextropropoxyphene 
Fish EC50 ECOSAR 13 Sanderson et al., 2003 
1 Daphnia EC50 ECOSAR 24 Sanderson et al., 2003 
Algae EC50 ECOSAR 1 Sanderson et al., 2003 
Diclofenac 
Fish EC50 ECOSAR 532 Sanderson et al., 2003 
9.7 
Daphnia EC50 ECOSAR 5057 Sanderson et al., 2003 
Algae EC50 ECOSAR 2911 Sanderson et al., 2003 
Daphnia  EC50 (48h-mortality) 22.4 Ferrari et al., 2004 
Algae EC50 (96h-growth) 16.3 Ferrari et al., 2004 
Bacteria EC50 (30 min-luminescence) 11.4 Ferrari et al., 2004 
Bacteria EC50 (15min-inhibition) 9.7 Ra et al., 2008 
Microtox EC50 (30min) 11.45 Ferrari et al., 2003 
Daphnia  EC50 (48h) 22.43 Ferrari et al., 2003 
C. dubia EC50 (48h) 22.7 Ferrari et al., 2003 
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Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Algae EC50 (96h-growth) 14.5 Ferrari et al., 2004 
Invertebrates EC50 90 Boillot, 2008 
Algae EC50-inhibition 72 Cleuvers,2004 
Daphnia  EC50-immobilization 68 Cleuvers, 2004 
 2004 
Ibuprofen 
Fish EC50 ECOSAR 5 Sanderson et al., 2003 
1.65 
Daphnia EC50 ECOSAR 38 Sanderson et al., 2003 
Algae EC50 ECOSAR 26 Sanderson et al., 2003 
Bacteria EC50 (15min-inhibition) 37.5 Ra et al., 2008 
Bacteria EC50 (15min) 12.1 Farré et al., 2001 
Daphnia EC50 (48h) 9.06 Halling-Sørensen et al., 1998 
Invertebrates EC50 (96h) 1.65 Quinn et al., 2008 
Invertebrates EC50 100 Boillot, 2008 
Algae EC50 500 Boillot, 2008 
Fish EC50 110 Boillot, 2008 
Algae EC50-inhibition 342.2 Cleuvers, 2004 
Daphnia  EC50-immobilization 101.2 Cleuvers, 2004 
Indomethacin 
Fish EC50 ECOSAR 3.9 Sanderson et al., 2003 
3.9 Daphnia EC50 ECOSAR 26 Sanderson et al., 2003 
Algae EC50 ECOSAR 18 Sanderson et al., 2003 
Ketoprofen 
Fish EC50 ECOSAR 32 Sanderson et al., 2003 
15.6 Daphnia EC50 ECOSAR 248 Sanderson et al., 2003 Algae EC50 ECOSAR 164 Sanderson et al., 2003 
Bacteria  EC50 (15min) 15.6 Farré et al., 2001 
Mefenamic acid 
 EC50 ECOSAR 0.43 Jones et al. 2002 0.43 
Naproxen 
Fish EC50 ECOSAR 34 Sanderson et al., 2003 
2.62 
Daphnia EC50 ECOSAR 15 Sanderson et al., 2003 
Algae EC50 ECOSAR 22 Sanderson et al., 2003 
Algae EC50-inhibition 626 Cleuvers, 2004 
Invertebrates  LC50(96h) 22.4 Quinn et al., 2008 
Bacteria  EC50(15min) 21.2 Farré et al., 2001 
Invertebrates  EC50(96h) 2.62 Quinn et al., 2008 
Invertebrates  EC50 150 Boillot, 2008 
Fish EC50 600 Boillot, 2008 
Daphnia EC50-immobilization 166.3 Cleuvers, 2004 
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Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Phenazone 
Fish EC50 ECOSAR 3 Sanderson et al., 2003 
1.1 Daphnia EC50 ECOSAR 6.7 Sanderson et al., 2003 
Algae EC50 ECOSAR 1.1 Sanderson et al., 2003 
Propyphenazone 
Fish EC50 ECOSAR 0.8 Sanderson et al., 2003 
0.8 Daphnia EC50 ECOSAR 3.5 Sanderson et al., 2003 
Algae EC50 ECOSAR 1 Sanderson et al., 2003 
Salicylic acid 
Fish EC50 ECOSAR 1.28 Sanderson et al., 2003 
1.28 
Daphnia EC50 ECOSAR 59 Sanderson et al., 2003 
Algae EC50 ECOSAR 48 Sanderson et al., 2003 
Invertebrates  EC50 (48h) 1147 Marques et al., 2004 
Invertebrates  LC50 (48h) 112 Han et al., 2006 
Algae EC50 (48h) >100 Henschel et al., 1997 
Bacteria  EC50 (15min) 43.1 Farré et al., 2001 
Tolfenamic acid 
Fish EC50 ECOSAR 0.4 Sanderson et al., 2003 
0.4 Daphnia EC50 ECOSAR 1.7 Sanderson et al., 2003 
Algae EC50 ECOSAR 1.3 Sanderson et al., 2003 
Amoxicillin   0.1 Kümmerer et al., 2003 0.0037 Algae EC 50 0.0037 Halling-Sørensen, 2000 
Azithromycin 
  0.15 Kümmerer et al., 2003 0.15 
Cefaclor 
Algae EC50 ECOSAR 734.05 Lee et al., 2008 
687.42 Daphnia EC50 ECOSAR 687.42 Lee et al., 2008 
Fish EC50 ECOSAR 11524 Lee et al., 2008 
Cefalexin   2.5 Kümmerer et al., 2003 2.5 
Cefotaxime   0.04 Kümmerer et al., 2003 0.04 
Chloramphenicol   1.6 Kümmerer et al., 2003 1.6 
Ciprofloxacin 
Fish EC50 ECOSAR 246000 Sanderson et al., 2003 
938 Daphnia EC50 ECOSAR 991 Sanderson et al., 2003 
Algae EC50 ECOSAR 938 Sanderson et al., 2003 
Clarithromycin Invertebrates  EC50 20 Boillot, 2008 0.07 Algae EC50 0.07 Boillot, 2008 
Clindamycin   0.5 Kümmerer et al., 2003 0.5 
Doxycycline   0.3 Kümmerer et al., 2003 0.3 
  316 Brain et al.,2004 
Enoxacin   0.15 Kümmerer et al., 2003 0.15 
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Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Erythromycin 
Fish EC50 ECOSAR 61 Sanderson et al., 2003 
0.02 
Daphnia EC50 ECOSAR 7.8 Sanderson et. al., 2003 
Algae EC50 ECOSAR 4.3 Sanderson et. al., 2003 
Invertebrates  EC50 15 Boillot, 2008 
Algae EC50 0.02 Boillot, 2008 
Fish EC50 900 Boillot, 2008 
Lincomycin 
Fish EC50 ECOSAR 1391 Sanderson et al., 2003 
82 Daphnia EC50 ECOSAR 82 Sanderson et. al., 2003 
Algae EC50 ECOSAR 86 Sanderson et. al., 2003 
Metronidazole 
  2.5 Kümmerer et al., 2003 
2.5 Algae EC50 39.1 Halling-Sørensen, 2000 
Algae EC50 40.4 Halling-Sørensen, 2000 
Norfloxacin Algae EC50 15 Boillot, 2008 15 
Ofloxacin 
Algae EC50 (96h- growth) 0.016 Ferrari et al., 2004 
0.016 Invertebrates  EC50 30 Boillot, 2008 Algae EC50 1.5 Boillot, 2008 
Fish EC50 10 Boillot, 2008 
Oxytetracycline 
Algae EC50 0.207 Halling-Sørensen, 2000 
0.207 
Fish EC50 ECOSAR 166000 Sanderson et al., 2003 
Daphnia EC50 ECOSAR 2432 Sanderson et al., 2003 
Algae EC50 ECOSAR 2294 Sanderson et al., 2003 
Invertebrates EC50 (96h) 40.13 Quinn et al., 2008 
Penicillin G Algae EC50 0.006 Halling-Sørensen, 2000 0.006 
Penicillin V Daphnia EC50 177 Jones et al., 2002 177 
Roxythromycin 
Fish EC50 ECOSAR 50 Sanderson et al., 2003 
4 Daphnia EC50 ECOSAR 6 Sanderson et al., 2003 
Algae EC50 ECOSAR 4 Sanderson et al., 2003 
Sulfachloropyridazine Bacteria EC 50(15 min-florescence) 26.4 Kim et al., 2007 26.4 
Sulfadiazine   5 Kümmerer et al., 2003 0.135 Algae EC50 0.135 Halling-Sørensen, 2000 
Sulfadimethoxine 
Fish EC50 ECOSAR 226 Sanderson et al., 2003 
3.5 Daphnia EC50 ECOSAR 3.5 Sanderson et al., 2003 
Algae EC50 ECOSAR 24 Sanderson et al., 2003 
Sulfamethoxazole Fish EC50 ECOSAR 890 Sanderson et al., 2003 0.027 
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Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Daphnia EC50 ECOSAR 4.5 Sanderson et al., 2003 
Algae EC50 ECOSAR 51 Sanderson et al., 2003 
Fish EC50 (96 h) 563 Kim et al., 2007 
Daphnia EC50 (48 h-mortality) >100 Ferrari et al., 2004 
Bacteria EC50 (15 min) 78.1 Kim et al., 2007 
Algae EC50 (96 h-growth) 0.15 Ferrari et al., 2004 
Algae EC50 (96 h- growth) 0.027 Ferrari et al., 2004 
Sulfapyridine Invertebrates EC50 (96h) 21.61 Quinn et al., 2008 21.61 
Sulfathiazole Daphnia EC50 (96h-immobility) 85.4 Kim et al., 2007 85.4 
Tetracycline   0.3 Kümmerer et al., 2003 0.09 Algae EC50 0.09 Halling-Sørensen, 2000 
Trimethoprim 
Fish EC50 ECOSAR 795 Sanderson et al., 2003 
2.6 
Daphnia EC50 ECOSAR 4.8 Sanderson et al., 2003 
Algae EC50 ECOSAR 2.6 Sanderson et al., 2003 
Bacteria EC50 (15min) 177 Kim et al., 2007 
Daphnia EC50 (96h-immobility) 121 Kim et al., 2007 
Invertebrates  LC50 (96h) >100 Quinn et al., 2008 
Fish EC50 (48h) >100 Kim et al., 2007 
Invertebrates  EC50 110 Boillot, 2008 
Algae EC50 90 Boillot, 2008 
Fish EC50 100 Boillot, 2008 
Diltiazem 
Daphnia EC50 (96 h-immobility) 8.2 Kim et al., 2007 
1.9 Fish EC50 ECOSAR 23 Sanderson et al., 2003 Daphnia EC50 ECOSAR 2.9 Sanderson et al., 2003 
Algae EC50 ECOSAR 1.9 Sanderson et al., 2003 
Atenolol Invertebrates  EC50 30 Boillot, 2008 30 
Metoprolol 
Fish EC50 ECOSAR 116 Sanderson et al., 2003 
8 
Daphnia EC50 ECOSAR 8 Sanderson et al., 2003 
Algae EC50 ECOSAR 14 Sanderson et al., 2003 
Invertebrates  LC50 (48h) >100 Huggett et al., 2002 
Invertebrates  LC50 (48h) 8.8 Huggett et al., 2002 
Invertebrates  LC50 (48h) 63.9 Huggett et al., 2002 
Fish LC50 (48h) >100 Huggett et al., 2002 
Nadolol Invertebrates  EC50 110 Boillot, 2008 110 
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Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Propranolol 
Fish EC50 ECOSAR 29.5 Sanderson et al., 2003 
0.244 
Daphnia EC50 ECOSAR 2.3 Sanderson et al., 2003 
Algae EC50 ECOSAR 5.5 Sanderson et al., 2003 
Bacteria EC50 (30min-luminescence) 61 Ferrari et al., 2004 
Algae EC50 (48h) 0.7 Cleuvers, 2005 
Diatoms  EC50 (96 h- growth) 0.244 Ferrari et al., 2004 
Invertebrates  LC50 (48h) 29.8 Huggett et al., 2002 
Invertebrates  LC50 (48h) 0.8 Huggett et al., 2002 
Invertebrates  LC50 (48h) 1.6 Huggett et al., 2002 
Fish  LC50 (48h) 24.3 Huggett et al., 2002 
Invertebrates  EC50 11 Boillot, 2008 
Algae EC50 0.8 Boillot, 2008 
Fish EC50 20 Boillot, 2008 
Timolol 
Fish EC50 ECOSAR 126 Sanderson et al., 2003 
9 Daphnia EC50 ECOSAR 9 Sanderson et al., 2003 
Algae EC50 ECOSAR 15.5 Sanderson et al., 2003 
Bezafibrate  
Fish EC50 ECOSAR 5.3 Sanderson et al., 2003 
5.3 Daphnia EC50 ECOSAR 25 Sanderson et al., 2003 Algae EC50 ECOSAR 18 Sanderson et al., 2003 
Invertebrates  EC50 50 Boillot, 2008 
Clofibrate 
Fish EC50 ECOSAR 5 Sanderson et al., 2003 
0.5 Daphnia EC50 ECOSAR 6.5 Sanderson et al., 2003 
Algae EC50 ECOSAR 0.5 Sanderson et al., 2003 
Clofibric acid  
Fish EC50 ECOSAR 53 Sanderson et al., 2003 
40.2 
Daphnia EC50 ECOSAR 293 Sanderson et al., 2003 
Algae EC50 ECOSAR 192 Sanderson et al., 2003 
Algae EC50 (96h-growth) 94 Ferrari et al., 2004 
Bacteria  EC50 (30min) 91.8 Ferrari et al., 2003 
Invertebrates  EC50 (48h) 83.5 Rosal et al., 2009 
Invertebrates  EC50 (48h) 72 Cleuvers, 2003 
Microtox  EC50 (30min) 91.8 Ferrari et al., 2003 
Algae EC50 (96h- growth) 40.2 Ferrari et al., 2004 
Fenofibrate  Fish EC50 ECOSAR 0.8 Sanderson et al., 2003 0.1 Daphnia EC50 ECOSAR 0.35 Sanderson et al., 2003 
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Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Algae EC50 ECOSAR 0.1 Sanderson et al., 2003 
Fenofibric acid 
Fish EC50 ECOSAR 7.6 Sanderson et al., 2003 
7.6 Daphnia EC50 ECOSAR 38 Sanderson et al., 2003 
Algae EC50 ECOSAR 26 Sanderson et al., 2003 
Gemfibrozil  
Fish EC50 ECOSAR 0.9 Sanderson et al., 2003 
0.9 
Daphnia EC50 ECOSAR 6 Sanderson et al., 2003 
Algae EC50 ECOSAR 4 Sanderson et al., 2003 
Bacteria EC50 (15 min) 35.3 Rosal et al., 2009 
Bacteria EC50 (15 min) 18.8 Farré et al., 2001 
Invertebrates  EC50 (48h) 10.4 Han et al., 2006 
Invertebrates  EC50 (96h) 1.18 Quinn et al., 2008 
Pravastatin  Fish EC50 1.8 Ginebreda et al., 2010 1.8 
Carbamazepine 
Fish EC50 ECOSAR 101 Sanderson et al., 2003 
13.8 
Daphnia EC50 ECOSAR 111 Sanderson et al., 2003 
Algae EC50 ECOSAR 70 Sanderson et al., 2003 
Algae EC50 (3days) 74 Cleuvers, 2003 
Bacteria  EC50 (15min) 52.2 Kim et al., 2007 
Fish EC50 (48h) 35.4 Kim et al., 2007 
Daphnia EC50 (48h-mortality) 13.8 Ferrari et al., 2004 
Diatoms  EC50 (96h- growth) 31.6 Ferrari et al., 2004 
C. dubia EC50 (48h) 77.7 Ferrari et al., 2003 
Diazepam 
Fish EC50 ECOSAR 28 Sanderson et al., 2003 
2 
Daphnia EC50 ECOSAR 2 Sanderson et al., 2003 
Algae EC50 ECOSAR 5.5 Sanderson et al., 2003 
Invertebrates  EC50 90 Boillot, 2008 
Algae EC50 12 Boillot, 2008 
Fish EC50 11 Boillot, 2008 
Fluoxetine 
Fish EC50 ECOSAR 1.7 Sanderson et al., 2003 
0.05 
Daphnia EC50 ECOSAR 0.17 Sanderson et al., 2003 
Algae EC50 ECOSAR 0.8 Sanderson et al., 2003 
Invertebrates  EC50 0.9 Boillot, 2008 
Algae EC50 0.05 Boillot, 2008 
Fish EC50 2 Boillot, 2008 
Cimetidine  Fish EC50 ECOSAR 571 Sanderson et al., 2003 35 
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Compounds Species  Assayed 
Test  
(endpoint) 
Toxicity 
(mg/l) References 
PNEC 
(µg/L) 
Daphnia EC50 ECOSAR 35 Sanderson et al., 2003 
Algae EC50 ECOSAR 40 Sanderson et al., 2003 
Daphnia EC50 (96h-immobility) 271.3 Kim, 2007 
Ranitidine  
Fish EC50 ECOSAR 1076 Sanderson et al., 2003 
63 Daphnia EC50 ECOSAR 63 Sanderson et al., 2003 
Algae EC50 ECOSAR 66 Sanderson et al., 2003 
Clenbuterol  
Fish EC50 ECOSAR 30 Sanderson et al., 2003 
2 Daphnia EC50 ECOSAR 2 Sanderson et al., 2003 
Algae EC50 ECOSAR 10 Sanderson et al., 2003 
Fenoterol 
Fish EC50 ECOSAR 20 Sanderson et al., 2003 
17.5 Daphnia EC50 ECOSAR 17.5 Sanderson et al., 2003 
Algae EC50 ECOSAR 25 Sanderson et al., 2003 
Terbutaline 
Fish EC50 ECOSAR 1.05 Sanderson et al., 2003 
1.05 Daphnia EC50 ECOSAR 27 Sanderson et al., 2003 
Algae EC50 ECOSAR 32 Sanderson et al., 2003 
Cyclophosphamide 
Fish EC50 ECOSAR 70 Sanderson et al., 2003 
11 Daphnia EC50 ECOSAR 1795 Sanderson et al., 2003 
Algae EC50 ECOSAR 11 Sanderson et al., 2003 
Ifosfamide 
Fish EC50 ECOSAR 140 Sanderson et al., 2003 
11 Daphnia EC50 ECOSAR 1795 Sanderson et al., 2003 
Algae EC50 ECOSAR 11 Sanderson et al., 2003 
Iopromide 
Fish EC50 ECOSAR 865000 Sanderson et al., 2003 
370000 Daphnia EC50 ECOSAR 766000 Sanderson et al., 2003 
Algae EC50 ECOSAR 370000 Sanderson et al., 2003 
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As seen in Fig. 2.22., fourteen compounds pose a high risk: 7 antibiotics 
(erythromycin, ofloxacin, sulfamethoxazole, clarithromycin, amoxicillin, tetracycline and 
azithromycin), 2 psychiatric drugs (fluoxetine and diazepam), 2 analgesics-
anti/inflammatories (ibuprofen and mefenamic acid) and 3 lipid regulators (fenofibric acid, 
fenofibrate and gemfibrozil). A medium risk is posed by twenty compounds: 7 analgesic-
anti/inflammatories (acetaminophene, aminopyrine, naproxen, phenazone, salicylic acid, 
codeine and dextropropoxyphene), 8 antibiotics (penicillin G, sulfadiazine, cefotaxime, 
enoxacin, trimethoprim, doxycycline, roxithromycin and metronidazole), 2 beta-blockers 
(propranolol and atenolol), 2 lipid regulators (clofibrate and bezafibrate) and 1 receptor 
antagonist (cimetidine). For the remaining 17 compounds included in Fig. 2.22., the 
environmental risk is considered low, as is that of the 16 PhCs excluded from the graph 
due to an RQ of less than 10-2 (clindamycin, ranitidine, acetylsalicylic acid, clofibric acid, 
timolol, norfloxacin, sulfachloropyridazine, fenoterol, cyclophosphamide, ciprofloxacin, 
lincomycin, nadolol, sulfathiazole, penicillin V, cefaclor, iopromide). 
Comparison of Figures 2.21. and 2.22. shows that the top compounds are not the 
same in the two rankings, with the exception of the two analgesics/anti-inflammatories 
ibuprofen and mefenamic acid. Compounds of different classes had the highest mass loads: 
the antihypertensive hydrochlorothiazide, the psychiatric drug carbamazepine, the receptor 
antagonist cimetidine, the beta-blocker atenolol and 5 analgesics/anti-inflammatories 
(naproxen, ibuprofen, diclofenac, ketoprofen and mefenamic acid), many of which are 
administered frequently and/or over long periods of time. In contrast, the highest risk is 
posed the 12 compounds cited just above belonging to the groups of antibiotics, lipid 
regulators and analgesics/anti-inflammatories. This fact onfirms the results obtained by 
other Authors (among them Escher et al., 2011) that high consumption does not mean high 
risk for the environment.  
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Figure 2.22. RQ of the investigated compounds 
 
2.14 Conclusion 
Most of the municipal WWTPs consist of preliminary, primary and secondary 
treatments (mainly activated sludge systems) with the final effluent being discharged into a 
surface water body and often indirectly reused for irrigation purposes or recreational 
activities. The present study shows that many PhCs are usually present in raw influent at 
concentrations in the range 10-3-102 µg/L and even more, and that common WWTPs are 
not able to efficiently remove all of them. Observed removal efficiencies vary in a wide 
range for the different compounds, as well as for the same substance, due to the different 
chemical and physical characteristics of PhCs and to operational conditions (mainly 
aerobic, anaerobic, anoxic reactors, SRT, pH and water temperature) as discussed above. 
MBRs seem (only 20 pilot plants were investigated and a limited number of PhCs were 
tested) to guarantee higher removal effciencies for most compounds and a better quality of 
the permeates with respect to CAS. 
This study highlights the fact that the occurrence of some PhCs in the secondary 
effluent discharged into surface water bodies may pose a medium–high (acute) risk to 
aquatic life. Furthermore, many other compounds, even if their environmental risk was 
found to be low, are discharged at high daily mass loads, which could contribute to 
negative effects on aquatic organisms in the long term due to chronic and mixture toxicity.  
For these reasons, it would be more prudent to begin monitoring the most frequently and 
most persistent administered PhCs, as well as those with the highest environmental risk, 
namely antibiotics (including erythromycin, ofloxacin, sulfamethoxazole, clarithromycin, 
10-1
1
10
102
10-2
High
Medium
Low
Risk 
level
Er
yt
hr
o
m
yc
in
O
flo
x
ac
in
Su
lfa
m
et
ho
x
az
o
le
Fl
uo
x
et
in
e
D
ia
ze
pa
m
Cl
ar
ith
ro
m
yc
in
Ib
up
ro
fe
n
Am
o
x
ic
illi
n
Te
tra
cy
cl
in
e
M
ef
en
am
ic
 
ac
id
Fe
n
o
fib
ric
 
ac
id
Fe
no
fib
ra
te
Az
ith
ro
m
yc
in
G
em
fib
ro
zil
Ac
et
am
in
o
ph
en
Am
in
o
py
rin
e
Pr
o
pr
an
o
lo
l
Pe
ni
ci
llin
 
G
Cl
o
fib
ra
te
Su
lfa
di
az
in
e
Ce
fo
ta
x
im
e
Na
pr
o
x
en
En
o
x
ac
in
Be
za
fib
ra
te
Ph
en
az
o
ne
Tr
im
et
ho
pr
im
D
o
x
yc
yc
lin
e
Sa
lic
yl
ic
 
ac
id
Ro
x
ith
ro
m
yc
in
At
en
o
lo
l
Co
de
in
e
D
ex
tro
pr
o
po
x
yp
h
M
et
ro
n
id
az
o
le
Ci
m
et
id
in
e
Ifo
sf
am
id
e
D
ic
lo
fe
na
c
Ca
rb
am
az
ep
in
e
Te
rb
ut
al
in
e
D
ilt
ia
ze
m
To
lfe
na
m
ic
 
ac
id
Ox
yt
et
ra
cy
cl
in
e
In
do
m
et
ha
ci
n
Pr
o
py
ph
en
az
o
ne
Ce
fa
le
x
in
M
et
o
pr
o
lo
l
Ch
lo
ra
m
ph
en
ic
o
l
Su
lfa
di
m
et
ho
x
in
e
Cl
en
bu
te
ro
l
Ke
to
pr
o
fe
n
Su
lfa
py
rid
in
e
Pr
av
as
ta
tin
RQ
Chapter 2: Background 
 
90 
 
amoxicillin, tetracycline and azithromycin), psychiatric drugs (like fluoxetine, diazepam 
and carbamazepine), analgesics/anti-inflammatories (ibuprofen, mefenamic acid, naproxen, 
diclofenac and ketoprofen) and lipid regulators (fenofibric acid, fenofibrate and 
gemfibrozil).  
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3.1 Introduction 
3.1.1 Hospital Wastewaters (HWWs) 
During recent years, the issue of PhCs in WWs has become a major concern in terms of 
both human health and the environment. This has prompted the launch of several 
monitoring studies into the most commonly administered compounds in UWWs (Lishman 
et al., 2006; Santos et al., 2007; Terzic et al., 2009) and surface water (Kolpin et al., 2002). 
However, a considerably smaller number of studies have been devoted to characterizing 
PhCs sources, mainly hospital effluents (Boillot et al., 2008; Kosma et al., 2010; 
Kummerer 2001; Sim et al., 2011). In fact, in quite all countries worldwide, no distinction 
is usually made between these WWs and urban effluent, and they, along with their 
potentially hazardous loads, are generally discharged directly into the public sewage 
network and conveyed for co-treatment at the nearest municipal WWTP. 
Nonetheless, considering the multiple research and laboratory activities carried out in 
these structures, as well as the treatments performed and pharmaceuticals administered and 
excreted within them, a wide range of concentrations of hazardous substances may be 
present in hospital effluent (Verlicchi et al., 2010b). HWWs are composed of the effluents 
of different services: kitchen, internal laundry, heating and cooling systems, laboratories, 
radiology departments, outpatients departments, transfusion centres and wards. Due to the 
nature and quantity of the micro-pollutants they harbour, such as active substances of 
medicines and their metabolites, chemicals, heavy metals, disinfectants, sterilizers, and 
radioactive markers, which are typically present at concentrations of µg L-1, they should be 
earmarked for special consideration. Previous studies investigated the occurrence in 
hospital effluents of detergents, disinfectants, organic compounds (alcohols, acetone, 
formaldehyde, acetaldehyde, phenols) and several metals (Emmanuel et al., 2005; Boillot 
et al., 2008) and the proliferation of drug-resistant microorganisms (Hawkshead 2008). The 
issue of PhC occurrence in hospital effluents has already been investigated by different 
Authors, among them Thomas et al., 2007a; Gomez et al., 2006, Mahnik et al., 2007, 
Suarez et al., 2009, Kummerer, 2001.  
 
It would therefore be of interest to discover the percentage contributions of PhCs from 
hospitals to those in the total municipal WWTP influent, in order to discover whether 
specific treatments for hospital effluent are necessary to reduce environmental 
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contamination by persistent and hazardous micropollutants. To date, however, very little 
data on this topic has been reported in the literature (Beier et al. 2011; Heberer and 
Feldman, 2005; Langford and Thomas, 2009; Ort et al., 2010a; Thomas et al., 2007a), and 
those studies have been conducted to a limited number of compounds. 
In order to investigate the differences between hospital and urban wastewaters, an 
assessment of the (acute and chronic) risk posed to aquatic organisms by the two effluents 
would be advisable. In fact, although the ecotoxicological effect of PhCs in treated UWWs 
has been investigated (Ferrari et al., 2003; Kostich et al., 2008), once again, very little data 
is available regarding hospital effluent, and what is available generally relies on predicted, 
rather than measured, concentrations (Escher et al., 2011). 
 
3.1.2 Ecotoxicity of HWWs  
HWWs is often assumed to be the most toxic to aquatic life and there are indeed 
several studies in which genotoxic activity of HWWs has been confirmed. Guiliani et al. 
(1996). found that out of over 800 hospital effluent samples from a large cancer hospital 
13% were genotoxic in the umuC assay. Genotoxic samples were detected throughout a 
24-h period with the morning hours showing the highest activity. of the toxic wastewater 
samples 96% showed genotoxic potential without detectable cytotoxic effects. the authors 
considered that anti-neoplastic agents were the possible causative agents however they 
concluded that there was no obvious pollution hazard attributable to the waste because no 
genotoxic activity was detected in the influx of the sewage treatment plant(STP) receiving 
the wastewater of the hospital. Steger-Hartmann et al. (1997) have tried to identify the 
causal agents of genotoxicity activity in HWWs investigating the effects of 
cyclophosphamide in the umuC assay. They found that there were no genotoxic effects at a 
concentration of 1 g L-1. this was in agreement with the SOS chromotest in which Hellmèr 
and Bolcsfoldi (1992). did not detect a genotoxic effect of cyclophosphamide at 
concentration of up to 4.6 g L-1. Hartmann et al.(1998) has found evidence to suggest that 
one single class of antibiotic drug, the fluoroquinolone antibiotics (e.g. ciprofloxacin) were 
responsible for the genotoxic activity for a specific hospital under investigation. Recently 
the toxicological effects of PhCs in HWWs has been performed by PILLS (2012), and as a 
results, raw HWWs was found to be moderately cytotoxic, estrogenic and toxic to various 
test organisms compared to municipal WW. 
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3.1.3 Antibiotic resistant bacteria in HWWs 
The widespread use of antibiotics in medicine and in intensive animal husbandry is 
indicative of the selection pressure exerted on bacteria (Klare et al. 1995). Although 
antibiotics have been used in large quantities for some decades, the existence of these 
substances in the environment has received little notice until recently. In the last years a 
more complex investigation of antibiotic has been undertaken in different countries in 
order to assess their environmental risks. It has been found that the concentrations of 
antibiotics are higher in hospital effluent than in municipal wastewater which are higher 
than in different surface waters, ground water and sea water (Kümmerer 2001). 
Bacteria have developed different mechanisms to render ineffective the antibiotics 
used against them. The genes encoding these defence mechanisms are located on the 
bacterial chromosome or on extrachromosomal plasmids, and are transmitted to the next 
generation (vertical gene transfer). Genetic elements, such as plasmids, can also be 
exchanged among bacteria of different taxonomic affiliation (horizontal gene transfer) 
(Davison 1999). Horizontal gene transfer by conjugation is common in nature, or in 
technical systems, where the density of bacteria is high and so, accordingly, is the chance 
of two suitable bacterial cells coming close to each other (Muela et al. 1994). 
Figure 3.1. shows the range of the measured concentrations of resistant integrons and 
the proportion of bacteria with resistant integrons in HWWs, domestic wastewater and in 
two rivers. As antibiotic resistant integrons are embedded on mobile genetic elements 
generally present in further copies, the relative abundance can be higher than 100%. 
Specialised medical centres with geriatric and psychiatric activities were not sources of  
bacteria harbouring resistant integrons. The elevated concentrations and relative abundance 
of hospital effluents (5 to 390%) when compared to the investigated rivers (0.6 to 1.9%) 
showed that the hospitals are a potential source of multidrug resistant bacteria. 
Furthermore, with regards to the relative abundance found in municipal waste water (13%) 
hospital effluents can be seen as a hotspot for antibiotic resistant bacteria (PILLS 2012). 
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Figure 3.1. Concentration of antibiotic resistance integrons and proportion of bacteria with antibiotic 
resistance integrons in hospital waste water in comparison to municipal waste water and river water( adapted 
from PILLS 2012).  
 
3.1.4 Hospitals as a point source of PhCs 
The aims of this chapter were to investigate the occurrence of 73 common PhCs from 
12 different therapeutic classes in the effluent of two hospitals (medium-sized and large) in 
the province of Ferrara, north Italy, and in the influent and effluent of the local municipal 
WWTP, which also receives and co-treats the wastewater from the larger hospital. In 
particular : (i) to compare the PhC concentrations discharged by the two hospitals over the 
same period, (ii) to evaluate the PhCs discharged by the large hospital over two different 
periods, (iii) to compare these concentrations with those found in the influent to the 
WWTP during the same period, (iv) to evaluate the contribution, in terms of the 
compounds detected, of the large hospital to the total influent to the WWTP, and finally (v) 
to assess and compare the potential environmental risk of hospital effluent and WWTP 
influent by mean of RQ. In this way, this study attempts to provide an initial assessment of 
these issues with a view to comparing the chemical and ecotoxicological characteristics of 
hospital effluent with those of the influent to the WWTP charged with co-treating hospital 
wastewater.  
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3.2 Experimental materials and methods 
3.2.1 Hospitals and WWTP under Investigation 
3.2.1.1 Lagosanto hospital ( Hospital A) 
It is a medium-sized hospital with 300 beds, 650 members of staff and twelve main 
wards. It is situated in the town of Lagosanto (5000 inhabitants), 30 km from Ferrara, in a 
coastal area that is densely populated in summertime due to tourist influx (in the peak 
months of July and August, the population is seven times higher than the resident one). 
Hospital flow rate is regularly monitored by the internal Water and Wastewater Network 
Managing Body. The resulting average flow rate is equal to 160 m3 d-1, corresponding to a 
specific water consumption of about 550 L bed-1 d-1. 
 
3.2.1.2 Ferrara hospital (Hospital B) 
It is a large hospital with 900 beds, 2000 members of staff and a total of over 50 
wards and departments. It is located in the centre of the city of Ferrara (135,000 
inhabitants) and its effluent is directly discharged into the combined sewage network, 
conveyed to the Ferrara WWTP and co-treated with the urban WWs. Ferrara Hospital flow 
rate is regularly monitored by the internal Water and Wastewater Network Managing 
Body. The resulting average flow rate is equal to 603 m3 d-1, corresponding to a specific 
water consumption of about 670 L bed-1 d-1, and its bed density, that is the number of beds 
per 1000 inhabitants, is roughly 6.5. 
 
3.2.1.3 Ferrara WWTP 
Designed for 120 000 population equivalent (pe), it performs preliminary 
treatments (screening and grit removal), a biological treatment and a final NaClO 
disinfection step. The biological treatment consists of a conventional activated sludge 
system including denitrification (V = 4000 m3) and nitrification (V = 6100 m3) steps, 
followed by secondary sedimentation (V = 6000 m3) Figure 3.2. It operates at a low-to-
medium load, at an average hydraulic retention time of 6 h, a sludge age of 8 d and a 
mixed liquor concentration of approximately 3.5 kg m-3. The WWTP influent flow rate is 
on average 28 000 m3 d-1, and Hospital B contributes roughly 2 % of the influent hydraulic 
load. 
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Figure 3.2. WWTP of Ferrara 
 
3.2.2 Target Compounds 
The 73 PhCs under investigation are reported in Table 3.1., grouped according to 
their therapeutic class. These compounds were selected due to their high prescription rates 
or volumes, the availability of a reliable analysis methods (Gros et al., 2006), as well as 
due to their occurrence and ubiquity in the aquatic environment (Bell et al., 2011; 
Daughton and Ternes, 1999, Fatta-Kassinos et al., 2011, Pal et al., 2010). The selected 
compounds represent the most consumed within their corresponding therapeutical class. It 
is quite evident that analgesics and anti-inflammatories are the groups most investigated, 
followed by beta-blockers and lipid regulators. 
 
Table 3.1. Investigated pharmaceutical compounds grouped according to therapeutic class. 
 
THERAPEUTIC 
CLASS COMPOUNDS 
A 
Analgesics / Anti-
inflammatories  
Acetaminophen, Codeine, Diclofenac, Ibuprofen, Indomethacin, Ketoprofen, 
Mefenamic acid, Naproxen, Phenazone, Phenylbutazone, Propyphenazone, 
Salicylic acid  
B Antibiotics  
Azithromycin, Chloramphenicol, Chlortetracycline, Ciprofloxacin, 
Clarithromycin, Danofloxacin, Doxycycline, Enoxacin, Enrofloxacin, 
Erythromycin, Josamycin, Metronidazole, Nifuroxazide, Norfloxacin, Ofloxacin, 
Oxytetracycline, Roxythromycin, Spiramycin, Sulfadiazine, Sulfamethazine, 
Sulfamethoxazole, Tetracycline, Tilmicosin, Trimethoprim, Tylosin A 
C Anti-diabetics Glibenclamide 
D Anti-hypertensives Enalapril, Hydrochlorothiazide, Lisinopril 
E Barbiturates Butalbital, Pentobarbital, Phenobarbital 
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F Beta-agonists Clenbuterol, Salbutamol 
G Beta-blockers 
Atenolol, Betaxolol, Carazolol, Metoprolol, Nadolol, Pindolol, Propranolol, 
Sotalol, Timolol 
H Diuretics Furosemide 
I Lipid regulators 
Atorvastatin, Bezafibrate, Clofibric acid, Fenofibrate, Gemfibrozil, Mevastatin, 
Pravastatin 
J Psychiatric drugs Carbamazepine, Diazepam, Fluoxetine, Lorazepam, Paroxetine 
K Receptor antagonists Cimetidine, Famotidine, Loratadine, Ranitidine 
L Antineoplastics Tamoxifen 
 
3.2.3 Sampling Sites and sample preparation  
Four sampling points were monitored: the effluents from Hospitals A and B and the 
influent and the effluent of Ferrara WWTP. Two experimental campaigns were carried out 
in August 2009 (summer) and in March 2010 (winter). In the first period, water samples 
were taken from the raw effluent of Hospital A (n = 4) and Hospital B (n = 4), while in the 
second one, from the effluent of hospital B (n = 4) and the influent and the effluent of the 
Ferrara WWTP (n = 4). Manholes located on the property line of each hospital were 
selected as sampling points, based on their suitability for covering all of the sewage 
discharges from the facility. Portable auto samplers (Sigma 900) were used to collect 
samples from each sampling point.  
24-hour composite water samples were collected over four days on each sampling 
point at a rate of one sample per hour (a total of 24 sub-samples, 125 mL each were 
collected over 24 hours). To insure representative sampling and consistency in the 
estimation of the mass loadings at the differing locations, identical sampling strategies (the 
same sampling frequencies) were used for both hospital B effluent and WWTP influent. 
Water samples were collected only in dry days in order to avoid dilution effects. 
Wastewater samples were collected in amber glass bottles, pre-rinsed with ultra-pure 
water, as 24-h composite samples. The samples were immediately transported to the near 
laboratory under cooled conditions (4 °C). Upon reception, samples were filtered through 
0.45 µm Nylon filters (Whatman, Maidstone, UK) to eliminate suspended solid matter and 
then frozen until analysis (less than a week) at -20 °C. It is important to observe that the 
fraction of the selected pharmaceutical sorbed onto the suspended solids is removed during 
preparation phase and, as a consequence, the values of (measured) concentrations found 
correspond to the dissolved fraction of the investigated compounds. 
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3.2.4 Standards  
All standard solutions used were of a high purity grade (>90%). Isotopically 
labelled compounds, used as internal standards, were: 13C-phenacetin, fluoxetine-d5 and 
flumequine from Sigma-Aldrich (Steinham, Germany), sulfathiazole-d4 from Toronto 
Research Chemicals, diazepam-d5 and phenobarbital-d5 from Cerilliant (Texas, USA), 
atenolol-d7, carbamazepine-d10, ibuprofen-d3 from CDN isotopes (Quebec, Canada) and 
mecoprop-d3 from Dr. Ehrenstorfer (Augsburg, Germany). Both individual stock standard 
and isotopically labelled internal standard solutions were prepared on a weight basis in 
methanol, except fluoroquinolones, which were dissolved in a water:methanol mixture 
(1:1) containing 0.2% v/v hydrochloric acid (Golet et al., 2002). After preparation, 
standards were stored at −20°C. Due to their limited stability, fresh stock solutions of 
antibiotics were prepared monthly, while stock solutions for the other substances were 
renewed every three months. A mixture of all pharmaceuticals was prepared by appropriate 
dilution of individual stock solutions in methanol–water (25:75, v/v). Working standard 
solutions, also prepared in a methanol–water (25:75, v/v) mixture, were renewed before 
each analytical run. A separate mixture of isotopically labelled internal standards, used for 
internal standard calibration, was prepared in methanol, and further dilutions in methanol–
water (25:75, v/v) mixture. 
 
3.2.5 Analytical methods 
The multiresidue analytical method developed by Gros et al. (2009) was used to 
measure the selected pharmaceuticals in wastewaters. Briefly, after filtration, an 
appropriate volume of aqueous solution of 5% Na2EDTA were added to 200 mL of 
WWTP effluent and 100 mL of influent (hospital and urban) wastewaters, respectively, to 
achieve a final Na2EDTA concentration of 0.1% in the samples. The measured volumes 
were afterwards preconcentrated onto a lipophilic–hidrophilic balanced Oasis HLB (60 mg 
and 3 mL) cartridge, using a Baker vacuum system (J.T. Baker, Deventer, The 
Netherlands) at a flow rate of 5 mL/min. After sample preconcentration, cartridges were 
rinsed with 5 mL of HPLC grade water and were dried under vacuum for 15–20 min, to 
remove excess of water. Elution of target compounds was performed with 2 × 4 mL pure 
methanol. Extracts were evaporated to dryness under a gentle nitrogen stream and 
reconstituted with 1 mL of methanol–water (25 :75, v/ v). Finally, 10 µL of a 1 ng µL-1 
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standard mixture containing the internal standards were added in the extract for internal 
standard calibration. Instrumental analysis was performed by liquid chromatography, using 
an Agilent HP 1100 HPLC (Palo Alto, CA, USA) system, equipped with an auto sampler 
and connected in series with a 4000 QTRAP hybrid triple quadrupole-linear ion trap mass 
spectrometer operating with a Turbo Ion Spray source (Applied Biosystems-Sciex, Foster 
City, CA, USA). Chromatographic separation was achieved with a Purospher Star RP-18 
endcapped column (125 mm × 2.0 mm, particle size 5 µm) preceded by a C18 guard 
column (4 × 4,5 µm), both supplied by Merck (Darmstadt, Germany). For the analysis in 
NI mode , eluent A was a mixture of acetonitrile–methanol (1:1, v /v) and eluent B was 
HPLC grade water at a flow rate of 0.2 mL/min, where as the analysis in PI mode was 
performed using acetonitrile as eluent A and HPLC grade water with 0.1% formic acid as 
eluent B. Appendix B.1. provides details of the optimized QqLIT-MS parameters (two 
SRMs, collision energies) for each investigated compound in negative and positive 
ionization modes. Limits of detection (LOD) for the investigated compounds were in the 
range 1-16 ng L-1 for the WWTP influent and the effluent form the two hospitals and in the 
range 1-18 ng L-1 for the WWTP effluent. Table 3.2. reports the values for each selected 
substance. Recoveries of the methods were determined by analysing fortified samples of 
each type of wastewater spiked in triplicate to 1 µg L-1. They were in the range 22-145 %. 
The single values with relative standard deviation (RSD) are reported in Table 3.2. 
 
3.2.6 Risk Quotients (RQ) and Ecotoxicological Risk Assessment 
The potential risk of PhCs was assessed by means of their risk quotient values 
(RQ), calculated as the ratio between their MEC and PNEC. PNEC values were estimated 
on the basis of toxicity data reported for several aquatic organisms: bacteria, algae, 
invertebrates and fish (as reported in Table 2.7.). According to (EC 2003; Tauxe-Wuersch 
et al., 2005), PNEC values were estimated as 1000 times lower than the most sensitive 
species assayed (marked in bold in the Table 2.7.), so as to take into account the effect on 
other, potentially more sensitive, aquatic species to those used in toxicity studies. A 
commonly used risk ranking criterion was applied: RQ < 0.1, minimal risk to aquatic 
organisms, 0.1 ≤ RQ < 1, median risk; RQ ≥ 1, high risk (De Souza et al., 2009; Hernando 
et al., 2006; Zhao et al., 2010).  
Chapter 3: Hospital effluent: Investigation of the concentrations and distribution of PhCs and environmental risk assessment 
 
102 
 
Table 3.2. Recovery and limits of detection (LOD) of the selected compounds. 
  
% Recovery (±RSD) LOD (ng L-1) 
Therapeutic 
Class Compound 
Hospital A 
(Summer) 
Hospital B 
(Summer) 
Hospital B 
(Winter) 
WWTP inf. 
(Winter) 
WWTP eff. 
(Winter) 
Hospital A 
(Summer) 
Hospital B 
(Summer) 
Hospital B 
(Winter) 
WWTP inf. 
(Winter) 
WWTP eff. 
(Winter) 
Analgesic/anti-
inflammatories 
A 
Acetaminophen 92 (±3) 121 (±1) 96 (±4) 131 (±9) 80 (±15) 2 3 7 11 8 
Codeine 86 (±8) 78 (±5) 113 (±3) 75 (±6) 94 (±2) 3 3 2 6 7 
Diclofenac 127 (±12) 89 (±3) 78 (±11) 100 (±9) 102 (±5) 4 5 5 2 2 
Ibuprofen 83 (±13) 91 (±7) 105 (±5) 111 (±14) 133 (±8) 8 6 11 9 9 
Indomethacin 80 (±13) 94 (±6) 116 (±1) 103 (±3) 81 (±5) 2 3 3 6 7 
Ketoprofen 55 (±3) 112 (±6) 89 (±8) 62 (±4) 73 (±13) 3 4 7 7 8 
Mefenemic acid 128 (±1) 124 (±5) 95 (±2) 86 (±7) 63 (±15) 6 7 4 5 3 
Naproxen 98 (±4) 118 (±2) 116 (±1) 104 (±1) 95 (±3) 11 5 5 6 3 
Phenazone 100 (±3) 103 (±1) 96 (±15) 85 (±13) 78 (±11) 2 3 8 5 6 
Phenylbutazone 120 (±9) 111 (±4) 81 (±4) 67 (±3) 92 (±16) 3 5 4 6 3 
Propyphenazone 119 (±9) 130 (±3) 104 (±15) 123 (±12) 98 (±21) 2 6 3 2 5 
Salicylic acid 91 (±4) 88 (±8) 78 (±25) 56 (±6) 91 (±7) 12 9 8 11 6 
Antibiotics 
B 
Azithromycin 45 (±3) 58 (±1) 85 (±9) 78 (±7) 76 (±13) 3 4 2 2 4 
Chloramphenicol 87 (±13) 95 (±2) 96 (±25) 86 (±1) 78 (±6) 9 8 4 9 7 
Chlortetracycline 56 (±4) 90 (±7) 100 (±8) 56 (±1) 74 (±9) 12 11 8 14 9 
Ciprofloxacin 103 (±3) 62 (±5) 105 (±5) 107 (±7) 123 (±13) 3 4 3 3 2 
Clarithromycin 89 (±23) 95 (±2) 91 (±1) 78 (±6) 121 (±9) 4 3 6 6 2 
Danofloxacin 101 (±9) 109 (±6) 104 (±3) 103 (±4) 95 (±2) 7 8 5 9 3 
Doxycycline 94 (±7) 56 (±3) 67 (±10) 41 (±26) 103 (±3) 11 8 15 16 18 
Enoxacin 120 (±6) 98 (±7) 121 (±4) 133 (±9) 89 (±17) 3 6 5 7 2 
Enrofloxacin 89 (±1) 107 (±3) 88 (±1) 79 (±4) 93 (±3) 4 5 5 2 3 
Erithromycin 99 (±3) 96 (±9) 112 (±16) 103 (±3) 95 (±5) 7 5 8 7 8 
Josamycin 112 (±9) 91 (±4) 87 (±7) 46 (±4) 23 (±8) 3 2 3 2 1 
Metronidazole 37 (±5) 22 (±1) 47 (±9) 56 (±3) 45 (±7) 6 5 3 4 1 
Nifuroxazide 111 (±2) 56 (±4) 79 (±5) 96 (±1) 87 (±1) 11 14 12 9 7 
Norfloxacin 56 (±3) 43 (±9) 112 (±2) 118 (±7) 109 (±1) 8 5 6 6 3 
Ofloxacin 135 (±1) 94 (±7) 79 (±25) 98 (±23) 79 (±1) 1 2 1 1 1 
Oxytetracycline 100 (±23) 105 (±18) 95 (±12) 78 (±8) 45 (±9) 6 8 7 12 15 
Roxithromycin 120 (±1) 94 (±5) 56 (±3) 99 (±9) 78 (±8) 4 5 6 3 2 
Spiramycin 145 (±5) 80 (±4) 98 (±7) 93 (±6) 109 (±11) 2 3 2 3 2 
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% Recovery (±RSD) LOD (ng L-1) 
Therapeutic 
Class Compound 
Hospital A 
(Summer) 
Hospital B 
(Summer) 
Hospital B 
(Winter) 
WWTP inf. 
(Winter) 
WWTP eff. 
(Winter) 
Hospital A 
(Summer) 
Hospital B 
(Summer) 
Hospital B 
(Winter) 
WWTP inf. 
(Winter) 
WWTP eff. 
(Winter) 
Sulfadiazine 131 (±6) 45 (±3) 105 (±3) 103 (±4) 56 (±24) 2 4 4 5 7 
Sulfamethazine 56 (±5) 97 (±8) 96 (±9) 124 (±3) 65 (±5) 2 4 5 2 6 
Sulfamethoxazole 73 (±1) 56 (±1) 98 (±3) 87 (±5) 120 (±3) 1 3 2 3 1 
Tetracycline 81 (±7) 85 (±28) 123 (±18) 99 (±5) 95 (±2) 7 9 12 14 13 
Tilmicosin 145 (±3) 103 (±3) 78 (±1) 94 (±1) 82 (±16) 1 2 1 3 6 
Trimethoprim 57 (±7) 51 (±7) 86 (±6) 119 (±11) 88 (±18) 1 1 2 1 1 
Tylosin A 103 (±3) 86 (±8) 107 (±19) 102 (±7) 145 (±1) 2 1 2 3 1 
Anti-diabetic C Glibenclamide 56 (±3) 76 (±1) 98 (±7) 112 (±21) 97 (±15) 3 5 2 4 2 
Anti-
hypertensives D 
Enalapril 92 (±11) 106 (±17) 65 (±8) 93 (±3) 69 (±7) 2 1 3 2 4 
Hydrochlorothiazide 83 (±15) 86 (±19) 100 (±1) 103 (±3) 87 (±9) 6 9 8 12 13 
Lisinopril 91 (±4) 98 (±7) 134 (±8) 111 (±6) 95 (±3) 2 3 12 15 9 
Barbiturates 
E 
Butalbital 103 (±3) 56 (±12) 45 (±2) 47 (±1) 69 (±1) 2 1 5 6 3 
Pentobarbital 45 (±7) 51 (±23) 119 (±4) 99 (±19) 103 (±6) 5 2 3 4 3 
Phenobarbital 35 (±1) 48 (±4) 75 (±3) 44 (±8) 26 (±2) 1 1 2 3 2 
Beta-agonists 
F 
Clenbuterol 105 (±23) 91 (±7) 95 (±2) 115 (±8) 117 (±7) 2 2 1 1 1 
Salbutamol 80 (±20) 89 (±11) 135 (±1) 97 (±1) 78 (±9) 1 1 1 2 1 
Beta-blockers 
G 
Atenolol 34 (±5) 83 (±13) 145 (±8) 58 (±4) 118 (±6) 4 5 11 13 9 
Betaxolol 118 (±3) 56 (±3) 95 (±2) 101 (±1) 120 (±5) 2 3 2 2 1 
Cerazolol 99 (±1) 98 (±7) 92 (±16) 79 (±9) 91 (±6) 1 1 1 2 1 
Metoprolol 113 (±5) 107 (±3) 129 (±1) 136 (±6) 95 (±2) 1 2 1 3 1 
Nadolol 106 (±12) 96 (±9) 90 (±1) 87 (±8) 97 (±3) 2 2 1 1 2 
Pindolol 45 (±3) 75 (±23) 103 (±3) 108 (±9) 49 (±16) 3 1 3 2 4 
Propranolol 69 (±8) 61 (±5) 104 (±1) 70 (±8) 57 (±9) 2 2 1 1 1 
Sotalol 73 (±9) 117 (±19) 110 (±4) 56 (±7) 91 (±7) 3 5 9 8 10 
Timolol 45 (±12) 79 (±3) 62 (±15) 56 (±6) 101 (±14) 2 1 5 3 2 
Diuretics H Furosemide 78 (±19) 59 (±9) 100 (±1) 96 (±7) 92 (±3) 3 5 6 8 9 
Lipid 
regulators 
I 
Atorvastatin 89 (±19) 131 (±12) 111 (±1) 118 (±3) 85 (±3) 1 3 5 3 4 
Bezafibrate 134 (±1) 95 (±1) 97 (±5) 95 (±7) 56 (±3) 1 1 2 2 2 
Clofibric acid 135 (±1) 120 (±7) 108 (±15) 71 (±3) 98 (±7) 1 2 1 1 1 
Fenofibrate 110 (±9) 117 (±18) 92 (±1) 79 (±9) 107 (±3) 2 1 3 1 1 
Gemfibrozil 145 (±1) 64 (±23) 67 (±1) 87 (±5) 96 (±9) 2 3 2 1 1 
Mevastatin 126 (±9) 113 (±2) 110 (±7) 72 (±9) 87 (±9) 5 6 8 9 7 
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% Recovery (±RSD) LOD (ng L-1) 
Therapeutic 
Class Compound 
Hospital A 
(Summer) 
Hospital B 
(Summer) 
Hospital B 
(Winter) 
WWTP inf. 
(Winter) 
WWTP eff. 
(Winter) 
Hospital A 
(Summer) 
Hospital B 
(Summer) 
Hospital B 
(Winter) 
WWTP inf. 
(Winter) 
WWTP eff. 
(Winter) 
Pravastatin 114 (±23) 69 (±3) 98 (±1) 90 (±7) 71 (±14) 12 11 9 13 15 
Psychiatric 
drugs 
J 
Carbamazepine 92 (±19) 68 (±9) 92 (±1) 145 (±8) 111 (±7) 3 4 2 4 5 
Diazepam 101 (±15) 45 (±26) 76 (±12) 103 (±3) 59 (±16) 1 1 2 1 2 
Fluoxetine 139 (±1) 96 (±5) 92 (±6) 109 (±9) 107 (±6) 3 2 2 1 2 
Lorazepam 100 (±3) 123 (±7) 103 (±3) 91 (±1) 98 (±12) 8 7 8 9 11 
Paroxetine 103 (±8) 135 (±15) 87 (±9) 45 (±18) 103 (±3) 2 3 2 2 3 
Receptor 
antagonists 
K 
Cimetidine 103 (±3) 56 (±25) 67 (±3) 78 (±1) 89 (±9) 1 3 3 5 2 
Famotidine 119 (±9) 109 (±13) 92 (±8) 95 (±2) 104 (±6) 2 3 2 4 3 
Loratadine 132 (±3) 79 (±1) 75 (±7) 103 (±3) 98 (±7) 3 1 2 3 2 
Ranitidine 138 (±4) 127 (±15) 94 (±9) 97 (±6) 135 (±1) 8 7 8 11 10 
Cytostatic L Tamoxifen 138 (±1) 65 (±3) 103 (±3) 145 (±2) 92 (±3) 1 1 2 1 1 
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3.3 Results and discussion 
Table 3.3. shows the ranges of concentrations and the corresponding average values 
(in brackets) of the investigated compounds in the effluents from Hospital A (in summer), 
Hospital B (in summer and in winter) and in the influent and effluent of Ferrara WWTP (in 
winter). The final row reports the number of compounds detected during the investigation 
periods (occurrence). In descending order, the highest occurrence of PhCs was detected in 
the WWTP influent (63), in Hospital B effluent in winter (62), Hospital A effluent in 
summer (61) and in the WWTP effluent (58). The lowest number of detected substances 
was found in the Hospital B effluent in summer (49).  
Among the analgesics/anti-inflammatories, also in descending order, the highest 
average concentrations were found for ketoprofen (5 µg L-1), acetaminophen (4.5 µg L-
1µg/L) in Hospital A effluent, acetaminophen (4.1 µg L-1) and indomethacin (2.2 µg L-1) in 
Hospital B effluent in summer, naproxen (4.9 µg L-1) and ibuprofen (2.6) in Hospital B 
effluent in winter, ibuprofen (1.0 µg L-1) and naproxen (0.83 µg L-1) in the WWTP 
influent, followed by mefenamic acid (0.66 µg L-1) and diclofenac (0.28 µg L-1) in the 
WWTP effluent.  
Among the antibiotics, the most prevalent compounds were: ofloxacin (19 µg L-1) 
and ciprofloxacin (12 µg L-1) in Hospital A effluent, ofloxacin (3.7 µg L-1) and 
sulfamethoxazole (1.8 µg L-1) in Hospital B effluent in summer, ofloxacin (31 µg L-1) and 
sulfamethoxazole (21 µg L-1) in Hospital B effluent in winter, ciprofloxacin (2.2 µg L-1) 
and ofloxacin (1.0 µg L-1) in the WWTP influent, followed by ciprofloxacin (0.64 µg L-1) 
and clarithromycin (0.28 µg L-1) in the WWTP effluent.  
 
Hydrochlorothiazide was the most present anti-hypertensive at the four sampling 
points, being detected at concentrations of 1.8 µg L-1 in Hospital A effluent, 0.68 µg L-1 in 
Hospital B effluent (summer), 2.2 µg L-1 in Hospital B effluent (winter), 2.7 µg L-1 in the 
WWTP influent, and 1.2 µg L-1 in the WWTP effluent. Among the barbiturates, 
pentobarbital had the highest concentrations in Hospital A effluent (0.035 µg L-1), and 
butalbital the highest concentrations in Hospital B effluent in summer (0.032 µg L-1) and 
winter (0.36 µg L-1), while phenobarbital was most prevalent in the WWTP influent (0.21 
µg L-1) and effluent (0.14 µg L-1). Salbutamol was the beta-agonist with the highest 
concentration in the effluent of Hospital A (0.062 µg L-1) and Hospital B in summer (0.028 
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µg L-1), whereas clenbuterol had the highest concentrations in Hospital B effluent in winter 
(0.18 µg L-1). The most represented beta blockers were: atenolol at 5.1µg L-1 and sotalol at 
4.8 µg L-1 in Hospital A effluent, and atenolol 2.4 µg L-1 in Hospital B effluent in summer; 
in winter atenolol was detected at 5.8 µg L-1 and sotalol at 5.1 µg L-1 in Hospital B 
effluent, while in the WWTP influent, atenolol was found at 2.1 µg L-1 and sotalol at 0.53 
µg L-1, in contrast with the 0.32 µg L-1 sotalol and 0.073 µg L-1 atenolol detected in the 
WWTP effluent. Among the lipid regulators, those with the highest concentrations were 
mevastatin in Hospital A effluent (1.1 µg L-1) and in Hospital B effluent in summer (0.49 
µg L-1), atorvastatin in Hospital B effluent in winter (0.27 µg L-1), and gemfibrozil in the 
WWTP influent (0.20 µg L-1) and effluent (0.11 µg L-1). The psychiatric drug 
carbamazepine and the receptor antagonist ranitidine displayed the highest concentrations 
of their type at all the sampling points.  
There are limited data that allow for a comparison referring to PhC occurrence in 
hospital effluents, however Verlicchi et al. (2010b) reviewed the variability ranges for 
some compounds of different therapeutic classes in raw hospital wastewater. Based on 
these findings, measured concentrations for PhCs in hospital A and B effluents are in 
agreement with those reported in Verlicchi et al. (2010b), except for erythromycin 
(measured concentrations are 2 order of magnitude lower than those of the review), 
propranolol and gemfibrozil (1 order of magnitude lower). More literature data are 
available regarding the presence of PhCs in urban wastewaters. A comparison with the 
variability intervals found in different countries by Jelicic and Ahel, (2003), Kasprzyk-
Hordern et al. (2009), Radjenovic et al. (2009), Roberts and Thomas (2006), Rosal et al. 
(2010) Sipma et al. (2010) Sui et al. (2010) and Verlicchi et al. (2010b) shows that 
measured concentrations in the influent of Ferrara WWTP is in good agreement with them 
except for codeine, erythromycin, propranolol and cimetidine that were at a concentrations 
of 1 order of magnitude lower than those reported by literature.  
 
On the basis of the concentration data reported above, the following comparisons 
were made between: the two hospital effluents in summer, the effluent of Hospital B in 
summer and winter, and Hospital B effluent and Ferrara WWTP influent (which, in 
addition to urban wastewater, receives that of Hospital B) in winter. 
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3.3.1 Comparison of PhC Concentrations in the Effluent from Hospitals A and B in 
Summer 
Data reported in Table 3.3. show that, for the majority of the compounds 
considered, concentrations were higher in the effluent of Hospital A than those in that of 
Hospital B. Only 12 out of the 73 investigated PhCs, codeine, phenylbutazone, 
azithromycin, chlortetracycline, josamycin, sulfadiazine, butalbital, phenobarbital, 
propranolol, atorvastatin, carbamazepine and fluoxetine, were detected in lower 
concentrations in Hospital A effluent than those found in Hospital B.  
The relatively large dose/population ratios detected in Hospital A could be due to 
the fact that: (i) Hospital A is situated in a coastal area, densely populated by tourists in the 
summertime, the period in which the water samples were taken; thus, analyses may reflect 
that a higher consumption of PhCs than average occurred; and/or (ii) Hospital A has a 
lower daily water demand, resulting in lesser dilution of the micropollutants present.  
 
3.3.2 Comparison between Summer and Winter Concentrations of PhCs in Hospital 
B Effluent  
Data of Table 3.3. show that 49 compounds were detected in summer and 62 in 
winter. Five compounds were found only in summer and 18 only in winter. Only 6 
compounds (phenazone, danofloxacin, enrofloxacin, tylosin A, fenofibrate and tamoxifen) 
were not detected at either sampling point at any time. Of the 44 compounds found at least 
in one sampling point, the winter concentrations were, on average, greater than those 
detected in the summer, with their ratio ranging between 1.1 (sulfamethoxazole) and 190 
(clarithromycin), with an average value of 10.4, a standard deviation of 31.3, and a 95th-
percentile equal to 16.9. Only 2 anti-inflammatories (acetaminophen and indomethacin), 5 
antibiotics (chlortetracycline, doxycycline, josamycin, oxytetracycline, tetracycline and 
trimethoprim), the anti-hypertensive lisinopril, the beta-blocker propanolol, the diuretic 
furosemide, the lipid regulator mevastatin and the psychiatric drug carbamazepine were 
found at 1.3-4 times higher summer concentrations than those detected in the winter (on 
average 2.3 times).  
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Table 3.3. Ranges and average concentration levels of pharmaceuticals in effluents from the two hospitals and in the influent and effluent of 
Ferrara WWTP. 
Therapeutic Class Compound, µg L
-1
 
Hospital A (Summer) Hospital B (Summer) Hospital B (Winter) WWTP Influent 
(Winter) 
WWTP Effluent (Winter) 
Analgesics/anti-
inflammatories A 
Acetaminophen 3.3-5.9 (4.5) 3.5-4.7 (4.1) 1.4-3.4 (2.5) 0.50-1.2 (0.81) 0.012-0.058 (0.030) 
Codeine 0.26-0.43 (0.36) 0.42-0.64 (0.53) 0.41-3.2 (1.9) 0.09-0.15 (0.11) 0.052-0.082 (0.066)) 
Diclofenac 0.17-0.46 (0.30) 0.18-0.27 (0.22) 0.48-0.53 (0.51) 0.36-0.48 (0.44) 0.22-0.33 (0.28) 
Ibuprofen 1.0-2.5 (1.7) 0.38-0.81 (0.60) 2.2-3.2 (2.6) 0.93-1.2 (1.0) 0.010-0.12 (0.081) 
Indomethacin 0.31-4.1 (2.5) 0.90-3.4 (2.2) 0.40-0.61 (0.53) 0.061-0.20 (0.16) 0.06-0.13 (0.10) 
Ketoprofen 2.2-9.8 (5.0) 0.83-1.4 (1.1) 1.1-1.8(1.4) 0.13-0.19 (0.17) 0.056-0.11 (0.085)) 
Mefenamic acid 0.18-0.50 (0.33) 0.10-0.13 (0.12) 0.33-0.75 (0.55) 0.56-1.2 (0.90) 0.41-0.91 (0.66) 
Naproxen 1.2-3.2 (2.3) 0.34-0.48 (0.41) 1.1-11 (4.9) 0.78-0.91 (0.83) 0.10-0.21 (0.18) 
Phenazone < LOD < LOD < LOD < LOD < LOD 
Phenylbutaz. 0.01-0.05 (0.04) 0.048-0.080 (0.063) 0.12-0.17 (0.14) 0.067-0.13 (0.11) 0.037-0.060 (0.052) 
Propyphen. <LOD-0.020 (0.011) < LOD 0.011-0.10 (0.038) 0.038-0.074 (0.053) 0.024-0.068 (0.042) 
Salicylic acid 0.90-1.9 (1.3) 0.99-1.1 (1.0) 1.9-2.4 (2.22) 0.21-1.1 (0.50) 0.11-0.13 (0.12) 
Antibiotics B 
Azithromycin <LOD-0.11 (0.030) 0.045-0.050 (0.047) 0.58-1.04 (0.80) 0.01-0.33 (0.13) 0.07-0.18 (0.13) 
Chloramphenicol <LOD-0.036 (0.012) < LOD < LOD-0.01 (0.078) 0.013-0.024 (0.019) < LOD 
Chlortetracycline 0.02-0.06 (0.04) 0.063-0.094 (0.077) < LOD < LOD < LOD 
Ciprofloxacin 10-15 (12) 1.4-1.9 (1.6) 15-26 (21) 1.1-3.7 (2.2) 0.29-1.1 (0.64) 
Clarithromycin 0.02-0.14 (0.06) 0.050-0.064 (0.058) 9.3-14 (11) 0.11-0.78 (0.31) 0.26-0.31 (0.28) 
Danofloxacin < LOD < LOD < LOD < LOD < LOD 
Doxycycline 0.10-0.27 (0.17) 0.056-0.97 (0.078) < LOD < LOD < LOD 
Enoxacin 0.33-0.48 (0.41) 0.058-0.10 (0.080) 0.18-0.45 (0.27) 0.081-0.13 (0.10) 0.03-0.10 (0.061) 
Enrofloxacin < LOD < LOD < LOD < LOD < LOD 
Erythromycin 0.06-0.32 (0.16) 0.080-0.086 (0.082) 0.091-0.23 (0.16) 0.010-0.072 (0.045) 0.010-0.033 (0.016) 
Josamycin <LOD-0.012 (0.003) 0.011-0.015 (0.012) < LOD-0.01 (0.01) < LOD -0.007 (0.0020) < LOD 
Metronidazole 0.33-1.64 (0.72) 0.26-0.39 (0.033) 0.85-1.1 (0.96) 0.028-0.056 (0.042) 0.013-0.041 (0.028) 
Nifuroxazide 0.10-2.56 (1.4) 0.10-0.16 (0.14) 0.22-0.33 (0.29) 0.019-0.076 (0.052) 0.010-0.022 (0.013) 
Norfloxacin 0.04-0.10 (0.07) 0.023-0.044 (0.034) 0.22-0.51 (0.35) 0.15-0.31 (0.020) 0.14-0.17 (0.15) 
Ofloxacin 13-22 (19) 3.3-4.1 (3.7) 25-37 (31) 0.45-2.2 (1.0) 0.22-0.52 (0.39) 
Oxytetracycline 0.30-1.3 (0.78) 0.074-0.10 (0.089) < LOD < LOD < LOD 
Roxithromycin < LOD < LOD 0.02-0.14 (0.079) <LOD-0.14 (0.063) 0.013-0.053 (0.029)) 
Spiramycin <LOD-0.040 (0.010) < LOD 0.034-0.11 (0.068) < LOD-0.15 (0.061) 0.019-0.053 (0.029) 
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Therapeutic Class Compound, µg L
-1
 
Hospital A (Summer) Hospital B (Summer) Hospital B (Winter) WWTP Influent 
(Winter) 
WWTP Effluent (Winter) 
Sulfadiazine 0.029-0.033 (0.032)  0.077-0.12 (0.10) 0.27-0.38 (0.33) 0.013-0.026 (0.022) 0.010-0.021 (0.017)  
Sulfamethazine <LOD-0.014 (0.0070) < LOD 0.013-0.03 (0.023) 0.010-0.033 (0.018) 0.010-0.015 (0.011) 
Sulfamethoxazole 3.0-6.5 (4.2) 0.90-2.7 (1.8) 0.94-3.4 (2.0) 0.28-0.74 (0.44) 0.17-0.24 (0.21) 
Tetracycline <LOD-0.026 (0.014) <LOD-0.033 (0.017) < LOD < LOD < LOD 
Tilmicosin 0.05-0.07 (0.06) 0.014-0.020 (0.015) 0.12-0.35 (0.26) 0.021-0.46 (0.25) <LOD-0.081 (0.036) 
Trimeth. 0.80-1.8 (1.2) 0.45-0.86 (0.65) 0.068-0.36 (0.18) 0.039-0.072 (0.058) 0.036-0.051 (0.040) 
Tylosin A < LOD < LOD < LOD < LOD < LOD 
Anti-diabetics C Glibenclamide 0.05-0.10 (0.07) 0.066-0.071 (0.068) 0.072-0.11 (0.10) 0.081-0.96 (0.087) 0.01-0.08 (0.055) 
Anti-hypertensives D 
Enalapril 0.15-0.27 (0.20) 0.091-0.18 (0.13) 0.24-0.40 (0.31) 0.071-0.10 (0.082) < LOD 
Hydrochlorotiazide 1.3-2.1 (1.8) 0.54-0.82 (0.68) 1.8-2.4 (2.2) 1.4-5.5 (2.7) 0.97-1.4 (1.2) 
Lisinopril 0.08-0.61 (0.25) 0.089-0.34 (0.21) < LOD < LOD < LOD 
Barbiturates E 
Butalbital 0.014-0.038 (0.022) 0.011-0.052 (0.032) 0.25-0.48 (0.36) 0.072-0.25 (0.13) 0.090-0.13 (0.10) 
Pentobarbital 0.011-0.074 (0.035) 0.014-0.025 (0.019) 0.11-0.15 (0.13) 0.021-0.043 (0.021) 0.01-0.028 (0.018)) 
Phenobarbital <lod-0.029 (0.0014) 0.013-0.030 (0.021) 0.13-0.36 (0.25) 0.11-0.27 (0.21) 0.11-0.17 (0.14) 
Beta-agonists F Clenbuterol < LOD < LOD 0.86-1.19 (1.1) 0.22-0.29 (0.26) 0.13-0.21 (0.18) Salbutamol 0.04-0.10 (0.062) 0.026-0.030 (0.028) 0.10-0.14 (0.12) 0.011-0.020 (0.013) 0.010-0.017 (0.012) 
Beta-blockers G 
Atenolol 3.5-6.2 (5.1) 2.2-2.6 (2.4) 5.1-6.6 (5.8) 1.8-2.4 (2.1) 0.55-0.98 (0.073) 
Betaxolol <LOD-0.020 (0.011) < LOD < LOD-0.01 (0.01) < LOD-0.007 (0.002) < LOD 
Cerazolol < LOD < LOD < 0.0018-0.0023 (0.002) < LOD-0.01 < LOD 
Metoprolol 0.58-0.99 (0.83) 0.51-0.97 (0.74) 0.86-1.2 (1.1) 0.22-0.29 (0.26) 0.13-0.21 (0.18) 
Nadolol < LOD < LOD < LOD-0.0034 (0.0012) < LOD-0.016 (0.011) < LOD 
Pindolol 0.032-0.26 (0.12) < LOD 0.034-0.048 (0.038) <LOD-0.011 (0.0030) < LOD 
Propranolol <LOD-0.051 (0.023) 0.076-0.094 (0.085) 0.030-0.061 (0.043)  0.014-0.045 (0.026) 0.013-0.026 (0.018) 
Sotalol 3.8-5.9 (4.8) 0.35-0.61 (0.048) 3.3-6.7 (5.1) 0.37-0.64 (0.53) 0.21-0.47 (0.32) 
Timolol < LOD < LOD 0.022-0.039 (0.033) 0.010-0.016 (0.014) < LOD-0.013 (0.010) 
Diuretics H Furosemide 11-18 (14) 6.4-7.7 (7.1) 5.3-6.3 (5.8) 0.39-0.47 (0.42) 0.08-0.35 (0.27) 
Lipid regulators I 
Atorvastatin 0.062-0.10 (0.083) 0.080-0.17 (0.13) 0.24-0.31 (0.27) < lod -0.018 (0.011) < LOD-0.010 (0.0060) 
Bezafibrate 0.057-2.9 (0.95) < LOD 0.042-0.51 (0.20) 0.063-0.12 (0.090) 0.011-0.048 (0.036) 
Clofibric acid <LOD-0.043 (0.017) < LOD 0.010-0.014 (0.013) < LOD-0.012 (0.010) < LOD-0.0060 (0.0020) 
Fenofibrate <LOD-0.026 (0.010) < LOD < LOD < LOD-0.020 (0.0060) < LOD-0.013 (0.0030) 
Gemfibrozil 0.018-0.020 (0.019) < LOD 0.014-0.064 (0.033) 0.16-0.28 (0.20) 0.04-0.17 (0.11) 
Mevastatin 0.38-2.0 (1.1) 0.45-0.53 (0.49) 0.068-0.20 (0.015) 0.12-0.28 (0.17) 0.03-0.14 (0.083) 
Pravastatin 0.19-1.1 (0.62) 0.064-0.080 (0.077) 0.081-0.27 (0.17) 0.080-0.14 (0.11) 0.04-0.07 (0.54) 
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Therapeutic Class Compound, µg L
-1
 
Hospital A (Summer) Hospital B (Summer) Hospital B (Winter) WWTP Influent 
(Winter) 
WWTP Effluent (Winter) 
Psychiatric drugs J 
Carbamazepine 0.64-0.87 (0.73) 0.76-1.2 (0.97) 0.75-1.1 (0.95) 0.30-1.17 (0.58) 0.28-0.44 (0.37) 
Diazepam < LOD < LOD 0.021-0.038 (0.031) 0.002-0.010 (0.076) < LOD 
Fluoxetine <LOD-0.018 (0.005) 0.024-0.033 (0.027) 0.035-0.069 (0.056) 0.055-0.19 (0.11) 0.010-0.063 (0.044) 
Lorazepam 0.62-0.79 (0.67) 0.17-0.20 (0.18) 0.46-0.70 (0.060) 0.17-0.25 (0.22) 0.08-0.14 (0.12) 
Paroxetine < LOD < LOD 0.056-0.076 (0.067) 0.020-0.080 (0.041) 0.010-0.018 (0.013) 
Receptor antagonists 
K 
Cimetidine 0.019-0.032 (0.026) < LOD 0.033-0.26 (0.11) 0.029-0.061 (0.047) 0.012-0.049 (0.031) 
Famotidine 0.087-0.29 (0.16) 0.035-0.048 (0.042) 0.075-0.13 (0.10) 0.010-0.022 (0.014) < LOD-0.0040 (0.0020) 
Loratadine <LOD-0.014 (0.003) < LOD 0.015-0.026 (0.020) < LOD-0.020 (0.013) < LOD-0.0050 (0.003) 
Ranitidine 0.24-2.2 (1.5) 1.1-1.5 (1.3) 1.4-4.1 (3.0) 0.093-0.13 (0.11) 0.04-0.10 0.078) 
Cytostatic agents L Tamoxifen < LOD < LOD < LOD < LOD < LOD 
 Occurrence, n° 61 49 62 63 58 
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3.3.3 Comparison between Winter Concentrations of PhCs in Hospital B effluent 
and WWTP Influent 
The data reported in Table 3.3. show that average concentrations of PhCs in 
Hospital B effluent were higher than those found in the influent of Ferrara WWTP, with 
the exception of two analgesics/anti-inflammatories (mefenamic acid and 
propyphenazone), two antibiotics (chloramphenicol and roxythromycin), the anti-
hypertensive hydrochlorothiazide, three beta-blockers (betaxolol, cerazolol and nadolol), 
two lipid regulators (gemfibrozil and mevastatin) and one psychiatric drug (fluoxetine). 
As regards the other compounds, the ratio between Hospital B effluent and WWTP 
influent concentrations ranged between 1.03 and 35.5, with an average value of 7, standard 
deviation of 8.5 and 95th-percentile of 27. 
 
3.3.4 Contribution of Hospital B Loads to WWTP influent  
Table 3.4. reports the percentage average contribution of Hospital B to the load of 
the investigated compounds in WWTP influent. Compounds were classified according to 
the average percentage contributions (≤ 5 %, 5-15 %, >15 %). Hospital contributions were 
≤ 5 % for 32 substances, between 5 and 15 % for 18 compounds and >15 for 12 PhCs (7 
antibiotics, 2 receptor antagonists, 1 analgesic, 1 diuretic and 1 lipid regulator). The 
highest contributions were found for ofloxacin (67%), azithromycin (67 %), clarithromycin 
(53%), ranitidine (52%) and metronidazole (45%). This confirms that antibiotics represent 
a critical class of compound, as reported in Verlicchi et al. (2012c) due to their high 
consumptions inside the hospital and their stability once excreted. 
Unfortunately, little data is available in the literature for comparison with our 
findings. Nevertheless, what little data is available is reported here below (Table 3.4.). For 
instance, (Thomas et al., 2007a; Langford and Thomas, 2009), evaluated the PhC 
contributions originating from the two main hospitals (in total 1800 beds) in the area of 
Oslo (440,000 inhabitants), Norway, with a bed density of 4 and (Ort et al., 2010a), 
evaluated the contributions for a 200-bed Australian hospital with a catchment area of 
45,000 people (bed density = 4.4). In Germany, (Heberer and Feldman, 2005), analysed 
contributions from the Berlin hospitals (12,000 beds) and their catchment area (1 million 
people, bed density = 12) and (Beier et al.,  2011), the contributions from Waldbrol 
hospital (342 beds) and its catchment area (10,200 inhabitants, bed density = 33.5). Their 
findings are reported in the last five columns of Table 3.4, which shows that percentage 
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hospital contributions for the detected compounds vary greatly, depending on bed density 
and the compound in question. Furthermore, differences are evident in the usage patterns 
of the various PhCs in the different countries, another influential factor. In fact, the highest 
levels of almost all compounds were found by (Beier et al., 2011); the hospital they studied 
had the highest bed density (33.5), of all those reported in the literature, thereby indicating 
the importance of this parameter.  
 
Another interesting study was conducted by Escher et al., 2011 on a Swiss general 
hospital (338 beds, average flow rate 115690 m3 year-1) whose effluent is conveyed to the 
near WWTP with conventional biological treatment which serves 54 000 inhabitants. 
Based on consumption data of the top 40 pharmaceuticals sold in pharmacies, drug stores 
and doctor’s practices, they found that the amount of pharmaceuticals discharged into the 
WWTP from households totals to 62 % of the total pharmaceutical load in the WWTP. 
Thus the remaining 38 % stems from the hospital. 
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Table 3.4. Hospital B average percentage contributions for the detected compounds with respect to the WWTP influent loads and comparison 
with other studies. 
Classification Compound PhC Class This study 
Heberer and 
Feldman 2005 
Thomas et al. 
2007 
Langford and Thomas  
2009 
Ort et al.  
2010 
Beier et al. 
2011 
Bed density   6.5 12 4 4 4.4 33.5 
Contribution ≤ 5% 
Betaxolol G 0.99      
Chloramphenicol B 1.1      
Gemfibrozil I 1.2    4.1  
Propyphenazone A 1.4      
Hydrochlorothiazide D 1.7      
Nadolol G 1.7      
Mefenamic acid A 1.8      
Roxythromycin B 2.1    26  
Diclofenac A 2.1 10 1.6  1 7-9 
Fluoxetine J 2.3      
Sulfamethazine B 2.3      
Pravastatin I 2.4      
Glibenclamide C 2.4      
Cerazolol G 2.4      
Carbamazepine J 2.5 15  1.7 0.4 3-8 
Mevastatin I 2.5      
Phenobarbital E 2.6      
Clofibric acid I 2.6      
Josamycin B 3.0      
Loratadine K 3.2      
Phenylbutazone A 3.2      
Trimethoprim B 3.2  14  10  
Naproxen A 3.9    2.3  
Ibuprofen A 4.0  0.7  4.6 3-7 
Acetaminophen A 4.2  12  5.1  
Butalbital E 4.3      
Timolol G 4.3      
Enoxacin B 4.3      
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Classification Compound PhC Class This study 
Heberer and 
Feldman 2005 
Thomas et al. 
2007 
Langford and Thomas  
2009 
Ort et al.  
2010 
Beier et al. 
2011 
Bed density   6.5 12 4 4 4.4 33.5 
Norfloxacin B 4.6      
Lorazepam J 4.6      
Propranolol G 4.7   11.4   
Atenolol G 4.7   2.52 1.8  
5% < Contribution ≤ 15% 
Cimetidine K 5.6      
Clenbuterol F 5.7      
Metoprolol G 5.7  1.5  4.1  
Paroxetine J 5.9   0.5   
Sulfamethoxazole B 6.1  1.2  0.8  
Indomethacin A 6.2      
Diazepam J 6.8      
Pentobarbital E 6.8      
Bezafibrate I 7.0     27 
Enalapril D 7.1      
Erythromycin B 7.7    2.6  
Pindolol G 8.2      
Nifuroxazide B 8.5      
Tilmicosin B 8.7      
Salicylic acid A 11    4.9  
Sotalol G 11      
Ketoprofen A 14   0.53   
Salbutamol F 14.7      
Contribution > 15% 
Ciprofloxacin B 15.5  311   19-36 
Famotidine K 16      
Sulfadiazine B 19      
Furosemide H 21    5.8  
Atorvastatin I 25   2.3 3  
Codeine A 28    1.5  
Spiramycin B 28      
Metronidazole B 45     84 
Ranitidine K 52    4.9  
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Classification Compound PhC Class This study 
Heberer and 
Feldman 2005 
Thomas et al. 
2007 
Langford and Thomas  
2009 
Ort et al.  
2010 
Beier et al. 
2011 
Bed density   6.5 12 4 4 4.4 33.5 
Clarithromycin B 53     61-94 
Azithromycin B 67      
Ofloxacin B 67      
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3.3.5 Environmental Risk Analysis  
A risk analysis was conducted on the effluent of Hospital B and the WWTP influent 
and effluent (all monitored in winter), using the quotient between the maximum MEC and 
the PNEC as a marker of risk. Each compound detected was subjected to evaluation, and 
values refer to acute toxicity. Neither chronic nor mixture toxicity was considered. Results 
for analgesic/anti-inflammatories, antibiotics and all the other classes are reported in 
Figure 3.3-3.5, respectively. 
These analyses reveal that 9 substances in Hospital B effluent (the four 
analgesics/anti-inflammatories acetaminophen, ibuprofen, naproxen and salicylic acid, the 
four antibiotics clarithromycin, erythromycin, ofloxacin and sulfamethoxazole and the 
psychiatric drug fluoxetine) pose a potential ecotoxicological risk. A high risk was found 
only for 5 compounds (the same antibiotics and the psychiatric drug) in the influent and the 
effluent of Ferrara WWTP.  
RQ classification proposed by (Hernando et al., 2006), showed that the levels of 
codeine, indomethacin, clenbuterol, atenolol, metoprolol and propranolol detected in the 
Hospital effluent pose a medium risk, as do the concentrations of acetaminophen, 
ibuprofen, naproxen, salicylic acid, clenbuterol, metoprolol, propranolol and gemfibrozil in 
the WWTP influent and, more importantly, salicylic acid, clenbuterol, propranolol, 
fenofibrate and gemfibrozil in the WWTP effluent. 
 
 
Figure 3.3. Risk quotients for analgesic/anti-inflammatories in Hospital B effluent and Ferrara WWTP 
influent and effluent 
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Figure 3.4. Risk quotients for antibiotics in Hospital B effluent and Ferrara WWTP influent and effluent. 
 
Figure 3.5. Risk quotients for other PhCs investigated in Hospital B effluent and Ferrara WWTP influent and 
effluent. 
 
These findings are closely correlated to the fact that the hospital effluent contained 
higher concentrations for analgesics/anti-inflammatories and antibiotics than the influent to 
the WWTP. In addition, they confirm that antibiotics are one of the most critical 
therapeutic classes used in hospitals, being highly resistant to degradation and removal; 
indeed, the same 4 antibiotics whose concentrations were found to pose a high risk in 
hospital effluent were also those found at high levels of potential toxicity in the influent 
and the effluent of the WWTP.  
This confirms that the conventional treatments exploited by this WWTP are unable 
to effectively remove these micropollutants, being constructed, and later upgraded, with 
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the aim of removing carbon, nitrogen and phosphorus compounds, pollutants which 
regularly arrive at the WWTP in concentrations to the order of mg L-1.  
This study evidences the fact that correct and specific management of hospital effluent on a 
local scale is necessary, and that further research is required to identify the best strategies 
for managing this type of effluent and evaluating the most suitable technologies for 
removing the most persistent contaminants, thereby reducing the risk posed to the 
environment and human health by these substances. 
 
3.4 Conclusions  
Hospital effluents are generally considered to possess the same pollutant nature as 
urban wastewaters and are therefore co-treated at the same WWTP, without any special 
consideration being given to the potentially harmful nature of the substances they may 
contain. This study, however, by means of an investigation into 73 PhCs from 12 different 
therapeutic classes, reveals that these compounds are found in consistently higher 
concentrations in hospital WW than in urban WW, particularly commonly used drugs such 
as analgesics and antibiotics.  
The characteristics of the hospital effluent seem to be influenced by the size of the 
structure (the smaller hospital discharged higher mean concentrations than the larger one), 
and season (concentrations tended to be higher in winter than in summer). The ratio 
between PhC concentration in hospital effluent and WWTP influent was, on average, 7. 
The highest values were found for ofloxacin (31) and clarithromycin (36), ranitidine (27), 
atorvastatin (25), metronidazole (23). Antibiotics, analgesics/anti-inflammatories and lipid 
regulator were the pharmaceutical compounds found at the highest concentrations. 
The percentage load contribution of the hospital varied among the investigated 
compounds; in particular 12 compounds yielded values between 16 and 67% (some 
antibiotics, receptor antagonists and lipid regulators). 
Environmental risk analysis showed that 9 compounds posed a high risk at the 
concentrations detected in hospital effluent, while in the WWTP influent and effluent, only 
5 of these PhCs were found to exhibit high ecotoxicity. As four out of these five PhCs were 
antibiotics, we can state that this class of compound should cause the most concern. 
These results confirm that, due to their micropollutant content, HWWs require more 
specific management and treatment in order to protect and safeguard the environment, in 
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particular the surface water body which will receive the final (treated) effluent from the 
WWTP.   
As co-treatment is common practice, and the usual (conventional) treatments are 
unable to efficiently remove PhCs, this issue needs urgent attention. Indeed, administrators 
and technicians will need to perform case-by-case analyses on a local scale, in particular 
during WWTP planning and design phases, in order to determine the best means of 
tackling the problem. 
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4.1 Introduction 
At present, approximately 3000 different pharmaceutical ingredients are used in the 
European Union, including antibiotics, beta-blockers, lipid regulators, antidepressants and 
many more, for human consumptions (therapeutic or diagnostic purposes) (Ternes and 
Joss, 2006). One important emission source of pharmaceuticals in the water cycle is via 
human metabolism: in fact, once administered, these compounds are only partially 
metabolized by the human body, and therefore enter the water cycle either as parent 
(unchanged) compounds, which are excreted largely through urine (generally 55-80 % of 
the total, with few exceptions) and partially in the faeces, or as a mixture of metabolites 
and/or conjugated compounds (Jjemba et al., 2006, Lienert et al., 2007).  
Unfortunately, municipal wastewater treatment plants (WWTPs) are generally 
unable to effectively remove either unaltered or metabolized forms of pharmaceutical 
compounds (PhCs) from wastewaters (Bendz et al., 2005; Castiglioni et al., 2006; 
Glassmeyer et al., 2004; Gomez et al., 2007; Joss et al., 2005; Verlicchi et al., 2012b). 
Their occurrence in surface water has been documented by a number of authors (Ashton et 
al., 2004; Calamari et al., 2003; Fatta-Kassinos et al., 2011; Gros et al., 2006, Kolpin et al., 
2002, 2004; Spongberg et al., 2011) from around the world. Sometimes the load of the 
main compounds discharged with the treated effluent was also evaluated. Andreozzi et al. 
(2003), Castiglioni et al. (2005) and Zuccato et al. (2010) have monitored the occurrence 
of compounds such as antibiotics and some antiphlogistics, lipid regulators, beta-blockers, 
antiepileptics and anticancer drugs in a few Italian municipal WWTPs, although, generally 
speaking, little data is yet available regarding Italian secondary effluents. In contrast, many 
studies have been carried out in other countries in Europe, America, Asia and Australia 
(among them Gulkowska et al., 2008; Kasprzyk-Hordern et al., 2009; Lishman et al., 2006; 
McAvoy et al., 2002; Nakada et al., 2006; Watkinson et al., 2007), focusing principally on 
analgesics/anti-inflammatories and antibiotics. These studies have confirmed the 
occurrence of most of the abovementioned PhCs and, in some cases, their metabolites in 
the secondary effluent from municipal WWTPs.  
As some of these substances have been detected in large concentrations (of the order 
of magnitude of hundred µg L-1-mg L-1) in the secondary effluent, there has been 
increasing interest in evaluating the environmental risk related to their discharge into 
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surface waters through treated effluent. PhCs are designed to exert specific biological 
effects within a given species; however, once excreted and released into the environment 
they may remain bioactive and could also pose a toxicological risk to non-target 
organisms, thereby altering the ecosystem dynamic (Boxall et al., 2002; Daughton and 
Ruhoy, 2009). As few of these substances are easily degradable, it is the characteristics of 
the receiving water body, in terms of (minimum and average) flow rate, biological, 
chemical and physical characteristics, auto-depurative capacity, water use and 
environmental quality standards, as well as environmental conditions (mainly solar 
radiation, temperature and precipitation), that will determine the extent to which it can 
tolerate the release of pharmaceuticals without perceptible adverse effects. 
The aims of this chapter were therefore (i) to evaluate the removal efficiency of 27 
PhCs, belonging to nine different therapeutic classes (six analgesics/anti-inflammatories, 
seven antibiotics, three lipid regulators, four beta-blockers, three psychiatric drugs, one 
antidiabetic, one antihypertensive, one diuretic and one beta-agonist) in a Full-scale 
WWTP,(ii) to evaluate the concentration of the same PhCs in the effluent from two 
municipal WWTPs, (iii) to evaluate the impact of the WWTPs (in terms of single 
compound concentrations and therapeutic class mass loads) on their respective receiving 
water bodies, which are characterized by different hydrodynamic characteristics. PhC 
concentrations were also monitored in the receiving surface waters, upstream and 
downstream of the effluent discharge point, and (iv) an environmental risk analysis 
assessment was performed for both the effluent and the receiving water body in the two 
case studies. 
 
4.2 Materials and methods 
4.2.1 Pharmaceutical compounds 
Compounds analyzed in this study were selected on the basis of several criteria: 
high consumption by the resident population (Gruppo di lavoro OsMed, 2011), interest for 
environmental and public health (De Voogt et al. 2009) and availability of detection 
techniques. Table 4.1. reports the PhCs selected, grouped according to their therapeutic 
class and compiled in alphabetic order. For each compound, Table 4.1. also reports the 
amounts of active compound consumed in Italy in 2010 in terms of defined daily doses per 
1000 inhabitants per day (DDD 1000 inh-1 d-1) (Gruppo di lavoro OsMed, 2011), as well as 
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their annual consumption (kg). This figure was obtained by multiplying the DDD of each 
drug by the conversion factor (CF) (mg active compound/DDD) provided by WHO (2012). 
The Italian reference population was that documented in 2010 (58 640 000 inhabitants), 
except in the case of bezafibrate consumption, where data refer to 2001 (population 56 996 
000 inhabitants). The same pattern of consumption of the selected PhCs found for the 
Italian population as a whole was assumed for the areas under study. 
Table 4.1. also reports data from the literature on percentage excretion rate and removal 
efficiency achieved in secondary biological municipal WWTPs (including an activated 
sludge system as secondary treatment).  
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Table 4.1. Consumption of selected compounds in Italy in 2010, expressed as defined daily dose per 1000 inhabitants per day (DDD 1000 inh-1 d-
1) and the corresponding amount of compound consumed in that year (kg) evaluated using the conversion factor CF (mg active compound/DDD); 
percentage of excretion through human body after administration and percentage removal efficiency found in the literature. 
Therapeutic class Compounds Amount used 
(DDD/1000 inh/d) 
CF 
(mg/DDD) 
Amount used 
(kg) 
Excretion 
(%) 
Removal efficiency 
(%) 
Analgesics/Anti-inflammatories Diclofenac 4.5 100 9602 39b 34f 
Indomethacin      
Ketoprofen 4.3 150 13763   
Mefenamic acid     36f 
Naproxen    1-10d  
Propyphenazone      
Antibiotics Azithromycin 1.3 500 13870  33f 
Ciprofloxacin 1.0 1000 21672 70b 83f 
Clarithromycin 3.0 1000 64470 25d 22f 
Metronidazole  1500 3.73 40d 24f 
Roxithromycin  300 577 1d 40g 
Sulfamethoxazole    39b 57f 
Trimethoprim  2000 13896 70b 32f 
Antidiabetics Glibenclamide 7.8 7 1165   
Antihypertensives Enalapril 15.3 10 3265   
 Hydrochlorothiazide 11.8 25 6295   
Beta-agonists Salbutamol 3.5 10 747 30e 95f 
Beta-blockers Atenolol 11.3 75 18084 90b 71f 
Metoprolol    10e 40f 
Sotalol     27f 
Timolol 4.5 20 1920   
Diuretics Furosemide 21.8 40 18606 40c 42f 
Lipid regulators Atorvastatin 18 20 7682 5c 0f 
Bezafibrate  600 7600a 69b  
Psychiatric drugs Carbamazepine  1000 31190 5b 0f 
Diazepam 1.5 10 320 1c 0f 
Lorazepam 13.3 2.5 709   
a
 Zuccato et al. (2005) (data referring to 2001). b Pal et al. (2010) . c Jjemba (2006) . d Verlicchi et al. (2010b) . e Kasprzyk-Horde rn et al. (2009) . f Escher et al. (2011) .g Karthikeyan and Meyer (2006) .
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4.2.2 sampling area and sample collection 
4.2.2.1 Area under study 
 Two conventional activated sludge plants WWTP A and WWTP B situated in the 
Po Valley, northern Italy, and their corresponding receiving water bodies were monitored 
in this study(Figure 4.1.). Table 4.2. summarizes the characteristics of the WWTPs 
investigated (population served, expressed as number of inhabitants N; capacity, as 
population equivalent PE; average influent flow rate; type of wastewater; hydraulic 
retention time, HRT and sludge retention time, SRT) and of the two receiving bodies (in 
terms of average flow rate during the observation period).  
 
4.2.2.2 Case study A 
 WWTP A discharges its final effluent into canal A, that is part of the local surface 
water body network commonly used for irrigation during summertime. This canal crosses 
an urban area, and many buildings and commercial premises have long been situated along 
its banks. At the time of the monitoring program, its flow rate was on average 50 m3 s-1, as 
reported in Table 4.2. Based on historical data sets, this may range between 7 and 55 m3 s-1, 
with an average value of 15 m3 s-1 on a monthly basis. Assuming the WWTP flow rate 
reported in Table 4.2. (47 520 m3 d-1 = 0.549 m3 s-1), its dilution factor, i.e. the ratio 
between canal flow rate and WWTP flow rate, equals 91 during the monitoring period. It 
may vary between 13 and 100 depending on the season with its lowest values occurring 
during summertime. 
 
4.2.2.3 Case study B 
 WWTP B discharges its treated effluent into the small and shallow canal B, that is 
part of the local surface water network that flows through a rural area. The surrounding 
land is predominantly agricultural, there are also herds of cattles and chickens and there are 
no buildings or commercial activities along its banks. Water from the canal is generally 
used for irrigation from May to October. The canal receives the runoff from agricultural 
land during rainy periods, and in dry periods, the WWTP effluent contributes about 50 % 
of the total average canal flow rate. As a consequence the corresponding dilution factor 
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amounts to 1. The flow rate of canal B is quite almost constant along the year as it is 
regularly controlled by the local irrigation Agencies. 
 
 These two case studies were chosen because they belong to an area that was first 
declared at risk of environmental crises, as recurrent prolonged drought periods could 
drastically reduce the availability of fresh water for the different needs and then declared as 
a sensitive area due to eutrophication phenomena. Conventional macropollutants, 
including carbon, nitrogen and phosphorus compounds, suspended solids, Escherichia coli, 
have long been and still are regularly monitored according to the Italian regulation 
(Decreto Legislativo 152/2006) In the last years, some research groups (Zuccato et al.2010, 
Verlicchi et al., 2010a, 2012a, b) have been carried on experimental investigations in this 
area aiming to monitor unregulated parameters such as pharmaceuticals, in order to 
provide useful information for local and regional environmental protection agencies (their 
occurrence and load) to evaluate the potentially ecological risks associated with the 
discharge of pharmaceuticals. Moreover these two case studies can be considered 
representative of two fairly common situations in the Po Valley: the presence of a large 
WWTP receiving the wastewater from an urban as well as industrial catchment area and 
discharging its final effluent in a medium size canal (case study A) mainly used for 
agricultural purposes, and the presence of a small WWTP treating the wastewater from an 
urban catchment area, discharging its final effluent into a small canal whose flow rate is 
regulated for irrigation needs and kept quite constant (case study B). 
 
4.2.2.4 Sampling 
 24-h composite flow proportional water samples of the influent, effluents of 
WWTP B and the effluent of WWTP A were taken over a period of three dry consecutive 
days in May 2011. In both cases, sampling sites were chosen on the basis of available 
access to the canal banks Fig 4.1. Unfortunately they were not at the same distance from 
the discharge point: roughly 1000 m upstream and downstream of the point of treated 
effluent discharge in canal A and 500 m in canal B. 4-h composite samples upstream and 
downstream of the WWTP discharge points. Surface water was collected from the central 
part of the canals, using 2 L clean plastic bottles for this purpose. All water samples were 
transferred to amber polyethylene terephthalate (PET) bottles and immediately transported 
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to the laboratory under cooled conditions (4 °C). Upon reception, samples were filtered 
through 0.45 µm nylon filters (Whatman, Maidstone, UK) to eliminate suspended solid 
matter, and then frozen (-20 °C) until analysis (less than a week later). 
 
 
Figure 4.1 Location of the WWTPs and the receiving surface water canals sampled in the case studies. 
 
Table 4.2. Characteristics of the two wastewater treatment plants under study 
WWTP 
(inhabitants) 
Capacity 
(PE) 
Average 
flow rate 
m3 d-1 
Receiving 
water body, 
average flow 
rate m3s-1 
Type of 
wastewater 
HRT (h)/ 
SRT(d) 
Secondary 
treatment 
A  
(138 000) 240 000 47 520 canal A, 50 
Urban (60 %) and 
industrial (40 %) 6/8 
Activated 
sludge 
B 
(5000) 5500 1360 canal B, 0.016 Urban 6/6 
Activated 
sludge 
 
4.2.3 Standards  
All the pharmaceuticals and the corresponding isotopically labelled internal 
standards were of high purity grade (>90%). Detailed information on the providers of the 
analytical standards, as well as about the preparation of the mixture solutions can be found 
elsewhere (Jelic et al., 2009). The solvents, HPLC grade methanol, acetonitrile, water 
(Lichrosolv) and formic acid (98%) were provided by Merck (Darmstadt, Germany). 
(Reproduced from Arpa Emilia-Romagna)
WWTP
Sabbioncello 
Canal
Adriatic 
Sea
Urban area
Urban area 
Ferrara
Lagosanto
Sampling point
Case study 1
Case study 2
Town
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4.2.4 Analytical methods 
Influent, Effluent wastewater and surface water samples were vacuum filtered 
through 1µm glass fibre filters and 0.45µm nylon membrane filters, after which an 
appropriate volume of aqueous solution of 5% Na2EDTA was added to 100mL of WWTP 
influent, 200 mL of WWTP effluent and 500 mL of surface water to achieve a final 
Na2EDTA concentration of 0.1% in the samples. The measured volumes were 
subsequently preconcentrated onto Oasis® HLB cartridges (60 mg and 3 mL) (Waters, 
Milford, MA, USA), at a flow rate of 5 mL/min, using a Baker vacuum system (J.T. Baker, 
Deventer, The Netherlands). After sample preconcentration, cartridges were rinsed with 5 
mL of HPLC grade water and vacuum dried for 15–20 min to remove excess water. 
Elution of target compounds was performed with 2 × 4 mL pure methanol. Extracts were 
evaporated to dryness under a gentle nitrogen stream, and reconstituted with 1 mL of 
methanol–water (25:75, v/v). Prior to analysis, all the samples were spiked with a standard 
mixture of isotope-labelled standards at concentration of 20 ng ml-1. Instrumental analysis 
was performed by high performance liquid chromatography coupled to a hybrid triple 
quadrupole – linear ion trap mass spectrometer (HPLC-QLIT-MS/MS) according to the 
previously developed multi-residual methodology for analysis of pharmaceuticals in 
wastewater (Gros et al., 2009). 
 
The internal standard calibration approach was used for quantification. To 
determine the recoveries, three samples of each matrix were spiked with a standard mixture 
of target analytes. For wastewater, the recoveries ranged from 43 to 121 % (RSD<13%) for 
effluent wastewater, and from 45 to 135 (RSD<15 %) for surface water samples. Matrix 
effect was 20 to 60% for most of the compounds. The instrumental intra-day precision 
ranged from 2 to 11%, for six injections/day of a 50 ng ml-1 standard mixture. Limit of 
detection (LOD) and limit of quantification (LOQ) were calculated as the minimum 
detectable amount of analyte with a signal-to-noise ratio of 3 and 10, respectively. LOD , 
LOQ and RSD (%) values are reported in Table 4.3. 
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4.2.5 Statistical analysis 
 Statistical analysis was performed by means of Student’s test in order to determine 
the significance of the differences found: between the average concentrations in the 
effluents of the two WWTPs, between average concentrations upstream and downstream in 
the two case studies, at a general confidence level of 99% (p-value = 0.01). 
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Table 4.3.Limits of detection (LOD), limits of quantification (LOQ) and precision of the method, expressed as a relative standard deviation 
(n=3). 
Classe compounds WWTP influent WWTP effluent Surfacewater 
  
 LOD 
ng L-1 
LOQ 
ng L-1 
RSD% LOD 
ng L-1 
LOQ 
ng L-1 
RSD% LOD 
ng L-1 
LOQ 
ng L-1 
RSD% 
Analgesics/anti-inflammatories Diclofenac 5 17 11 4 13 5 1 3 14 
Indomethacine 4 13 8 3 10 13 1 3 9 
Ketoprofen 8 27 14 5 17 12 4 13 9 
Mefenamic acid 13 43 18 4 13 9 1 3 12 
Naproxen 12 40 13 4 13 12 1 3 16 
Propyphenazone 4 13 5 2 7 4 1 3 8 
Antibiotics Azithromycin 7 23 5 5 17 10 1 3 17 
Ciprofloxacin 5 17 9 2 7 13 1 3 17 
Clarithromycin 5 17 3 4 13 10 0.5 2 5 
Metronidazole 6 20 9 2 7 19 0.5 1 3 
Roxithromycin 3 10 5 2 7 9 0.5 2 3 
Sulfamethoxazole 4 13 7 2 7 18 1 3 6 
Trimethoprim 3 10 2 2 7 12 0.5 2 16 
Antidiabetic Glibenclamide 5 17 7 4 13 15 1 3 8 
Antihypertensive Enalapril 3 10 5 1 3 12 0.5 2 11 
Hydrochlorothiazide 11 37 6 6 20 5 5 17 12 
Beta-agonists Salbutamol 2 7 13 2 7 7 0.5 2 3 
Beta-blockers Atenolol 10 33 13 8 27 16 0.5 2 9 
Metoprolol 4 13 6 3 10 2 1 3 11 
Sotalol 5 17 16 3 10 11 1 3 14 
Timolol 1 3 3 1 3 7 0.5 2 9 
Diuretics Furosemide 3 10 12 2 7 13 0.5 2 16 
Lipid regulators Atorvastatin 4 13 16 3 10 9 0.2 1 12 
Bezafibrate 4 13 12 1 3 7 0.5 2 14 
Psychiatric drugs Carbamazepine 5 17 3 3 10 1 0.5 2 7 
Diazepam 4 13 12 2 7 5 1 3 6 
Lorazepam 7 23 11 5 17 8 1.5 5 9 
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4.2.6 Environmental risk assessment 
The potential risk posed by each PhC was assessed by calculating its risk quotient 
(RQ) as the ratio between its maximum measured environmental concentration (MEC) and 
its predicted no-effect concentration (PNEC), as discussed in section 3.2.6.  
PNEC values assumed for this risk analysis correspond to the lowest ecotoxicological 
PNEC values found in literature. For 19 out of the 27 investigated compounds, 
ecotoxicological data are available. Table 4.5. compiles the assumed values. Conforming 
to EC (EC, 2003), the values of PNECs to use in the risk analysis (those of Table 4.5.) are 
1000 times lower than the ecotoxicity concentration values found for the most sensitive 
species assayed (among bacteria, algae, invertebrates and fish), so as to take into account 
the effect on other, potentially more sensitive, aquatic species to those used in toxicity 
studies. A commonly used risk ranking criterion was applied, after Hernando et al. (2006), 
De Souza et al. (2009) and Zhao et al. (2010): RQ < 0.1, minimal risk to aquatic 
organisms, 0.1 ≤ RQ < 1, median risk; RQ ≥ 1, high risk. 
 
4.3 Results and discussion 
Experimental data are reported in Table 4.4., in terms of measured average values, 
standard deviations SD, corresponding variability ranges and percentage detection 
frequencies f of each selected compound in the two sampled effluents. PhCs are grouped 
according to their therapeutic class and listed in alphabetical order. The last two columns 
of Table 4.4. show measured concentration intervals reported in secondary effluents from 
other WWTPs in Italy and other world countries.  
Analytical variations due to analysis for WWTP effluents are in general % RSD <18 , RSD 
< 19, and RSD <17 (n=3) in influent , effluent and surface water respectively. 
4.3.1 Removal of selected pharmaceuticals in the WWTP B. 
Influent and effluent concentrations of selected PhCs in the WWTP B are depicted 
together in Figure 4.2. in order to evaluate percentage removal efficiency of this WWTP. 
Data are ranked with decreasing percentage removal efficiency that shown between the 
parenthesis after the name of the selected compounds in Figure 4.2. The observed effluent 
concentration of selected PhCs in Table 4.4. is clearly correlate to the influent 
concentration and the percentage elimination in the WWTP, all the detected 
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pharmaceuticals in the influent of the WWTP B, are detected in the effluent of the same 
with the exception of Enalapril, Atorvastatin and Glibenclamide due the complete Removal 
in the WWTP. The average percentage removal efficiency vary between 0% 
(Carbamazepine) and 97% (Bezafibrate and Naproxen), negative removal efficieny were 
observed for Diazepam, Furosemide, Azithromycin and hydrochlorothiazide. 
 
Figure 4.2. Influent and effluent concentration of selected PhCs in WWTP B. 
 
4.3.2 Occurrence of selected pharmaceuticals in the investigated WWTP effluents 
Overall, 24 out of the 27 selected pharmaceuticals were detected at least once in 
each sample of the two monitored WWTP effluents, 10 compounds were always detected 
(f = 100 %). The compounds indomethacine, atorvastatin and enalapril were those never 
detected in the two effluents investigated during this study. The average number of 
detected compounds in each water sample was 17 (SD = 2). No compound has never 
exceeded 1 µg L-1: the maximum concentrations were found for diclofenac (800, 605, 589, 
533 ng L-1) and hydrochlorothiazide (520 ng L-1). The highest overall average values were 
found for diclofenac (502 ng L-1), hydrochlorothiazide (265 ng L-1), atenolol (264 ng L-1) 
and sotalol (262ng L-1).  
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In 47 cases out of 162 (= 27 compounds x 2 sampling sites x 3 samplings), 
measured concentration was > 100 ng L-1. It happened 6 times for diclofenac, sotalol and 
metoprolol, 5 times for clarithromycin, atenolol, hydrochlorothiazide and carbamazepine, 3 
times for azithromycin and furosemide, twice for ciprofloxacin and once for 
sulfamethoxazole. The value of 100 ng L-1 was chosen as it was previously used by Beier 
et al. (2011) as a target value for pharmaceuticals discharged with treated effluents. 
Overall, rather broad ranges of variability were observed for diclofenac (578 ng L-1), 
ciprofloxacin (470 ng L-1), hydrochlorothiazide (436 ng L-1) and atenolol (409 ng L-1), 
while much smaller intervals were observed for timolol (9 ng L-1), diazepam (10 ng L-1), 
roxithromycin (13 ng L-1) and metronidazole (18 ng L-1). 
Average concentrations found in this investigation are consistent with those 
reported by Andreozzi et al. (2003), Castiglioni et al. (2005) and Zuccato et al. (2010) 
referring to the occurrence of selected PhCs in different Italian WWTP effluents (Table 
4.4), except in the case of the analgesic naproxen and the antibiotic clarithromycin. With 
respect to variability ranges found in this investigation, occurrence of naproxen has been 
reported at an order of magnitude higher (literature range equal to 290–5220 ng L-1 against 
our measured range < LOD–21 ng L-1), and clarithromycin at an order of magnitude lower 
(literature data included in the range 8–37 ng L-1 against our measured range 189–374 ng 
L-1). Other studies carried out in different countries in Europe, America, Asia and Australia 
found ranges of PhC variability (Table 4.4., last column) even two (diclofenac, ketoprofen, 
naproxen, trimethoprim, hydrochlorothiazide, atenolol, sotalol, carbamazepine) or three 
(diazepam) orders of magnitude higher than those found in this investigation.  
 
4.3.2.1 WWTP A Effluent 
As shown in Table 4.4. and in Fig. 4.3., out of the 27 selected substances, 19 PhCs 
were detected in WWTP A effluent and among these 12 pharmaceuticals were always 
detected (f = 100 %): the analgesic diclofenac, the antibiotics azithromycin, ciprofloxacin, 
clarithromycin, metronidazole and roxithromycin, the antidiabetic glibenclamide, the 
antihypertensive hydrochlorothiazide, the beta-blockers atenolol, metoprolol and sotalol 
and the psychiatric drug carbamazepine. In addition, the 4 compounds: ketoprofen, 
mefenamic acid, furosemide and lorazepam were detected with f = 67 % and finally the 
three compounds sulfamethoxazole, salbutamol and timolol were detected at a frequency 
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of 33 %. The number of detected compounds was on average 16 in the three samples (SD = 
2). 
The highest average values were found for the analgesic diclofenac (339 ng L-1), 
the beta-blockers sotalol (197 ng L-1) and metoprolol (184 ng L-1). The other compounds 
exhibiting an average concentration > 100 ng L-1 were: the antihypertensive 
hydrochlorothiazide (145 ng L-1), the psychiatric drug carbamazepine (125 ng L-1), the 
beta-blocker atenolol (111 ng L-1) and the antibiotic clarithromycin (102 ng L-1).  
On the basis of the all 81 data collected for this effluent (=27 compounds x 3 samples), 17 
times measured concentrations were > 100 ng L-1. The highest ranges of variability were 
observed for diclofenac (310 ng L-1), followed by hydrochlorothiazide (134 ng L-1) and 
sotalol (106 ng L-1), while the smallest one was found for roxithromycin (3 ng L-1). 
 
4.3.2.2 WWTP B Effluent 
As shown in Table 4.4. and in Fig. 4.4., out of the 27 selected substances, 21 PhCs were 
detected in WWTP B effluent and among these 17 PhCs were always detected (f = 100 %): 
the analgesic diclofenac, the antibiotics azithromycin, ciprofloxacin, clarithromycin, 
metronidazole, sulfamethoxazole and trimethoprim, the antihypertensive 
hydrochlorothiazide, the beta-agonist salbutamol, the beta-blockers atenolol, metoprolol, 
sotalol and timolol, the diuretic furosemide and all the psychiatric drugs carbamazepine, 
diazepam and lorazepam. In addition, the 2 compounds: ketoprofen and propyphenazone 
were detected with f = 67 % and finally the two compounds naproxen and bezafibrate were 
detected at a frequency of 33 %. The average number of detected compounds in this 
sampling point was 19 (SD = 1). 
The highest average values were found for diclofenac (665 ng L-1), atenolol (417 ng 
L-1), hydrochlorothiazide (385 ng L-1), sotalol (327 ng L-1), ciprofloxacin (284 ng L-1) and 
clarithromycin (283 ng L-1). Other compounds detected at concentrations > 100 ng L-1 
were: carbamazepine (240 ng L-1), furosemide (235 ng L-1), metropol (210 ng L-1) and 
azithromycin (175 ng L-1). On the basis of all the 81 data collected for this effluent, 30 
times measured concentrations were > 100 ng L-1. The highest ranges of variability were 
observed for hydrochlorothiazide (474 ng L-1), followed by ciprofloxacin (453 ng L-1) and 
carbamazepine (230 ng L-1), while the smallest one was found for timolol (2 ng L-1). 
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4.3.2.3 Comparison between the two effluents 
Out of the 27 investigated compounds, 16 were found in both effluents. An analysis 
of data reported in Table 4.4. shows that for 13 out of the common 16 detected 
pharmaceuticals average concentrations were higher for WWTP B effluent than WWTP A 
effluent. The only exceptions were for ketoprofen, sulfamethoxazole and timolol exhibiting 
quite similar values. 
This could be explained by different reasons: (i) the fact that WWTP A treats both urban 
and industrial wastewaters, the latter of which, being from petrochemical activities that do 
not release PhCs, have a dilution effect on their inlet concentrations; (ii) possible different 
pharmaceutical consumption patterns between the two areas under investigation, resulting 
in different inlet concentration and (iii) possible different removal efficiencies achieved in 
the two activated sludge systems whose values depend on many design and operational 
factors, mainly reactor configuration, types and way of feeding in the biological tank, SRT, 
HRT, temperature as discussed in Verlicchi et al. (2012b).  
As reported above, average concentrations > 100 ng L-1 were found for 7 
compounds in effluent A and 10 in effluent B (the same pharmaceuticals of effluent A and 
3 in addition). These elevated figures could be due to their high consumption, which range 
from 6–64 tons on a national basis, and to the inefficiency of conventional treatments in 
removing most of them, the percentage removal rates being less than 40 % (Table 4.1.). 
These results are also illustrated in Figures 4.3. and 4.4. which report, in descending order, 
the average concentrations of the monitored compounds measured in the two effluents. 
The seven PhCs found at the highest concentrations in both effluents (diclofenac, 
clarithromycin, hydrochlorothiazide, atenolol, metoprolol, sotalol and carbamazepine) are 
generally consumed for long periods, especially among the elderly (beta-blockers, 
antihypertensives, anti-inflammatories and diuretics). 
To complete the comparison, a statistical analysis has been conducted for the two effluents 
as well as for the classes of analgesics/anti-inflammatories, antibiotics, beta-blockers and 
psychiatric drugs. The aim was to verify if the average concentrations of compounds are 
different in the two effluents from a statistical point of view and how significant are these 
differences. Student’s test applied to the whole effluents and to the single reported classes 
showed that there is enough evidence (p-value lower than 0.01) for the whole effluents and 
for the class of antibiotics to state that the corresponding. average concentrations are 
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different (level of significance greater than 99%). For the other classes the differences 
should seem not statically significant but, in our opinion, further research and experimental 
data should be necessary to confirm this result. 
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Table 4.4. Occurrence of pharmaceuticals in the effluents of WWTP A and WWTP B: Concentration ranges (ng L-1) with their mean values 
(n=3), their standard deviation SD and the frequency of detection f. Comparison with literature values referring to Italy and worldwide 
 
Compounds 
WWTP A WWTP B Range in Italya 
(ng L-1) 
Worldwideb 
(ng L-1) Class Mean±SD Range f Mean±SD Range f 
 (ng L-1) (ng L-1) (%) (ng L-1) (ng L-1) (%) 
Analgesics/anti- Diclofenac 339±138 223-533 100 665±96 589-800 100 470-5450 6-10000 
Inflammatories Indomethacine n.d.* n.d. n.d. n.d. n.d. n.d  20-600 
 Ketoprofen 23±15 n.d.-23 67 21±10 n.d. -21 67  n.d. -2270 
 Mefenamic acid 26±12 n.d.-27 67 n.d. n.d. n.d  2-3000 
 Naproxen n.d. n.d. n.d 21±10 n.d. -21 33 290-5220 1-5090 
 
Propyphenazone n.d. n.d. n.d 33±20 n.d -48 67  1-120 
Antibiotics Azithromycin 44±16 22-55 100 175±47 109-209 100  40-380 
 Ciprofloxacin 25±11 10-33 100 284±186 46-499 100 27-514 7-5700 
 Clarithromycin 102±10 89-112 100 283±75 189-374 100 8-37 150-460 
 Metronidazole 16±5 9-21 100 19±6 14-27 100  55-561 
 Roxithromycin 12±1 10-13 100 n.d n.d. n.d  10-540 
 Sulfamethoxazole 97±46 n.d. -97 33 91±67 35-185 100 10-317 3-840 
 Trimethoprim n.d. n.d. n.d 27±8 21-39 100 30-130 5-1880 
Antidiabetics Glibenclamide 36±7 27-43 100 n.d < n.d n.d   
Antihypertensives Enalapril n.d. n.d. n.d n.d n.d n.d   
 
Hydrochlorothiazide 145±56 85-219 100 385±98 294-520 100  679-11000 
Beta-agonists Salbutamol 9±4 n.d. -9 33 18±6 13-26 100 1.1-18 10-170 
Beta-blockers Atenolol 111±41 65-164 100 417±48 356-474 100 27-1168 10-73000 
 Metoprolol 184±17 161-199 100 210±9 198-219 100 10-100 5-2200 
 Sotalol 197±45 152-258 100 327±33 285-366 100  249-1320 
 
Timolol 9±4 n.d.-9 33 7±1 6-8 100  10-70 
Diuretics Furosemide 14±7 n.d.-18 67 235±68 184-331 100 0.2-2102 20-1823 
Lipid regulators Atorvastatin n.d. n.d. n.d n.d n.d n.d   
 Bezafibrate n.d. n.d. n.d 3±1 n.d -3 33 0.3-910 4800 
Psychiatric drugs Carbamazepine 125±24 94-152 100 240±2 216-265 100  2-19800 
 Diazepam n.d n.d n.d 9±1 7-10 100  15-19300 
 Lorazepam 46±22 n.d -46 67 76±5 71-82 100  196 
N of detected compounds  19   21   11 24 
n.d. = not detected, a Data from: Castiglioni et al., 2005; Andreozzi et al., 2003; Zuccato et al., 2010, b Data from: Verlicchi et al., 2012b.
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4.3.3 Occurrence of selected pharmaceuticals in the two receiving surface water 
bodies 
Overall, 22 out of the selected 27 substances were detected in surface water; no 
compound was always detected in each sample (see Appendix C.1.); the most detected 
PhCs were: carbamazepine (10 out of 12 times), naproxen, atenolol and sotalol (9 times), 
azithromycin, ciprofloxacin, clarithromycin and bezafibrate (7 times). Atorvastatin, 
enalapril, mefenamic acid and roxithromycin and ketoprofen were never detected. The 
number of compounds detected in surface water samples ranged between 5 and 22, with an 
average value equal to 11 (SD = 7). 
The highest concentrations were found for sotalol (504, 502 and 373 ng L-1), 
hydrochlorotiazide (128 and 116 ng L-1), clarithromycin (128 and 103 ng L-1), 
ciprofloxacin (124 ng L-1) and furosemide (114 ng L-1). Overall, concentrations were > 100 
ng L-1 for 9 times and for the just reported 5 compounds. Overall, rather broad ranges of 
variability were observed for sotalol (504 ng L-1), atenolol (231 ng L-1), clarithromycin and 
hydrochlotothiazide (128 ng L-1), while much smaller intervals were observed for 
naproxen, bezafibrate, metronidazole, propyphenazone (16 ng L-1), timolol, (8 ng L-1).  
Out of the 27 selected compounds investigated in this work, only 13 compounds have 
previously been monitored in major Italian surface water bodies, including the Rivers Po, 
Arno and Lambro (Calamari et al. 2003; Ferrari et al. 2011; Perrett et al. 2006; Zuccato et 
al. 2000, 2006, 2008, 2010). The ranges of variability measured in these studies are 
consistent with our findings.  
A further comparison between our data and ranges of variability of the same PhCs 
found in water surface bodies observed in other countries (Gros et al., 2010; Fatta Kassinos 
et al., 2011; Spongberg et al., 2011; Tamtam et al., 2008; Wang et al. 2010) reveals that 
reported surface concentrations can be much higher than those found in our study (for 
instance two orders of magnitude higher for the antibiotics ciprofloxacin and 
clarithromycin), presumably reflecting different patterns of PhC consumption in different 
countries.  
Figures 4.3. and 4.4. report the average concentrations of each selected compound 
measured in the receiving water bodies of the two WWTP effluents (canals A and B), 
upstream and downstream of the corresponding discharge point (WWTP A and WWTP B), 
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together with the corresponding average concentrations found in the secondary effluents. 
In each graph, the X-axis reports the selected compounds, in order of decreasing 
concentrations found in the secondary effluent. The two numbers in brackets after each 
name correspond to the upstream and downstream detection frequencies, respectively. PhC 
concentration profiles detected in the two case studies are analyzed below. For easier 
viewing, the error due to analysis (RSD %) are not shown in the figures, and they ranged 
from 3-17% (n=3) depending on compound ( see table 4.3.). 
  
4.3.3.1 Case study A (WWTP A- canal A) 
As reported in Figure 4.3., out of the 19 PhCs detected in the WWTP A effluent, 
only five (clarithromycin, atenolol, sotalol, carbamazepine and salbutamol) were detected 
upstream of the WWTP discharge (for three compounds f = 67 % and for the remaining 
two f = 100 %), while eleven (diclofenac, clarithromycin, sulfamethoxazole, azithromycin, 
ciprofloxacin, atenolol, sotalol, metoprolol, carbamazepine, lorazepam and furosemide) 
were found downstream at detection frequencies of 33 % (four compounds), 67 % (five 
compounds) and 100 % (six compounds). Although the two compounds naproxen and 
bezafibrate were never detected in WWTP A effluent, they were always detected (f = 100 
%) both upstream and downstream in the canal A. Although trimethoprim and 
propyphenazone were never detected in the effluent, they were found downstream (f = 67 
% each) of the discharge point and not upstream.  
This could be explained by the presence of illegal raw discharge from buildings and 
commercial activities present along the banks of the canal, or, in some cases, of buildings 
not yet connected to the sewage network. Further reasons could be the release or 
resuspension of settled materials. Contaminations during extraction analysis have to be 
excluded. 
Average measured concentrations of the selected compounds were generally below 10 ng 
L-1 in canal A, with a few exceptions: sotalol (30 ng L-1), ciprofloxacin (25 ng L-1) and 
atenolol (11 ng L-1) (Fig. 4.3.). Student’s test applied to the two series of upstream and 
downstream concentrations showed that there is enough evidence (p-value lower than 0.01) 
to state that the measured average concentrations are different with a level of significance 
greater than 99%. Referring to all the collected data in this case study, 29 out of 81 times 
pharmaceutical concentration was detected in the effluent A and not in canal A 
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downstream the discharge point, 10 out of 81 times pharmaceutical concentration was 
found only downstream the discharge point but not in the effluent and 22 out of 81 times 
selected pharmaceuticals were not detected in both the sampling points. In the remaining 
20 cases, surface water concentration was found on average 20 times lower than the 
corresponding effluent concentration (with the ratio effluent concentration/surface water 
concentration varying between 6 and 64, SD = 19). 
These considerations lead to think that the high dilution factor in canal A (roughly 
91 during the observation period, estimated as above) could explain why surface water 
concentrations of the investigated PhCs remain quite low after effluent discharge. Sorption 
onto solids and sediments and photodegradation could also contribute to the decrease of 
pharmaceutical concentrations between the discharge point and the sampling site during 
the campaign. According to data reported in Verlicchi et al. (2012b) among the selected 
compounds, only azithromycin, ciprofloxacin, hydrochlorothiazide and diazepam tend to 
adsorb. Referring to Fig. 4.3. this mechanism could be of interest for the first three 
compounds, being the last one always not detected. Further attenuation of PhCs could be 
due to different biological, chemical and photochemical degradation processes occurring 
within the surface water (Jones et al., 2005): for many of organic compounds, 
photochemistry may be expected to play a much larger role than biodegradation, especially 
in sunlit waters. In particular, PhCs containing aromatic rings , heteroatoms (all the 27 
compounds), and other functional groups or structural moieties such as phenol, nitro, and 
napthoxyl groups (most of them), thought to undergo consistent reduction in their 
concentration along the course of the receiving water body (Boreen et al., 2003, Andreozzi 
et al., 2003, Jones et al., 2005). Half-life time is the factor to consider to evaluate if the 
photodegradation can be of interest between the discharge and sampling points. According 
to Buser et al (1998) for those compounds with half-life time for direct photolysis < 1 h, 
such as diclofenac, photodegradation significantly contributes to reduce concentration in 
surface water together with dilution factor. For most of the investigated compounds, half-
life time is much higher (Buser et al., 1998). Carbamazapine is the worst compound among 
those investigated: as it does not biodegrade, it does not adsorb onto solids and it requires 
more than 100 days to photodegrade (Andreozzi et al., 2003), it is only subjected to 
dilution effect. 
 
Chapter 4: Evaluation of the removal and release of PhCs from full-scale WWTPs 
and their impacts on the receiving water bodies 
 
143 
 
4.3.3.2 Case study B (WWTP B- Canal B) 
As reported in Figure 4.4., out of the 21 PhCs detected in the WWTP B effluent, 
only four (ciprofloxacin, azithromycin, trimethoprim and carbamazepine) were detected 
upstream of the discharge point, all with a detection frequency of 100 %, except for 
trimethoprim (f = 33 %), while 20 (hydrochlorothiazide, diclofenac, indomethacin, 
naproxen, propyphenazone, azithromycin, ciprofloxacin, clarithromycin, metronidazole, 
sulfamethoxazole, trimethoprim, glibenclamide, atenolol, sotalol, timolol, metoprolol, 
furosemide, lorazepam, salbutamol, carbamazepine, diazepam and bezafibrate) were found 
downstream. At this sampling point, their detection frequencies were always 100 %, except 
for bezafibrate and glibenclamide, which occurred in only 33 % of samples. The 
antidiabetic glibenclamide was never found in the effluent, and its presence downstream of 
the discharge point cannot rationally be explained by the very scarce literature data 
available about its concentration and behaviour upon release into the environment. 
Sorption onto solids and sediments and photodegradation could contribute to the decrease 
of surface water concentration, downstream only for the four compounds discussed above: 
hydrochlorothiazide, ciprofloxacin, azithromycin and diazepam.  
Student’s test applied to the two series of upstream and downstream average 
concentrations showed that there is enough evidence (p-value lower than 0.01) to state that 
the measured average concentrations are different at a level of significance greater than 
99%. 
Referring to all the collected measures, only 2 out of 81 times (=27 compounds x 3 
samples) pharmaceutical concentration was detected in the effluent B and not in canal B 
downstream the discharge point, 7 out of 81 times pharmaceutical concentration was found 
only downstream the discharge point but not in the effluent and 17 out of 81 times selected 
pharmaceuticals were not detected in both the sampling points. In the remaining 55 cases, 
surface water concentration was found on average 3 times lower than the corresponding 
effluent concentration (with the ratio effluent concentration/surface water concentration 
varying between 0.35 and 14 and SD = 2.6). Moreover, based on average concentrations 
(Fig. 4.4.), canal B clearly shows a PhC concentration profile similar to that found in the 
WWTP B effluent: the dilution effect of the receiving surface water almost always results 
in a reduction of the final surface water concentration by one order of magnitude: the ratio 
between average effluent concentration and average downstream concentration was in the 
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range 0.7–12, with an average value of 2.9. In canal B, average measured concentrations 
were generally much higher than 10 ng L-1, as shown in Figure 4.4. (The value of 10 ng L-1 
was chosen as it is one order of magnitude lower than the target value adopted by Beier et 
al. (2011) as discussed above). The highest values were found for sotalol (460 ng L-1) and 
atenolol (160 ng L-1), followed by hydrochlorothiazide, ciprofloxacin, clarithromycin, 
carbamazepine, furosemide and azithromycin, which occurred at an average concentration 
ranging between 80 and 100 ng L-1.  
This analysis and the concentration profiles in Figures 4.3. and 4.4. confirm that, 
due to an (expected) incomplete removal of PhCs in conventional WWTPs, the discharge 
of these treatment plants seems to represent an important source of PhCs in surface waters. 
The reason for the higher concentrations in canal B with respect to canal A is mainly the 
modest flow rate of the former and the resulting poor dilution after mixing with the 
discharge. Even if for most compounds, effluent B exhibited higher average concentrations 
than effluent A, WWTP B flow rate is much lower than WWTP A flow rate (Table 4.2.), 
resulting in lower overall mass loads (referred to the whole catchment area, as discussed 
later) discharged in the receiving water body B than in canal A. This fact confirms a 
greater dilution capacity of canal A than canal B. As reported above, water sampling was 
possible at a different downstream distances from the discharge points: 1000 m in canal A 
and 500 m in canal B. A contribution in the reduction of measured concentration of 
pharmaceuticals in canal A could be also due to degradation processes occurring in the 
river before sampling. But as the selected compounds are scarcely subjected to 
photodegradation reactions, as discussed above, this contribution keeps quite modest. 
According to Gros et al. (2010) the dilution capacity of the receiving water bodies can be 
considered the first and the primary measure in mitigating the potential toxicological 
effects of PhCs released into the environment. 
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Figure 4.3 Average concentrations of pharmaceuticals detected in WWTP A effluent and its receiving water 
body, the canal A (case study A). 
 
 
 
Figure 4.4 Average concentrations of pharmaceuticals detected in WWTP B effluent and its receiving water 
body, the canal B (case study B). 
Receiving water body
Receiving water body
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4.3.4 Pharmaceutical load discharged into the environment  
In order to evaluate environmental input of PhCs due to WWTP effluent, an initial 
rough estimate of the average mass load L of each therapeutic class j (j = 1, 2, ..., 9) 
associated with the WWTP effluent h (h = 1, 2) and the 27 selected compounds was 
calculated by multiplying the average WWTP effluent flow rate Qh by the sum of the 
average concentrations measured for each compound i belonging to the same class j (as 
reported in Table 4.4.), and dividing the result by the population served N (N values 
reported in Table 4.2.). The mass load usually refers to 1000 inhabitants, as in eq. 4.1:  
 
 =
∑ ,
 	

	1000			        (eq.4.1) 
 
The average mass loads for the nine classes and the two WWTP effluents are 
shown in Figure 4.5., in descending order of values found for the WWTP B effluent. They 
ranged from 3 to 173 mg/d/1000 inhabitants in WWTP A effluent and from 0 to 262 
mg/d/1000 inhabitants in WWTP B effluent, the WWTP B mass loads being consistently 
greater than those in the WWTP A effluent, except for that of the sole antidiabetic selected, 
which was not found to be present in the WWTP B effluent (Lantidiabetic = 0).  In both cases, 
the highest mass loads were found for beta-blockers, although the descending order 
distribution is different for the two WWTP effluents, i.e. WWTP A effluent: beta-blockers 
> analgesics/anti-inflammatories > antibiotics > psychiatric drugs > antihypertensives > 
antidiabetics > diuretics > beta-agonists (lipid regulators were never detected); and WWTP 
B effluent: beta-blockers > antibiotics > analgesics/anti-inflammatories > antihypertensives 
> psychiatric drugs > diuretics > beta-agonists > lipid regulators (antidiabetics were not 
detected).  
 
As regards the single selected PhCs, the highest average mass loads were found for 
diclofenac in both effluents: 181 mg 1000 inhabitants-1 d-1 for the case study B and 117 for 
the case study A. Among the selected antibiotics, the highest values were found for 
clarithromycin and ciprofloxacin (77 mg 1000 inhabitants-1 d-1) and azithromycin (48 mg 
1000 inhabitants-1 d-1) in the effluent of WWTP B, and for clarithromycin (35 mg 1000 
inhabitants-1 d-1) in the effluent of WWTP A. 
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Figure 4.5. Average mass loads for the nine therapeutic classes based on occurrence of the selected 
pharmaceuticals. 
 
Considerable mass loads were found in WWTP B effluent for atenolol (114 mg 
1000 inhabitants-1 d-1), hydrochlorothiazide (105 mg 1000 inhabitants-1 d-1), sotalol (89 mg 
1000 inhabitants-1 d-1), carbamazepine (65 mg 1000 inhabitants-1 d-1) and metoprolol (57 
mg 1000 inhabitants-1 d-1). In WWTP A effluent, the highest mass loads were consistently 
lower: sotalol (68 mg 1000 inhabitants-1 d-1), hydrochlorothiazide (50 mg 1000 inhabitants-
1
 d-1) and carbamazepine (43 mg 1000 inhabitants-1 d-1), except for metoprolol, whose mass 
load was slightly higher (63 mg 1000 inhabitants-1 d-1). 
 
The total (referred to the selected compounds) average mass loads discharged by 
the two effluents were estimated at 539 mg 1000 inhabitants-1 d-1 for WWTP A and 965 
mg 1000 inhabitants-1 d-1 for WWTP B. It is important to observe that the daily overall 
pharmaceutical mass load discharged with the whole effluent into the receiving water body 
depends on the whole resident population (hence on the WWTP flow rate). Assuming the 
values reported in Table 4.2. for the two WWTPs, the overall mass loads discharged with 
effluent A amounts to 74 g d-1 and it is much higher than that discharged with effluent B (5 
g d-1).  
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4.3.5 Environmental impact of the selected PhCs  
Based on EMEA guidelines (EMEA, 2006), the risk quotient RQ between MEC 
and PNEC was calculated for the different compounds to estimate their potential adverse 
effects on aquatic organisms in both WWTP effluents and surface water. Unfortunately 
PNECs are known only for 19 out of the 27 selected compounds investigated here.  In this 
study, in order to simulate the worst-case scenario referring to this observation period, 
maximum measured concentrations were used to calculate RQ for both the WWTP 
effluents and receiving water bodies. Table 4.5. reports the calculated RQ values. Values 
greater than 1 (high risk) or between 0.1 and 1 (medium risk) are reported in bold. 
 
Sulfamethoxazole, clarithromycin and azithromycin were found to be the most 
critical compounds, due to their high RQ values. In fact, according to the risk ranking 
system proposed by Hernando et al. (2006), these compounds posed a high environmental 
risk (RQ > 1): sulfamethoxazole and clarithromycin in the two WWTP effluents and in 
canal B and azithromycin in effluent B and canal B. Moreover a medium risk (RQ in the 
range 0.1-1) was found to be posed by sulfamethoxazole and clarithromycin in canal A, 
azithromycin in effluent A. 
 
For all the other PhCs, calculated RQs were consistently < 0.1, corresponding to a 
minimal risk. It is important to underline that the two receiving surface water bodies were 
investigated at different distances from the discharge points, defined by the characteristics 
of the banks not always accessible, as presented above. Comparison of the results must 
take into account this fact. Experimental investigations evidence that the discharge of a 
small WWTP in a small receiving water body may result in high RQs (even >1), as in the 
case study B.  
 
Previously, other studies have reported high RQs in surface water due to the 
presence of pharmaceuticals in high concentrations, such as analgesics, psychiatric drugs 
and antibiotics: ibuprofen, naproxen, ketoprofen and carbamazepine (Hernando et al., 
2006), diclofenac (Hernando et al., 2006, Zhao et al., 2010), mefenamic acid (Jones et al., 
2002; Tauxe-Wuersch et al., 2005), sulfamethoxazole (Garcia-Galan et al., 2011), 
paracetamol, amoxicillin and oxytetracycline (Jones et al., 2002). These data all indicate 
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that WWTP discharges may pose a high risk for the aquatic environment, and that the 
hydraulic characteristics of the receiving water bodies should therefore be taken into 
consideration in their management, as supported by Gros et al. (2010), in order to mitigate 
their potential toxicological effects. 
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Table 4.5. Predicted no-effect concentrations (PNECs, ng L-1) and corresponding risk quotients (RQs) for the selected compounds in the both two 
WWTP effluents and receiving water bodies. 
   Case study A - RQ Case study B- RQ 
Compounds PNEC Reference WWTP effluent Surface water WWTP effluent Surfacewater 
Diclofenac 9700 Ra et al., 2008 0.05 0.001 0.08 0.006 
Indomethacin 3900 Sanderson e al., 2003 - - - 0.001 
Ketoprofen 15600 Farré et al., 2001 0.001 - 0.001 - 
Mefenamic acid 428 Jones et al., 2002 0.06 - - - 
Naproxen 2620 Quinn et al., 2008 - 0.006 0.008 0.003 
Propyphenazone 800 Sanderson et al., 2003 - 0.009 0.06 0.02 
Azithromycin 150 Kummerer and Henninger, 2003 0.366 0.046 1.3933 0.59 
Ciprofloxacin 938000 Sanderson et al., 2003 0.00004 0.00003 0.001 0.0001 
Clarithromycin 70 Boillot, 2008 1.6 0.100 5.3 1.8 
Metronidazole 2500 Kummerer and Henninger, 2003 0.0084 - 0.01 0.0064 
Roxithromycin 4000 Sanderson et al., 2003 0.003 - - - 
Sulfamethoxazole 27 Ferrari et al., 2004 3.6 0.19 6.9 3.4 
Trimethoprim 2600 Sanderson et al., 2003 - 0.001 0.015 0.01 
Atenolol 30000 Boillot, 2008 0.01 0.0005 0.02 0.008 
Metoprolol 8000 Sanderson et al., 2003., 0.02 0.001 0.03 0.006 
Timolol 9000 Sanderson et al., 2003 0.001 - 0.0008 0.0008 
Bezafibrate 5300 Sanderson et al., 2003 - 0.003 0.001 0.0008 
Carbamazepine 13800 Ferrari et al., 2004 0.01 0.001 0.02 0.006 
Diazepam 2000 Sanderson et al., 2003 - - 0.005 0.003 
- = not detected 
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Moreover, it should be mentioned that the environmental risk analysis conducted in 
this work was based on the acute toxicity of single compounds, not taking into account the 
synergistic effects of a mixture of pharmaceuticals, which, according to previous study 
(Gros et al., 2010), are likely to be even more harmful at lower single concentrations. 
 
4.4 Conclusions 
 These results show and confirm that PhC concentrations may exceed their PNECs 
in the effluents from conventional municipal WWTPs. In the area under investigation, the 
most critical compounds are the antibiotics sulfamethoxazole, clarithromycin and 
azithromycin. Other substances, including some analgesics/anti-inflammatories, other 
antibiotics and the antiepileptic carbamazepine, could also be considered as PhCs to add to 
the list of potential critical compounds from an environmental risk point of view. From a 
legislative point of view, up to now, limits for the concentrations of PhCs in WWTP 
effluent have not yet been set. The discussion is open, as reported in Verlicchi et al., 
2012b. In this context, the study by Perazzolo et al. (2010) discussed a method to 
determine a list of pharmaceuticals to survey in surface water. Inclusion of substances on 
the list was based on a screening procedure, the analytical feasibility, and previous 
knowledge of pharmaceuticals detected in water. A recent review made by European 
Community Commission about the new priority substances to begin monitoring in aquatic 
environment include hormones (ethinylestradiol, estradiol) and diclofenac. (EC, 2012). 
Hydrodynamic characteristics of the receiving water body, principally its average flow 
rate, contribute to mitigating the risks to the environment associated with the presence of 
toxic substances. The dilution capacity of the receiving water bodies can therefore be 
considered of prime importance in reducing and controlling the potential toxicological 
effects of PhCs released into the environment. Nonetheless, even after the discharge of the 
treated effluent into a receiving body characterized by a high flow rate, PhC concentrations 
do not appear to be reduced to level of minimal environmental risk. Furthermore, if 
environmental risk analysis is extended to a mixture of compounds, even more harmful 
effects are likely to be seen due to synergistic effects. Hence, further measures are needed 
to reduce the environmental risk posed by PhCs, including source control of the most 
critical compounds and enhancement of PhC removal by appropriately upgrading existing 
WWTPs. 
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5.1 Introduction  
Antibiotic drugs have been identified as a category of trace chemical contaminants 
that warrant close scrutiny (Al Aukidy et al., 2012; Verlicchi et al., 2012b). Much of the 
concern regarding the presence of antibiotics in wastewater and their persistence after 
treatment processes is related to suspicions that they may generate antibiotic resistance in 
bacterial species in wastewaters and surface waters down the discharge of the wastewater 
treatment plants (WWTPs) (Baquero et al., 2008), which may have consequences on the 
ecosystem as a whole.  
 
Once this issue was brought to the fore, researchers began to investigate the 
environmental occurrence of PhCs, first via chemical analysis (Daughton and Ternes 
1999), and later risk assessment studies (Carlsson et al., 2006;Verlicchi et al., 2012a, b). 
Environmental risk assessments are generally conducted by either monitoring programs, 
which provide measured environmental concentrations MECs) (as presented in Chapter 3 
and 4) or prediction models, based mainly on consumption data, which furnish predicted 
environmental concentrations PECs) (Cunningham, 2008; Escher et al., 2011). 
Hence the aim of this chapter is to determine the relative accuracy of the prediction 
models, and the limitations of on-site monitoring campaigns in order to investigate their 
effect on the estimation of the environmental risk, measured and predicted environmental 
concentrations of 12 selected prescription drugs (11 antibiotics and one antiepileptic) at 
three sampling points: the influent and the effluent of a large municipal WWTP and 
downstream of its discharge point in the receiving water body have been compared. 
 
5.2 Materials and methods 
5.2.1 WWTP and receiving water body 
The investigated WWTP is the WWTP of Ferrara that investigated in Chapter 3 and 
its water receiving body that investigated in Chapter 4 under the name of “case study A”. 
This case study is representative of many other catchment areas in the Po Valley that 
feature similar environmental conditions (meteorological conditions, water body 
characteristics and destination of receiving water body use, catchment size, legal standards 
for the discharge into the receiving water body, etc.). 
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5.2.2 Selected compounds 
Selected compounds were all common prescription drugs, 11 antibiotics and one 
antiepileptic, chosen on the basis of their high prescription and sale figures. The annual 
consumption of each could be documented through Territorial Office records and 
databases. Their consumptions in the investigated area are reported in the fourth column of 
Table 5.1. in terms of total amount (kg year-1). The analytical technology required to detect 
each selected pharmaceutical in water is well known and documented. 
 
5.2.3 Measured environmental concentration (MEC) 
Measured environmental concentration of the selected PhCs under investigation are 
reported in Chapter 3 for the influent and effluent from the WWTP, while chapter 4 reports 
the measured environmental concentration in surface water, in this case maximum 
observed concentrations have been considered. 
 
5.2.4 Predicted environmental concentrations (PEC) for the selected PhCs  
5.2.4.1 WWTP Influent and effluent 
The quantity of each selected pharmaceutical consumed in one year in the 
investigated catchment area Aarea, j (j = 1, 2, ...12) was evaluated by means of eq. 5.1. 
According to this model, already adopted in other studies (Le Corre et al., 2012; Ort et al., 
2010a) Aarea, j corresponds to a fraction of the national consumption AItaly, j, and depends on 
the Italian resident population PItaly, which, is equal to 58.6 million people, and the local 
population Parea, equal to 138 thousand (ISTAT, 2010). 
 
Aarea,j = 
AItaly,j 
PItaly
×Parea          (eq. 5.1) 
 
Eq. 5.1 assumes that in the area under investigation the pattern of consumption for 
the selected compounds is the same as that determined for the Italian population as a 
whole. The amounts of pharmaceuticals consumed in Italy in 2010  are provided (by the 
local Territorial Pharmaceutical Office and the OsMed Work Group, 2011) in terms of 
Defined Daily Doses (DDD). In order to obtain their annual consumption AItaly,j expressed 
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in kg year-1, DDD values were multiplied by the corresponding conversion factor (CFj) 
(mg active compound DDD-1, defined by WHO, 2012).  
 
Table 5.1. reports the selected compounds: first the 11 antibiotics, in alphabetical 
order, and then the anti-epileptic carbamazepine. The amount of active compound 
consumed in Italy in 2010 in terms of DDD, as well as its annual consumption AItaly,j (kg) 
and local consumption Aarea,j (kg) is reported for each compound. Table 5.1. also reports 
literature data on the percentage excretion rate Ej, as well as the removal efficiencies Rj 
observed in the WWTP monitored by Galletti, (2011) (except for a few compounds for 
which literature data were used). 
Table 5.1. Amounts of the selected compounds used in Italy in 2010, in terms of DDD and 
kg/year, together with the conversion factor, excretion rate (from the literature) and 
removal efficiency (observed value) of each compound 
Compound Amount used (DDD) 
Conversion  
factor CF 
(mg DDD-1) 
Amount  
used in Italy  
(kg year-1) 
Amount  
used in the area 
(kg year-1) 
Ej  
[%] 
Rj 
[%] 
Azithromycin 27 739 328 500 13 870 33 14c 11 
Ciprofloxacin 21 672 142 1000 21 672 51 55a 71 
Clarithromycin 64 469 749 1000 64 470 152 25a 8 
Doxycycline 3 961 205 100 396 0.93 41c 14d 
Erythromycin 60 2000 0.12 0.00028 5b 73 
Metronidazole 2492 2000 4.98 0.011 80c 34 
Norfloxacin 3 548 335 800 2839 6.68 30a 25 
Ofloxacin 198 300 400 79.3 0.18 80c 61 
Roxithromycin 1 924 410 300 577 1.35 85a 65 
Tetracycline 2 037 101 1000 2037 4.8 58c 40e 
Trimethoprim 6 948 177 400 2780 6.54 80b 31 
Carbamazepine 31 189 639 1000 31 190 73 30a 36 
a
 Ternes and Joss 2006; b Verlicchi et al. 2010b; c rxlist (http://www.rxlist.com/); d Lindberg et al. 2005; e 
Ghosh et al. 2009 
  
Predicted environmental concentrations for each compound j, PECj,k in the influent (k = 
inf) and the effluent (k = eff) of the WWTP were calculated according to eq. 5.2, suggested 
by Tauxe-Wuersch et al. 2005: 
 
PECj,k= 
Aarea,j ×109×Ej×1-Rj 
WWinh ×Parea×365
        (eq. 5.2) 
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where Aarea is the amount of pharmaceutical consumed per year in the catchment area 
under investigation (Table 5.1.), Rj is the fraction of the compound j removed during 
sewage treatment, (by adsorption to sludge particles, hydrolysis and biodegradation) (Table 
5.1.); Ej is the fraction assumed to be excreted by a human body (Table 5.1.) of the 
compound j, Parea is the number of residents in the catchment area under investigation, and 
WWinh is the volume of wastewater produced per capita per day in the catchment area, 
assumed to be equal to 200 L inh -1 d-1. 
 
For each compound, PECj, inf was evaluated assuming that no removal occurred, that 
is Rj= 0 in eq. 5.2, while in evaluating PECj,eff, Rj values were taken as those listed in Table 
5.1.  
 
5.2.4.2 Surface water 
Predicted concentrations of the selected compounds in the receiving water body 
PECj,swI of the WWTP final discharge were estimated by applying the procedure of 
Environmental risk assessment according to EMEA guidelines (EMEA, 2006). These 
suggest first evaluating a crude measure based on their maximum daily dose MDD (Phase 
I) by means of eq. 5.3:  
 
PECj,swI=
MDDj×Fpen,j
WWinh×D
×1000        (eq. 5.3) 
 
where MDDj is expressed in mg inh-1 d-1, Fpen,j is the market penetration, that is the 
fraction of the local population being treated daily with a specific drug substance (default 
value is equal to 0.01, corresponding to 1% of the population), WWinh is the volume of 
wastewater produced daily by each inhabitant (default value equal to 200 L inh -1 d-1) and 
D is the factor for dilution of the wastewater by surface water flow rate (default value equal 
to 10). The guidelines recommend that any drug exceeding the concentration of 0.01 µg L- 
1 in surface water, considered as a threshold for environmental risk, should progress to 
Phase II.  
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Phase II consists of two steps in series: Phase IIA and Phase IIB. Phase IIA involves 
the refinement of the PECj,sw values. By means of eq. 5.4, a revision of Fpen,j is made, 
taking into consideration specific commercial information about the geographical 
distribution of the drug. Its calculation is based on total prescription quantities in the 
catchment area Aarea,j, in addition to DDD data. In general, the figures do not include over-
the-counter (OTC) sales, which is why the compounds selected were prescription drugs. 
 
Fpen,j=
Aarea, j×100
DDDj×Parea×365
         (eq. 5.4) 
 
The surface concentration is then recalculated using this new Fpen,j figure, providing 
PECj,sw IIA values. These are then compared with the corresponding predicted no-effect 
concentration (PNEC) reported in Table 5.2.  
Each PNEC value was assumed to be 1000 times lower than the toxicity concentration 
value found for the most sensitive species assayed, so as to take into account the effect on 
other, potentially more sensitive aquatic species to those used in toxicity studies (Verlicchi 
et al., 2012b). 
 
From these figures the ratio PECj,sw IIA/PNEC was then calculated. For compounds 
whose ratio is higher than 1, a new refinement of the surface concentration must be 
performed (Phase IIB), according to eq. 5.5, which takes into account excretion rate (Ej) 
and removal processes (Rj) during the passage through the WWTP. 
 
PECj,swIIB=
MDDj×Fpen,j
WWinh×D
×Ej×1-Rj×1000      (eq. 5.5) 
 
5.3 Results and discussion  
5.3.1 Predicted environmental concentrations 
Table 5.2. reports the values of predicted concentrations for the selected compounds 
(j = 1,.., 12) in the WWTP influent (PECj,inf) and effluent (PECj,eff), estimated by means of 
eq. 5.2, and in the receiving water body (PECj,sw I), on the basis of eq. 5.3. As all values 
exceeded the threshold of 0.01 µg/L, a refinement of PECj,sw was conducted in all cases, 
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involving first an estimation of Fpen j (through eq. 5.4) and then the recalculation of PECj,sw 
IIA, once again applying eq. 5.3 with the re-evaluated Fpen j (Table 5.2.). In this step, a re-
evaluation of the surface water concentration is required for compounds with PECj,sw IIA > 
PNECj, and was performed by means of eq. 5.5, which yields PECj,sw IIB. Eq. 5.5 relies on 
MDD values, which are duly listed in Table 5.2. This procedure was only necessary for 
azithromycin, clarithromycin and tetracycline, and their corresponding PECj,sw IIB values 
are also reported in Table 5.2.  
For the remaining compounds, PECj,sw IIA are considered. The predicted surface 
concentrations for the selected compounds are those listed in the last column of Table 5.2. 
 
5.3.2 Measured environmental concentrations 
The results of the monitoring campaign at the three sampling points (influent, 
effluent and receiving water body) that reported and discussed well in Chapter 3 for the 
influent and effluent of the WWTP and in Chapter 4 for surface water body are re-
summarised in Table 5.3. as average values of the measured concentrations (MEC), 
alongside the corresponding standard deviation SD.  
 
Again, in the influent and effluent samples, 10 out of the 12 selected compounds 
were detected in every sample (the antibiotics doxycycline and tetracycline were never 
found), whereas in surface water samples azithromycin, ciprofloxacin, clarithromycin, 
trimethoprim and carbamazepine were found in only one sample, and the remaining 
compounds, metronidazole, roxithromycin were never detected in any sample. 
doxycycline, erythromycin, norfloxacin, ofloxacin and tetracycline were not monitored. 
For this reason, SDs for surface water are not reported in Table 5.3.  
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Table 5.2. Maximum daily dose, predicted environmental concentrations and predicted no 
effect concentrations for the selected compounds in WWTP influent, effluent and receiving 
water body 
Compounds 
M
D
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Azithromycin 800 0.454 0.40 4.0 0.13 0.52 0.15 0.064 0.064 
Ciprofloxacin 1200 2.78 0.81 6.0 0.10 0.60 938  0.60 
Clarithromycin 1000 3.76 3.46 5.0 0.30 1.5 0.07 0.35 0.346 
Doxycycline 200 0.0380 0.033 1.0 0.019 0.018 0.3  0.018 
Erythromycin 4000 1.4 10-6 4 10-7 20 2.8 10-7 5.6 10-6 0.02  5.6 10-6 
Metronidazole 2000 0.00093 6 10-4 10 1.2 10-5 1.1 10-4 2.5  1.1 10-4 
Norfloxacin 800 0.20 0.15 4.0 0.016 0.066 15  0.066 
Ofloxacin 800 0.015 0.0058 4.0 9.2 10-4 0.0037 0.016  0.0037 
Roxithromycin 600 0.12 0.040 3.0 0.0089 0.026 4  0.026 
Tetracycline 2000 0.28 0.17 10 0.0095 0.095 0.09 0.033 0.033 
Trimethoprim 640 0.52 0.36 3.2 0.032 0.10 2.6  0.10 
Carbamazepine 1600 2.2 1.4 8.0 0.15 1.2 13.8  1.16 
a
 PNEC are from Verlicchi et al., 2012b 
 
Table 5.3. Average environmental concentrations and standard deviations (µg L-1) for the 
selected pharmaceuticals in the WWTP influent, effluent and receiving surface water body 
Compound 
MEC ± SD 
influent 
MEC± SD 
effluent 
MEC± SD  
surface water 
Azithromycin 0.11 ±0.15 0.13±0.046 0.007 
Ciprofloxacin 2.2±1.8 0.63±0.349 0.025 
Clarithromycin 0.30±0.32 0.28±0.024 0.006 
Doxycycline < LOD < LOD n.m 
Erythromycin 0.058±0.016 0.023±0.014 n.m 
Metronidazole 0.042±0.013 0.028±0.012 <LOD 
Norfloxacin 0.20±0.07 0.15±0.013 n.m 
Ofloxacin 1.0±0.82 0.39±0.138 n.m 
Roxithromycin 0.084±0.049 0.029±0.018 <LOD 
Tetracycline < LOD < LOD n.m 
Trimethoprim 0.058±0.014 0.040±0.007 0.002 
Carbamazepine 0.58±0.39 0.37±0.069 0.007 
n.m: not measured 
Selected pharmaceuticals were found in the range 0.042–2.2 µg L-1 in the influent, 
0.023–0.64 µg L-1 in the effluent and 0.002–0.07 µg L-1 in the receiving body. On the 
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whole, these results are in accordance with those found at other Italian municipal WWTPs 
and their corresponding receiving water bodies (Al Aukidy et al., 2012; Andreozzi et al., 
2003; Castiglione et al., 2005; Ferrari et al., 2011; Zuccato et al., 2010). 
 
5.3.3 Comparison of PEC and MEC 
A comparison of the predicted and measured concentrations for the investigated 
compounds at the three sampling points was first performed by means of the ratio 
PEC/MEC, to establish whether the model underestimates or overestimates measured 
values, and then by the ranking criteria proposed by the Knappe Project and used in the 
study by Coetsier et al. (2009) to assess the acceptability of the results of the adopted 
model.  
 
Predicted values used for evaluating this ratio are those reported in Table 5.2., in 
particular PECj, inf (third column of Table 5.3.) for the influent, PECj,eff (four column) for 
the effluent, and PECj,sw (last column) for the surface water. The 3D diagrams in Fig. 5.1. 
clearly show that PECs are greater than the corresponding MECs in 6 out of the 10 
detected compounds (as mentioned above, two antibiotics were not detected at any of the 
three sampling points). In particular, for azithromycin, ciprofloxacin, clarithromycin, 
trimethoprim and carbamazepine, PEC/MEC was greater than 1 at all the three sampling 
points, whereas for roxithromycin, the ratio is greater than 1 in the WWTP influent and 
effluent. In contrast, the influent and effluent concentrations of erythromycin, ofloxacin 
and metronidazole were underestimated by the prediction formula (PEC/MEC < 1). Only 
for norfloxacin were the predicted and measured concentrations of the same order of 
magnitude (PEC/MEC=1). For erythromycin, the PEC was roughly zero at influent and 
effluent sampling point. 
These findings evidence that predicted values are often greater than measured values, but 
not in all cases, as noted by other studies carried out in France (Coetsier et al., 2009), the 
UK (Bound and Voulvolis 2006) and Spain (Carballa et al., 2008). 
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Figure 5.1. Comparison of predicted and measured concentrations of the selected compounds at the three 
sampling points by means of the ratio PEC/MEC. In the third axis of the graph: inf = WWTP influent, eff = 
WWTP effluent, sw= receiving surface water.  
 
In order to evaluate whether predicted values may be accepted or rejected, it can be 
useful to adopt the following ranking criteria (Coetsier et al., 2009):  
 
0.2 < PEC/MEC <1, PEC acceptable, slightly underestimated; 
1 < PEC/MEC < 4, PEC acceptable, slightly overestimated; 
4 < PEC/MEC < 8, PEC significantly overestimated; 
PEC/MEC > 8, PEC strongly overestimated. 
 
Table 5.4. shows that in this case study the adopted model yields acceptable predicted 
values for almost the same compounds in the influent and effluent (norfloxacin, 
ciprofloxacin, carbamazepine and, only in the effluent, azithromycin), while for surface 
water, the equations adopted always furnished a large overestimation. The worst 
predictions were found for the antibiotics clarithromycin and trimethoprim (PEC/MEC 
always > 8) and for azithromycin (PEC/MEC> 4 in the influent and >8 in surface water). 
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Table 5.4. Evaluation of the PEC/MEC ratio for the study area 
Sampling point 
PE
C/
M
EC
 
≤
 
0.
2 
0.
2 
<
PE
C/
M
EC
 
≤
 
1 
1 
<
PE
C/
M
EC
 
≤
 
4 
4 
<
PE
C/
M
EC
 
≤
 
8 
PE
C/
M
EC
 
>
 
8 
Influent Erythromycin, 
Metronidazole, 
Ofloxacin 
Norfloxacin Ciprofloxacin, 
Roxithromycin, 
Carbamazepine 
Azithromycin Clarithromycin, 
Trimethoprim 
Effluent Erythromycin, 
Metronidazole, 
Ofloxacin 
Norfloxacin Azithromycin, 
Ciprofloxacin, 
Roxithromycin 
Carbamazepine 
 Clarithromycin, 
Trimethoprim 
Surface water     Azithromycin, 
Ciprofloxacin, 
Clarithromycin, 
Trimethoprim, 
Carbamazepine 
 
5.3.4 Explanation of discrepancies 
Discrepancies found between MEC and PEC at the three sampling points can be 
ascribed to various different causes. The most important of these causes are reported in 
Table 5.5. Depending on the compound and on the sampling point, some of these factors 
can be considered as principle or secondary. For instance, inaccuracy of the sales data 
pertaining to the twelve investigated compounds in this area could be due to a local 
consumption pattern different from the national one, as the substances are not OTC 
products and other sources of PhCs such as veterinary use on farms are not present in the 
catchment area. 
 
Excretion rate is a critical parameter in these calculations, as it is strictly correlated to 
individual human characteristics (gender, age, health status, consumption of other 
pharmaceuticals) as well as to those of a particular pharmaceutical. Regarding the latter, 
the latest generations of compounds have been designed with a view to consistently 
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incrementing their adsorption rate during metabolism. Furthermore, it is important to note 
that for many substances a wide range of (observed) values of E are reported in the 
literature, and the choice of the most appropriate value to adopt in PEC estimation may 
therefore be difficult. However, as a precautionary measure it is wise to use the highest 
values in the model.  
 
In addition, improper disposal of unused medicines, i.e., by flushing them down the toilet 
or throwing them out with the household waste rather than returning them to a pharmacist, 
will also affect the prediction accuracy. In this case the medicine would bypass the 
metabolic processes within the body that would modify it to different extents, and only the 
residual fraction would be excreted. Some compounds are almost completely metabolized 
to inactive metabolites prior to excretion with little or no parent compound appearing in 
urine or feces, so the appearance of significant concentrations of the parent form of these 
pharmaceuticals in wastewater might suggest that they were not introduced by excretion 
(Mankes and Silver 2013, Jelic et al., 2012). 
 
It is rare that the removal efficiencies used in PhC prediction are the fruit of direct 
measurement at the WWTP under investigation; more often they refer to “similar” WWTPs 
whose data are available in literature. But, as Verlicchi et al. (2012b) have previously 
pointed out, removal efficiencies are strictly correlated to the specific WWTP configuration 
(C, N and P removal, biological reactor shape), operating conditions (SRT, HRT, pH, T, 
redox conditions, etc.) and feeding mode, and PEC calculations are therefore at high risk of 
inaccuracy. To compensate, Le Coetsier et al. (2009) suggest adopting the mean of a wide 
range of literature data when available, or a removal efficiency equal to 0, should data be 
lacking, in order to simulate the worst case scenario. Estimating the dilution in the 
receiving water body is another calculation highly susceptible to error, which is therefore 
passed on to the PEC. If the receiving body has a fairly constant flow rate (for instance in a 
mechanically regulated artificial canal) the error plaguing the estimation of dilution is quite 
small, but in other cases it depends on the flow rate of the receiving body and on the flow 
rate of the discharged effluent during the monitoring period.  
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On a related note, it is also important to point out that the investigation was limited to 
unchanged molecules, and did not encompass their corresponding metabolites. 
Another aspect that EMEA guidelines fail to consider in their model is an estimation of the 
pharmaceutical removal processes occurring once the effluent is discharged into the 
surface water body. Indeed, processes such as partitioning, interactions with environmental 
media, photoreactions, photodegradation, settlements, biodegradation, etc., can all result in 
an overestimation of the PEC.  
Last but not least, sampling protocols, as remarked by Ort et al. (2010b) and Johnson et al. 
(2008), as well as instrument and human errors, may cause further discrepancies between 
MEC and PEC, especially for those compounds detected at very low concentrations 
(several ng L-1). 
 
Table 5.5. Factors behind discrepancies between measured and predicted environmental 
concentrations of pharmaceuticals in raw wastewater, treated effluent and surface waters. 
 Factor 
W
W
TP
 
 
In
flu
en
t 
W
W
TP
 
 
ef
flu
en
t 
Su
rfa
ce
 
 
w
at
er
 
1 Erroneous estimation of pharmaceutical consumption (sales data and 
consumption pattern: over-the-counter OTC products are not 
included in the consumption data; presence of further sources such as 
farms) 
   
2 Inaccurate excretion rate assumed in PEC evaluation    
3 Improper disposal of unused medicines (in household waste or via 
the toilet)    
4 Inaccurate expected removal efficiency for the compound under 
investigation, after its passage through the WWTP    
5 Inaccurately evaluated dilution effects due to possible variability in 
the flow rate in the receiving water body    
6 Failure to consider further removal mechanisms occurring in the 
surface water body after the discharge of the treated effluent, also 
due to photoreactions and photodegradation, etc.  
  
7 Sampling protocols    
8 Instrument error, especially for those compounds detected at very 
low concentrations (ng/L).     
 
5.4 Conclusions 
Although in our case the observed differences between PEC and MEC varied among 
the selected compounds and the sampling points investigated (influent, effluent and surface 
water), both predicted and measured concentrations are plagued by uncertainty.  
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In fact, unless MEC values can be extrapolated to a longer period characterized by 
identical PhC consumption patterns and environmental conditions (including flow rate, 
meteorological conditions), they can only be considered valid for a particular sampling 
period. Indeed, to obtain annual data, monitoring campaigns would be even more complex 
and expensive. On the other hand, irrespective of the model used, PEC values need to be 
considered as theoretical values, extrapolated from annual data (the year the values 
assumed for each variable in the EMEA models refer to).  
 
As exposure assessment is the first (screening) step in environmental risk 
assessment, it is vital that PECs should not underestimate actual environmental 
concentrations to avoid putting the environment under considerable strain. These 
considerations have prompted several Authors (among them Bound and Voulvoulis 2006; 
Castiglioni et al., 2004; Coetsier et al., 2009; Liebig et al., 2006) to question whether 
predicted concentrations should be used at all. According to Carballa et al. (2008), PECs 
should not be used in place of direct measurements, and instead should merely be 
considered a useful tool for defining target compound classes for monitoring or for 
identifying the forms of the compound (conjugated or free forms) and compartments 
(liquid or solid fraction) to be investigated.  
 
Indeed, the differences between MECs and PECs documented by our findings, as 
well as in other studies, indicate that calculation models still need considerable refinement 
to increase model reliability and discriminative power. At present, however, great 
discrepancies between measured and predicted values are discouraging, as risk assessments 
should always err on the side of caution and produce false positives that lead to further 
investigation rather than false negatives, which could leave a potential risk unexplored. 
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6.1 Introduction  
The consumption of PhCs is on the increase in both hospitals and households (van 
der Aa et al. 2011). As the human body only metabolizes a fraction of the administered 
PhC, it enters the water cycle as the parent compound and/or its metabolites via excretion, 
mainly in urine and to a lesser extent the faeces. (Jjemba et al. 2006). As shown in Chapter 
2 and 3, conventional municipal WWTPs are unable to efficiently remove all the different 
compounds found in sewage, and treated effluent is therefore one of the main sources of 
PhC release into the environment. Hence, over the last ten to fifteen years, PhC 
concentrations in raw and treated urban WW have been extensively monitored. 
Nevertheless, this is still a largely unregulated area, and there is ongoing debate within the 
scientific community regarding which PhCs to include among the priority substances 
(Bottoni et al. 2010). Indeed, according to the European Draft (EC 2012), the anti-
inflammatory diclofenac and the hormones 17β-estradiol and 17α-ethinylestradiol are 
prime candidates to be added to the European Priority List, while according to the U.S. 
EPA, erythromycin, nitroglycerin, and 9 hormones (17α-ethinylestradiol, 17α-estradiol, 
17β-estradiol, equilenin, equilin, estriol, estrone, mestranol and norethindrone), need to be 
considered a priority (Richardson and Ternes 2011). 
HWWs represents a particular concern, but has only recently been investigated, and 
in a far fewer number of studies. Not only high analysis costs, but also the difficulties in 
organizing water-sampling campaigns inside health facilities have delayed these 
investigations. Nonetheless, according to the recent literature( Verlicchi et al. 2012c, 
Verlicchi et al. 2010a,b; Ort et al. 2010a) HWWs may be considered a hot spot in terms of 
PhC load generated, prompting the scientific community to question the acceptability of 
the general practice of discharging HWWs into public sewers ( Verlicchi et al. 2010 b), 
where they are conveyed to municipal WWTPs and co-treated with urban WWs (Verlicchi 
et al. 2010 a,b; Pauwels and Verstraete 2006; Kummerer and Helmers 2000). Initially the 
discussion centered on the concentrations of regulated (e.g. organic substances, N and P 
compounds, and microorganisms) and unregulated (residual of PhCs) pollutants in both 
hospital and urban WWs (Pauwels and Verstraete 2006). Then the focus shifted to 
evaluation of the load of selected (the most critical) PhCs produced by a hospital and its 
catchment area (Verlicchi et al. 2012a; Ort et al. 2010a). This made it possible to estimate 
the relative contributions of each investigated compound made by the hospital and its 
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catchment area, revealing that in some cases the hospital is indeed the main source of 
certain PhCs in WW, for example the antibiotics ciprofloxacin, spiramycin, clarithromycin, 
azithromycin and oflaxacin (Verlicchi et al. 2012a, Le Corre et al. 2012) and the lipid 
regulator atorvastatin (Verlicchi et al. 2012a, Ort et al. 2010a).  
At the same time, several research groups set out to quantify the environmental risk 
generated by selected PhCs in raw hospital and urban WWs as well as in municipal 
WWTP effluents ( Eascher et al. 2011, Verlicchi et al. 2012a). Through evaluation of a 
compound’s risk quotient (RQ), that is the ratio between its measured or predicted 
concentration and its predicted no-effect concentration (PNEC), these studies have shown 
that for some compounds the risk is high (RQ > 1) in raw WWs and remains high in the 
WWTP effluent. However, once the effluent is discharged into the receiving water body, 
its dilution with surface water can mitigate the effect of residual PhCs and the associated 
risk quotient may decrease ( Gros et al. 2010) sometimes even to moderate or low levels.  
All cited studies were conducted with the aid of local PhC consumption data and/or 
field monitoring campaigns. Unfortunately, however, in the real world these types of 
investigations are unfeasible due to time and monetary constraints. Therefore, in the case 
of the construction of a new hospital, for example, a simple and rapid tool able to provide a 
rough estimation of the potential impact on the local environment of the PhCs in its 
effluent would be invaluable for the authorities and decision-makers responsible for 
hospital management and environmental protection. To this end, the aim of this chapter is 
to provide The authorities responsible for hospital management and environmental health a 
tool to evaluate the potential impact of hospital effluents taking in consideration the site 
specific information such as the contribution of human population and hospital sizes, their 
location in the catchment area, WWTP capacity, and available dilutions which can differ 
between catchment area. 
This chapter also aims to assess the relative importance of PhCs pathways ( 
HWWs, UWWs) for the priority candidate diclofenac as a case study for individual 
WWTP. Such information will then be discussed to demonstrate its potential to assist with 
options for reducing PhCs risk in discharges, and to highlight the need to adopt 
management options 
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6.2 Methodology 
The PhCs discussed in this study focused on the minimum number of compound that 
should be considered in any study on PhC in water management and defined as high 
priority or priority substances by different research groups worldwide (GWRC 2008, Sui et 
al.,2012, Perazzolo et al., 2010, Roos et al., 2012, Ruel et al. 2012, Besse et al., 2008, 
Ginebreda et al.,2012, NRMMC1 2008, Richardson and Ternes 2011, Verlicchi et al., 
2012b), six analgesics and anti-inflammatories, eleven antibiotics, one antihypertensive, 
three beta-blockers, one contrast media, three hormones, one Lipid regulators, one 
Psychiatric Receptor and one antagonists drugs (Table 6.1.). These pollutants are quite 
often unregulated as yet but may be included in the ongoing and future reviews of the 
Priority Substances List under WFD ( Bottoni et al.2010). Some of these compounds are 
candidate to be within the list of priority substances (Diclofenac, Erythromycin, 17α-
ethinylestradiol, 17α-estradiol, 17β-estradiol, equilenin, equilin, estriol, estrone, mestranol 
and norethindrone) in Europe and United state (EC, 2012, Richardson and Ternes 2011).  
To understand the significance level of PhC in HWWs, removal rate in WWTP and PNEC 
values a systematic review of literature and experimental investigations were carried out as 
reported in Chapters 2,3 and 4. 
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Table 6.1. PhCs proposed to be a priority compounds by different research groups. 
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Analgesic/Anti-inflammatory Acetaminophen                5 
Analgesic/Anti-inflammatory Codeine             2 
Analgesic/Anti-inflammatory Diclofenac                     10 
Analgesic/Anti-inflammatory Ibuprofen                 6 
Analgesic/Anti-inflammatory Ketoprofen            1 
Analgesic/Anti-inflammatory Naproxen                 6 
Antibiotics Chlortetracycline            1 
Antibiotics Ciprofloxacin               4 
Antibiotics Clarythromycin            1 
Antibiotics Doxycycline             2 
Antibiotics Erythromycin                 6 
Antibiotics Lincomycin              3 
Antibiotics Metronidazol              3 
Antibiotics Norfloxacin            1 
Antibiotics Ofloxacin               4 
Antibiotics Sulfamethoxazole                  7 
Antibiotics Tetracyclin            1 
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Therapeutic Class Compounds 
G
W
R
C
 
2
0
0
8
 
S
u
i
 
e
t
 
a
l
.
 
2
0
1
2
 
P
e
r
a
z
z
o
l
o
 
e
t
 
a
l
.
 
2
0
1
0
 
R
o
o
s
 
e
t
 
a
l
.
 
2
0
1
2
 
R
u
e
l
 
e
t
 
a
l
.
 
2
0
1
2
 
B
e
s
s
e
 
e
t
 
a
l
.
 
2
0
0
8
 
G
i
n
e
b
r
e
d
a
 
e
t
 
a
l
.
 
2
0
1
2
 
N
R
M
M
C
1
 
2
0
0
8
 
R
i
c
h
a
r
d
s
o
n
 
e
t
 
a
l
.
 
2
0
1
1
 
V
e
r
l
i
c
c
h
i
 
e
t
 
a
l
.
2
0
1
2
 
N
.
 
o
f
 
s
t
u
d
i
e
s
 
s
u
g
g
e
s
t
i
n
g
 
t
h
e
 
s
u
b
s
t
a
n
c
e
 
a
s
 
p
r
i
o
r
i
t
y
 
Antibiotics Trimethoprim                 6 
Antihypertensive Diltiazem            1 
B-blockers Atenolol                5 
B-blockers Metoprolol              3 
B-blockers Propranolol              3 
Contrast media Iopromide             2 
Hormones Estradiol             2 
Hormones Estriol             2 
Hormones Estrone             2 
Lipid regulators Bezafibrate                5 
Lipid regulators Gemfibrozil                5 
Psychiatric drugs Carbamazepine                   8 
Receptor antagonists Ranitidine             2 
1
 NRMMC 2008: Australian guidelines for water recycling: Managing health and envieonmental risks (Phase 2). 
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6.2.1 Evaluation of the environmental Risk posed by PhCs in HWWs. 
The expected range of risk associated with the presence of PhCs in HWWs is 
calculated by the mean of minimum and maximum risk quotient (RQ), RQ is calculated by 
dividing the minimum and maximum pharmaceutical concentration in HWWs by the 
PNEC values for each compound ( equation 6.1). Data are re-summarized in Table.6.2. 
regard the occurrence of PhCs in HWWs investigated in Chapter 3 and those reported by 
literature ( Verlicchi et al. 2010b, Nagarnaik et al. 2010,2011). 
,	
	 = [


	 , 	


	]  (eq. 6.1) 
Where: 
HRQmin: minimum risk associated with the presence of PhCs in HWWs. 
HRQmax: maximum risk associated with the presence of PhCs in HWWs. 
Chmin: minimum HWWs pharmaceutical concentration in µg L-1 (Literature data) 
Chmax: maximum HWWs pharmaceutical concentration in µg L-1 (Literature data) 
PNEC: predicted no effect concentration in µg L-1 ( Literature data) 
 
6.2.2 Evaluation of the environmental risk in surface water posed by PhCs originated from 
HWWs 
In order to quantify the range of the risk posed by HWWs due to the presence of 
PhCs in the environment (surface water), the following reference scenario has been 
considered: The hospital discharges its effluent in the sewers system where the 
pharmaceutical concentration was reduced by the dilution factor that depends on hospital 
and catchment area size, subsequently this effluent is treated by the local WWTP 
undergoing the various removal mechanisms and finally the discharge into receiving water 
body where the reduction in the concentration is due to the dilution factor of surface water. 
In this case the dilution in sewers system, removal in WWTP and the dilution in the 
surface water, should be taken into account and case by case should be evaluated and RQ 
in the environment (surface water) is calculated by Eq.(6.2) 
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[,] = [
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	]	 (eq. 6.2) 
Where: 
ERQmin: minimum risk in surface water posed by PhCs originated from HWWs. 
ERQmax: maximum risk in surface water posed by PhCs originated from HWWs. 
R: percentage removal rate of PhCs in WWTP ( literature data). For conservative reason, minimum values 
reported in literature has been adopted.  
Dfu: dilution factor, due to the discharge of HWWs in the sewer system (from local conditions data). The 
dilution factor is the ratio by which a HWWs will be diluted in a sewers system, and is dependent on two 
variables: the first being the size of the hospital and the second being the size of the catchment area-Eq. (6.3). 
Dfe: dilution factor, due to the discharge of WWTP into the receiving water body (from local conditions 
data). The dilution factor is the ratio by which a STW effluent will be diluted in a receiving water body, and 
is dependent on two variables, the first being the size of the STWs and the second being  the size of the 
receiving water body (Metcalf & Eddy, 2004). It is clearly that flow of receiving water body varies with the 
season, and even within a season a great variation can occur, so The lowest flow of receiving water body 
should be accounted for when calculating the dilution factor to avoid the worst case. When the flow of the 
receiving water body is not available a 10 value was used Ashton et al.2004.-Eq.(6.4). 
 
123 =
456×778+9
&456×778+9:;<==>×77 !?/8 @/!@*
		 (eq. 6.3) 
 
125 =
;<==>×77 !?/8 @/!@
ABC35	B$	D5E5AF	G=5D	<B6H
		 (eq. 6.4) 
Where: 
Bed: number of hospital beds under investigation (local conditions data) 
WWbed: the volume of WWs per bed and day (local conditions data) 
Inhabitants: number of inhabitants in the catchment area under investigation (local conditions data) 
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WWinhabitants: the volume of WWs per capita and day (200 L) Ashton et al.2004. 
 
This tool is applied for three case studies with different characteristics ( different Bed 
density) as discussed below in order to estimate the environmental risk in different 
catchments area. The values of RQ were classified into three risk levels: low (values < 0.1), 
medium (between 0.1 and 1) and high (values >1) (Hernando et al., 2006). 
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Table 6.2. Minimum and maximum concentration of selected PhCs in HWWS, Percentage removal rate in WWTPs and PNEC values. 
Class Compound 
Concentration in HWWs 
 (µg L-1) 
Removal in WWTP 
% 
PNEC 
(µg L-1) 
min max 
Analgesic/Anti-inflammatory Acetaminophen 5.4 330 80 1 
Analgesic/Anti-inflammatory Codeine 0.2 50 29 16 
Analgesic/Anti-inflammatory Diclofenac 0.2 15 5 9.7 
Analgesic/Anti-inflammatory Ibuprofen 0.069 22 26 1.65 
Analgesic/Anti-inflammatory Ketoprofen 1.7 17.4 7 15.6 
Analgesic/Anti-inflammatory Naproxen 0.698 13 35 2.62 
Antibiotics Chlortetracycline 0.011 0.011 - - 
Antibiotics Ciprofloxacin 0.038 125 50 938 
Antibiotics Clarithromycin 0.058 11 4.5 0.07 
Antibiotics Doxycycline 0.0005 7 14 0.3 
Antibiotics Erythromycin 0.019 83 4.3 0.02 
Antibiotics Lincomycin 0.3 4.82 - - 
Antibiotics Metronidazole 0.2 6 38.7 2.5 
Antibiotics Norfloxacin 0.029 44 - - 
Antibiotics Ofloxacin 0.2 35.5 - - 
Antibiotics Sulfamethoxazole 0.004 83 10 0.027 
Antibiotics Tetracyclin 0.0015 2 24 0.09 
Antibiotics Trimethoprim 0.05 15 5.1 2.6 
Antihypertensive Diltiazem 0.71 1.6 - - 
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Class Compound 
Concentration in HWWs 
 (µg L-1) 
Removal in WWTP 
% 
PNEC 
(µg L-1) 
min max 
B-blockers Atenolol 1.6 3166 14 30 
B-blockers Metoprolol 0.4 25 7 8 
B-blockers Propranolol 0.054 22 1 0.244 
Contrast media Iopromide 0.2 2500 - - 
Hormones Estradiol 0.017 0.04 - - 
Hormones Estriol 0.353 1 - - 
Hormones Estrone 0.017 0.13 - - 
Lipid regulators Bezafibrate 0.2 7 9.1 5.3 
Lipid regulators Gemfibrozil 0.4 1.2 - - 
Psychiatric drugs Carbamazepine 0.037 1 5 13.8 
Receptor antagonists Ranitidine 0.98 3 24.5 63 
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6.2.3 Evaluation of the relative importance of hospitals and catchments area on the risk of 
PhCs in the influent of WWTPs 
The expected range of risk has been also investigated in the influent of each WWTP 
by means of Equations 6.5 and 6.6. Taking in consideration the pharmaceutical loads 
originated from both HWWS and its catchment area, in order to estimate the importance of 
the risk posed by these latter for a single compound. As a case study we examined the case 
of the analgesics diclofenac which is candidate to be among the priority substances that 
European states should control and monitor (EC 2012). 
 
I = ;J
,-.
		 (eq. 6.5) 
 
IE =
&?×456×778+9*:&K×;<==>×77 !?/8 @/!@L*
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<==>×77 !?/8 @/!@L*
		 (eq. 6.6) 
Where: 
IRQ: WWTP Influent Risk quotient of PhC under investigation (diclofenac) 
Ic: WWTP influent concentration of PhC under investigation (diclofenac) µgL-1 
Ch: Concentration of PhC under investigation (diclofenac) in HWWs µgL-1 (literature data) 
CU: Concentration of PhC under investigation (diclofenac) in UWWs µgL-1 (literature data) 
 
The results obtained from Equation 6.5, represent the WWTP influent risk generated 
from the occurrence of diclofenac in HWWs and UWWs. We simulated all the possible 
scenarios at each WWTP under investigation by assuming that the concentration of the 
diclofenac in both WWs is occurred within the variable observed range in Chapters 2 and 
3, and the results of their combination represent the influent concentration in a site-specific 
WWTP. the results is a 3D surface chart. 
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6.2.4 Case studies 
case study 1: 
A large size hospital with 900 beds, 2000 people of the medical staff and more than 
50 between wards and departments. It is placed in the centre of the town of Ferrara 
(138000 inhabitants) and its effluent is directly discharged into the combined sewage 
network and conveyed to the Ferrara WWTP (design capacity 120 000 p.e.) and co-treated 
with the UWWs. The hospital bed density for the whole STP catchment is 6.5 beds per 
1000 inhabitants. Average flow rate from the hospital is about 603 m3 d-1, corresponding to 
a specific water consumption of about 670 L bed-1 d-1. The average urban influent flow rate 
to the WWTP is about 28 000 m3 d-1, hence the hospital contributes for the 2 % to the 
influent hydraulic load. 
Case study 2: 
A medium size hospital with 300 beds, 650 people of the medical staff working in 
twelve main wards. It is placed 30 km far from Ferrara, in the town of Lagosanto (5000 
inhabitants), in a coastal and tourist area, densely populated in summertime. Its effluent is 
directly discharged into the public combined sewage and conveyed to a small WWTP in 
Lagosanto (design capacity 5500 p.e.) where it is co-treated with the local UWWs. The 
hospital bed density for the whole STP catchment is 60 beds per 1000 inhabitants. Hospital 
effluent has an average flow rate of about 160 m3 d-1, resulting in a specific water 
consumption of about 550 L bed-1 d-1. The average WWTP total influent flow rate is about 
1360 m3 d-1 and the hospital flow rate corresponds to the 12 % of the total influent. 
Case study 3: 
A large size hospital with 900 beds and a staff of 2400, including medical, 
administrative and technical services, in addition to 250 university students and elderly 
people staying in the on-site accommodations. It is situated six kilometres from the town of 
Ferrara in the first outskirts, in the small urban centre of Cona. Due to the building growth 
connected with the hospital construction, the nearby urban centres (Cona and Gualdo) are 
under expansion and their estimated residential population is expected to climb to 1700 
persons over the next years. In addition, there are local businesses and industries, 
corresponding to 500 p.e. Currently in this area, combined urban and industrial 
Chapter 6: Environmental risk assessment of PhCs as a tool for the management of 
hospital effluents 
 
 
183 
 
wastewaters (respectively UWWs and IWWs) are conveyed to a small WWTP at Gualdo 
designed for 1000 p.e. Treatment includes screening, primary sedimentation, conventional 
activated sludge treatment and disinfection. This WWTP is not adequate to treat all the 
wastewaters coming from the new hospital and the new urban development. The hospital 
bed density for the whole WWTP catchment is 529 beds per 1000 inhabitants. The 
Expected average flow rate from the hospital is about 603 m3 d-1, corresponding to a 
specific water consumption of about 670 L bed-1 d-1 
 
6.3 Results 
6.3.1 Environmental risk posed by PhCs in HWWs 
The results of the expected range of Risk posed by PhCs in HWWs are presented in 
Figure 6.1. The variability of the range for each compound is determinant by the fact that 
some compounds have been well investigated in HWWs, so a wide range of data regards 
their occurrence in HWWs are available with respect to another compounds ( Table 6.2.). 
The data are ranked with decreasing RQmax. For ten compounds values of PNEC were not 
available, so the results were depicted for only twenty compounds. For some compounds 
(erythromycin, acetaminophen, clarithromycin) the range of the risk vary within the 
intervals of high level (RQ>1), which mean that based on the investigated occurrence of 
these compounds in HWWs, they always pose a high risk in the HWWs. sulfamethoxazole, 
propanolol, naproxen and ketoprofen have a risk ranged within the intervals of medium 
and high level (RQ> 0.1), atenolol, doxycycline, tetracycline, ibuprofen, trimethoprim, 
codeine, metoprolol, metronidazole, diclofenac and bezafibrate have a Risk range between 
low and high level . Ciprofloxacin and carbamazepine and ranitidine have a risk range 
within the low interval level (RQ<0.1). 
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Figure 6.1. Expected range of Risk posed by PhCs in HWWs 
 
6.3.2 Environmental Risk in surface water posed by PhCs originated from HWWs 
Figure 6.2. shows the expected range of risk downstream the WWTP in each 
catchment area. Due to the assumptions of the proposed tools, the expected risk’s range of 
each compounds is keep constant in each catchment area with the variation of solely risk 
level. As expected, the number of compounds that posed high risk is increased with the 
increased of the bed density. Among twenty compounds , the compounds that observed to 
have an expected range that fall within the high Risk level(RQ>1) were: two compounds ( 
erythromycin and sulfamethoxazole) in case study 1, nine compounds (erythromycin, 
sulfamethoxazole, acetaminophen, clarithromycin, atenolol, propanolol, doxycycline, 
tetracycline, ibuprofen) in case study 2 and thirteen compounds (erythromycin, 
sulfamethoxazole, acetaminophen, clarithromycin, atenolol, propanolol, doxycycline, 
tetracycline, ibuprofen, trimethoprim, naproxen, codeine, metoprolol) in case study 3 . 
The Antibiotics erythromycin and sulfamethoxazole were found to pose the highest 
risk in HWWS and their risk is still high downstream the WWTP in all the case studies 
notwithstanding the dilution in sewer systems , removal in WWTPs, and dilution in surface 
water have been occurred. This is determinate by their high toxicity ( low PNEC values) 
and high exposure. The high RQ associated with the beta-blocker atenolol is found to be 
determinant by their high exposure which found to be 3166 µg/L in HWWS. 
Carbamazepine and ranitidine were found to have a low risk level (RQ<1) due to their low 
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toxicity and exposure, while the antibiotic ciprofloxacin, has a low RQ due to its low 
toxicity nevertheless it high exposure in HWWs that could arrive to 125 µg/L. 
 
Figure 6.2. Expected environmental range of risk in surface water posed PhCs originated from HWWs in 
different catchments area. 
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Since the removal in WWTP was assumed to be equal in all the case studies, it is 
evident that dilution in sewer systems and surface water had a larger effect on the decrease 
of RQ and this is also evidenced by Escher et al. 2011. In general , simulating the current 
situation of the management of HWWS (co-treatment with UWWS in the municipal 
WWTP), the risk posed by HWWS due to the presence of PhCs could be reduced with 
various degree, and it is relevant to the characteristics of each catchment area where the 
hospital is situated. The range of the risk posed by HWWS (Fig. 6.1.) is reduced three 
order of magnitude in case study 1, one order of magnitude in case study 2 and still in 
same order of magnitude in case study 3. The Analgesics Acetaminophen exhibit a little 
more reduction with respect to the another compounds and this is effected by its high 
removal rate in WWTP (80%). 
 
6.3.3 The relative importance of hospitals and catchments area on the risk of PhCs in the 
influent of WWTPs 
The estimated risk posed by PhCs originated from HWWs and its catchment area 
(UWWs) in the influent of site-specific WWTP is depicted in Figure 6.3. X-Y axes are the 
two input parameter which represent the literature concentration range of PhC under 
investigation (diclofenac) in HWWs and UWWs respectively, while the vertical Z axes 
represents the associated RQ value for each of the X and Y point.  
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Figure 6.3. Risk patterns posed by diclofenac in the influent of WWTP. case study 1 (Low bed density), case 
study 2 ( medium bed density), case study 3 (high bed density). 
 
In all the case studies the results showed that the risk posed by diclofenac in the 
influent of WWTP varies from low to high risk with a maximum value of RQ= 1.5. In case 
study 1, medium and high risk could be present when the occurrence of diclofenac in 
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UWWs is in high concentration (> 1 µg L-1) independently of the level of concentration in 
HWWS. This pattern is different in case study 2,3 where the effect of HWWs to the Risk 
began to be present, in these cases the medium risk could be present also when the 
diclofenac occurred in high concentration in HWWS independently of the concentration in 
UWWs. The observed high Risk in case study 1 and 2 with respect to study case 3, is due 
to the high load discharged in sewer systems from their catchments area. 
 
6.4 Discusion 
The results generated from the proposed tool, suggest that due to the presence of 
PhCs, HWWs could pose a risk for the receiving environment and their risk is relevant to 
many factors. Erythromycin and sulfamethoxazole are potentially compounds of concern 
in the HWWs and they required a management, whilst other compounds may not required 
any management due to their low risk. In some cases, HWWs contribute significantly to 
the risk in the influent of a site-specific WWTP, and their contribution is correlated to the 
bed density. In fact the measured contribution of the hospital effluent to the total load of 
diclofenac in the influent of WWTP of case study 1 was observed to be 2% as shown in 
Chapter 3 while the contribution in another catchment area with different hospital bed 
density from another countries was observed to be 10, 1.6, 1 and 7-9% in Germany (bed 
density= 12), Norway (bed density= 4), Australia (bed density= 4.4) and Germany (bed 
density= 33.5) respectively (Chapter 3). 
Based on the results obtained from the proposed tool, the implementation of 
decentralized WWTP for the HWWs as a strategy to reduce pharmaceutical impacts seems 
not efficient in case study 1 and 2, where the RQ could by >1 even when the concentration 
in HWWs is at low levels, while for case study 3 seems efficient since RQ>1 is caused 
mainly by HWWs. Using a Multiple-Criteria Decision Analysis (MCDA) , Lienert et al. 
(2011) evaluated diﬀerent alternatives that decrease pharmaceuticals in the hospitals’ 
wastewater, based on two case studies(general hospital and psychiatric hospital). The 
technical alternatives included were reverse osmosis, ozonation, and activated carbon ; 
while organizational alternatives included urine separation. For the general hospital that 
contributed 38% to the total pharmaceuticals load at the wastewater treatment plant, 
alternatives removing all pharmaceuticals (especially reverse osmosis, or vacuum-toilets 
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and incineration), performed systematically better than releasing wastewater to municipal 
wastewater treatment plant or urine separation , despite higher costs. For the psychiatry 
with a lower pharmaceutical load(5%), costs were more critical. Stakeholder feedback 
concerning MCDA was very positive, especially because the results were robust across 
diﬀerent stakeholder-types. 
As a result, Proper management of HWWs should take into consideration the 
characteristics of the catchment area in which the hospital is situated, i.e. (i) size of area, 
number of residents and non residents (p.e.), average and maximum urban flow rate, (ii) 
industrial activities present in the area (type, WW flow rate, adopted pre-treatments within 
the battery limits, final disposal of the effluent, cotreatment with other kind of WWs), (iii) 
characteristics of existing WWTPs (nominal capacity, residual capacity, treatment 
sequence, authorized limits for the final discharge), (iv) characteristics of the receiving 
water body (hydraulic regime, auto-depurative capacity, irrigation, recreational and 
industrial uses), (v) legal and regulatory constraints. 
In case of cotreatment of HWW and UWW, it is important to evaluate the 
percentage of hospital flow rate with respect to the total WWTP influent flow rate 
(Verlicchi et al. 2010a). This value depends on hospital size (small size with < 300 beds, 
medium size with 300-700 beds and large size with > 700 beds), and on the size of the 
resident population in the urban centre.  
 
6.5 Method limitations 
Evaluating the potential risk of HWWs due the occurrence of PhCs requires the 
availability of data regarding the concentration of PhCs in HWWs and removal rate in 
WWTP, PNEC values. Finding previous studies on actual pharmaceutical levels yielded a 
paucity of information and the final data that were employed by the calculation were 
limited to twenty compounds. The assumptions made by employing these data suggest that 
pharmaceutical concentration will be the same for each hospital, and the variation between 
hospitals will only be a result in variation flow (resulting from variation in beds number). 
This is obviously not the case as within each hospital there will be variations in 
pharmaceuticals concentration levels due to the differences in consumption profile, 
services, department and research activity. 
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6.6 Application of the tool and management options 
Despite the limitation of the proposed tool, estimating the risk posed by PhCs 
originated from HWWs to the receiving environment could provide a viable information 
on the magnitude of the risk posed by HWWs and subsequently on the type of 
management options that should be adopted. As there is no specific treatment able to 
remove, to a high percentage, the many kinds of PhCs typically found in HWws, due to 
their differing behaviour during treatments, and as many PhCs are resistant to conventional 
treatments, innovative solutions to this problem are required. Different operational 
configurations should be developed and calibrated, in order to provide information for 
potential practitioners about the financial aspects and overall risks associated with putative 
treatments of HWWs (Pauwels and Verstraete 2006). 
As soon as the risk identified through this tool, the different options to reduce this risk 
could be examined by applying the parameters input that regard each scenario to the tool. 
The options available to reduce the risk of HWWs could be dedicated treatment, upgrading 
of the existing municipal WWTP and Source management. A dedicated treatment for 
HWWs is always desirable, especially for large hospitals in rural areas, where its treated 
effluent may be indirectly reused for irrigation after its discharge into a surface water body. 
In fact, although co-treatment with UWWs at a municipal WWTP is common practice, it 
has several fundamental drawbacks. In the first place, dilution of HWWs with UWWs is 
not the correct procedure, as some substances in the hospital effluents may cause inhibition 
of the treatment plant biomass and thereby reduce the removal efficiency. 
Furthermore, as many micro-pollutants tend to adsorb/absorb to the biomass flocks, 
efficient solid/liquid separation can greatly improve their removal from wastewater and, at 
the same time, guarantee a consistently good effluent quality. MBRs have been suggested 
for this purpose by many authors (Daigger et al. 2005; Pauwels et al. 2006; Radjenovic et 
al. 2009), some of whom found that ultrafiltration (UF) membranes are more efficient than 
MF membranes (Beier et al. 2010, Verlicchi et al., 2010b). MBR processes have also been 
suggested as better alternatives for the removal of pathogenic microorganisms, including 
some viruses (Ottoson et al. 2006; Zhang and Farahbakhash 2007). 
Ozonation and advanced oxidation processes (AOPs) are also promising candidates for 
efficient degradation of pharmaceuticals in water and wastewaters (Zwiner and Frimmel 
2003; Chiang et al. 2003; Huber et al. 2003; Balcioglu and Otker 2003; Ternes et al. 2003; 
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Machado et al. 2007; Zimmermann et al. 2008). In fact, treatment with ozone can reduce 
the concentration of many pharmaceuticals: 15 mg L-1 of ozone at 18 min contact time 
could be an adequate dose (Gagnon et al. 2008). However, as AOPs are not affordable at 
many municipal WWTPs, Kim et al. 2008 proposed that prolonging the SRT in biological 
WWTP may be the best practicable solution to reducing levels of pharmaceuticals in 
treated WWs. 
An alternative to end-of-pipe upgrading of treatment plants, and an effective 
precautionary measure, could be source control . As reported above, administered PhCs are 
excreted from the human body via faeces and urine at a percentage that depends on the 
compounds in question. Although it will never be the perfect solution, separate collection 
of urine can contribute to keeping these substances away from wastewaters. Furthermore, 
source separation of urine (Nomix technology) can be conveniently adopted for other 
reasons, for instance, limitation of nutrient pollution of water. In this case, facilitated 
removal of pharmaceuticals could be a very welcome side effect (Lienert et al. 2007). In 
fact, Larsen et al. 2004 found that source separation of urine, which contains many of the 
pharmaceuticals and their transformation products from human metabolism, may offer the 
most effective solution to the problem of pharmaceuticals contaminating the environment. 
Due to the higher concentrations of micropollutants, biological as well as physical 
processes are expected to be more efficient for urine than for diluted wastewater. However, 
economic and practical feasibility must be carefully evaluated. 
 
6.7 Conclusion 
This chapter developed a tool to provide the authorities responsible for hospital 
management and environmental health a useful information on the magnitude of 
environmental risk posed by PhCs originated from HWWs, taking in consideration the site 
specific information such as the contribution of human population and hospital sizes, their 
location in the catchment area, WWTP capacity, and available dilutions in the receiving 
water body. 
The results suggest that due to the presence of PhCs, HWWs could pose a risk for 
the receiving environment and their risk is relevant to many factors. Erythromycin and 
sulfamethoxazole are potentially compounds of concern in the HWWs and they required a 
management, whilst other compounds may not required any management due to their low 
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risk. The risk posed by HWWS due to the presence of PhCs could be reduced with various 
degree, and it is relevant to the characteristics of each catchment area where the hospital is 
situated. In some cases, the pathway of HWWs contribute significantly to the risk in the 
influent of a site-specific WWTP, and their contribution is correlated to the bed density. 
Nevertheless the limitation that the proposed tool experienced, it is provide a useful 
information about the management options that should be adopted to reduce the risk of 
HWWs. 
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The general aims of this thesis were to characterized the sources and pathways of 
PhCs in the environment, to assess the occurrence, removal and fate of selected PhCs in 
WWTPs and in the water environment, and carry out environmental risk analysis based on 
their occurrence as a basis to priorities the hazardous compounds and to manage the risk 
posed by their exposure. In particular, this work focused on HWWs in order to assess their 
potential as a point source of selected 73 PhCs and their role in spreading these compounds 
into the environment, and consequently the impact of WWTPs on the receiving water 
bodies in terms of 27 PhCs concentration. The last aim was to develop a tool to estimate 
the level of environmental risk posed by PhCs originated from HWWs at site specific 
catchment area to aid the authorities and decision makers in the management of HWWs 
and the reduction of PhCs discharged into the environment. 
7.1 Main Findings 
• The literature review highlighted that: 
•  PhCs are usually present in raw influent at concentrations in the range 10-3-102 µg 
L-1 and even more. Common WWTPs are not able to efficiently remove all of PhCs 
and observed removal efficiencies vary in a wide range for the different compounds, 
as well as for the same substance, due to the different chemical and physical 
characteristics of PhCs and to operational conditions (mainly aerobic, anaerobic, 
anoxic reactors, SRT, pH and water temperature). MBRs seem to guarantee higher 
removal effciencies for most compounds and a better quality of the permeates with 
respect to CAS. 
•  The occurrence of some PhCs in the secondary effluent discharged into surface 
water bodies may pose a medium–high (acute) risk to aquatic life. Furthermore, 
many other compounds, even if their environmental risk was found to be low, are 
discharged at high daily mass loads, which could contribute to negative effects on 
aquatic organisms in the long term due to chronic and mixture toxicity.  
•  For these reasons, it would be more prudent to begin monitoring the most 
frequently and most persistent administered PhCs, as well as those with the highest 
environmental risk, namely antibiotics (including erythromycin, ofloxacin, 
 
Chapter 7: Conclusions 
 
196 
 
sulfamethoxazole, clarithromycin, amoxicillin, tetracycline and azithromycin), 
psychiatric drugs (like fluoxetine, diazepam and carbamazepine), analgesics/anti-
inflammatories (ibuprofen, mefenamic acid, naproxen, diclofenac and ketoprofen) 
and lipid regulators (fenofibric acid, fenofibrate and gemfibrozil).  
• Raw HWWs has a higher ecotoxicity potential compared to municipal waste water. 
• Raw HWWs is a hot spot for antibiotic resistant bacteria. 
 
• The experimental investigation conducted in the area of Ferrara, Italy, on the 
effluent of two different sized hospitals and the influent and effluent of the receiving 
municipal WWTP of one of the examined hospitals and on in the effluent from two 
wastewater treatment plants (WWTPs) and their receiving water bodies highlighted these 
results: 
•  The investigated PhCs are found in consistently higher concentrations in HWWs 
than in UWWs, particularly commonly used drugs such as analgesics and antibiotics.  
•  The characteristics of the HWWs seem to be influenced by the size of the structure 
(the smaller hospital discharged higher mean concentrations than the larger one), and 
season (concentrations tended to be higher in winter than in summer). 
•  The ratio between PhC concentration in HWWs and WWTP influent was, on 
average, 7. The highest values were found for ofloxacin (31) and clarithromycin (36), 
ranitidine (27), atorvastatin (25), metronidazole (23). Antibiotics, analgesics/anti-
inflammatories and lipid regulator were the pharmaceutical compounds found at the 
highest concentrations. 
•  The percentage load contribution of the hospital varied among the investigated 
compounds; in particular 12 compounds yielded values between 16 and 67% (some 
antibiotics, receptor antagonists and lipid regulators), and as a result hospital could 
be a hot spot for pharmaceutical emission. 
•  Environmental risk analysis showed that 9 compounds posed a high risk at the 
concentrations detected in hospital effluent, while in the WWTP influent and 
effluent, only 5 of these PhCs were found to exhibit high ecotoxicity. As four out of 
these five PhCs were antibiotics, we can state that this class of compound should 
cause the most concern. 
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•  Due to their micropollutant content, HWWs require more specific management and 
treatment in order to protect and safeguard the environment, in particular the surface 
water body which will receive the final (treated) effluent from the WWTP. 
  
•  As co-treatment is common practice, and the usual (conventional) treatments are 
unable to efficiently remove PhCs, this issue needs urgent attention. Indeed, 
administrators and technicians will need to perform case-by-case analyses on a local 
scale, in particular during WWTP planning and design phases, in order to determine 
the best means of tackling the problem. 
•  PhC concentrations may exceed their PNECs in the effluents from conventional 
municipal WWTPs. In the area under investigation, and the most critical compounds 
are the antibiotics sulfamethoxazole, clarithromycin and azithromycin. Other 
substances, including some analgesics/anti-inflammatories, other antibiotics and the 
antiepileptic carbamazepine, could also be considered as PhCs to add to the list of 
potential critical compounds from an environmental risk point of view. 
•  Hydrodynamic characteristics of the receiving water body, principally its average 
flow rate, contribute to mitigating the risks to the environment associated with the 
presence of toxic substances. The dilution capacity of the receiving water bodies can 
therefore be considered of prime importance in reducing and controlling the potential 
toxicological effects of PhCs released into the environment. 
•  Nonetheless, even after the discharge of the treated effluent into a receiving body 
characterized by a high flow rate, PhC concentrations do not appear to be reduced to 
level of minimal environmental risk.  
•  If environmental risk analysis is extended to a mixture of compounds, more 
harmful effects are likely to be seen due to synergistic effects. Hence, further 
measures are needed to reduce the environmental risk posed by PhCs, including 
source control of the most critical compounds and enhancement of PhC removal by 
appropriately upgrading existing WWTPs. 
• The environmental risk analysis conducted in this work was on the basis of selected 
PhCs concentration in the water, and did not consider the quantity of the compound 
under investigation adsorbed onto sludge and sediments that could be released again 
to the water. 
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• Assessing the relative accuracy of the prediction models, and the limitations of on-
site monitoring campaigns, that environmental risk assessment depends on their accuracy, 
indicate that: 
•  differences between PEC and MEC varied among the selected compounds and the 
sampling points investigated (influent, effluent and surface water), both predicted 
and measured concentrations are plagued by uncertainty. 
•  differences between MECs and PECs documented by our findings, as well as in 
other studies, indicate that calculation models still need considerable refinement to 
increase model reliability and discriminative power. At present, however, great 
discrepancies between measured and predicted values are discouraging, as risk 
assessments should always err on the side of caution and produce false positives that 
lead to further investigation rather than false negatives, which could leave a potential 
risk unexplored. 
 
• A low cost tool to provide the authorities responsible for hospital management and 
environmental health a useful information on the potential impact of PhCs originated from 
hospital effluents, taking in consideration the site specific information such as the 
contribution of human population and hospital sizes, their location in the catchment area, 
WWTP capacity, and available dilutions in the receiving water body, and to assess the 
relative importance of PhCs pathways ( HWWs, UWWs) at site specific WWTP  has been 
developed. The results indicate that: 
•  The environmental risk posed by PhCs originated from HWWs, varies from low to 
high level. 
•  Due to the presence of PhCs, HWWs could pose a risk for the receiving 
environment and their risk is relevant to many factors. 
•  Erythromycin and sulfamethoxazole are potentially compounds of concern in the 
HWWs and they required a management, whilst other compounds may not required 
any management due to their low risk. 
•  In some circumstances, HWWs may represent an important point source of the risk 
posed by priority candidate compound “diclofenac” in the influent of WWTP. 
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•  A dedicated treatment for HWWs is always a good solution, especially in the case 
of a large hospital in a scarcely populated area. The treatment sequence that seems to 
be the most appropriate one is a multi barrier system with a combination of 
biological, physical and chemical mechanisms (ultrafiltration MBR followed by 
advanced oxidation processes by means of O3/UV). In this way a combination of 
different mechanisms can occur in the different treatment phase, giving the 
possibility to compounds with great differences in their chemical-physical 
characteristics to find operational conditions where they can be effectively removed. 
7.2 Suggestions for future research. 
Due to the gap of data in the literature and in order to understand the issue of PhCs in the 
environment in a comprehensively way , the following recommendations are suggested: 
1. Carrying out a monitoring program to analyse the occurrence of 
scarcely investigated PhCs in the influent and effluent of municipal 
WWTPs.  
2. Define PNECs values for a wider spectrum of compounds.  
3. Further researches are needed to evaluate the environmental impact of 
mixtures of different PhCs. 
4. Evaluate the chronic effect of authentic PhC mixtures on the aquatic 
life.  
5. Evaluate the best end-of-pipe measures for the existing WWTPs to 
guarantee better removal of the most persistent compounds.  
6. Suggest source control options to reduce the quantity and variety of 
PhCs in the water cycle.  
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Appendix A 
Physico-chemical properties of the selected PhCs, and their 
ranges of concentration in the influent and effluent of 
WWTPs and removal efficiencies reported in literature. 
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 Table A.1. Physico-chemical properties of the selected pharmaceuticals. Data with a star as apex refer to MBR systems.
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5-aminosalicylic acid 
CAS # 89-57-6 
5.02E-012 
 
Acetaminophen 
CAS # 103-90-2 
6.42E-013 
 
Acetylsalicylic acid 
CAS # 50-78-2 1.3E-009 
Aminopyrine  
CAS # 58-15-1 
1.38E-011 
 
Codeine 
CAS # 76-57-3 
7.58E-014 
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 Dextropropoxyphene 
CAS # 469-62-5 
2.34E-009 
 
Diclofenac 
CAS # 15307-86-5 
4.73E-012 
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pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
   
  Negative 
9.38 0.46 3.035 104 3.06t 58-80 106*-240* Neutral 
3.5h 1.13 5295   Negative 
 0.6 4191   Neutral 
8.21 1.19 1.21 104 1.15j 4.7-4.8 j Positive 
   
  Positive 
4.15a 4.51/0.7 4.52 1.2l 
<0.04-1.2 o 
≤0.1 
≤0.1* 
<0.002*-<0.1* s 
Negative 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Dipyrone 
CAS # 68-89-3 
1.1E-015 
 
 -4.76 1 106    
 
Fenoprofen 
CAS # 31879-05-7 
1.28E-009 
 
7.3 3.9 30.13  10-14 3.3*-5.9* Negative 
 
Flurbiprofen 
CAS # 5104-49-4 
5.26E-009 
 
 3.81 17.7.13   Negative 
 
A
n
a
l
g
e
s
i
c
s
/
A
n
t
i
-
i
n
f
l
a
m
m
a
t
o
r
i
e
s
 
Hydrocodone 
CAS # 125-29-1 
6.37E-012 
 
8.48 2.16 1788 1.23j  Positive 
 
Ibuprofen 
CAS # 15687-27-1 
1.5E-007 
 
4.51e 3.97/0.45 41.05 0.9l 
1.5-20 o 
21-35 
9*-22* 
1.33*->3* s 
Negative 
 
Indomethacin 
CAS # 53-86-1 
3.13E-014 
 
4.5 4.27 3.114  ≤0.3 
≤0.21* Negative 
 
 
 
 
  
Pharmaceutical Henry’s Law constant (atm-m3/mole)
Ketoprofen 
CAS # 22071-15-4 
2.12E-011 
 
Ketorolac 
CAS # 74103-06-3 
3.35E-013 
 
Meclofenamic acid 
CAS # 644-62-2 
1.28E-011 
 
Mefenamic acid 
CAS # 61-68-7 
2.57E-011 
 
Naproxen 
CAS # 22204-53-1 
3.39E-010 
 
Phenazone 
CAS # 60-80-0 
6.65E-010 
 
Phenylbutazone 
CAS # 50-33-9 
6.56E-009 
 
A
n
t
i
-
i
n
f
l
a
m
m
a
t
o
Propyphenazone 
CAS # 479-92-5 
1.84E-009 
 
Appendix A 
 
 
pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
4.45f 3.12/-0.44 120.4 1.2t  Negative 
 2.32 572.3   Negative 
 6.02 0.0934   Negative 
4.2 5.12 1.121 2.6t  Negative 
4.2b 3.18/-0.34 144.9 1.1o 
<0.2-9 o 
1.0-1.9 
0.4*-0.8* 
0.08*-0.4* s 
Negative 
1.4 0.38 2.376 104   Neutral 
4.5 3.16 21.95   Negative 
 
--- 1.96 668.2   Neutral 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Salicylic acid  
CAS # 69-72-7 
7.34E-009 
 
3.5 b 2.26/-2.42 3808   Negative 
 
Tolfenamic acid 
CAS # 13710-19-5 
1.73E-011 
 
 5.38 0.782   Negative 
 
Tramadol 
CAS # 27203-92-5 
1.54E-011 
 
 3.01 1151 1.11j ≤0.11-≤0.13 j Positive 
 
 
A
n
t
i
b
i
o
t
i
c
s
 
Amoxicillin 
CAS # 26787-78-0 
2.49E-021 
 
2.4d 0.87 b 3433   Neut./Neg. 
 
A
n
t
i
b
i
o
t
i
c
s
 
Azithromycin 
CAS # 83905-01-5 
5.3E-029 
 
pK1 =8.7 
pK2= 9.5 
4.02 0.06204 2.5-2.7k 
≤0.1 
≤1.2* 
0.17* s 
 
positive 
 
Cefaclor 
CAS # 53994-73-3 
1.27E-017 
 
 0.35 119    
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Cefalexin 
CAS # 15686-71-2 
2.77E-017 
 
   
  Neut./Neg. 
 
Cefotaxime 
CAS # 63527-52-6 
3.09E-024 
 
 0.64 394.5   Negative 
 
A
n
t
i
b
i
o
t
i
c
s
 
Chloramphenicol 
CAS # 56-75-7 
2.29E-018 
 
5.5 1.14 388.5   Neut./Neg. 
 
Chlortetracycline 
CAS # 57-62-5 
3.45E-024 
 
pK1= 3.3 
pK2= 7.4 
pK3= 9.3 
-0.62 615.7   Negative 
 
Ciprofloxacin 
CAS # 85721-33-1 
5.09E-019 
 
6.38g 0.4j 1.148 104 4.3k  Pos./Neut. 
 
Clarithromycin 
CAS # 81103-11-9 
1.73E-029 
 
8.99 3.16 0.342 2.5-2.6k 
≤0.4 
≤1.7* 
0.034*-0.2* s 
Positive 
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Pharmaceutical Henry’s Law constant (atm-m3/mole)
Clindamycin 
CAS # 18323-44-9 
2.89E-022 
 
A
n
t
i
b
i
o
t
i
c
s
 
Cloxacillin 
CAS # 61-72-3 
1.89E-017 
 
Doxycycline 
CAS # 564-25-0 
4.66E-024 
 
Enoxacin 
CAS # 74011-58-8 
1.14E-021 
 
Enrofloxacin 
CAS # 93106-60-6 
1.5E-018 
 
Erythromycin 
CAS # 114-07-8 
5.42E-029 
 
Appendix A 
 
 
pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
 2.01 30.61   Pos./Neut. 
 3.22 13.94   Negative 
pK1= 3.5 
pK2= 7.7 
pK3= 9.5 
-0.02 312.9    
pK1= 6.3 
pK2= 8.7 
-0.2 3.43 104   Neutral 
6.27g 1.1h 3397 4.5u  Neut./Neg. 
8.8-8.9 b 3.06 0.5168 2.2l 0.15-6 o Positive 
 
Molecular structure 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
A
n
t
i
b
i
o
t
i
c
s
 
Lincomycin 
CAS # 154-21-2 
3E-023 
 
 0.29 92.19   Pos./Neut. 
 
Lomefloxacin 
CAS # 98079-51-7 
1.35E-018 
 
 0.31 2.72 104 4.16u  Neutral 
 
 
Metronidazole 
CAS # 443-48-1 
1.69E-011 
 
2.5 -0.1; -0.02 2.573 104   Neutral 
 
Norfloxacin 
CAS # 70458-96-7 
 
8.7E-019 
 
pK1= 6.3, 
pK2= 8.4 
-1.03 1.779 105 4.2k  Positive 
 
 
Ofloxacin 
CAS # 82419-36-1 
4.98E-020 
 
5.97 0.35 2.826 104 4.2u  Neut./Neg. 
 
A
n
t
i
b
i
o
t
i
c
s
 
Oxytetracycline 
CAS # 79-57-2 
1.7E-025 
 
pK1= 
3.27 
pK2= 7.3 
pK3= 9.1 
-0.90; 
-1.6 (pH 
7.5) 
1.22 
1399   Negative 
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Pharmaceutical Henry’s Law constant (atm-m3/mole)
Penicillin G 
CAS # 61-33-6 
1.16E-014 
 
Penicillin V 
CAS # 87-08-1 
4.42E-015 
 
Roxithromycin 
CAS # 80214-83-1 
4.97E-031 
 
Spiramycin 
CAS # 8025-81-8  
A
n
t
i
b
i
o
t
i
c
s
 
Sulfachloropyridazine 
CAS # 80-32-0 
2.05E-012 
 
Sulfadiazine 
CAS # 68-35-9 
1.58E-010 
 
Sulfadimethoxine 
CAS # 122-11-2 
1.3E-014 
 
Appendix A 
 
 
pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
2.74     Negative 
 
2.79 1.87 101.1   Negative 
 
8.8c 2.75 0.01887 2.2-2.7
k
 
2.3-2.6l 
0.2-9 o 
≤0.2 
≤0.3* 
0.022*-0.023* s 
Positive 
 
8.0     Positive 
 
 0.31 8235   Neut./Neg. 
pK1= 
6.36 
pK2= 2.1 
-0.09 2.814 104   Neut./Neg. 
 1.17 433.1   Neut./Neg. 
Molecular structure 
 
 
 
 
 
 
 
 
 
  
Pharmaceutical Henry’s Law constant (atm-m3/mole)
Sulfamethazine 
CAS # 57-68-1 
3.05E-013 
 
A
n
t
i
b
i
o
t
i
c
s
 
Sulfamethoxazole 
CAS # 723-46-6 
6.42E-013 
 
Sulfapyridine 
CAS # 144-83-2 
1.08E-013 
 
Sulfasalazine 
CAS # 599-79-1 
2.19E-018 
 
Sulfathiazole 
CAS # 72-14-0 
5.85E-014 
 
A
n
t
i
b
i
o
t
i
c
s
 
Tetracycline 
CAS # 60-54-8 
4.66E-024 
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pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
2.65q 0.89h 1.124 104   Neut./Neg. 
5.7c 0.89i 3942 2.1-2.7
k
 
2.3-2.6l 0.3
 o
 Neut./Neg. 
Pk1= 
8043 
Pk2=2.3 
0.35 1.199 104 2.3-2.6k  Neut./Neg. 
 3.81 2.44   Negative 
 0.72 2.003 104   Negative 
pK1= 3.3 
pK2= 7.7 
pK3= 9.7 
-1.30 3877 3.9k  Negative 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Trimethoprim 
CAS # 738-70-5 
2.39E-014 
 
7.2 0.91 2334 2.2-2.6
k
 
2.3l 0.15 
o
 Pos./Neut. 
 
Tylosin  
CAS # 1401-69-0 
5.77E-038 
 
7.1p 1.63 0.5065   Pos./Neut. 
 
A
n
t
i
d
i
a
b
e
t
i
c
s
 
Glibenclamide 
CAS # 10238-21-8 
7.56E-019 
 
5.3 4.8 0.0635 2.4t  Negative 
 
A
n
t
i
f
u
n
g
a
l
s
 
Clotrimazole 
CAS # 23593-75-1 
3.12E-008 
 
 6.26 0.0299   Pos./Neut. 
 
A
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
s
 
Diltiazem 
CAS # 42399-41-7 
8.61E-017 
 
 2.79 12.3   Positive 
 
 
A
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
s
 Enalapril 
CAS # 75847-73-3 
3.34E-016 
 
--- 2.45 34.88   Negative 
 
Hydrochlorothiazide 
CAS # 58-93-5 
4.39E-012 
 
7.9 -0.07 1292 1.8t  Negative 
 
 
 
 
  
Pharmaceutical Henry’s Law constant (atm-m3/mole)
B
a
r
b
i
t
u
r
a
t
e
s
 
Phenobarbital 
CAS # 50-06-6 
3.8E-016 
 
B
e
t
a
-
b
l
o
k
e
r
s
 
Acebutolol 
CAS # 37517-30-9 
 
3.01E-020 
 
Atenolol 
CAS # 29133-68-7 
 
 
Betaxolol 
CAS # 63659-18-7 
 
1.45E-013 
 
Bisoprolol 
CAS # 66722-44-9 
2.89E-015 
 
B
e
t
a
-
b
l
o
k
e
r
s
 
Carazolol 
CAS #57775-29-8 
5.56E-016 
 
Celiprolol 
CAS # 56980-93-9 
6.27E-021 
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pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
7.3 1.47 1644   Negative 
 
 1.71i 259    
9.6 0.16 685.2 -0.68i 1.1-1.9 j positive 
--- 2.81 450.7  6.0 j Positive 
 1.84 2240  0.64-0.77 j Positive 
--- 3.59 8.254   Positive 
 1.93 93.92  0.18-0.24 j Positive 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Metoprolol 
CAS # 37350-58-6 
1.4E-013 
 
9.6 1.88 4777  0.35-0.40 j Positive 
 
Nadolol 
CAS # 42200-33-9 
 
1.37E-014 
 
9.67 0.81 2.24 104   Positive 
 
Oxprenolol 
CAS # 6452-71-7 
6.35E-013 
 
 
1.83 
 
 
3182   Positive 
 
B
e
t
a
-
b
l
o
k
e
r
s
 
Propranolol 
CAS # 525-66-6 
7.98E-013 
 
9.42 3.48 228 2.6t 0.36-0.46 j Positive 
 
 
Sotalol 
CAS # 3930-20-9 
2.49E-014 
 
pK1=8.2 
pK2=9.8 
0.24 5513  0.40-0.43 j positive 
 
Timolol 
CAS # 26839-75-8 
4.35E-017 
 
9.21 1.83 2741   Positive 
 
 
D
i
u
r
e
t
i
c
s
 
Bendroflumethiazide 
CAS # 73-48-3 
5.51E-012 
 
 1.82 4.87   Neut./Neg. 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Furosemide 
CAS # 54-31-9 
3.94E-016 
 
3.9 2.03 149.3   Negative 
 
 
L
i
p
i
d
 
r
e
g
u
l
a
t
o
r
s
 
Bezafibrate 
CAS # 41859-67-0 
2.12E-015 
 
3.6c 4.25 1.224  
2.1-3.0 
3.4*-4.5* 
0.77*->2.9* s 
Negative 
 
 
L
i
p
i
d
 
r
e
g
u
l
a
t
o
r
s
 
Clofibrate 
CAS # 637-07-0 
9.31E-006 
 
 3.62 20.97   Neutral 
 
 
Clofibric acid 
CAS # 882-09-7 
2.19E-008 
 
-3.18m 2.57 582.5  
0.3-0.8 
0.1*-0.23* 
0.09*-0.1* s 
Negative 
 
 
Etofibrate 
CAS # 31637-97-5 
5.74E-012 
 
 3.43 6.033   Neutral 
 
 
Fenofibrate 
CAS # 49562-28-9 
4.46E-009 
 
--- 5.19 0.1957   Neutral 
 
Fenofibric acid 
CAS # 42017-89-0 
7.9E-012 
 
 2.9   7.2-10.8 0.4*-1.7*; Negative 
 
Gemfibrozil 
CAS # 25812-30-0 
1.19E-008 
 
4.8 4.77 4.964 1.28t 6.4-9.6 0.5*-1.8* 
Negative 
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Pharmaceutical Henry’s Law constant (atm-m3/mole)
Pravastatin 
CAS # 81093-37-0  
L
i
p
i
d
 
r
e
g
u
l
a
t
o
r
s
 
Simvastatin 
CAS # 79902-63-9 
2.81E-010 
 
P
s
y
c
h
i
a
t
r
i
c
 
d
r
u
g
s
 
Amitriptyline 
CAS # 50-48-6 
6.85E-008 
 
Carbamazepine 
CAS # 298-46-4 
1.08E-010 
 
Diazepam 
CAS # 439-14-5 
3.64E-009 
 
Fluoxetine 
CAS # 54910-89-3 
8.9E-008 
 
Appendix A 
 
 
pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
--- -0.23 2464   Negative 
 
 5.19 0.765   Neutral 
 
 4.95 0.823   Positive 
 
13.9 b 2.45 17.66 0.1l 
≤0.1 j 
<0.03-<0.06 o 
<0.005*-
<0.008* s 
Neutral 
 
3.4 2.82 58.78 1.3l ≤0.16 
j
 
<0.25-<0.4 o 
Neutral 
 
9.5 4.05 38.35 0.7n 5-9 o positive 
Molecular structure 
 
 
 
 
 
 
 
 
CH
3
N
H
3
C
  
Pharmaceutical Henry’s Law constant (atm-m3/mole)
Gabapentin 
CAS # 60142-96-3 
1.81E-010 
 
P
s
y
c
h
i
a
t
r
i
c
 
d
r
u
g
s
 
Lorazepam 
CAS # 846-49-1 
4.1E-010 
 
Norfluoxetine 
CAS # 126924-38-7  
Oxcarbazepine 
CAS # 28721-07-5 
6.92E-013 
 
Paroxetine 
CAS # 61869-08-7 
1.78E-012 
 
Valproic acid 
CAS # 99-66-1 
3E-006 
 
R
e
c
e
p
t
o
r
 
a
n
t
a
g
o
n
i
s
t
s
 
Cimetidine 
CAS # 51481-61-9 
9.5E-016 
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pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 
  4491   Neutral 
pK1=1.3 
pK2=11.5 
2.39 83.87   Neutral 
 
9.05d 4.07d     
 1.11 202.8   Neutral 
 
9.0 3.95 35.27   Positive 
 
 2.96 894.6   Negative 
6.8 0.40 1.046 104   Pos./Neut. 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Famotidine 
CAS # 76824-35-6 
5.44E-024 
 
--- -0.64 1271   Positive 
 
R
e
c
e
p
t
o
r
 
a
n
t
a
g
o
n
i
s
t
s
 
Loratadine 
CAS # 79794-75-5 
3.19E-013 
 
--- 5.20 0.01099 3.5t  Neutral 
 
 
Omeprazole 
CAS # 73590-58-6 
3.04E-019 
 
 3.4 82.28   Neutral 
 
 
Ranitidine 
CAS # 66357-35-5 
3.42E-015 
 
2.4 0.27 2.466 104   Positive 
 
Valsartan 
CAS # 137862-53-4       
Negative 
 
 
H
o
r
m
o
n
e
s
 
Estradiol 
CAS # 50-28-2 
3.64E-011 
 
10.27m 3.94 81.97 2.4-2.8l 175-460 
r
 
280*-950* r 
Neutral 
 
 
Estriol 
CAS # 50-27-1 
1.33E-012 
 
 2.81 440.8   Neutral 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Estrone 
CAS # 53-16-7 
3.8E-010 
 
10.25m 3.43 146.8 2.4-2.9l 
10-162 r 
28*-430* r 
>20 s 
Neutral 
 
 
Ethinylestradiol 
CAS # 57-63-6 
7.94E-012 
 
10.24m 4.12 116.4 2.5-2.8l 
0.4-20 o 
1.2-8 r 
1.5*-6* r 
>0.5->0.7 s 
Neutral 
 
 
B
e
t
a
-
a
g
o
n
i
s
t
s
 
Clenbuterol 
CAS # 037148-27-9 
2.96E-014 
 
--- 2.00 3320   Positive 
 
Salbutamol 
CAS # 35763-26-9  
pK1= 9.3, 
pK2=10.3 
0.6, 0.01 --   Positive 
 
Fenoterol 
CAS # 13392-18-2 
1.04E-023 
 
 1.22 4.13 104   Positive 
 
 
Terbutaline 
CAS # 23031-25-6 
1.65E-018 
 
 0.67 2.128 105   Positive 
 
 
A
n
t
i
n
e
o
p
l
a
s
t
i
c
 
Cyclophosphamide 
CAS # 50-18-0 
1.4E-011 
 
 0.97 5943   Neutral 
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Pharmaceutical Henry’s Law constant (atm-m3/mole) pKa Log Kow 
Sw 25ºC 
(mg l-1) Log Kd 
kbiol 
(L gSS-1 d-1) 
Charge 
at pH 7 Molecular structure 
Ifosfamide 
CAS # 3778-73-2 
1.36E-011 
 
 0.97 3781   Neutral 
 
 
Tamoxifen 
CAS # 10540-29-1 
4.49E-010 
 
 6.30 0.1936   Positive 
 
 
T
o
p
i
c
a
l
 
P
r
o
d
u
c
t
s
 Crotamiton 
CAS # 483-63-6 
1.53E-007 
 
 2.73 195.3   Neutral 
 
A
n
t
i
s
e
p
t
i
c
s
 
Triclosan 
CAS # 3380-34-5 
4.99E-009 
 
8.1n 5.34 4.621   Neut./Neg. 
 
C
o
n
t
r
a
s
t
 
m
e
d
i
a
 
Iopromide 
CAS # 73334-07-3 
1E-028 
 
 -2.49 23.75 1l 
1.6-2.5 
1.0*-2.0* 
0.12*-0.026* s 
Pos./Neut. 
 
Data were from Ternes and Joss, 2006;http:// esc.syrres.com/interkow/physdemo.htm  (Henry’s Law constant), Petrovic and Barcelò 2007 (pKa), EPISuite v4.00 (Sw, logKow, 
logKoc); Chemamox (charge at pH=7). For LogKd, references are specified.  
References  
aAvdeef et al. 2002; b Jones et al. 2002; c Huber et al. 2003; d Khan and Ongerth 2002; e Wan et al. 2002; f Tixier et al. 2003; g Nowara et al. 1997; h Meylan 1993; i Vieno et al.,2007; j Wick et 
al.,2009; k Le-Minh et al., 2010; l Suárez et al., 2008; m Zorita et al.2009; n Munoz et al.2009; o Suárez et al.,2010; p Wollenberger 2000; q Papastephanou and Frantz 1997; r Joss et al., 2004 s 
Abegglen et al., 2009; t Radjenovic et al., 2009; u Jia et al., 2012 
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Simple criteria 
kbiol < 0.1 L/(gSS d)   poor degradability 
0.1< kbiol < 10 L/(gSS d)  quite good biodegradability 
kbiol > 10 L/(gSS d)   very good degradability 
 
Log Kow < 2.5   high hydrophilic compound 
2.5 < Log Kow < 4  moderate hydrophilic compound 
Log Kow > 4   high lipophilic compound 
 
Log Kd < 2.7   low adsorption potential 
Log Kd > 2.7   high adsorption potential 
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Table A.2. Ranges of concentration in the influent for the selected pharmaceuticals 
together with their corresponding references. Data with an asterix as apex (*) refer to 
MBRs; (loq= limit of quantification) 
Therapeutic 
class 
Pharmaceutical 
compound Municipal WWTP influent References 
Analgesics/ 
Anti-
inflammatories 
A 
 
5-aminosalicylic acid 3.16-27.9 Kasprzyk-Hordern et al., 2009 
Acetaminophen 0.013-0.057 
18-71 
29-246 
104 
7.1-11.4 
4.16 
1.57-37.5 
172* 
0.96 
Choi et al., 2008; 
Foster, 2007;  
Gómez et al., 2007;  
Khan and Ongerth, 2005;  
Radjenovic et al., 2007, 2009;  
Roberts and Thomas, 2006;  
Rosal et al., 2010; 
Snyder et al., 2006; 
Yu et al., 2006 
Acetylsalicylic acid 1.32-5.44 Kasprzyk-Hordern et al., 2009 
Codeine 0.1-35 
2.8-11 
2.49-12.6 
0.15-2.09 
0.12 
Foster, 2007; 
Gómez et al., 2007; 
Kasprzyk-Hordern et al.,2009;  
Rosal et al., 2010;  
Wick et al., 2009 
Dextropropoxyphene 0.03 Roberts and Thomas, 2006 
Diclofenac 0.16 
3.19*/0.9-3.19 
0.9-4.1 
0.2-3.6 
0.06-1.16 
0.25-1 
0.3-0.6 
0.2 
0.2-0.7 
2.8* 
1-1.6 
7 
0.98* 
0.23 
<loq 
<loq 
0.05* 
0.78 
11 
0.3-2.09 
0.33-0.49 
0.46 
1.23 
0.11 
0.23 
Bendz et al., 2005;  
Clara et al 2005a,  
Clara et al 2005b;  
Gómez et al., 2007;  
Kasprzyk-Hordern et al., 2009; 
Kimura et al 2007;  
Lindqvist et al., 2005;  
Lishman et al., 2006;  
Paxéus, 2004;  
Quintana et al., 2005;  
Radjenovic et al., 2009; 
Reif et al., 2008;  
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Santos et al., 2007,  
Santos et al., 2009;  
Snyder et al., 2006;  
Stumpf et al., 1999;  
Suárez et al., 2005; 
Tauxe-Wuersch et al., 2005;  
Thomas and Foster, 2005; 
Vieno et al., 2005;  
Weigel et al., 2004;  
Yu et al., 2006; 
Zorita et al., 2009  
Dipyrone 4.7-24 Gómez et al., 2007 
Fenoprofen <loq 
<loq 
0.009-0.08 
Bendz et al., 2005;  
Lishman et al., 2006;  
Nakada et al., 2006; 
Flurbiprofen <loq Bendz et al., 2005 
Hydrocodone 0.11* Snyder et al., 2006 
Ibuprofen 3.59 
2.6-5.7 
2.44*/1.2-3.6 
1.2-2.6 
34-168 
0.98-6.32 
2.7 
1.9 
Bendz et al., 2005;  
Carballa et al., 2004,  
Clara et al., 2005a,  
Clara et al., 2005b;  
Gómez et al., 2007; 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005;  
Kimura et al., 2007;  
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Therapeutic 
class 
Pharmaceutical 
compound Municipal WWTP influent References 
9.8-19.8 
8.45 
0.38-1.13 
0.8-11 
5.7* 
14.6-31.3 
9.8* 
2.6 
2.8-5.8 
<loq-4.11 
12.1-373 
<loq-353 
12* 
0.32 
10 
1.1-4.6 
9.5-14.7 
23.4 
1.66 
1.9 
6.9 
Lindqvist et al., 2005;  
Lishman et al., 2006;  
Nakada et al., 2006; 
 Paxéus, 2004;  
Quintana et al., 2005;  
Radjenovic et al., 2009;  
Reif et al., 2008; 
Roberts and Thomas, 2006;  
Rodriguez et al., 2003;  
Rosal et al., 2010;  
Santos et al., 2007, 
Santos et al., 2009;  
Snyder et al., 2006;  
Stumpf et al., 1999;  
Suárez et al., 2005;  
Tauxe-Wuersch et al., 2005;  
Thomas and Foster, 2005; 
Vieno et al., 2005;  
Weigel et al., 2004;  
Yu et al., 2006; 
Zorita et al., 2009 
Indomethacin <loq 
0.23 
0.66-1 
<loq-0.11 
0.95 
Bendz et al., 2005;  
Lishman et al., 2006,  
Radjenovic et al., 2009;  
Rosal et al., 2010; 
Stumpf et al., 1999;  
Ketoprofen 0.94 
0.031-0.34 
0.9 
0.97 
1.3-3 
0.15 
0.1-0.37 
0.5* 
0.7-1.2 
<loq-0.8 
<loq-3.59 
<loq-6.47 
0.52 
0.15-0.41 
0.41-0.52 
2.9 
1.2 
Bendz et al., 2005; 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005; 
Kimura et al., 2007;  
Lindqvist et al., 2005; 
Lishman et al., 2006; 
Nakada et al., 2006; 
Quintana et al., 2005; 
Radjenovic et al., 2007,  
Rosal et al., 2010; 
Santos et al., 2007, 
Santos et al., 2009;  
Stumpf et al., 1999; 
Tauxe-Wuersch et al., 2005; 
Thomas and Foster, 2005; 
Vieno et al., 2005;  
Yu et al., 2006  
Ketorolac <loq-2.8 Rosal et al., 2010 
Mefenamic acid <0.017-0.03 
0.22 
0.8-1.2 
0.23 
0.1-0.22 
0.75-2.9 
Kasprzyk-Hordern et al., 2009;  
Kimura et al., 2007; 
 Radjenovic et al.,2009;  
Roberts and Thomas, 2006;  
Rosal et al., 2010;  
Tauxe-Wuersch et al., 2005 
Naproxen 3.65 
1.79-4.6 
0.62-3.5 
6.5 
0.27 
3.6-8.2 
5.58 
0.04-0.23 
1.8-3.6 
1* 
0.13-0.67 
Bendz et al., 2005; 
 Carballa et al., 2004, 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005;  
Kimura et al., 2007;  
Lindqvist et al., 2005;  
Lishman et al., 2006;  
Nakada et al., 2006;  
Paxéus, 2004;  
Quintana et al., 2005;  
Radjenovic et al.,2009; 
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Therapeutic 
class 
Pharmaceutical 
compound Municipal WWTP influent References 
6.2* 
3.5-4.5 
1.19-5.23 
1.1-27.4 
2.02-52.1 
12.5* 
0.6 
10 
10.3-12.8 
8.6 
3.2 
4.9 
Reif et al., 2008; 
Rodriguez et al., 2003; 
Rosal et al., 2010; 
Santos et al., 2007,  
2009; 
Snyder et al., 2006; 
Stumpf et al., 1999; 
Suárez et al., 2005; 
Thomas and Foster, 2005; 
Vieno et al., 2005; 
Yu et al., 2006; 
Zorita et al., 2009 
Phenazone  <loq-0.07 Rosal et al., 2010; 
Propyphenazone 0.0016-0.07 
0.04-0.09 
Nakada et al., 2006; 
Radjenovic et al., 2009 
Salicylic acid 5.6-32.08 
13 
13.7 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005; 
Lishman et al., 2006;  
Tramadol 23.03-85.8 
0.23-0.47 
Kasprzyk-Hordern et al, 2009; 
Wick et al., 2009 
Antibiotics 
B 
Amoxicillin 0.19-0.28 Watkinson et al., 2007 
Azithromycin 0.16-1.34 
0.09-0.38 
0.26 
Ghosh et al., 2009; 
Göbel et al., 2005,  
Yasojima et al., 2006 
Cefaclor 0.5-0.98 Watkinson et al., 2007 
Cefalexin  2 
0.67-2.9 
4.6 
Costanzo et al., 2005; 
Gulkowska et al., 2008; 
Watkinson et al., 2007  
Cefotaxime 0.004-0.024 Gulkowska et al., 2008 
Chloramphenicol 0.15-0.45 
1.73-2.43 
Kasprzyk-Hordern et al., 2009; 
Peng et al., 2006 
Chlortetracycline <loq Watkinson et al., 2007 
Ciprofloxacin 0.09 
0.231-0.195 
0.315-0.57 
0.21 
0.09-0.194 
0.21-0.228 
0.16-13.6 
3.8 
0.32 
Costanzo et al., 2005; 
Ghosh et al., 2009; 
Golet et al., 2003; 
Karthikeyan and Meyer, 2006; 
Lindberg et al., 2005,  
Lindberg et al., 2006; 
Rosal et al., 2010; 
Watkinson et al., 2007; 
Zorita et al., 2009 
Clarithromycin 1.129-4.82 
0.33-0.6 
0.647 
Ghosh et al., 2009; 
Göbel et al., 2005,  
Yasojima et al., 2006 
Clindamycin 0.002-0.005 Watkinson et al., 2007 
Cloxacillin <loq Watkinson et al., 2007 
Doxycycline <loq-0.11 
- 
Lindberg et al., 2005; 
Watkinson et al., 2007  
Enrofloxacin 0.023-0.085 
0.01 
Ghosh et al., 2009; 
Watkinson et al., 2007 
Erythromycin  0.06-0.19 
0.47-0.74 
0.48-1.2 
0.14-10.02 
0.32-2.7 
10* 
0.11 
0.34 
1.05* 
0.22 
Göbel et al., 2005,  
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Radjenovic et al., 2007,  
Reif et al., 2008; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Xu et al., 2007 
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Therapeutic 
class 
Pharmaceutical 
compound Municipal WWTP influent References 
Lincomycin 0.06-0.08 Watkinson et al., 2007 
Metronidazole 0.34-0.962 
0.044-0.17 
Kasprzyk-Hordern et al., 2009; 
Rosal et al., 2010 
Norfloxacin 0.155-0.468 
0.343-0.52 
0.46 
0.075-0.174 
0.246-0.319 
0.17 
0.033 
0.018 
Ghosh et al., 2009; 
Golet et al., 2003; 
Gulkowska et al., 2008; 
Lindberg et al., 2005, 
 2006; 
Watkinson et al., 2007; 
Xu et al., 2007; 
Zorita et al., 2009 
Ofloxacin 0.47 
0.287 
0.52-5.56 
0.89-31.7 
0.84-5.29 
0.077 
0.022 
Brown et al., 2006; 
Lindberg et al., 2005; 
Peng et al., 2006; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Xu et al., 2007; 
Zorita et al., 2009 
Oxytetracycline <loq Watkinson et al., 2007 
Penicillin G <loq 
<loq 
Gulkowska et al., 2008; 
Watkinson et al., 2007 
Penicillin V 0.05-0.16 Watkinson et al., 2007 
Roxithromycin 0.025-0.078 
0.096-0.209 
0.01-0.04 
17* 
0.08 
0.018 
0.04 
Clara et al., 2005b; 
Ghosh et al., 2009; 
Göbel et al., 2005, 
Reif et al., 2008; 
Ruel et al., 2010; 
Watkinson et al., 2007; 
Xu et al., 2007 
Sulfachloropyridazine <loq-0.47 Choi et al., 2008 
Sulfadiazine 5.1-5.15 Peng et al., 2006 
Sulfadimethoxine <loq-0.21 Choi et al., 2008; 
Sulfamethazine 0.11-0.21 
<loq 
Karthikeyan and Meyer., 2006; 
Sahar et al., 2011 
Sulfamethoxazole 0.02 
0.39 
<loq-0.58 
0.15-0.98 
0.02-0.075 
<0.2 
0.23-0.57 
0.17-1.25 
0.02-0.27 
0.14-0.23 
5.45-7.91 
0.25-1.3 
10* 
0.16-0.53 
0.53 
1.11* 
0.36 
0.01 
Bendz et al., 2005; 
Brown et al., 2006; 
Carballa et al., 2004,  
Choi et al., 2008; 
Clara et al., 2005b; 
Foster, 2007; 
Göbel et al., 2005,  
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Lindberg et al., 2005; 
Peng et al., 2006; 
Radjenovic et al., 2009; 
Reif et al., 2008; 
Rosal et al., 2010; 
Ruel et al., 2010; 
Snyder et al., 2006; 
Watkinson et al., 2007; 
Xu et al., 2007 
Sulfapyridine 0.06-0.15 
2.16-12.39 
Göbel et al., 2005,  
Kasprzyk-Hordern et al., 2009 
Sulfasalazine <loq-0.06 Watkinson et al., 2007 
Sulfathiazole <0.03-0.53 
0.002 
Choi et al., 2008; 
Watkinson et al., 2007 
Tetracycline 0.065-0.089 
0.096-1.3 
0.24-0.79 
Ghosh et al., 2009; 
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
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Therapeutic 
class 
Pharmaceutical 
compound Municipal WWTP influent References 
<loq Watkinson et al., 2007 
Trimethoprim 0.53 
0.08 
0.59 
0.1 
0.011-0.026 
0.21-0.44 
0.12-0.32 
0.58-1.1 
1.51-4.67 
<loq-0.49 
0.17-0.65 
1.03-1.86 
0.1-0.3 
0.15-0.43 
10.5* 
0.25 
0.07-0.2 
0.69* 
0.34 
Batt 2006; 
Bendz et al., 2005; 
Brown et al., 2006; 
Foster, 2007; 
Ghosh et al., 2009; 
Göbel et al., 2005, 
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Choi et al., 2008; 
Lindberg et al., 2005,  
2006; 
Paxéus, 2004; 
Radjenovic et al., 2009; 
Reif et al., 2008; 
Roberts and Thomas, 2006; 
Rosal et al., 2006; 
Snyder et al., 2006; 
Watkinson et al., 2007 
Tylosin  <loq-0.055 Watkinson et al., 2007 
Antidiabetics C Glibenclamide 0.12-15.9 Radjenovic et al., 2009 
Antifungals D Clotrimazole 0.029 Roberts and Thomas, 2006 
Antihypertensives 
E 
Diltiazem <0.005-0.019 
<0.2-1.6 
0.405-5.258 
Choi et al., 2008 
Foster, 2007; 
Kasprzyk-Hordern et al., 2009; 
Hydrochlorothiazide 2.3-4.8 
0.61-10 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Barbiturates F Phenobarbital 0.07 Yu et al., 2006 
Beta-blockers G Atenolol 2.29 
0.03 
8.1-25.14 
1.69-2.54 
0.84-2.8 
0.66-2.43 
0.72 
Alder et al. 2010 
Bendz et al., 2005; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Wick et al., 2009 
Betaxolol 0.006-0.009 Wick et al., 2009 
Bisoprolol 0.21-0.38 Wick et al., 2009 
Celiprolol 0.1-0.16 Wick et al., 2009 
Metoprolol 0.24 
0.056-0.14 
0.14-0.23 
0.3 
0.026-0.063 
0.02 
1.2 
Alder et al., 2010; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Paxéus, 2004; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Wick et al., 2009 
Propranolol 0.05 
0.05 
0.11-1.9 
0.05-0.17 
0.1-1.13 
0.08 
0.012-0.06 
0.073 
Alder et al., 2010; 
Bendz et al., 2005; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Radjenovic et al., 2009; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Wick et al., 2009 
Sotalol 0.29 
0.3 
0.17-0.85 
1.1 
Alder et al., 2010; 
Maurer et al., 2007; 
Radjenovic et al., 2009; 
Wick et al., 2009 
Diuretics H 
 
Bendroflumethiazide <0.008-0.1 Kasprzyk-Hordern et al., 2009 
Furosemide 1.58-6.02 Kasprzyk-Hordern et al., 2009; 
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Therapeutic 
class 
Pharmaceutical 
compound Municipal WWTP influent References 
0.41 Rosal et al., 2010 
Lipid regulators I 
 
Bezafibrate 6.84*/1.55-7.6 
1.55-7.6 
0.6 
0.1-1 
2.6* 
1.9-29.8 
0.048-0.36 
1.18 
2.2 
Clara et al., 2005a,  
Clara et al., 2005b; 
Kasprzyk-Hordern et al., 2009; 
Lindqvist et al., 2005; 
Quintana et al., 2005; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Vieno et al., 2005 
Clofibric acid 0.028 
0.49 
0.03 
1 
0.17-0.37 
0.17 
0.05 
Kimura et al.,  2007; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Tauxe-Wuersch et al., 2005; 
Weigel et al., 2004; 
Zorita et al., 2009 
Fenofibric acid <loq-0.12/0.079 
0.42 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Gemfibrozil 0.71 
1.5 
0.45 
0.6-1.1 
2-5.9 
0.41-17.1 
2.21* 
0.3 
0.41 
Bendz et al., 2005; 
Khan and Ongerth, 2005; 
Lishman et al., 2006; 
Paxéus, 2004; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Stumpf et al., 1999; 
Yu et al., 2006 
Pravastatin <0.06 
0.46-1.5 
Kasprzyk-Hordern et al., 2009; 
Radjenovic et al., 2009 
Simvastatin <0.007 Kasprzyk-Hordern et al., 2009 
Psychiatric drugs 
J 
 
Amitriptyline 0.504-6.7 Kasprzyk-Hordern et al., 2009 
Carbamazepine 1.68 
0.7*/0.32-0.7 
0.32-1.2 
0.3 
<0.2-0.59 
0.12-0.31 
0.1-3.11 
0.5 
<0.005-0.45 
0.015-0.27 
1.3-2 
0.054-0.22 
19.5* 
0.1-0.17 
<loq/2.15 
<loq-3.78 
0.2* 
21.5 
1 
Bendz et al., 2005; 
Clara et al., 2005a, 
Clara et al.,  2005b; 
Conti et al., 2011; 
Foster, 2007; 
Gómez et al., 2007; 
Kasprzyk-Hordern et al., 2009; 
Khan and Ongerth, 2005; 
Choi et al., 2008; 
Nakada et al., 2006; 
Paxéus, 2004; 
Radjenovic et al., 2009;  
Reif et al., 2008; 
Rosal et al., 2010; 
Santos et al., 2007, 
Santos et al., 2009; 
Snyder et al., 2006; 
Suárez et al., 2005; 
Wick et al, 2009 
Diazepam 23* 
21 
Reif et al., 2008; 
Suárez et al., 2005; 
Fluoxetine 0.1 
0.191 
0.12-2.3 
0.58 
<0.1* 
0.011 
Foster, 2007; 
Metcalfe et al. 2010; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Zorita et al., 2009 
Gabapentin 10.67-25 Kasprzyk-Hordern et al., 2009; 
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Therapeutic 
class 
Pharmaceutical 
compound Municipal WWTP influent References 
0.1 Yu et al., 2006 
Norfluoxetine 0.011 
0.011 
Metcalfe et al. 2010; 
Zorita et al., 2009 
Oxcarbazepine 0.011-0.046 Conti et al., 2011  
Paroxetine 0.016 Metcalfe et al. 2010; 
Valproic acid 0.14 Yu et al., 2006 
Receptor 
antagonists K 
 
Cimetidine 0.014-10 
0.68-6.5 
Choi et al., 2008  
Kasprzyk-Hordern et al., 2009; 
Famotidine 0.027-0.14 Radjenovic et al., 2009 
Loratadine 0.015-0.043 Radjenovic et al., 2009 
Omeprazole 0.057-2.13 Rosal et al., 2010 
Ranitidine 2-11.15 
0.072-0.54 
0.52 
Kasprzyk-Hordern et al., 2009; 
Radjenovic et al., 2009, 
Rosal et al., 2010 
Valsartan 0.35-5.3 Kasprzyk-Hordern et al., 2009 
Hormones L 
 
Estradiol 0.012-0.02 
0.008-0.016 
0.035-0.067/0.067* 
<0.08-3 
0.04*/0.003 
0.01 
0.003 
Andersen et al., 2003; 
Baronti et al., 2000; 
Clara et al., 2005a 
Foster, 2007; 
Joss et al., 2004; 
Lishman et al., 2006; 
Zorita et al., 2009 
Estriol 0.05-0.12 
0.023-0.336/0.326* 
0.08-0.25 
Baronti et al., 2000; 
Clara et al., 2005a 
Nakada et al., 2006 
Estrone 0.05-0.07 
0.03-0.07 
0.002 
0.071*/0.034-0.67 
0.025*/0.032 
0.03 
0.02-0.19 
0.014 
Andersen et al., 2003; 
Baronti et al., 2000; 
Carballa et al., 2004,  
Clara et al., 2005a; 
Joss et al., 2004; 
Lishman et al., 2006; 
Nakada et al., 2006; 
Zorita et al., 2009  
Ethinylestradiol 0.002-0.004 
0.004-0.07/0.02* 
0.04 
0.002 
Baronti et al., 2000; 
Clara et al., 2005a 
Foster, 2007; 
Joss et al., 2004; 
Beta-agonists M Salbutamol 0.05-0.15 Kasprzyk-Hordern et al., 2009; 
Antineoplastics N Ifosfamide 0.038-0.36 Kummerer et al., 1997 
Tamoxifen 0.17 Roberts and Thomas, 2006 
Topical product 
O 
Crotamitron 0.38-3.03 Nakada et al., 2006 
Antiseptic P Triclosan 1.7-2.7 
0.39-4.2 
7 
0.21-1.8 
0.4-2.2 
0.86 
0.45 
1.28* 
3-3.6 
0.38 
0.8 
Foster, 2007; 
Gómez et al., 2007; 
McAvoy et al., 2002; 
Nakada et al., 2006;, 
Paxéus, 2004; 
Rosal et al., 2010; 
Ruel et al., 2010; 
Snyder et al., 2006; 
Thomas and Foster, 2005; 
Weigel et al., 2004;  
Yu et al., 2006 
Contrast agent Q Iopromide 0.2 
6.6 
0.03-3.84 
Batt et al., 2006; 
Carballa et al., 2004; 
Clara et al., 2005b 
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Table A.3. Ranges of concentration for the selected pharmaceuticals in the effluent of CAS 
and MBR together with their corresponding references. Data with an asterix as apex (*) 
refer to MBRs. (loq= limit of quantification) 
Therapeutic 
class 
Pharmaceutical 
compound Secondary effluent References 
Analgesics/ 
Anti-
inflammatories 
A 
 
5-aminosalicylic acid 0.17-1.21 Kasprzyk-Hordern et al., 2009 
Acetaminophen <0.005-0.009 
0.11 
0.025 
<loq-4.3 
0.08-1.57 
0.23 
0.0018-0.019 
<20 
<0.01 
6 
Choi et al., 2008; 
Coetsier et al., 2009;  
Foster, 2007;  
Gómez et al., 2007;  
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005;  
Kim et al., 2007; 
Roberts and Thomas, 2006;  
Snyder et al., 2006; 
Ternes, 1998  
Acetylsalicylic acid <0.003-0.065 
1.5-0.22 
Kasprzyk-Hordern et al., 2009; 
Ternes, 1998 
Aminopyrine  <loq 
1 
Andreozzi et al., 2003;  
Ternes, 1998 
Codeine 0.025 
0.9-8.1 
1.45-4.17 
0.16 
0.025 
Foster, 2007; 
 Gómez et al., 2007; 
 Kasprzyk-Hordern et al.,2009;  
Rosal et al., 2010;  
Wick et al., 2009 
Dextropropoxyphene 0.1 Roberts and Thomas, 2006 
Diclofenac 0.47-5.45 
0.12 
2.14*/0.78-1.68 
2.03*/0.78-1.5 
0.4 
0.14-2.2 
0.006-0.5 
0.008-0.12 
0.04*/0.07 
0.046*-0.12*/0.145 
0.15-0.33 
0.19 
0.006-1.3 
0.14-1.48 
1.9* 
7.5* 
0.34 
0.006-0.43 
<loq 
0.07 
<0.01* 
0.19 
10.67 
0.6-2.4 
1.3 
0.81 
0.068-0.083 
0.4 
0.09 
0.48 
Andreozzi et al., 2003; 
Bendz et al., 2005;  
Clara et al 2005a,  
Clara et al 2005b;  
Coetsier et al., 2009;  
Gómez et al., 2007;  
Kasprzyk-Hordern et al., 2009; 
 Kim et al., 2007;  
Kimura et al., 2005, 
 Kimura et al 2007;  
Lindqvist et al., 2005;  
Lishman et al., 2006;  
Muñoz et al., 2009; 
Paxéus, 2004;  
Quintana et al., 2005;  
Reif et al., 2008;  
Roberts and Thomas, 2006; 
 Rosal et al., 2010; 
 Santos et al., 2007,  
Santos et al., 2009;  
Snyder et al., 2006;  
Stumpf et al., 1999;  
Suárez et al., 2005; 
Tauxe-Wuersch et al., 2005;  
Ternes et al., 2003; 
Ternes, 1998; 
Thomas and Foster, 2005; 
Vieno et al., 2005;  
Yu et al., 2006; 
Zorita et al., 2009  
Dipyrone 2.4-7.5 Gómez et al., 2007 
Fenoprofen <loq 
<loq 
0.015 
- 
Andreozzi et al., 2003;  
Bendz et al., 2005;  
Coetsier et al., 2009;  
Lishman et al., 2006;  
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0.0015-0.009 
<loq 
Nakada et al., 2006; 
Ternes, 1998 
Flurbiprofen 0.34 
<loq 
Andreozzi et al., 2003; 
Bendz et al., 2005 
Hydrocodone <0.01* Snyder et al., 2006 
Ibuprofen 0.02-0.18 
0.15 
2.1 
0.02-2.4/0.069* 
<loq-2.4/0.02* 
0.067 
0.24-7.1 
0.065-0.49 
0.22 
0.01-0.13 
0.01*-0.2* 
0.04/0.03*-0.1* 
0.05-3.9 
0.77 
0.54 
0.0014-1.18 
0.02-1.9 
0.18* 
2.9 
0.91-1.87 
<loq-0.65 
0.78-48.24 
<loq-40.2 
0.04* 
0.08 
1.8 
0.1-2.1 
1.13 
3.4 
0.015-0.023 
0.005 
0.08 
Andreozzi et al., 2003;  
Bendz et al., 2005;  
Carballa et al., 2004,  
Clara et al., 2005a,  
Clara et al., 2005b;  
Coetsier et al., 2009; 
Gómez et al., 2007; 
Kasprzyk-Hordern et al., 2009; 
Khan and Ongerth, 2005;  
Kim et al., 2007;  
Kimura et al., 2005, 
Kimura et al., 2007;  
Lindqvist et al., 2005;  
Lishman et al., 2006;  
Muñoz et al., 2009;  
Nakada et al., 2006; 
 Paxéus, 2004;  
Quintana et al., 2005;  
Roberts and Thomas, 2006;  
Rodriguez et al., 2003;  
Rosal et al., 2010;  
Santos et al., 2007, 
Santos et al., 2009;  
Snyder et al., 2006;  
Stumpf et al., 1999;  
Suárez et al., 2005;  
Tauxe-Wuersch et al., 2005;  
Ternes et al., 2003;  
Ternes, 1998;  
Thomas and Foster, 2005; 
Vieno et al., 2005;  
Zorita et al., 2009 
Indomethacin <loq 
0.19 
0.02-0.05 
0.16 
0.1 
0.27 
Bendz et al., 2005;  
Lishman et al., 2006,  
Rosal et al., 2010; 
Stumpf et al., 1999; 
 Ternes et al., 2003;  
Ternes, 1998  
Ketoprofen <loq 
0.33 
0.007-0.37 
0.59 
0.01*-0.02*/0.28 
<0.02*-0.17*/0.44 
0.05-0.9 
0.12 
0.06-0.21 
0.18* 
0.27-0.53 
<loq-1.5 
<loq-2.27 
0.19 
0.1-0.37 
0.2 
0.015-0.041 
0.23 
Andreozzi et al., 2003; 
 Bendz et al., 2005; 
 Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005; 
 Kimura et al., 2005,  
2007;  
Lindqvist et al., 2005; 
 Lishman et al., 2006; 
 Nakada et al., 2006; 
 Quintana et al., 2005; 
Rosal et al., 2010; 
 Santos et al., 2007, 
Santos et al.,  2009;  
Stumpf et al., 1999; 
Tauxe-Wuersch et al., 2005; 
Ternes, 1998; 
Thomas and Foster, 2005; 
Vieno et al., 2005;  
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0.28 Yu et al., 2006  
Ketorolac <loq-0.607 Rosal et al., 2010 
Meclofenamic acid 0.025 Ternes, 1998 
Mefenamic acid <0.005-0.1 
0.008*-0.018*/0.035 
0.015*-0.05*/0.062 
0.96 
0.087-0.16 
0.5-3 
Kasprzyk-Hordern et al., 2009;  
Kimura et al., 2005, 
 2007; 
Roberts and Thomas, 2006;  
Rosal et al., 2010;  
Tauxe-Wuersch et al., 2005 
Naproxen 0.29-5.2 
0.25 
0.8-2.6 
<0.002-0.2 
0.35 
0.02-0.4 
0.005*-0.02*/0.05 
<0.01*-0.01*/0.099 
0.15-1.93 
0.45 
0.012-0.14 
0.2-1.51 
0.17* 
1* 
1.87-2.1 
0.35-2.2 
0.22-4.28 
0.22-5.09 
<0.01* 
1.32 
3.2 
0.3 
0.1 
0.012-0.038 
0.42 
0.38 
0.34 
Andreozzi et al., 2003;  
Bendz et al., 2005; 
 Carballa et al., 2004, 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005;  
Kim et al., 2007;  
Kimura et al., 2005,  
2007;  
Lindqvist et al., 2005;  
Lishman et al., 2006;  
Nakada et al., 2006;  
Paxéus, 2004;  
Quintana et al., 2005;  
Reif et al., 2008; 
Rodriguez et al., 2003; 
Rosal et al., 2010; 
Santos et al., 2007,  
2009; 
Snyder et al., 2006; 
Stumpf et al., 1999; 
Suárez et al., 2005; 
Ternes, 1998; 
Ternes et al., 2003; 
Thomas and Foster, 2005; 
Vieno et al., 2005; 
Yu et al., 2006; 
Zorita et al., 2009 
Phenazone  <loq 
<loq-0.058 
0.16-0.41 
Andreozzi et al., 2003;  
Rosal et al., 2010; 
Ternes, 1998 
Propyphenazone 0.0014-0.12/0.007 Nakada et al., 2006 
Salicylic acid <0.001-0.39 
0.38 
0.1 
0.14 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005; 
Lishman et al., 2006;  
Ternes, 1998 
Tolfenamic acid 0.025 Ternes, 1998 
Tramadol 12.77-56.81 
0.23-0.37 
Kasprzyk-Hordern et al, 2009; 
Wick et al., 2009 
Antibiotics 
B 
Amoxicillin 0.007 Watkinson et al., 2007 
Azithromycin 0.04-0.38 
0.06 
Göbel et al., 2005,  
Yasojima et al., 2006 
Cefaclor 0.009 Watkinson et al., 2007 
Cefalexin  0.08 
0.24-0.33 
<loq 
Costanzo et al., 2005; 
Gulkowska et al., 2008; 
Watkinson et al., 2007  
Cefotaxime <loq-0.034 Gulkowska et al., 2008 
Chloramphenicol <0.006-0.069 
<loq 
Kasprzyk-Hordern et al., 2009; 
Peng et al., 2006 
Chlortetracycline <loq Watkinson et al., 2007 
Ciprofloxacin 0.04-0.07 
0.13 
Andreozzi et al., 2003; 
Costanzo et al., 2005; 
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0.079-0.1 
0.06 
0.007-0.032 
0.03-0.05 
2 
2.37 
0.64 
0.094 
Golet et al., 2003; 
Karthikeyan and Meyer, 2006; 
Lindberg et al., 2005,  
Lindberg et al., 2006; 
Muñoz et al., 2009; 
Rosal et al., 2010; 
Watkinson et al., 2007; 
Zorita et al., 2009 
Clarithromycin 0.15-0.46 
0.21 
0.35 
Göbel et al., 2005,  
Ternes et al., 2003; 
Yasojima et al., 2006 
Clindamycin 0.005 Watkinson et al., 2007 
Cloxacillin 0.001 Watkinson et al., 2007 
Doxycycline 0.064 
<loq-0.04 
Lindberg et al., 2005; 
Watkinson et al., 2007  
Enoxacin 0.03 Andreozzi et al., 2003 
Enrofloxacin 0.01 Watkinson et al., 2007 
Erythromycin  0.05-0.14 
0.52-0.6 
0.27-0.3 
0.023-2.77 
0.0089-0.29 
0.89 
0.9* 
0.2 
0.33 
0.03* 
0.62 
<loq 
0.21 
Göbel et al., 2005,  
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Kim et al., 2007; 
Muñoz et al., 2009; 
Reif et al., 2008; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Ternes et al., 2003; 
Watkinson et al., 2007; 
Xu et al., 2007 
Lincomycin 0.05-0.06 Watkinson et al., 2007 
Lomefloxacin 0.22-0.32 Andreozzi et al., 2003  
Metronidazole 0.13-0.56 
0.055 
Kasprzyk-Hordern et al., 2009; 
Rosal et al., 2010 
Norfloxacin 0.06-0.07 
0.12 
0.21 
0.06-0.07 
0.08-0.1 
0.007-0.021 
0.046-0.07 
0.025 
0.027 
0.019 
Andreozzi et al., 2003; 
Coetsier et al., 2009; 
Costanzo et al., 2005; 
Golet et al., 2003; 
Gulkowska et al., 2008; 
Lindberg et al., 2005, 
 2006; 
Watkinson et al., 2007; 
Xu et al., 2007; 
Zorita et al., 2009 
Ofloxacin 0.31-0.58 
0.11 
0.045 
0.04-0.86 
0.81 
0.048 
0.019 
Andreozzi et al., 2003; 
Brown et al., 2006; 
Lindberg et al., 2005; 
Peng et al., 2006; 
Rosal et al., 2010; 
Xu et al., 2007; 
Zorita et al., 2009 
Oxytetracycline <loq-0.02 Watkinson et al., 2007 
Penicillin G <loq 
0.004 
Gulkowska et al., 2008; 
Watkinson et al., 2007 
Penicillin V 0.02-0.03 Watkinson et al., 2007 
Roxithromycin 0.042*/0.045/0.057/0.036 
0.01-0.03 
5* 
0.05 
0.54 
Clara et al., 2005b; 
Göbel et al., 2005, 
Reif et al., 2008; 
Ruel et al., 2010; 
Ternes et al., 2003, 
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0.1 
0.035 
Watkinson et al., 2007; 
Xu et al., 2007 
Sulfachloropyridazine <0.03-0.14 Choi et al., 2008 
Sulfadiazine 0.07 Peng et al., 2006 
Sulfadimethoxine <0.01-0.7 Choi et al., 2008 
Sulfamethoxazole 0.01-0.09 
0.07 
0.31 
0.25 
0.025-0.5 
0.05-0.09/<loq* 
0.025 
0.13-0.84 
0.05-0.21 
0.004-0.044 
0.003-0.4 
0.13 
0.18 
<loq 
5* 
0.1-0.3 
0.3 
<0.01* 
0.62 
0.27 
Andreozzi et al., 2003; 
Bendz et al., 2005; 
Brown et al., 2006; 
Carballa et al., 2004,  
Choi et al., 2008; 
Clara et al., 2005b; 
Foster, 2007; 
Göbel et al., 2005,  
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Kim et al., 2007; 
Lindberg et al., 2005; 
Muñoz et al., 2009; 
Peng et al., 2006; 
Reif et al., 2008; 
Rosal et al., 2010; 
Ruel et al., 2010; 
Snyder et al., 2006; 
Ternes et al., 2003; 
Watkinson et al., 2007 
Sulfapyridine 0.02-0.23 
0.46-1.11 
Göbel et al., 2005,  
Kasprzyk-Hordern et al., 2009 
Sulfasalazine 0.0015 
<loq-0.01 
Kasprzyk-Hordern et al., 2009;  
Watkinson et al., 2007 
Sulfathiazole <0.03 
0.005 
Choi et al., 2008; 
Watkinson et al., 2007 
Tetracycline 0.18-0.37 
0.07-0.16 
0.03 
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
Watkinson et al., 2007 
Trimethoprim 0.04-0.13 
0.25 
0.04 
0.18 
0.025 
0.08-0.4 
0.12-0.14 
0.55 
0.38-1.2 
<0.01-0.87 
0.01-0.18 
0.21-1.34 
0.61-1.88 
0.02-0.24 
6.7* 
0.4 
0.099 
<0.01 
0.34 
0.05 
Andreozzi et al., 2003; 
Batt 2006; 
Bendz et al., 2005; 
Brown et al., 2006; 
Foster, 2007; 
Göbel et al., 2005, 
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Choi et al., 2008; 
Kim et al., 2007; 
Lindberg et al., 2005,  
Lindberg et al., 2006; 
Paxéus, 2004; 
Reif et al., 2008; 
Roberts and Thomas, 2006; 
Rosal et al., 2006; 
Snyder et al., 2006; 
Ternes et al., 2003; 
Watkinson et al., 2007 
Tylosin  <loq Watkinson et al., 2007 
Antifungals D Clotrimazole 0.02 Roberts and Thomas, 2006 
Antihypertensives 
E 
Diltiazem <0.005-0.013 
0.025 
0.1-1.15 
Choi et al., 2008 
Foster, 2007; 
Kasprzyk-Hordern et al., 2009 
Hydrochlorothiazide 1.8-11 
0.67-1.7 
Muñoz et al., 2009; 
Rosal et al., 2010 
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Barbiturates F Phenobarbital < loq Yu et al., 2006 
Beta-blockers G 
 
Acebutolol 0.01-0.11 Andreozzi et al., 2003; 
Atenolol 1.33 
0.16 
1.3-3.16 
0.4-0.6 
0.14-73 
0.01-0.73 
0.51-2.4 
0.36 
0.37 
Alder et al., 2010; 
Bendz et al., 2005; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Muñoz et al., 2009; 
Paxéus, 2004; 
Rosal et al., 2010; 
Ternes et al., 2003; 
Wick et al., 2009 
Betaxolol <loq 
0.057-0.19 
<loq 
Andreozzi et al., 2003; 
Ternes, 1998; 
Wick et al., 2009 
Bisoprolol 0.37 
0.21-0.27 
Ternes, 1998; 
Wick et al., 2009 
Carazolol <loq-0.12 Ternes, 1998 
Celiprolol 0.28 
0.12-0.16 
Ternes et al., 2003; 
Wick et al., 2009 
Metoprolol 0.16 
0.01-0.1 
0.034-0.057 
0.103-0.161 
<0.01-0.39 
<loq-0.038 
2.2 
1.7 
1.1 
Alder et al., 2010; 
Andreozzi et al., 2003; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Paxéus, 2004; 
Rosal et al., 2010; 
Ternes, 1998; 
Ternes et al., 2003; 
Wick et al., 2009 
Nadolol 0.025-0.06 Ternes, 1998 
Oxprenolol 0.01-0.03 Andreozzi et al., 2003 
Propranolol 0.03 
0.01-0.09 
0.03 
0.56 
0.13-0.523 
0.032-0.123 
0.39 
<loq-0.057 
0.17-0.29 
0.18 
0.058 
Alder et al., 2010; 
Andreozzi et al., 2003; 
Bendz et al., 2005; 
Coetsier et al., 2009; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Ternes, 1998; 
Ternes et al., 2003; 
Wick et al., 2009 
Sotalol 0.21 
0.249-0.251 
1.32 
1.2 
Alder et al., 2010; 
Maurer et al., 2007; 
Ternes et al., 2003; 
Wick et al., 2009 
Timolol <loq-0.07 Ternes, 1998 
Diuretics H 
 
Bendroflumethiazide <0.008 Kasprzyk-Hordern et al., 2009 
Furosemide <0043-1.823 
<loq-0.666 
Kasprzyk-Hordern et al., 2009; 
Rosal et al., 2010 
Lipid regulators I 
 
Bezafibrate <loq-0.91 
0.692-4.8/1.55* 
<loq-4.8/0.073* 
0.094-0.393 
<loq-0.83 
0.01* 
0.033-0.28 
0.59 
2.2-4.6 
0.14 
Andreozzi et al., 2003; 
Clara et al.,  2005a,  
Clara et al., 2005b; 
Kasprzyk-Hordern et al., 2009; 
Lindqvist et al., 2005; 
Quintana et al., 2005; 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Ternes, 1998; 
Vieno et al., 2005 
Clofibrate <loq-0.8 Andreozzi et al., 2003; 
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<loq Ternes, 1998 
Clofibric acid <loq-0.68 
<loq 
<0.001-0.048 
0.028/0.004*-0.02* 
0.014/0.005*-0.014* 
- 
0.078 
<loq-0.091 
0.66 
0.15-0.27 
0.36-1.6 
0.12 
0.11 
0.024 
Andreozzi et al., 2003; 
Bendz et al., 2005; 
Kasprzyk-Hordern et al., 2009; 
Kimura et al., 2005, 
 2007; 
Lishman et al., 2006; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Tauxe-Wuersch et al., 2005; 
Ternes, 1998; 
Ternes et al., 2003; 
Weigel et al., 2004; 
Zorita et al., 2009 
Etofibrate 0.05 Ternes, 1998 
Fenofibrate 0.16 
<loq 
<loq-0.03 
Andreozzi et al., 2003; 
Lishman et al., 2006; 
Ternes, 1998 
Fenofibric acid 4.7-80 
<loq-0.129 
0.231 
0.38-1.2 
0.13 
Muñoz et al., 2009; 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Ternes, 1998; 
Ternes et al., 2003 
Gemfibrozil 0.71-4.76 
0.18 
0.2 
0.004-0.017 
0.246-0.436 
0.003-5.2 
0.06-0.84 
0.003-5.233 
<0.01* 
0.162 
0.4-1.5 
Andreozzi et al., 2003; 
Bendz et al., 2005; 
Khan and Ongerth, 2005; 
Kim et al., 2007; 
Lishman et al., 2006; 
Muñoz et al., 2009; 
Paxéus, 2004; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Stumpf et al., 1999; 
Ternes, 1998 
Pravastatin <0.007 
<0.06 
Coetsier et al., 2009; 
Kasprzyk-Hordern et al., 2009 
Simvastatin <0.003 Kasprzyk-Hordern et al., 2009 
Psychiatric drugs Amitriptyline <0.002-0.335 Kasprzyk-Hordern et al., 2009 
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J 
 
Carbamazepine 0.3-1 
1.18 
0.794*/0.465-0.952 
1.147*/0.465-1.337 
1.519 
<0.05-0.15 
0.11-0.23 
0.15-2.32 
0.5 
<0.005-0.195 
0.073-0.729 
0.14-0.26 
0.011-0.16 
0.1-1.2 
17.8* 
0.069-0.173 
<loq-1.29 
<loq-1.29 
<0.01* 
19.8 
2.1-6.3 
2.1 
0.74-0.92 
Andreozzi et al., 2003; 
Bendz et al., 2005; 
Clara et al.,  2005a, 
Clara et al.,  2005b; 
Coetsier et al 2009; 
Foster, 2007; 
Gómez et al., 2007; 
Kasprzyk-Hordern et al., 2009; 
Khan and Ongerth, 2005; 
Choi et al., 2008; 
Kim et al., 2007; 
Muñoz et al., 2009; 
Nakada et al., 2006; 
Paxéus, 2004; 
Reif et al., 2008; 
Rosal et al., 2010; 
Santos et al., 2007, 
Santos et al., 2009; 
Snyder et al., 2006; 
Suárez et al., 2005; 
Ternes, 1998; 
Ternes et al., 2003; 
Wick et al, 2009 
Diazepam <loq*/<loq 
17* 
19.3 
<loq-0.04 
- 
Clara et al., 2005b; 
Reif et al., 2008; 
Suárez et al., 2005; 
Ternes, 1998; 
Wick et al., 2009 
Fluoxetine <0.05-0.025 
0.0017 
0.127-0.154 
0.016-2 
0.034-0.929 
<0.01* 
<loq 
Foster, 2007; 
Kim et al., 2007; 
Metcalfe et al. 2010; 
Muñoz et al., 2009; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Zorita et al., 2009 
Gabapentin 1.786-3.514 
<loq 
Kasprzyk-Hordern et al., 2009; 
Yu et al., 2006 
Lorazepam 0.196 Coetsier et al., 2009 
Norfluoxetine <loq 
0.006 
Metcalfe et al. 2010; 
Zorita et al., 2009 
Paroxetine 0.007 Metcalfe et al. 2010; 
Valproic acid <loq Yu et al., 2006 
Receptor 
antagonists K 
 
Cimetidine 0.02-7.763 
0.253-0.781 
Choi et al., 2008  
Kasprzyk-Hordern et al., 2009 
Omeprazole <loq-0.922 Rosal et al., 2010 
Ranitidine 0.015-0.783 
<loq-0.942 
Kasprzyk-Hordern et al., 2009; 
Rosal et al., 2010 
Valsartan 0.006-0.711 Kasprzyk-Hordern et al., 2009 
Hormones L 
 
Estradiol <0.001 
0.0007-0.002 
<loq  
<loq-0.03/<loq* 
<0.02-0.054 
0.0002 
<0.001 
<loq  
0.0025 
Andersen et al., 2003; 
Baronti et al., 2000; 
Carballa et al., 2004, 
Clara et al., 2005a; 
Foster, 2007; 
Joss et al., 2004; 
Kim et al., 2007; 
Lishman et al., 2006; 
Zorita et al., 2009 
Estriol 0.00072-0.0036 
<loq-0.275/<loq* 
0.0089-0.025 
0.0003-0.0008 
Baronti et al., 2000; 
Clara et al., 2005a; 
Kim et al, 2007; 
Nakada et al., 2006 
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class 
Pharmaceutical 
compound Secondary effluent References 
Estrone 0.0005 
0.005-0.044 
<loq-0.0044 
<loq-0.072/0.002* 
0.002/0.002* 
0.002-0.036 
0.0076-0.038 
0.0028-0.11 
0.07 
Andersen et al., 2003; 
Baronti et al., 2000; 
Carballa et al., 2004, 
Clara et al., 2005a; 
Joss et al., 2004; 
Kim et al., 2007; 
Lishman et al., 2006; 
Nakada et al., 2006; 
Zorita et al., 2009  
Ethinylestradiol 0.0004-0.0008 
<loq-0.005/0.004* 
<0.02-0.01 
0.0002/0.0002* 
0.0013 
<loq 
Baronti et al., 2000; 
Clara et al., 2005a; 
Foster, 2007; 
Joss et al., 2004; 
Kim et al., 2007; 
Zorita et al., 2009 
Beta-agonists M 
 
Clenbuterol <loq-0.08 Ternes, 1998  
Fenoterol <loq-0.06 Ternes, 1998 
Salbutamol <0.001-0.022 
<loq-0.17 
Kasprzyk-Hordern et al., 2009; 
Ternes, 1998 
Terbutaline <loq-0.12 Ternes, 1998 
Antineoplastics N 
 
Cyclophosphamide <loq-0.02 Ternes, 1998 
Ifosfamide <0.0038 
<loq-2.9 
Coetsier et al., 2009; 
Ternes, 1998 
Tamoxifen 0.083 
0.6 
Coetsier et al.,  2009; 
Roberts and Thomas, 2006 
Topical product 
O 
Crotamitron 0.245-0.968 Nakada et al., 2006 
Antiseptic P Triclosan 0.015-0.039 
0.08-0.4 
0.0013-0.032 
0.41 
0.052-2.5 
0.0266-0.33 
0.09-0.58 
<loq-0.512 
<loq 
<0.01* 
0.054-0.082 
0.18 
0.25 
Foster, 2007; 
Gómez et al., 2007; 
Kim et al., 2007; 
McAvoy et al., 2002; 
Muñoz et al., 2009; 
Nakada et al., 2006;, 
Paxéus, 2004; 
Rosal et al., 2010; 
Ruel et al., 2010; 
Snyder et al., 2006; 
Thomas and Foster, 2005; 
Weigel et al., 2004;  
Yu et al., 2006 
Contrast agent Q Iopromide 0.1 
9.3 
<loq-5.06/<loq* 
1.17-4.03 
Batt et al., 2006; 
Carballa et al., 2004; 
Clara et al., 2005b; 
Kim et al., 2007 
 
Table A.4. Ranges of removal efficiency for the selected pharmaceuticals with their 
corresponding references. Data with an asterix as apex (*) refer to MBRs; data in italics 
and underlined are obtained by applying eq. 2.1 of the manuscript to the provided data in 
the reported reference. 
Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
Analgesics/ 
Anti-
inflammatories 
A 
 
5-aminosalicylic acid 94 Kasprzyk-Hordern et al., 2009 
Acetaminophen 80-93 
99.94 
99.8 
91.93 
100 
Choi et al., 2008; 
Foster, 2007;  
Gómez et al., 2007;  
Jones et al., 2007;  
Khan and Ongerth, 2005;  
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
86.4/99.6* 
99.9/99.8*-99.9* 
100 
100 
100* 
99.5 
Radjenovic et al., 2007, 
Radjenovic et al., 2009;  
Roberts and Thomas, 2006;  
Rosal et al., 2010; 
Snyder et al., 2006; 
Yu et al., 2006 
Acetylsalicylic acid 99.2 
81 
Kasprzyk-Hordern et al., 2009; 
Ternes, 1998 
Aminopyrine  38 Ternes, 1998 
Codeine 99.86 
29 
60.9 
69.3 
81.66 
Foster, 2007; 
 Gómez et al., 2007; 
 Kasprzyk-Hordern et al.,2009;  
Rosal et al., 2010;  
Wick et al., 2009 
Diclofenac 22 
24/58* 
60/60* 
7.14-47.34/32.92* 
7.1-62.7 
50.6* 
40 
31.2 
42/51*-82* 
9-46 
9-60 
0 
5-80 
23* 
50.1/87.4* 
21.8/62.6*-65.8* 
-7* 
65.1 
5 
50 
50 
90* 
75 
3 
-11-3 
69 
13 
-36.6 
18 
-111 
Bendz et al., 2005;  
Bernhard et al., 2006; 
Clara et al., 2004, 
Clara et al 2005a,  
Clara et al 2005b;  
Coetsier et al., 2009;  
Gómez et al., 2007;  
Kasprzyk-Hordern et al., 2009; 
Kimura et al 2007;  
Kreuzinger et al., 2004; 
Lindqvist et al., 2005;  
Lishman et al., 2006;  
Paxéus, 2004;  
Quintana et al., 2005;  
Radjenovic et al., 2007,  
Radjenovic et al., 2009; 
Reif et al., 2008;  
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Santos et al., 2007,  
Santos et al., 2009;  
Snyder et al., 2006;  
Stumpf et al., 1999;  
Suárez et al., 2005; 
Tauxe-Wuersch et al., 2005;  
Ternes, 1998; 
Vieno et al., 2005;  
Weigel et al., 2004;  
Yu et al., 2006; 
Zorita et al., 2009  
Dipyrone 65 Gómez et al., 2007 
Fenoprofen 65.6-97.5 Nakada et al., 2006 
Hydrocodone 95.76* Snyder et al., 2006 
Ibuprofen 96 
97/99* 
64 
70 
55 
97/97* 
-4.35-99.18/97.18* 
-4.3-98/99.2* 
92 
86 
93.8 
92 
98/95*-98* 
Bendz et al., 2005;  
Bernhard et al., 2006;  
Carballa et al., 2004,  
Carballa et al., 2005; 
Castiglioni et al., 2006;  
Clara et al., 2004, 
Clara et al., 2005a,  
Clara et al., 2005b;  
Gómez et al., 2007; 
Jones et al., 2007;  
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005;  
Kimura et al., 2007;  
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
92-99/97*-99* 
78/100 
96 
84.3/99.7/ 
52/99 
97* 
82.5/99.8* 
99.1/99.2*-99.5* 
98* 
-12.8 
65 
95 
88.4-89.5 
84-87 
100* 
75 
82 
26-79 
90 
99.8 
98.2 
87 
99 
Kreuzinger et al., 2004; 
 Lindqvist et al., 2005;  
Lishman et al., 2006;  
Nakada et al., 2006; 
Paxéus, 2004;  
Quintana et al., 2005;  
Radjenovic et al., 2007,  
Radjenovic et al., 2009;  
Reif et al., 2008; 
Roberts and Thomas, 2006;  
Rodriguez et al., 2003;  
Rosal et al., 2010;  
Santos et al., 2007, 
Santos et al., 2009;  
Snyder et al., 2006;  
Stumpf et al., 1999;  
Suárez et al., 2005;  
Tauxe-Wuersch et al., 2005;  
Ternes, 1998;  
Vieno et al., 2005;  
Weigel et al., 2004;  
Yu et al., 2006; 
Zorita et al., 2009 
Indomethacin 24 
23.4/46.6* 
5/39.7*-41.4* 
11.1 
83 
75 
Lishman et al., 2006,  
Radjenovic et al., 2007,  
Radjenovic et al., 2009;  
Rosal et al., 2010; 
Stumpf et al., 1999; 
Ternes, 1998  
Ketoprofen 65 
85.4 
34 
55/83*-99* 
51/100 
16 
14-68.4 
62* 
51.5/91.9* 
54.6/43.9*-44* 
11.2 
30-37 
52-56 
63 
7-51 
92.1 
77 
Bendz et al., 2005; 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005; 
 Kimura et al., 2007;  
Lindqvist et al., 2005; 
Lishman et al., 2006; 
Nakada et al., 2006; 
Quintana et al., 2005; 
Radjenovic et al., 2007,  
Radjenovic et al., 2009;  
Rosal et al., 2010; 
Santos et al., 2007, 
Santos et al.,  2009;  
Stumpf et al., 1999; 
Tauxe-Wuersch et al., 2005; 
Vieno et al., 2005;  
Yu et al., 2006  
Ketorolac 43.9 Rosal et al., 2010 
Mefenamic acid 91.54 
72/77*-93* 
29.4/74.8* 
5/35.5*-40.5* 
1.8 
2-53 
Jones et al., 2007;  
Kimura et al., 2007; 
 Radjenovic et al., 2007, 
 2009;  
Rosal et al., 2010;  
Tauxe-Wuersch et al., 2005 
Naproxen 93 
47 
47 
85.5 
95 
64/96*-98* 
55-98 
93 
Bendz et al., 2005; 
Carballa et al., 2004, 
Carballa et al., 2005;  
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005;  
Kimura et al., 2007;  
Lindqvist et al., 2005;  
Lishman et al., 2006;  
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
-1.89-82.9 
42-93 
71* 
85.1/99.3* 
71.8 
84* 
44.62 
60.9 
35.1-89.4 
43-71/90.7*-91.6* 
100* 
78 
68 
66 
95.1 
88 
93 
Nakada et al., 2006;  
Paxéus, 2004;  
Quintana et al., 2005;  
Radjenovic et al., 2007, 
Radjenovic et al., 2009; 
Reif et al., 2008; 
Rodriguez et al., 2003; 
Rosal et al., 2010; 
Santos et al., 2007,  
Santos et al., 2009; 
Snyder et al., 2006; 
Stumpf et al., 1999; 
Suárez et al., 2005; 
Ternes, 1998; 
Vieno et al., 2005; 
Yu et al., 2006; 
Zorita et al., 2009 
Phenazone  87.2 
33 
Rosal et al., 2010; 
Ternes, 1998 
Propyphenazone 14-86.4 
42.7/64.6* 
37.6/60.7*-64.5* 
Nakada et al., 2006; 
Radjenovic et al., 2007,  
Radjenovic et al., 2009 
Salicylic acid 99.4 
97 
99 
Kasprzyk-Hordern et al., 2009;  
Khan and Ongerth, 2005; 
Lishman et al., 2006; 
Tramadol 42 
4.16 
Kasprzyk-Hordern et al, 2009; 
Wick et al., 2009 
Antibiotics 
B 
Amoxicillin 96 Watkinson et al., 2007 
Azithromycin 45/39 
18 
5*-24* 
74.3 
Ghosh et al., 2009; 
Göbel et al., 2005,  
Göbel et al., 2007; 
Yasojima et al., 2006 
Cefaclor 98 Watkinson et al., 2007 
Cefalexin  96 
64.2-88.6 
53-91 
100 
Costanzo et al., 2005; 
Gulkowska et al., 2008; 
Li and Zhang, 2011 
Watkinson et al., 2007  
Cefotaxime 83.3 
43 
Gulkowska et al., 2008 
Li and Zhang, 2011 
Chloramphenicol 92 
Not evaluated 
96-97 
Kasprzyk-Hordern et al., 2009; 
Li and Zhang, 2011 
Peng et al., 2006 
Chlortetracycline 82-85 Li and Zhang, 2011 
Ciprofloxacin 73* 
63 
-44 
50-73 
78 
71.43 
18/55 
72-96 
79 
57 
86 
83 
71 
Baumgarten et al., 2007 
Castiglioni et al., 2006; 
Costanzo et al., 2005; 
Ghosh et al., 2009; 
Golet et al., 2003; 
Karthikeyan and Meyer, 2006; 
Li and Zhang, 2011; 
Lindberg et al., 2005,  
Lindberg et al., 2006; 
Rosal et al., 2010; 
Vieno et al., 2007; 
Watkinson et al., 2007; 
Zorita et al., 2009 
Clarithromycin 0 
50-83 
32 
4.5/41*-88* 
62/92* 
Castiglioni et al., 2006; 
Ghosh et al., 2009; 
Göbel et al., 2005,  
Göbel et al., 2007; 
Sahar et al., 2011; 
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
45.9 Yasojima et al., 2006 
Clindamycin -150 Watkinson et al., 2007 
Doxycycline 14-100 Lindberg et al., 2005 
Enrofloxacin 56* 
38-70 
Baumgarten et al., 2007; 
Ghosh et al., 2009 
Erythromycin  0 
-14 
26*-87* 
-11-18.9 
43.75-75 
72 
15-26 
23.8/67.3* 
35.4/25.2*-43* 
91* 
-84 
4.3 
19/79* 
97* 
4.42 
Castiglioni et al., 2006; 
Göbel et al., 2005,  
Göbel et al., 2007; 
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Li and Zhang, 2011 
Radjenovic et al., 2007,  
Radjenovic et al., 2009; 
Reif et al., 2008; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Sahar et al., 2011; 
Snyder et al., 2006; 
Xu et al., 2007 
Lincomycin 0 
33/57 
Castiglioni et al., 2006; 
Ghosh et al., 2009; 
Metronidazole 38 
38.7 
Kasprzyk-Hordern et al., 2009; 
Rosal et al., 2010 
Norfloxacin 75-90 
84 
22.7-78.3 
30/45 
72-96 
79 
85 
18.18 
-6 
Ghosh et al., 2009; 
Golet et al., 2003; 
Gulkowska et al., 2008; 
Li and Zhang, 2011 
Lindberg et al., 2005, 
Lindberg et al., 2006; 
Watkinson et al., 2007; 
Xu et al., 2007; 
Zorita et al., 2009 
Ofloxacin 77 
57 
26-59 
84 
85-99 
23.8/94* 
75.8/91.3*-95.2* 
64 
83 
37.66 
13 
Brown et al., 2006; 
Castiglioni et al., 2006; 
Li and Zhang, 2011 
Lindberg et al., 2005; 
Peng et al., 2006; 
Radjenovic et al., 2007,  
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Vieno et al., 2007; 
Xu et al., 2007; 
Zorita et al., 2009 
Oxytetracycline 44 Li and Zhang, 2011 
Penicillin V 60 Watkinson et al., 2007 
Roxithromycin -80-43.8/34.4* 
-32-39 
0 
19/39*-62* 
-4-61/75* 
40-46 
71* 
37.5 
22/59* 
12.5 
Clara et al., 2005b; 
Ghosh et al., 2009; 
Göbel et al., 2005, 
Göbel et al., 2007; 
Kreuzinger et al., 2004; 
Li and Zhang, 2011 
Reif et al., 2008; 
Ruel et al., 2010; 
Sahar et al., 2011; 
Xu et al., 2007 
Spiramycin 0 Castiglioni et al., 2006 
Sulfachloropyridazine 26-82 Choi et al., 2008 
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
Sulfadiazine 78-98 
87-100 
99 
García-Galán et al., 2011 
Li and Zhang, 2011 
Peng et al., 2006 
Sulfadimethoxine 66-90 
100 
Choi et al., 2008 
García-Galán et al., 2011 
Sulfamethazine 16-100 
100 
García-Galán et al., 2011 
Li and Zhang, 2011 
Sulfamethoxazole 21 
57 
46 
24 
41-80 
32 
75 
54-71 
26-39 
35 
4.5/37*-38* 
-24-96 
83 
62/57* 
62-90 
42-100 
99 
55.6/60.5* 
73.8/78.3*-80.8* 
50* 
17.3 
41.5 
10/0* 
100* 
25 
-20 
Brown et al., 2006; 
Carballa et al., 2004,  
Carballa et al., 2005; 
Castiglioni et al., 2006; 
Choi et al., 2008; 
Clara et al., 2005b; 
Foster, 2007; 
García-Galán et al., 2011 
Ghosh et al., 2009; 
Göbel et al., 2005,  
Göbel et al., 2007; 
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Kreuzinger et al., 2004; 
Li and Zhang, 2011 
Lindberg et al., 2005; 
Peng et al., 2006; 
Radjenovic et al., 2007, 
Radjenovic et al., 2009; 
Reif et al., 2008; 
Rosal et al., 2010; 
Ruel et al., 2010; 
Sahar et al., 2011; 
Snyder et al., 2006; 
Watkinson et al., 2007; 
Xu et al., 2007 
Sulfapyridine 6-89 
22 
50*-60* 
91 
García-Galán et al., 2011 
Göbel et al., 2005,  
Göbel et al., 2007; 
Kasprzyk-Hordern et al., 2009 
Sulfasalazine -50 Kasprzyk-Hordern et al., 2009 
Sulfathiazole 94-95 
65-100 
75 
Choi et al., 2008; 
García-Galán et al., 2011 
Watkinson et al., 2007 
Tetracycline 40-72 
-87-71.5 
70.8-79.7 
24-36 
Ghosh et al., 2009; 
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006 
Li and Zhang, 2011 
Trimethoprim 52.8 
49 
69 
75 
-88-35 
31 
7/30*-87* 
-17-62.5 
50 
70 
-11-79 
13-42 
-106-41 
14 
30-40 
40.4/47.5*-66.7* 
Batt 2006; 
Bendz et al., 2005; 
Brown et al., 2006; 
Foster, 2007; 
Ghosh et al., 2009; 
Göbel et al., 2005, 
Göbel et al., 2007; 
Gulkowska et al., 2008; 
Karthikeyan and Meyer, 2006; 
Kasprzyk-Hordern et al., 2009; 
Choi et al., 2008; 
Li and Zhang, 2011 
Lindberg et al., 2005,  
Lindberg et al., 2006; 
Paxéus, 2004; 
Radjenovic et al., 2009; 
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
36* 
-56 
5.1 
0/88* 
99* 
85 
Reif et al., 2008; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Sahar et al., 2011; 
Snyder et al., 2006; 
Watkinson et al., 2007 
Antidiabetics 
C 
Glibenclamide 44.5/47.3* 
46.1/82.2*-95.6* 
Radjenovic et al., 2007, 
Radjenovic et al., 2009 
Antifungals D Clotrimazole 31 Roberts and Thomas, 2006 
Antihypertensives 
E 
 
Diltiazem 41-77 
97 
77 
Choi et al., 2008 
Foster, 2007; 
Kasprzyk-Hordern et al., 2009 
Enalapril 69 Castiglioni et al., 2006 
Hydrochlorothiazide 44 
76.3/66.3* 
5* 
53.2 
Castiglioni et al., 2006; 
Radjenovic et al., 2007,  
Radjenovic et al., 2009 
Rosal et al., 2010 
Barbiturates F Phenobarbital 99.5 Yu et al., 2006 
Beta-blockers 
G 
 
Acebutolol 60 Vieno et al., 2007 
Atenolol 41 
70.9 
21 
85 
73.35-76.11 
65.5* 
61.2/69.5*-76.7* 
14 
63 
44.44 
Alder et al., 2010; 
Carucci et al., 2006; 
Castiglioni et al., 2006; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Radjenovic et al., 2007, 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Vieno et al., 2007; 
Wick et al., 2009 
Bisoprolol 0 Wick et al., 2009 
Metoprolol 31 
56 
29.45-31.48 
10 
58.7* 
24.7/29.5*-44.2* 
7 
83 
34 
20.98 
Alder et al., 2010; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Paxéus, 2004; 
Radjenovic et al., 2007, 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Ternes, 1998; 
Vieno et al., 2007; 
Wick et al., 2009 
Propranolol 33 
59 
28.48-34.69 
58.8/65.5*-77.6* 
1 
96 
0 
Alder et al., 2010; 
Kasprzyk-Hordern et al., 2009; 
Maurer et al., 2007; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Ternes, 1998; 
Wick et al., 2009 
Sotalol 27 
26.3-26.6 
21.4/30.4*-53.1* 
54 
18.3 
Alder et al., 2010 
Maurer et al., 2007; 
Radjenovic et al., 2009; 
Vieno et al., 2007; 
Wick et al., 2009 
Diuretics 
H 
 
Bendroflumethiazide 91 Kasprzyk-Hordern et al., 2009 
Furosemide 15 
77 
59.8 
Castiglioni et al., 2006; 
Kasprzyk-Hordern et al., 2009; 
Rosal et al., 2010 
Lipid regulators 
I 
 
Bezafibrate 30 
97/97* 
36.6-89.8/77.34* 
36.8-99.98/96* 
Castiglioni et al., 2006; 
Clara et al., 2004, 
Clara et al., 2005a,  
Clara et al., 2005b; 
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
71 
36-99/76*-94* 
-11/100 
91* 
48.4/95.8* 
80.8/88.2*-90.3* 
9.1 
50 
83 
93.6 
Kasprzyk-Hordern et al., 2009; 
Kreuzinger et al., 2004; 
Lindqvist et al., 2005; 
Quintana et al., 2005; 
Radjenovic et al., 2007,  
Radjenovic et al.,2009; 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Ternes, 1998; 
Vieno et al., 2005 
Clofibric acid 26/54* 
50/50*-82* 
27.7/71.8* 
84.2 
54.2 
34/51 
8-10 
35.3 
55 
Bernhard et al., 2006; 
Kimura et al., 2007; 
Radjenovic et al., 2007; 
Roberts and Thomas, 2006; 
Rosal et al., 2010; 
Stumpf et al., 1999; 
Tauxe-Wuersch et al., 2005; 
Weigel et al., 2004; 
Zorita et al., 2009 
Fenofibrate 64 Ternes, 1998 
Fenofibric acid 1.3 
45 
Rosal et al., 2010; 
Stumpf et al., 1999 
Gemfibrozil 75 
87 
39 
43-75 
38.8/89.6* 
32.5*-42.2* 
76 
100* 
46 
69 
68 
Bendz et al., 2005; 
Khan and Ongerth, 2005; 
Lishman et al., 2006; 
Paxéus, 2004; 
Radjenovic et al., 2007, 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Stumpf et al., 1999; 
Ternes, 1998; 
Yu et al., 2006 
Pravastatin 61.8/90.8* 
59.4/83.1*-86.1* 
Radjenovic et al., 2007,  
Radjenovic et al., 2009 
Simvastatin 57 Kasprzyk-Hordern et al., 2009 
Psychiatric drugs Amitriptyline 96 Kasprzyk-Hordern et al., 2009 
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
J 
 
Carbamazepine 30 
7/13* 
0 
0/0* 
-47-(-3)/-13* 
-43-(-3)/4.4* 
75 
13 
13 
0 
30-64 
14/35/11* 
-122-77.6 
10-53 
5 
5 
9* 
9.5 
-67-(-4) 
7-11 
97* 
7.9 
7 
-44 
-12 
Bendz et al., 2005; 
Bernhard et al., 2006; 
Castiglioni et al., 2006; 
Clara et al., 2004, 
Clara et al., 2005a, 
Clara et al., 2005b; 
Foster, 2007; 
Gómez et al., 2007; 
Kasprzyk-Hordern et al., 2009; 
Khan and Ongerth, 2005; 
Choi et al., 2008; 
Kreuzinger et al., 2004; 
Nakada et al., 2006; 
Paxéus, 2004; 
Radjenovic et al., 2007,  
Radjenovic et al., 2009;  
Reif et al., 2008; 
Rosal et al., 2010; 
Santos et al., 2007, 
Santos et al., 2009; 
Snyder et al., 2006; 
Suárez et al., 2005; 
Ternes, 1998; 
Vieno et al., 2007; 
Wick et al, 2009 
Diazepam 20 
26* 
8.1 
Kreuzinger et al., 2004; 
Reif et al., 2008; 
Suárez et al., 2005 
Fluoxetine 75 
33.1/98* 
61.9 
90* 
54.5 
Foster, 2007; 
Radjenovic et al., 2009; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Zorita et al., 2009 
Gabapentin 86 
99.5 
Kasprzyk-Hordern et al., 2009; 
Yu et al., 2006 
Norfluoxetine 47.8 Zorita et al., 2009 
Paroxetine 90.6/89.7* Radjenovic et al., 2007  
Valproic acid 99.5 Yu et al., 2006 
Receptor 
antagonists 
K 
 
Cimetidine 27-60 
79 
Choi et al., 2008  
Kasprzyk-Hordern et al., 2009 
Famotidine 60.1/47.4*-64.6* Radjenovic et al., 2009 
Loratadine 15/<10*-33.5* Radjenovic et al., 2009 
Omeprazole 8.5 Rosal et al., 2010 
Ranitidine 28.5 
96 
92 
42.2/95* 
24.7/29.5*-44.2* 
31.2 
Carucci et al., 2006; 
Castiglioni et al., 2006; 
Kasprzyk-Hordern et al., 2009; 
Radjenovic et al., 2007, 
Radjenovic et al., 2009; 
Rosal et al., 2010 
Valsartan 84.1 Kasprzyk-Hordern et al., 2009 
Hormones 
L 
 
Estradiol 75-92.22 
46 
98 
98/99* 
75 
99.9 
21.8 
Baronti et al., 2000; 
Carballa et al., 2005; 
Foster, 2007; 
Joss et al., 2004; 
Lishman et al., 2006; 
Ternes et al., 1999a; 
Zorita et al., 2009 
Estriol 84.55-99.19 
99.7-99.8 
Baronti et al., 2000; 
Nakada et al., 2006 
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Therapeutic class Pharmaceutical 
compound 
Removal Efficiencies for CAS and 
MBR References 
Estrone 99.24 
12-92.53 
-83 
-40 
112-99.93/97.18* 
96/96* 
57 
83.9-90.3 
83 
Andersen et al., 2003; 
Baronti et al., 2000; 
Carballa et al., 2004, 
Carballa et al., 2005; 
Clara et al., 2005a; 
Joss et al., 2004; 
Lishman et al., 2006; 
Nakada et al., 2006; 
Ternes et al., 1999 
Ethinylestradiol 60-86.66 
70/70* 
75 
94/76* 
70-81/25*-66* 
78 
Baronti et al., 2000; 
Clara et al., 2004, 
Foster, 2007; 
Joss et al., 2004; 
Kreuzinger et al., 2004; 
Ternes et al., 1999 
Beta-agonists 
M 
 
Salbutamol 0 
94.6 
89 
Castiglioni et al., 2006; 
Jones et al., 2007; 
Kasprzyk-Hordern et al., 2009 
Topical product 
O 
Crotamitron -32.5-64.5 Nakada et al., 2006 
Antiseptics 
P 
Triclosan 98.8 
88.89 
94.14 
46.2-92.3 
55-94 
74.5 
99.61* 
52.6 
69 
Foster, 2007; 
Gómez et al., 2007; 
McAvoy et al., 2002; 
Nakada et al., 2006;, 
Paxéus, 2004; 
Rosal et al., 2010; 
Snyder et al., 2006; 
Weigel et al., 2004;  
Yu et al., 2006 
Contrast agent  
Q 
Iopromide 50 
-41 
-32 
50 
Batt et al., 2006; 
Carballa et al., 2004; 
Clara et al., 2005b; 
Kreuzinger et al., 2004 
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Appendix B 
Details of the optimized QqLIT-MS parameters (two SRMs, 
collision energies) for each investigated compound in 
negative and positive ionization modes. 
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Table B.1. Investigated compounds and their optimized QqLIT-MS/MS parameters in 
SRM-negative and -positive ionization modes. 
Compounds 
Pr
ec
u
rs
o
r 
 
io
n
 
(m
/z
) 
SR
M
 
1 
Co
lli
sio
n
 
En
er
gy
 
1 
SR
M
 
2 
Co
lli
sio
n
 
En
er
gy
 
2 
R
t 
 
(m
in
) 
IS
 
u
se
d 
fo
r 
 
qu
an
tif
ic
at
i
o
n
 
Compounds Analysed in Negative Mode 
Acetaminophen 150 107 22 
  
3.6 mecoprop-d3 
Bezafibrate 360 274 26 154 38 16.7 ibuprofen-d3 
Butalbital 223 180 16 85 18 16.6 ibuprofen-d3 
Chloramphenicol 323 152 22 194 18 15.1 ibuprofen-d3 
Clofibric acid 213 127 26 85 14 12.9 mecoprop-d3 
Diclofenac 294 250 16 214 30 19.9 ibuprofen-d3 
Furosemide 329 205 22 285 32 13.3 ibuprofen-d3 
Gemfibrozil 249 121 20 127 14 24.3 ibuprofen-d3 
Hydrochlorothiazide 296 78 28 
  
6.1 mecoprop-d3 
Ibuprofen 205 161 10 
  
19.2 ibuprofen-d3 
Ibuprofen-d3 (IS) 208 164 10 
  
19.1 
 
Indomethacin 356 312 12 297 24 20.6 ibuprofen-d3 
Ketoprofen 253 209 12 197 6 14.9 mecoprop-d3 
Mecoprop-d3 (IS) 218 146 24 
  
14.8 
 
Mefenamic acid 240 196 20 180 38 21.1 ibuprofen-d3 
Naproxen 229 185 10 169 38 14.3 mecoprop-d3 
Pentobarbital 225 182 18 85 18 18.6 ibuprofen-d3 
Phenobarbital 231 188 14 
  
14.2 phenobarbital-d5 
Phenobarbital-d5 (IS) 236 193 16 
  
14.2 
 
Salicylic acid 137 93 20 66 38 4.1 mecoprop-d3 
Compounds Analysed in Positive Mode 
13C-Phenacetin (IS) 181 139 23 
  
12.7 
 
Atenolol 267 145 35 190 35 6.2 atenolol-d7 
Atenolol-d7 (IS) 274 145 37 
  
6.2 
 
Atorvastatin 559 440 27 250 63 19.8 carbamazepine-d10 
Azithromycin 749 591 43 573 50 10.9 carbamazepine-d10 
Betaxolol 308 116 40 121 40 12.9 atenolol-d7 
Carazolol 299 116 35 222 35 11.8 atenolol-d7 
Carbamazepine 237 194 29 
  
14.7 carbamazepine-d10 
Carbamazepine-d10 (IS) 247 204 31 
  
14.5 
 
Chlortetracycline 479 462 29 444 29 11.4 13C-Phenacetin 
Cimetidine 253 95 30 159 23 6.3 atenolol-d7 
Ciprofloxacin 332 288 25 231 51 9.4 flumequine 
Clarithromycin 748 591 35 158 40 14.6 carbamazepine-d10 
Clenbuterol 277 203 23 132 33 10.3 atenolol-d7 
Codeine 300 152 85 115 105 7.4 
 
Danofloxacin 358 340 35 314 27 9.7 flumequine 
Diazepam 285 193 45 154 50 17.6 diazepam-d5 
Diazepam-d5 (IS) 290 198 43 
  
17.6 
 
Doxycycline 445 410 29 154 41 9.7 13C-Phenacetin 
Enalapril 377 234 29 303 35 12.5 diazepam-d5 
Enoxacin 321 303 30 234 33 8.9 flumequine 
Enrofloxacin 360 316 29 245 39 9.9 flumequine 
Erythromycin 734 158 41 576 35 13.4 carbamazepine-d10 
Famotidine 338 189 27 259 20 6.3 atenolol-d7 
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Compounds 
Pr
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Fenofibrate 361 139 43 
  
25.2 diazepam-d5 
Flumequine (IS) 262 202 47 
  
15.4 
 
Fluoxetine 310 44 93 148 13 15.1 fluoxetine-d5 
Fluoxetine-d5 (IS) 315 153 13 
  
15.3 
 
Glibenclamide 494 369 23 169 55 20.7 carbamazepine-d10 
Josamycin 828 174 45 600 37 15.6 carbamazepine-d10 
Lisinopril 406 84 75 
  
8.1 atenolol-d7 
Loratadine 383 337 33 267 47 17.5 carbamazepine-d10 
Lorazepam 323 174 45 229 45 15.7 diazepam-d5 
Metoprolol 268 121 35 133 35 10.2 atenolol-d7 
Metronidazole 172 172 21 82 37 5.8 13C-Phenacetin 
Mevastatin 391 185 19 159 39 21.5 carbamazepine-d10 
Nadolol 310 254 30 201 35 8.5 atenolol-d7 
Nifuroxazide 276 121 25 65 73 12.8 13C-Phenacetin 
Norfloxacin 320 302 35 
  
9.3 flumequine 
Ofloxacin 362 261 39 
  
9.2 flumequine 
Oxytetracycline 461 426 25 201 51 9.2 13C-Phenacetin 
Paroxetine 330 192 31 123 45 14.4 fluoxetine-d5 
Phenazone 189 56 40 147 33 9.8 carbamazepine-d10 
Phenylbutazone 309 77 77 160 29 20.7 carbamazepine-d10 
Pindolol 249 116 30 98 30 8.8 atenolol-d7 
Pravastatin 447 327 29 
  
14.2 carbamazepine-d10 
Propranolol 260 116 35 183 30 12.5 atenolol-d7 
Propyphenazone 231 56 57 189 35 15.3 carbamazepine-d10 
Ranitidine 315 176 25 130 39 6.5 atenolol-d7 
Roxythromycin  838 158 49 679 31 15.1 carbamazepine-d10 
Salbutamol 240 148 25 166 20 5.7 atenolol-d7 
Sotalol 273 213 25 255 25 6.1 atenolol-d7 
Spiramycin 843 174 53 540 43 10.7 carbamazepine-d10 
Sulfadiazine 253 156 25 92 43 7.3 sulfathiazol-d4 
Sulfamethazine 279 186 25 124 33 9.5 sulfathiazol-d4 
Sulfamethoxazole 254 156 25 92 41 12.5 sulfathiazol-d4 
Sulfathiazol-d4 (IS) 260 160 23 
  
8.2 
 
Tamoxifen 372 72 43 327 35 19.4 carbamazepine-d10 
Tetracycline 445 428 20 
  
11.8 13C-Phenacetin 
Tilmicosin 869 696 61 174 55 11.8 carbamazepine-d10 
Timolol 317 261 30 244 30 9.8 atenolol-d7 
Trimethoprim 291 230 33 261 31 8.8 
 
Tylosin A 916 174 63 773 41 14.1 carbamazepine-d10 
 
251 
 
Appendix C 
Concentrations of selected PhCs in surface waters and 
summary of the experimental investigations. 
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Table C. 1.Concentration of Selected PhCs (ng L-1) upstream and downstream the discharge point of WWTPs A and B. 
Class Compounds 
Ferrara ( case study A) Lagosanto (case study B) 
Up stream Down stream Up stream Down stream 
1 st  
sample 
2 nd  
samples 
3 rd  
samples  
1 st 
sample 
2 nd  
samples 
3 rd  
samples  
1 st 
sample 
2 nd  
samples 
3 rd  
samples  
1 st 
sample 
2 nd  
samples 
3 rd  
samples  
analgesics/anti-
inflammatories 
Diclofenac <LOQ <LOQ <LOQ 8 4 4 <LOQ <LOQ <LOQ 44 62 63 
analgesics/anti-
inflammatories 
Indomethacine <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 4 4 3 
analgesics/anti-
inflammatories 
Ketoprofen <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
analgesics/anti-
inflammatories 
Mefenamic acid <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
analgesics/anti-
inflammatories 
Naproxen 3 4 3 8 16 6 <LOQ <LOQ <LOQ 7 8 9 
analgesics/anti-
inflammatories 
Propyphenazone <LOQ <LOQ <LOQ 7 <LOQ 4 <LOQ <LOQ <LOQ 5 6 16 
antibiotics Azithromycin <LOQ <LOQ <LOQ <LOQ <LOQ 7 3 3 9 56 77 89 
antibiotics Ciprofloxacin <LOQ <LOQ <LOQ <LOQ <LOQ 25 30 9 40 91 124 88 
antibiotics Clarithromycin 2 <LOQ 2 5 <LOQ 7 <LOQ <LOQ <LOQ 86 103 128 
antibiotics Metronidazole <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 14 11 16 
antibiotics Roxithromycin <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
antibiotics Sulfamethoxazole <LOQ <LOQ <LOQ 4 <LOQ 5 <LOQ <LOQ <LOQ 30 45 92 
antibiotics Trimethoprim <LOQ <LOQ <LOQ 2 <LOQ 2 <LOQ 2 <LOQ 18 28 30 
lipid regulators Atorvastatin <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
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Class Compounds 
Ferrara ( case study A) Lagosanto (case study B) 
Up stream Down stream Up stream Down stream 
1 st  
sample 
2 nd  
samples 
3 rd  
samples  
1 st 
sample 
2 nd  
samples 
3 rd  
samples  
1 st 
sample 
2 nd  
samples 
3 rd  
samples  
1 st 
sample 
2 nd  
samples 
3 rd  
samples  
lipid regulators Bezafibrate 3 11 16 3 4 4 <LOQ <LOQ <LOQ <LOQ <LOQ 4 
lipid regulators Hydrochlorothiazide <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 83 116 128 
diuretics Furosemide <LOQ <LOQ <LOQ 5 2 2 <LOQ <LOQ <LOQ 49 76 114 
beta-agonists Salbutamol <LOQ 2 2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 6 5 6 
beta-blockers Atenolol 4 14 7 14 12 7 <LOQ <LOQ <LOQ 117 132 231 
beta-blockers Metoprolol <LOQ <LOQ <LOQ 8 <LOQ <LOQ <LOQ <LOQ <LOQ 36 33 49 
beta-blockers Sotalol 12 24 14 35 30 25 <LOQ <LOQ <LOQ 373 502 504 
beta-blockers Timolol <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 5 6 8 
antihypertensive Enalapril <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
psychiatric drugs Carbamazepine 3 <LOQ 3 9 <LOQ 6 2 2 2 76 77 74 
psychiatric drugs Diazepam <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 3 4 5 
psychiatric drugs Lorazepam <LOQ <LOQ <LOQ 5 <LOQ <LOQ <LOQ <LOQ <LOQ 37 47 59 
antidiabetic Glibenclamide <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 3 
 
Table C. 2. Summary of experimental investigations carried out in this thesis. 
Site Type of analyzed waters Period Searched Detected Samples Kind of samples Section Table Page 
Ferrara 
Ferrara 
Lagosanto 
Ferrara 
HWW 
HWW 
HWW 
UWW 
08/2009 
03/2010 
08/2009 
03/2010 
73 
73 
73 
73 
49 
62 
61 
63 
4 
4 
4 
4 
24 hours 
24 hours 
24 hours 
24 hours 
3.3 
3.3 
3.3 
3.3 
3.3 
3.3 
3.3 
3.3 
108 
108 
108 
108 
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Site Type of analyzed waters Period Searched Detected Samples Kind of samples Section Table Page 
Ferrara 
Ferrara 
Ferrara 
Ferrara 
Lagosanto 
Lagosanto 
Lagosanto 
Lagosanto 
Treated UWW 
Treated UWW 
Surface water(up stream) 
Surface water (down stream) 
UWW 
Treated UWW 
Surface water (up stream) 
Surface water (down stream) 
03/2010 
05/2011 
05/2011 
05/2011 
05/2011 
05/2011 
05/2011 
05/2011 
73 
27 
27 
27 
27 
27 
27 
27 
58 
19 
7 
14 
24 
21 
4 
21 
4 
3 
3 
3 
3 
3 
3 
3 
24 hours 
24 hours 
4 hours 
4 hours 
24 hours 
24 hours 
4 hours 
4 hours 
3.3 
4.3.2 
4.3.3 
4.3.3 
4.3.1 
4.3.2 
4.3.3 
4.3.3 
3.3 
4.4 
C.1. 
C.1. 
Fig 4.2. 
4.4 
C.1. 
C.1. 
108 
138 
253 
253 
133 
138 
253 
253 
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Appendix D 
This Appendix reports the scientific pubblications and partecipation in conferences made 
during the years of this Ph.D work. Above each paper the number of journal impact factor 
and number of citations are reported. 
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List of Publications 
Juornal’s Impact factor is 3.28, Number of Citations of this paper in scopus till February 
2013 is 13. 
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Juornal’s Impact factor is 3.28 , Number of Citations of this paper in scopus till February 
2013 is 7. 
 
 
Appendix D 
 
261 
 
 
Juornal’s Impact factor is 3.28, Number of Citations of this paper in scopus till February 
2013 is 1. 
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 Juornal’s Impact factor is 3.28 , Number of Citations of this paper in scopus till February 
2013 is 0. 
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Submitted Papers 
• Verlicchi P., Galletti A., Al Aukidy M., Zambello E., Petrovic M., Barcelo D. Removal of 
Selected Pharmaceuticals from Domestic Wastewater in an Activated Sludge System followed 
by a Horizontal Subsurface Flow Bed – Analysis of their respective contributions. Submitted to 
the journal Science of the Total Environment. 
Book Chapters 
• Verlicchi P., Galletti A., Al Aukidy M., Masotti L., Perspectives in Water disinfection, In. 
WATER DISINFECTION, Nova Publisher, Kelly M. Buchanan, 2011, p. ISBN 978-1-61122-
021-6. 
 
• Verlicchi P, Galletti A, Al Aukidy M. Hospital Wastewaters: Quali-quantitative 
Characterization and Strategies for Their Treatment and Disposal, Springer. In: SK Sharma and 
R Sanghi (Eds), Water Treatment And Pollution Prevention: Advances in Research, Springer, 
UK, 2012. 
 
Attendance at conferences - Platform presentations:  
• Galletti A., AL Aukidy M., Verlicchi P., Petrovic M., Barcelò D.;Pharmaceuticals removal in a 
H-SSF treating a secondary domestic wastewater – an experimental investigation, Proc. IWA 
Conference Wetland Systems for Water Pollution Control, Venice October 2010, 382-384, 
ISBN 978-88-6060-300-5. 
 
• Verlicchi P., Galletti A., Al Aukidy M., Pasti L., Marchetti N., Evaluation of sulphametoxazole 
and ciprofloxacin removal processes in a horizontal subsurface flow system: an experimental 
investigation. Proc. IWA Conference Wetland Systems for Water Pollution Control, Venice 
October 2010, 1045-1047, ISBN 978-88-6060-300-5. 
 
• Verlicchi P., Al Aukidy M., Galletti A., Chiloiro E., Ranieri E., Experimental investigations on 
Heavy Metals Removal in H-SSF Systems in Northern and Southern Italy, Proc. IWA 
Conference Wetland Systems for Water Pollution Control, Venice October 2010, 1048-1050, 
ISBN 978-88-6060-300-5. 
 
• Verlicchi P., Galletti A., Al Aukidy M., BEST PRACTISES IN THE MANAGEMENT OF 
HOSPITAL EFFLUENTS, proc .VI EWRA International symposium-Water Engineering and 
Management in a Changing Environment. Catania June 29-July 2, 2011. 
 
• Al Aukidy M.,Galletti A., Verlicchi P., Petrovic M., Barcelò D .Hospital as a source of 
emerging contaminants (pharmaceuticals): results of an investigation on its final effluent 
chemical characteristics. Proc. 12th International Conference on Environmental Science and 
Technology. 8-10 September 2011-Rhodes, Greece. P.578-587 
 
• Verlicchi P., Al Aukidy M., Galletti A., Masotti L., Zambello E., Zanni  G. A project for the 
reuse of reclaimed wastewater in the sensitive area of the Po Valley: treatment sequence and 
cost/benefit analysis. Proc. 8th International Conference on Water Reclamation and Reuse.26-
29 September 2011- Barcelona, Spain.  
 
Appendix D 
 
264 
 
• Verlicchi P., Galletti A., Al Aukidy M., Ranieri E. Ability in removing heavy metals by 
horizontal subsurface flow constructed wetlands treating secondary effluents. MAGGIOLI 
EDITORE, Quaderni di ecomondo, pp: 733-738, Anno: 2010.  
 
• Verlicchi P., Al Aukidy M., Jelic A., Petrovic M. Exposure assessment of pharmaceuticals in 
wastewaters and surface water - the case study of the catchment area of Ferrara. oral 
presentation at 12th on Tecnologie Sostenibili per la Tutela dell’Ambiente, Milano, 26 – 29 
Giugno 2012. 
 
• Al Aukidy M., Verlicchi P., Galetti A., Masotti L. Gli Effluenti Ospedalieri: Caratterizzazione, 
Trattabilità E Sequenze Di Trattamento Più Adeguate. Il monitoraggio, il controllo e la 
rimozione dei composti xenobiotici ed emergenti nelle acque reflue civili industriali e di falda: 
il contributo della ricerca nei programmi di Ricerca di Interesse Nazionale (PRIN), Acquaria 
Verona, 24 ottobre 2012. 
 
 
Attendance at conferences - Poster presentations: 
• M. Al Aukidy , P. Verlicchi, A. Jelic , M. Petrovic. Monitoring and Risk Assessment of 
Pharmaceutical Compounds in Two WWTP Effluents and Their Receiving Rivers in the Po 
Valley, Italy.  oral presentation at the Ecotechnologies for Wastewater Treatment 2012 
International Conference, 25-27 June 2012 Santiago de Compostela, Spain. 
• Al Aukidy M, Verlicchi P, Zambello E. Environmental Risk Assessment of Pharmaceutical 
Compounds as a Tool for the Management of Hospital Effluents. Accepted for poster 
presentation at the Micropol & Ecohazard Conference 2013 (Zurich, Switzerland 16-20 June 
2013). 
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